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Imaging is the foundation of almost all clinical pathways and an increasingly influential tool for both the 
diagnosis and treatment of a wide spectrum of conditions. This thesis describes three individual 
studies, one randomised controlled trial (RCT) and two observational studies, performed in the context 
of an organisation-wide transformation initiative called TOHETI (Transforming Outcomes and Health 
Economics Through Imaging) at Guy’s and St Thomas’ NHS Foundation Trust (GSTT). All three 
studies converged in the evaluation of the effectiveness and cost-effectiveness associated with the 
innovative use of advanced imaging in the context of clinical pathways in the National Health Service 
(NHS). 
The economics associated with the utilisation of advanced imaging has changed over time due to the 
combined effect of growth in demand and technological developments that have led to advanced 
imaging becoming more accurate, accessible and less costly. However, there is still limited evidence 
around the cost and health economic implications associated with the use of advanced imaging. A 
systematic review conducted by the student assessed the challenges and methodological approaches 
used in the economic evaluation of diagnostic tests and constituted the foundation for the study design 
and statistical analyses employed in all three empirical studies.  
The first study, a single-centre RCT, assessed the immediate use of Magnetic Resonance Imaging 
(MRI) in the management of suspected scaphoid fractures in the emergency department (ED) at GSTT. 
This study followed a published systematic review conducted by the student that highlighted the lack 
of both empirical economic evidence and appropriate economic modelling evidence on the immediate 
use of advanced imaging in the management of suspected scaphoid fractures. One-hundred and thirty 
six participants entered the study and were randomised to receive either the intervention with 
immediate MRI or follow routine care, which did not consider the use of MRI in the acute setting. This 
study was truly innovative as, to our knowledge, MRI is not considered in the context of acute care. 
The primary outcome was to estimate the cost implications from the healthcare payer perspective. 
Secondary outcomes included wider costs, cost-effectiveness and cost-utility (cost per quality-adjusted 
life years), diagnostic accuracy, clinical findings, time taken to reach a definitive diagnosis and patient 
satisfaction. Generalised linear models (GLM) were undertaken to estimate the main effect of group in 
all cost analyses. Based on intention-to-treat principles, the use of immediate MRI led to cost savings 
and, given the available data, there was a 96% to 100% probability of being cost-effective at 
conventional willingness-to-pay thresholds in the UK. 
The second study, a single-centre pragmatic observational study, evaluated the utilisation of GP direct 
access to MRI compared to referral to neurology services for patients with chronic headache. Despite 
the benign nature of most headaches, headache management is associated with high healthcare 
utilisation, accounting to up to one third of neurologist appointments. The study’s underlying hypothesis 
was that the early use of an advanced and accurate diagnostic tool (in this case MRI) would reassure 
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both patients and GPs that no serious underlying cause (particularly brain tumour) was present. This 
would in turn reduce the headache burden and NHS resource use associated with the patient’s 
subsequent management. For this purpose, a total of two-hundred and forty nine patients were 
recruited for both groups (MRI and neurology groups) as per standard care. The primary outcome was 
to estimate the cost implications from the healthcare payer perspective. Secondary outcomes 
considered further cost and cost-effectiveness analyses, accessibility to care, time off-work and patient 
satisfaction. Cost analyses were conducted using GLMs and, given the study’s non-randomised 
design, adjusted for potential imbalances at baseline. Based on intention-to-treat principles, direct 
referral to brain MRI from primary care led to cost savings, quicker access to care but lower patient 
satisfaction levels when compared with referral to neurology services.  
The third study, a single-centre pragmatic observational study, evaluated the utilisation of Computed 
Tomography Colonography (CTC) compared to Optical Colonoscopy (OC) as the first line colonic 
investigation in the assessment of patients with low to intermediate risk of colorectal cancer (CRC). 
CRC is one of the leading causes of mortality and morbidity worldwide, with the UK presenting five-
year survival rates significantly lower compared to other countries. Recent clinical guidelines aimed to 
increase early diagnosis of CRC by lowering the threshold for colonic investigations. However, this led 
to a substantial increase in colonic investigations, particularly OC, the diagnostic reference test for 
CRC, which remains technically difficult and resource intensive. This study evaluated the substitution 
of CTC as a first-line colonic investigation for patients deemed at low to intermediate risk of CRC. The 
underlying rationale was that CTC, a non-invasive and less costly colonic investigation, would be able 
to rule-out CRC or large polyps, thereby avoiding the need for invasive OC tests. Moreover, this would 
release much needed OC resources to test patients with known CRC or at a higher risk of CRC. The 
primary outcome was to estimate the cost implications from the healthcare payer perspective. 
Secondary outcomes considered cost-effectiveness and cost-utility, accessibility to care and patient 
satisfaction. Based on intention-to-treat principles, the use of CTC generated cost savings and 
presented a probability of 84%-91% of being cost-effective at conventional willingness-to-pay 
thresholds. The use of CTC also improved access to care, with no impact in patient satisfaction. 
The role of observed data versus economic modelling is discussed taking into consideration published 
economic literature and its implications to interventions in the medical imaging field. The findings from 
a priori decision-analytical models were then compared to the empirical evidence retrieved from the 
three studies. Additionally, the student investigated whether the two methodological approaches would 
have led to different decisions from policy makers and ultimately affect the adoption of medical imaging 
technologies. 
The last chapter completes the thesis with an overarching discussion of the main findings from model 
and real-world studies and their implications in the wider context of real-world NHS clinical practice. 
The implementation plans for the three different clinical pathways are detailed with the aim of bridging 
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Chapter 1. Introduction 
1.1. Context and rationale 
Medical imaging encompasses diverse imaging modalities, from radiograph-based examinations to 
advanced imaging modalities such as Computed Tomography (CT) and Magnetic Resonance Imaging 
(MRI). Medical imaging is the foundation of many clinical pathways, being used in the diagnosis, 
monitoring or treatment of new or existing clinical conditions. The demand for medical imaging, 
particularly advanced imaging modalities, is growing across developed healthcare systems. At the 
same time, these healthcare systems are under increasing financial pressures. To date, there has 
been limited economic evidence around the use of medical imaging in real-world patients and clinical 
pathways. 
This thesis aims to fill the gap between the economics and the medical imaging fields. It will examine 
whether the innovative use of advanced imaging may not only improve clinical outcomes and patient 
satisfaction but also, and despite the higher initial costs, could hold the potential to contribute to the 
National Health Service (NHS) financial sustainability agenda. This will be achieved using a detailed 
and consistent health economics methodology across different clinical conditions and imaging 
modalities. Furthermore, the use of real-world patients and clinical pathways, as opposed to decision 
analytical modelling only, will provide observed data on which to base potential changes in clinical 
practice.   
This PhD was undertaken in the context of a wide transformation initiative - TOHETI (Transforming 
Outcomes and Health Outcomes Through Imaging) - at Guy’s and St Thomas’ NHS Foundation Trust 
(GSTT), a Tertiary Hospital in Central London. This programme was fully funded by the Guy’s and St 
Thomas Charity (£13 million over a 4-year period). The overarching aim of this transformation 
programme was to evaluate the innovative use of medical imaging applied to real-world clinical 
pathways. 
The TOHETI programme consisted of four phases (Figure 1). Phase 1 entailed the identification and 
selection of imaging-based transformational initiatives across the Trust. This process aimed to include 
any initiative that relied on the new or novel use of advanced imaging for the holistic transformation of 
the entire clinical pathway. Phase 2 included the proposal submission to secure funding. This process 
was based on a priori economic evaluation using decision analytical modelling. Phase 3 comprised the 
research studies which evaluated whether the intervention had the anticipated effects on costs and 
outcomes. This included preparation (i.e. study design, development of supporting documents, 
securing ethical and health research authority approval) and subsequent data collection and analysis 
and dissemination of findings. Lastly, phase 4 encompassed the implementation of the proposed 
initiatives as part of the normal clinical practice for patients at GSTT. This phase was dependent on 
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the findings from the research studies and the ability to overcome operational challenges associated 
with the proposed intervention across different clinical specialties and directorates. 
 
Figure 1. Four phases associated with the TOHETI programme. 
As part of phase 1 of the TOHETI programme, and from over twenty potential initiatives, a total of six 
projects were selected (illustrated in Figure 2).  
 
Figure 2. Six projects evaluated as part of the TOHETI programme. 
Out of these six projects, three are included in this thesis: 
1. The use of MRI in the acute management of suspected scaphoid fractures compared to the 
diagnostic strategy based on conventional radiograph only. 
2. The direct referral from primary care to MRI for the management of chronic headache 
compared to the standard management of referral to a neurology clinic. 
3. The use of CT colonography as the first line imaging investigation in the management of 
patients with low-risk colorectal cancer compared with optical colonoscopy. 
21 
 
The selection of initiatives was undertaken based on three criteria: (i) the alternative use of advanced 
imaging; (ii) high impact initiative and/or high volume clinical pathway; and (iii) the holistic 
transformation of diagnostic and treatment pathways. These criteria are explained in more detail below. 
(i) All three projects involved the use of first-line advanced imaging in the diagnostic pathway. The 
suspected scaphoid fracture study investigated the use of MRI in the Emergency Department setting. 
To our best knowledge, this approach was unique worldwide. Likewise, the research involving patients 
with suspected colorectal cancer involved the use of non-invasive advanced imaging as a direct 
alternative to the invasive standard care optical colonoscopy in low-risk patients. The study with chronic 
headache patients investigated the use of advanced imaging as a direct alternative to a referral to a 
clinical specialist.   
(ii) The suspected scaphoid fracture project involved the implementation of a high impact initiative, 
capable of affecting both clinical and efficiency outcomes given the superior diagnostic performance 
of wrist MRI compared to plain radiographs (Yin et al. 2010). The chronic headache and colorectal 
cancer pathways represented two high volume clinical pathways. In fact, chronic headache 
management, albeit being mainly managed within primary care, is the most common cause for referral 
accounting for up to 22% of GP referrals to neurologists (Thomas et al. 2010). According to NICE 
CG131, colorectal cancer is the third most common cancer in the UK (after breast and lung) and the 
second most common cause of cancer death in the UK (NICE 2011). Additionally, the UK 5-year 
survival rates for colorectal cancer are significantly lower than other countries (Coleman et al. 2011), 
with one of the possible contributing factors being the lack of timely diagnostic scans. 
(iii) A holistic approach was present in all three research studies as the proposed interventions 
considered the transformation of the entire diagnostic and treatment pathways as a direct consequence 
of the advanced imaging findings. This meant that the innovative use of advanced imaging was the 
driver for change across the entire clinical pathway. As an example, a proportion of participants with 
no clinical findings in the wrist MRI will not require any follow-up at all. Hence, by using a more 
advanced and accurate imaging modality earlier in the clinical pathway, we will be able to change the 
participant’s subsequent care. Similarly, a proportion of patients with chronic headache directly referred 
for a head MRI will not require a subsequent formal medical consultation with a neurologist.  
1.2. Aims and questions addressed 
This thesis applied methods of economic evaluation to assess three advanced imaging-based 
interventions in real-world patients across three different NHS clinical pathways. The overall aim of this 
thesis was to evaluate whether the innovative use of advanced imaging led to lower total costs from a 
healthcare payer perspective, thereby contributing to the NHS financial sustainability agenda. Second, 
the effectiveness and cost-effectiveness of the proposed interventions were also examined using 
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methodologies consistent with those recommended by the National Institute for Health and Care 
Excellence (NICE). These aims were then translated into individual research objectives organised by 
clinical study since the use of advanced imaging will lead to different findings in varied clinical contexts.  
Three specific questions were addressed: 
1. What are the economic and clinical benefits of using immediate wrist MRI in the acute 
management of suspected scaphoid fractures? 
2. What are the economic and clinical benefits of using direct referral from primary care to head 
MRI in the management of patients with chronic headache? 
3. What are the economic and clinical benefits of using CT colonography (virtual colonoscopy) in 
the management of patients with low risk suspicion of colorectal cancer? 
1.3. Thesis structure 
This thesis consists of seven chapters, organised around the three clinical studies completed as part 
of the PhD programme.  
The present chapter (chapter 1) introduces the thesis and summarises the rationale around the 
selection of each intervention. 
Chapter 2 provides background information around different diagnostic imaging modalities, with 
particular emphasis on advanced imaging. Considerations around the past, present and future 
utilisation rates, and its potential implications to the healthcare system, are summarised. The main 
challenges and methodological approaches used in the economic evaluation of diagnostic tests are 
also included in this chapter. Expanding on this, a systematic literature review was performed to assess 
the historical evolution and critically appraise different economic evaluation frameworks applied to 
diagnostic tests. Finally, the assessment of the published economic evidence of medical imaging 
technologies over a period of thirty years was performed using two existing systematic literature 
reviews (the most recent one dating from 2018). 
Chapters 3, 4 and 5 are written as standalone chapters representing each individual research study, 
individual introduction, methods, results, discussion, conclusion and reference sections included within 
each chapter. Chapter 3 describes a randomised clinical trial assessing the innovative use of MRI in 
the acute management of suspected scaphoid fractures. Given the randomised design in the context 
of an acute pathway, particular attention was given to the challenges associated with this type of 
research. Chapter 4 investigates the use of MRI in the management of one of the most common clinical 
conditions, chronic headache, using non-randomised observational cohorts. Chapter 5 explores the 
use of CT as first line investigation in the assessment of patients with suspected colorectal cancer.  
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Chapter 6 compares the findings from a priori decision-analytical models to real-world prospective 
studies in the evaluation of specific medical imaging interventions applied to clinical pathways within 
the NHS. The role of observed data versus economic modelling is discussed taking into consideration 
published economic literature and the implications for interventions in the medical imaging field. 
Additionally, chapter 6 assesses whether the two methodological approaches would have led to 
different decisions from policy makers and, ultimately, affect the adoption of medical imaging 
technologies. 
Chapter 7 completes the thesis with an overarching discussion of the main findings from the economic 
models and subsequent real-world studies and the implications in the wider context of the real-world 
NHS clinical practice. The implementation plans for the three different clinical pathways are detailed 
with the aim of bridging the gap between the clinical and economic evidence and the actual delivery of 
care across the NHS. Lastly, chapter 7 includes the considerations around the limitations and strengths 
of the work performed and recommendations for further research. 
1.4. Student contribution  
The current PhD was conducted in the context of a wide transformation initiative at a Tertiary Hospital 
in Central London - GSTT - and funded with £13 million by a local charity - Guy’s and St Thomas’ 
Charity. The idea for each clinical studies was chosen from over twenty advanced imaging initiatives 
proposed by clinicians from different clinical areas. The student, with special interest and academic 
background in medical imaging, was included in the process of triage and discussion of the proposed 
interventions. Subsequently, the student was involved in the write-up of the grant proposal, drafting 
the five clinical studies to be performed and the anticipated clinical and economic benefits based on 
decision-analytical models. As part of this thesis, three studies were selected whilst three other studies 
were not included (around the use of CT in acute chest pain, the feasibility of using CT in the diagnosis 
of lung cancer among asymptomatic participants and the use of MRI in the management of suspected 
prostate cancer).  
Once the initiatives to be included as part of TOHETI were selected, the student developed the 
methodological approaches in coordination with the academic supervisors (Professor Paul McCrone, 
Professor Vicky Goh and Dr James Shearer) and statistical experts (Professor Janet Peacock and her 
team). All documents (e.g. study protocol, patient information sheet and other supporting documents) 
for all clinical studies were written by the student. Moreover, given the inclusion of real-world patients, 
all studies were centrally submitted for ethical approval (via the Integrated Research Application 
System). This entire process was conducted by the student in close coordination with different 
stakeholders (Chief Investigator, Principal Investigator and other NHS professionals - e.g. doctors, 
nurses, radiographers, managers).  
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Given the complexity of each study and the number of participants recruited simultaneously across 
different medical specialties (over 500 participants), participant data were mainly collected by research 
assistants and members of the clinical care team (e.g. emergency nurse practitioners, research 
nurses). The student was responsible for enrolling a small proportion of participants (~10%), and was 
responsible for providing training and continuously supporting all recruiters across the different studies. 
For one study, this meant, for instance, attending to regular handover meetings in the Emergency 
Department. 
All collected data were manually entered into a web-based Case Report Form software (RedCap) by 
the student or research assistants. All database maintenance and data cleansing was carried out by 
the student. All statistical analyses of clinical and economic data described in this thesis were carried 
out by the student with support from the academic supervisors and statistical experts. The student 
wrote the first draft of the thesis which then was circulated among all academic supervisors who 
provided the student with invaluable comments and suggestions and proofread the final version of the 
thesis. 
The student would like to highlight that the scientific approach associated with the TOHETI programme 
was well received by both managers and clinicians alike as a methodology to assess clinical pathways. 
This led to the inception a new Trust wide transformation initiative, called Care Redesign, which 
embodies the approach summarised in this thesis. At the time of writing of the thesis, over sixty 
multidisciplinary teams have looked at their operating systems and are aiming to them using some of 
the methods implemented in this PhD (e.g. cost analyses, economic modelling). Apart from the clinical 
impact of the three studies considered, this is one of the major legacies resulting from this PhD. 
1.5. Publications and conferences 
The findings from the three studies included in this PhD have resulted in the following peer-reviewed 
publications (listed in chronological order from the oldest to the most recent):  
1. Rua T, Vijayanathan S, Parkin D, Goh V, McCrone P, Gidwani S. Rationale and design of the 
SMaRT trial: a randomised, prospective, parallel, non-blinded, one-centre controlled trial to 
evaluate the use of Magnetic Resonance Imaging in acute setting in patients presenting with 
suspected scaphoid fracture. Journal of Clinical Trials, 2017. 
2. Rua T, Gidwani S, Parkin D, Goh V, McCrone P. The economic evidence for advanced imaging 
in the diagnosis of suspected scaphoid fractures: Systematic review of evidence. Journal of 
Hand Surgery, January 2018. 
3. Rua T, Malhotra B, Vijayanathan S, Hunter L, Peacock J, Shearer J, Goh V, McCrone P and 
Gidwani S. Clinical and cost implications of utilising immediate Magnetic Resonance Imaging 
(MRI) in the management of patients with suspected scaphoid fracture and negative 
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radiographs: results from the SMaRT trial. The Bone & Joint Journal, vol. 101-B, no. 8, pp. 984–
994, Jul. 2019. 
4. Rua T, Gidwani S, Malhotra B, Vijayanathan S, Hunter H, Peacock J, Goh V, McCrone P, 
Shearer J (2020). Cost and cost-effectiveness implications of utilising immediate acute Magnetic 
Resonance Imaging (MRI) in the management of patients with suspected scaphoid fracture: 
results from a randomised clinical trial in England. Value in Health (in press). 
5. Rua T, Mazumder A, Akande Y, Margariti C, Ochulor J, Turville J, Razavi R, Peacock J, 
McCrone P,  Goh V, Shearer J, Afridi S. The management of chronic headache with referral 
from primary care to direct access to Magnetic Resonance Imaging (MRI) compared to 
Neurology services: an observational prospective study. BMJ Open (in press). 
6. Rua T, Watson H, Malhotra B, Margariti C, Turville J, Razavi R, Peacock J, McCrone P,  Goh 
V, Shearer J, Griffin N (2020). An observational study to compare the utilisation of Computed 
Tomography Colonography with Optical Colonoscopy as the first diagnostic imaging tool in 
patients with suspected colorectal cancer. Clinical Radiology (in press). 
In addition, the PhD work has been presented at different national and international conferences. The 
student was responsible for submission of all abstracts, being the presenter in health management 
and health economics conferences and delegating to the senior clinical author the presentation role in 
most clinical conferences. The list of conferences and type of presentation (oral presentation or poster 
presentation) are presented in chronological order, with the presenter identified with an asterisk: 
1. Rua T*, Vijayanathan S, Shearer J, Goh V, McCrone P, Gidwani S. Transforming healthcare 
using medical imaging as the driver for change (oral communication). 28th Congress of the 
European Association of Hospital Managers, September 2018 in Lisbon, Portugal. A ‘best 
presentation’ award was granted to the student (out of over 100 oral communications). 
2. Rua T*, Malhotra B, Vijayanathan S, Hunter L, Sharer J, Peacock J, Goh V, McCrone P, Gidwani 
S. Clinical and cost implications of utilising immediate MRI in the management of patients with 
suspected scaphoid fracture and negative radiographs (oral communication). Annual Congress 
of the British Society for Surgery of the Hand, April 2019 in Swansea, Wales. 
3. Rua T*, Malhotra B, Vijayanathan S, Hunter L, Sharer J, Peacock J, Shearer J, Goh V, McCrone 
P, Gidwani S. The use of advanced imaging as the driver for change across the suspected 
scaphoid fracture pathway: single-centre trial results (poster presentation). International Forum 
for Quality and Safety in Healthcare, March 2019 in Glasgow, Scotland. 
4. Rua T*, Gidwani S, Malhotra B, Vijayanathan S, Isaac A, Hunter L, Sharer J, Peacock J, Goh 
V, Shearer J, McCrone P. The use of advanced imaging as the driver for change across the 
suspected scaphoid fracture pathway: single-centre trial results (poster presentation). 
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International Conference of the International Society for Pharmacoeconomics and Outcomes 
Research, May 2019 in New Orleans, USA. 
5. Rua T, Isaac A*, Malhotra B, Vijayanathan S, Hunter L, Sharer J, Peacock J, Goh V, Shearer J, 
McCrone P, Gidwani S. The scaphoid MR Imaging in Trauma (SMaRT) trial (oral 
communication). Annual Congress of the European Society of Musculoskeletal Radiology, June 
2019 in Lisbon, Portugal. 
6. Rua T, Afridi S, Akande Y, Margariti C, Turville J, Razavi R, Peacock J, Shearer J, Goh V, 
McCrone P, Mazumder A*. An observational study to evaluate the management of patients with 
chronic headache with referral from primary care to direct access to magnetic resonance 
imaging (MRI) compared to neurology services (oral communication). 42th Conference of the 
European Society of Neuroradiology, September 2019 in Oslo, Norway. 
7. Rua T, Vijayanathan S, Mak D*, Zavareh A, Isaac A, Malhotra B, Hunter L, Sharer J, Peacock 
J, Goh V, Shearer J, McCrone P, Gidwani S. Clinical and cost-effectiveness implications of 
utilizing immediate acute Magnetic Resonance Imaging (MRI) in the management of patients 
with suspected scaphoid fracture and negative initial radiographs: results from a randomized 
clinical trial (oral communication). A ‘case of the day’ award was granted to the presentation. 
Annual Conference of the Radiological Society of North America, December 2019 in Chicago, 
USA. 
8. Rua T, Afridi S, Akande Y, Margariti C, Turville J, Razavi R, Peacock J, Shearer J, Goh V, 
McCrone P, Mazumder A*. An Observational Study to Evaluate the Management of Patients 
with Chronic Headache with Referral from Primary Care to Direct Access to Magnetic 
Resonance Imaging (MRI) Compared to Neurology Services (oral communication). A ‘case of 
the day’ award was granted to the presentation. Annual Conference of the Radiological Society 
of North America, December 2019 in Chicago, USA. 
9. Turville J*, Rua T, Malhotra B, Cronin B, Akande Y, Razavi R. Transforming Healthcare and 
Outcomes Using Medical Imaging as The Driver for Change (TOHETI): Transformation Program 
in a Central London NHS Trust Services (oral communication). Annual Conference of the 
Radiological Society of North America, December 2019 in Chicago, USA. 
10. Rua T, Watson H, Malhotra B, Cleary J*, Margariti C, Turville J, Razavi R, Peacock J, McCrone 
P,  Goh V, Shearer J, Griffin N. An observational study to compare the utilisation of Computed 
Tomography Colonography with Optical Colonoscopy as the first diagnostic imaging tool in 
patients with suspected colorectal cancer (poster presentation). European Congress of 
Radiology, March 2020 in Vienna, Austria. 
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Chapter 2. Background 
2.1. Evolution of medical imaging  
Medical imaging is used to visualise the human body in order to diagnose, monitor or treat medical 
conditions. Medical imaging is used across a wide range of clinical conditions, from simple injuries to 
potential life-threatening conditions, as well as clinical pathways, from emergency to elective care.  
Medical imaging includes a wide range of modalities, from basic technologies such as conventional 
radiograph (X-ray) and ultrasound, to more advanced modalities like Computed Tomography (CT), 
Magnetic Resonance Imaging (MRI) or Positron Emission tomography (PET). More recently, as 
illustrated in Figure 3, hybrid imaging modalities i.e. imaging that utilises more than one imaging 
modality simultaneously have been introduced into clinical practice (e.g. PET/CT or PET/MRI).  
 
Figure 3. Key milestones in the development of the medical imaging field. 
Medical imaging is an increasingly influential tool in the healthcare context. Furthermore, medical 
imaging is an evolving field, characterised by continuous improvement as well as disruptive innovations 
that hold the potential to revolutionise entire models of care. In fact, the increase in utilisation of medical 
imaging has historically surpassed the growth of the total healthcare expenditure, with the latest years 
however suggesting a slowdown in this trend in developed countries (Lang et al. 2013; Lee, Duszak, 
and Hughes 2013). 
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2.2. Past, present and future trends in medical imaging  
2.2.1. Utilisation rates per inhabitant 
As illustrated in Figure 4, the utilisation rates have increased over the last five years in England across 
all imaging modalities (Cake, Cavanagh, and Gordon 2015). This growth is particular relevant in the 
two advanced imaging modalities (CT and MRI), with annual growth rates of over 9%.  
 
Figure 4. Annual growth rates by modality imaging over the last five years (Cake, Cavanagh, and 
Gordon 2015). 
Additionally, Cake, Cavanagh, and Gordon (2015) estimated that the utilisation rates of advanced 
imaging modalities will increase even further, with projected annual growth rates over 10% between 
2016 and 2020. This meant that in less than eight years, the utilisation rates for advanced imaging will 
have more than doubled. This growth of CT and MRI utilisation, illustrated in Figure 5, derives from 
demographic growth (estimated at 1.3% per year) but also from a change in clinical guidelines for the 
use of advanced imaging (for new or surveillance patients) and the lowering of clinical referral 
thresholds for a diagnostic test (e.g. direct access to imaging from primary care). In other words, it is 
the novel clinical use of advanced imaging modalities that is expected to drive the increase in utilisation 













Figure 5. Expected annual growth rates for CT and MRI over the coming five years with the individual 
contribution of different factors (Cake, Cavanagh, and Gordon 2015). 
These figures are relative to the baseline absolute utilisation rates for both CT and MRI in the United 
Kingdom (UK). In fact, the utilisation rates per inhabitant for both CT and MRI are significantly lower in 
the UK compared to other countries (see Figure 6 and Figure 7, respectively). The UK utilisation rates 
of CT and MRI in 2016 were, respectively, 45% and 19% lower than the average of the 29 countries 
considered from the Organisation for Economic Co-operation and Development (OECD) (see Figure 
6 and Figure 7). In the case of CT, the UK is in the bottom three countries ranked by utilisation rates. 
This number however does not take into consideration exams performed outside hospital such as CT 
scans performed in private outpatient clinics but these are unlikely to significantly affect the overall UK 
position when compared to other developed countries. 
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Note: 1: CTs outside hospital excluded; 2: CTs on public patients excluded; 3: CTs privately-funded 
excluded. 
Figure 6. Utilisation rate of CT per inhabitant in 2016 (or nearest year) (OECD 2018). 
 
Note: 1: MRIs outside hospital excluded; 2: MRIs on public patients excluded; 3: MRIs privately-funded 
excluded. 
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2.2.2. Number of scanners per inhabitant 
The UK also has a lower number of both CT and MRI scanners per million inhabitants compared to 
the majority of OCDE countries. The UK had in 2016 fewer CT and MRI scanners, with a proportion 
63% and 55% lower than the average of the 34 countries considered from the OECD (see Figure 8 
and Figure 9), respectively. For example, the UK had a total of 9.5 CT scanners per million of 
inhabitants, much lower than the United States (US) (41.0), Germany (35.1) or France (16.6). Similarly, 
with regards to MRI, the UK had 7.2 scanners per million of inhabitants, again lower than the US (39.0), 
Germany (33.6) or France (12.6). 
 
Note: 1- Equipment outside hospital excluded; 2- Only equipment eligible for public reimbursement. 
























































Note: 1- Equipment outside hospital excluded; 2- Only equipment eligible for public reimbursement. 
Figure 9. Number of MRI scanners per inhabitant in 2016 (or nearest year) (OECD 2018). 
2.2.3. Utilisation rate per scanner 
A very important metric that is commonly ignored relates to the number of diagnostic tests per scanner. 
This metric is relevant as estimates the actual overall occupancy rates per scanner and hence is a 
proxy to the existing system capacity to accommodate any increase in demand. Although these data 
should not be seen in isolation, as it depends on different factors such as the type of healthcare system, 
other healthcare resources (e.g. radiologists) or even the countries’ geography, the number of scans 
per scanner provides a solid indication of the current situation of advanced imaging in the NHS. 
In the case of CT, the UK had a total of 8,383 CT scans per scanner, 20% higher than the average 
(6,999), 38% higher than the US (6,063) or 104% higher than Germany (4,098) but 28% lower than 
France (11,653) (Figure 10). A similar situation occurs with MRI, with the UK having 7,275 MRI scans 
per scanner, 32% higher than the average, 120% higher than the US (3,287) or 86% higher than 
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Figure 10. Number of CT scans per CT scanner in 2016 (or nearest year) (OECD 2018). 
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2.2.4.  Advanced imaging in the UK: supply and demand 
Figure 12 illustrates the background on the current and expected use of advanced imaging in the 
context of the UK healthcare market.  
First, from the perspective of demand, the UK utilisation of advanced imaging (e.g. MRI, CT) is lower 
when compared with other countries, such as France, Germany or the US. Second, given the 
increasing use of advanced imaging in all healthcare systems and the UK utilisation gap when 
compared to these countries, the very high annual growth rates of advanced imaging in the UK are 
expected to continue in the near future. Hence, from a demand point of view, these two factors 
converge towards the expansion of advanced imaging in the NHS. 
Third, from the supply perspective, the UK has a lower number of advanced imaging scanners (both 
CT and MRI scanners) when compared to other countries such as Germany, France or the US. Fourth, 
not only does the UK have a lower number of scanners per inhabitant, its occupancy rate is higher 
when compared to most countries. The latter means that the existing scanners are running to a higher 
occupancy rate and therefore have a limited ability to respond to an increase in workload. Thus, from 
a supply point of view, as the existing NHS capacity is not enough to accommodate the increasing 
demand needs, capital investment in the NHS will be needed over the coming years. This situation 
places an extra emphasis on the need for economic evaluation concerning the current utilisation of 
advanced imaging within the NHS. 
 
Figure 12. Demand and supply analysis associated with the use of advanced imaging the UK. 
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2.3. Economic evaluation of medical imaging 
2.3.1.  Rationale  
Developments in the medical imaging field have simultaneously led to: (i) an increase in the accuracy 
of CT and MRI in the diagnosis of different clinical conditions; and (ii) a decrease in the acquisition and 
processing time associated with CT and MRI scans. The latter means that newer scanners enable 
more accurate and faster diagnostic scans, leading to an increased throughput per scanner (i.e. higher 
number of exams per scanner). Given that the acquisition costs of new CT and MRI scanners have 
remained relatively stable, the faster acquisition time per imaging test has led to a decrease in the 
operational unit cost per CT or MRI scan (European Society of Radiology, 2014). This trend is expected 
to continue over time. Hence, as advanced imaging becomes more accurate, accessible and cheaper, 
its use in the NHS needs to be reassessed. Although the purchase and implementation of new 
diagnostic equipment is associated with quicker access and improved diagnostic accuracy, there is 
limited evidence that this leads to improved health outcomes (Baker, Atlas, and Afendulis 2008). In 
conclusion, due to the increase in both the demand and the supply of medical imaging, there is an 
imperative need to establish economic criteria regarding its use in the context of the NHS (illustrated 
in Figure 13).  
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2.3.2.  Key challenges 
It is recognised that there is more economic evidence around the evaluation of therapeutic (e.g. 
pharmaceutical drugs) than for diagnostic interventions (Drummond, Griffin, and Tarricone 2009). This 
is mainly due to a fundamental difference between assessing a therapeutic intervention (e.g. 
pharmaceutical drug or cardiac stent) and a diagnostic test (e.g. MRI). This difference is a cause and 
effect relationship (Hollingworth 2005). Whilst, for instance, the link between a pharmaceutical drug 
(the cause) and its impact at different outcomes (the effect) can be established in the context of a 
properly designed trial, the latter is harder with diagnostic tests (Drummond, Griffin, and Tarricone 
2009). In fact, medical imaging, as other diagnostic tests, is used to generate diagnostic information of 
a potential or confirmed clinical condition. This diagnostic information may in turn impact the 
therapeutic decision, which can then have different outcomes (measure of effect). Figure 14 and the 
paragraphs below illustrate the five layers of uncertainty associated with the evaluation of value of 
diagnostic tests:  
 
Figure 14. Uncertainty in the assessment of value in the use of a diagnostic tool.  
 First, the rationale behind a newer and better diagnostic test is that it will improve the 
probability of achieving the right diagnosis. However, the accuracy of diagnostic tests is not 
perfect, given the presence of false positives (ruling in a disease in patients without the 
disease) and false negative findings (ruling out a disease in patients with the disease). Figure 
15 illustrates a hypothetical scenario where the distribution of false positive (FP), true positive 
(TP), true negative (TN) and false negative (FN) findings is dependent on: (i) the disease 
prevalence or incidence (hypothesised at 20% in Figure 15); and (ii) the accuracy 
(hypothesised at 80% sensitivity and 90% specificity in Figure 15) of the diagnostic test for that 
condition. In this hypothetical clinical scenario, the diagnostic test led to the right diagnosis in 
88% of the cases (16% TP + 72% TN) and the wrong diagnosis in 12% of the cases (8% FP 
+ 4% FN). This introduces the first level of uncertainty, the test’s ability to correctly identifying 
the disease in patients with the condition (sensitivity) and exclude the disease in patients 




Figure 15. Decision tree associated with the use of an imaging test to a hypothetical cohort of patients. 
 Second, even if the correct diagnosis is achieved, it will only be relevant if it affects the 
clinician’s diagnostic decision. This can either be to change or to reassure the clinician’s 
diagnostic thinking. The diagnostic test can also impact on patients’ confidence in the 
diagnosis, affecting their perceptions and behaviours.  
 The third layer of uncertainty relates to the probability of the right management decision or 
treatment (if any) being chosen. Indeed, the use of medical imaging might not lead to a change 
in the treatment options or, even if the treatment choice is impacted, there is uncertainty about 
whether the right treatment is chosen. Again, the diagnostic test can impact both the clinicians’ 
and the patients’ behaviours, e.g. reassuring the clinician that the right treatment is chosen or 
reassuring the patient and thereby improving their adherence to the treatment.  
 The fourth layer of uncertainty is associated with the clinical effectiveness of the treatment 
itself. The same treatment applied to different patients with the same condition might result in 
different outcomes (clinical or otherwise). 
 Fifth, there are several value propositions associated with diagnostic tests. A diagnostic test 
might be used as an add-on or replacement test in the context of specific clinical pathways or 
might be used for operational purposes (e.g. speed up the diagnosis), reduce costs or improve 
care. Furthermore, the same diagnostic technology applied in different clinical settings might 
have different value propositions and multiple applications (Drummond, Griffin, and Tarricone 
2009). 
Table 1 further details the main features associated with medical imaging tests that lead to the above 


























Table 1. Key features responsible for the layers of uncertainty in the evaluation of medical imaging technology. 
Uncertainty layer Feature Description 






The test’s sensitivity defines its ability to identify the clinical condition in patients with that condition whilst its 
specificity refers to the test’s ability to identify patients without the clinical condition. False positive and false 
negative results occur from the use of imaging tests which are not 100% accurate. 
1.2. Machine 
variability 
The same imaging technology (e.g. CT) can be implemented in the same clinical condition using CT 
equipment from different companies. These machines are intrinsically different and this has the potential to 
affect the outcomes of the intervention. 
1.3. Reader 
variability 
The same imaging scan can be reported differently by two readers. Given its subjectivity compared to other 
technologies (e.g. pharmaceutical drugs), this introduces uncertainty as the result from the reader’s report 
(and not the images themselves) are the actionable information on which the patients’ diagnosis and 
treatment might be changed.  
1.4. Reference 
test 
The introduction of new imaging technology is usually compared against other imaging tests. The 
comparator tests are normally assumed to be the reference, with perfect accuracy (100% sensitivity and 
specificity) as part of decision-analytical models. This assumption is associated with uncertainty as no 
imaging test is actually 100% accurate. 
1.5. Incidental 
findings 
The use of medical imaging tests might lead to the incidental identification of clinical condition(s) unrelated 
to the original request for the imaging test. Some of these incidental findings are clinically relevant and 
hence require follow-up and have the potential to affect the evaluation of the imaging test. However, the 
inclusion of incidental findings in decision-analytical models is typically ignored. 
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The diagnostic medical algorithm is usually based on clinical, laboratory and radiological findings. Hence, 
the imaging test’s diagnosis is a central element that might affect the clinician’s diagnostic thinking by either 
corroborating or rejecting the anticipated diagnosis.  
2.2. Clinician’s 
reassurance 
Even if the imaging test corroborates the known diagnosis, there is added value to the diagnostic test. In 
real-world clinical practice, clinicians request imaging tests for reassurance that the right diagnosis has been 
achieved. However, the added psychological value of the test is difficult to measure and evaluate.   
2.3. Patient’s 
reassurance 
Similarly to clinicians, patients’ reassurance that the right diagnosis has been achieved might differ based 
on the imaging test. In fact, the use of imaging tests might impact on the patients’ perception that the 







Based on a given diagnosis, clinicians subsequently decide on the management/treatment strategy – if any 
at all (with do nothing as a possibility). Hence, the imaging test has contributed to a given diagnosis that, in 
turn, led to a specific treatment. However, the link between these events is often associated with uncertainty 
in real-world clinical practice. 
3.2. Clinician’s 
reassurance 
The use of imaging tests not only reassures the clinician that the right diagnosis was made but also that the 
management decision or treatment is appropriate. 
3.3. Patient’s 
reassurance 
The imaging test might affect the patients’ perception that a given diagnosis and subsequent treatment is 
right or wrong, thus affecting their behaviours. One of these behaviours is adherence to treatment. If the 
patient is reassured that a given diagnosis/treatment is right, he/she is more likely to adhere to the treatment 




A medical imaging test can be used to optimise operational efficiencies (e.g. waiting times), streamline 
patient management (e.g. speed up diagnosis) and overall efficiency gains (e.g. reduce costs) and/or 
improve clinical outcomes (e.g. increased survival rates).  
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Given the lack of long-term evidence, surrogate or intermediate references to evaluate clinical endpoints are 
commonly considered in economic evaluations. However, the statistical relationship and epidemiological 
causality between the surrogates and the clinical endpoints and the lack of standard in the use of surrogates 
adds to the uncertainty of evaluating diagnostic tests. As an example, diabetes is a known risk factor for 
cardiovascular events but there is little evidence that a tight control of diabetes (measured using the 
surrogate haemoglobin 1Ac) will reduce cardiovascular events (Weintraub, Lüscher, and Pocock 2015). 
Hence, the use of surrogate references as an alternative to empirical data from clinical studies, particularly 
randomised trials, can be problematic and misleading (Ciani et al. 2017). 




The introduction of imaging tests in clinical pathways is associated with a value proposition such as: 
increased accuracy; faster and cheaper; ability to replace a more expensive test; early diagnosis. 
5.2. Functional 
utilisation  
Imaging tests are used widely for: risk assessment, screening of asymptomatic patients, diagnostic test 
based on symptoms, monitoring the evolution of a known clinical condition (e.g. cancer surveillance), 
prognosis (e.g. risk stratification, measure response to cancer treatment) and support to treatment purposes 
(e.g. image-guided intervention). 
5.3. Role across 
clinical pathways 
Imaging tests can be used as a triage, add-on or replacement tool in different clinical pathways. 
Furthermore, the same imaging test can be used differently in the context of varied clinical pathways. 
5.4. Multiple uses 
of the same test 
in different 
clinical pathways 
The multiple uses of the same imaging test in different clinical contexts adds uncertainty because an 
imaging test might be cost-effective for a given clinical use and not cost-effective for another. Hence, in 
order to deal with this situation, the evidence needs to be somehow weighted to support/reject the 





There is a lack of long-term real-world evidence of imaging tests from randomised trials. Decision-analytical 
models are typically used to circumvent this limitation but the lack of observed data adds uncertainty in the 
use of decision-analytical models. 
41 
 
Given the different levels of uncertainty associated with the evaluation of diagnostic tests, the 
assessment of such technologies is inherently complex when compared to other technologies (e.g. 
pharmaceutical drugs) (Drummond, Griffin, and Tarricone 2009). The next subsection summarises the 
evidence surrounding the use of evaluation frameworks specific to the evaluation of diagnostic tests 
(e.g. medical imaging) and appraises how these layers of uncertainty are to be addressed. 
2.3.3. Evaluation frameworks to assess diagnostic tests 
Whilst the framework for the evaluation of pharmaceutical drugs is well established as a four to five 
phase hierarchical model, the same does not happen in the evaluation of diagnostic tests (Gatsonis, 
2012). Indeed, partly due to the intrinsic challenges associated with the evaluation of diagnostic tests, 
different conceptual models have been developed over time to support economic evaluations of these 
interventions.  
A systematic review research paper (search run in January 2009) evaluated and described the different 
frameworks for the evaluation of medical tests (Lijmer, Leeflang, and Bossuyt, 2009). The study 
methods reported the search of key databases (Medline, Web of Science and Embase) with variations 
of the word “diagnostic” in the document and variations of the concept “phased model” in the title or 
abstract. This search criteria aimed to maximise the number of hits. A total of 19 models were identified, 
with the first one being published in 1978 and the most recent one in 2007. Models subsequent to the 
systematic literature review performed by Lijmer, Leeflang, and Bossuyt (2009) were included based 
on a second systematic literature review performed by the student using the same search terms and 
databases. This review further identified an additional four evaluation frameworks. Out of the 23 
evaluation frameworks identified in the two systematic literature reviews, most were iterative 
improvements or amendments of previous frameworks. Although summarily described for 
completeness and better understanding of the continuous improvement historical approach, this 
section mainly focuses on the following four evaluation frameworks:  
 Fryback and Thornbury (1991); 
 Houn et al. (2000) from the Food and Drug Administration (FDA); 
 Gazelle et al. (2011); 
 National Institute for Health and Clinical Excellence (2011). 
The selection of these specific four frameworks was based on novelty and impact both in terms of 
research and applicability to the real-world evaluation of diagnostic tests in the context of the NHS. 
2.3.3.1. Fryback and Thornbury (1991): 6-tier evaluation framework 
The first cohesive evaluation framework specific to diagnostic tests was presented by Fryback and 
Thornbury (1991) following on evidence from earlier manuscripts, with particular emphasis on Loop 
and Lusted (1978) and the equivalence between diagnostic studies and standard classification of 
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clinical trials proposed by Freedman (1987). The authors proposed a six-tier hierarchical framework of 
efficacy exclusive to diagnostic tests (Figure 16) (Fryback and Thornbury 1991). The first level of 
efficacy, described as technical efficacy, relates to the physical parameters assessing the technical 
quality of the image (e.g. number of lines per image or number of artefacts). The second tier of efficacy 
addresses the technology’s diagnostic accuracy, typically described as the receiver operating curve or 
specificity/sensitivity. The model inherently considers that the uncertainty regarding the diagnosis is 
associated not only with the quality of the image (tier one) but also with the interpretation of such 
images by the reporter, i.e. the radiologist. The third tier, the diagnostic thinking efficacy, addresses 
the change in the diagnostic differential of the clinician due to information provided by the diagnostic 
test. In a given context, clinical outcomes are not affected by a diagnostic test unless that test leads to 
a change in the referrer’s opinion. This level of efficacy is difficult to estimate without empirical research 
as diagnostic tests may not only change the referrer’s decision but also strengthen or reassure him/her 
that a given diagnosis is correct. The fourth tier recognised the ability of the diagnostic test to actually 
impact the patient’s clinical management (e.g. the percentage of times that the diagnostic test changed 
the subsequent clinical practice). Hence, the model considers that some tests might change the 
referrer’s diagnosis and still hold no impact in terms of clinical management. The fifth tier considers 
the efficacy in terms of patient clinical outcomes (e.g. morbidity or mortality outcomes). The authors 
pointed that this level of evidence typically require randomised controlled trials or, alternatively, 
decision-analytic approaches based on existing empirical data and/or assumptions. Finally, the sixth 
tier considered the overall efficacy associated with the distribution of resources from a societal 
perspective.  
 
Figure 16. Six level efficacy model [adapted from (Fryback and Thornbury 1991)]. 
The hierarchic nature of this evaluation framework means that for an imaging test to be efficacious at 
higher levels, it also needs to be efficacious at lower levels, whilst the opposite is not necessarily true 
(Fryback and Thornbury 1991). The innovative nature of the model proposed by Fryback and 
Thornbury (1991) was based on the evaluation of the contribution of medical imaging as a part of a 
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broader system whose ultimately goal is to improve care for patients as opposed to the traditional 
concerns about the quality or accuracy of diagnostic tests. Furthermore, the authors proposed the 
design of before and after tests to estimate the test’s impact on the clinician’s medical decision 
algorithm (Fryback and Thornbury 1991). 
Subsequent models have added upon the one proposed by Fryback and Thornbury (1991). Kent and 
Larson (1992) proposed three dimensions of analysis: disease, type of assessment, and the quality of 
research methods. Whilst the dimension type of assessment is similar to the model proposed by 
Fryback and Thornbury (1991), the dimension disease describes the clinical condition(s) shown by a 
diagnostic test and the dimension quality of research methods is classified into four groups (excellent, 
good, fair or poor) (Kent and Larson 1992). Mackenzie and Dixon (1995) proposed a 5-level framework, 
very similar to the one defined by Fryback and Thornbury (1991). Other authors, like Silverstein and 
Boland (1994) and particularly Pearl (1999), further explored the initial model presented by Fryback 
and Thornbury (1991), providing specific examples on how the different levels of efficacy might be 
estimated. Similar to previous authors, van der Schouw, Verbeek, and Ruijs (1995) defended a phased 
approach to diagnostic tests, reserving the inclusion of expensive research clinical trials to influence 
the decision to actually use or not use the test. However, all these authors proposed specific 
adjustments to the original model by Fryback and Thornbury (1991) rather than a novel evaluation 
framework. 
2.3.3.2. Houn et al. (2000): 4-phase evaluation framework 
Houn et al. (2000), members of the Food and Drug Administration (FDA), proposed a novel framework 
aimed at providing practical recommendations regarding the evaluation of diagnostic tests. With this 
aim in mind, the authors explored the rationale of establishing a parallel between the assessment of 
diagnostic tests and therapeutic methods. These authors proposed a four-phased model for test 
evaluation similar to the existing framework for therapeutic technologies such as pharmaceutical drugs 
(Figure 17).  
 
Figure 17. Four level efficacy model [adapted from Houn et al. (2000)]. 
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Despite both aiming to assess the efficacy of diagnostic tests, the models proposed by Fryback and 
Thornbury (1991) and Houn et al. (2000) constituted two different approaches. Whilst Fryback and 
Thornbury (1991) proposed a model discerning the different levels from a more basic level, technical 
accuracy, to the highest level, the implications of accuracy to society, Houn et al. (2000) proposed a 
research-based framework with different levels of efficacy implicitly embedded in the 4-phase model. 
Figure 18 illustrates the equivalence between these two types of models.  
 
Figure 18. Equivalence in the evaluation of efficacy between the models proposed by Fryback and 
Thornbury (1991) and Houn et al. (2000). 
Despite the conceptual differences, the evaluation models present several common features (Lijmer, 
Leeflang, and Bossuyt, 2009): (i) start with a phase I, i.e. test development around the technical and 
diagnostic accuracy of the test; (ii) the application of the diagnostic test to a specific group of individuals 
with a given clinical disease; (iii) the impact of the test in the clinician’s therapeutic decision; (iv) the 
impact of the test at patient-level and societal outcomes; and (v) the hierarchical nature of the model, 
i.e. the evaluation of efficacy at higher levels only if in the presence of positive evidence at lower levels.  
The systematic literature review by Lijmer, Leeflang, and Bossuyt (2009) considered evidence 
published up to January 2009. Hence, any model created over the past decade was not included. In 
order to supplement the information provided by Lijmer, Leeflang, and Bossuyt (2009), a second 
systematic literature review was performed by the student to update the timeline up to November 2018. 
The search strategy considered was equal to the one proposed by Lijmer, Leeflang, and Bossuyt 
(2009) and is detailed in Appendix I. The systematic search of academic publications was conducted 
in accordance with national guidance (Centre for Reviews and Dissemination 2009) and based on 
PRISMA guidelines (Higgins and Green 2011) as illustrated in Figure 19. The following databases 
were considered: Ovid Classic and EMBASE (1990 to 23 November 2018), Ovid MEDLINE(R) In-
Process & Other Non-Indexed Citations, Ovid MEDLINE(R) (1990 to 23 November 2018), Cochrane 
Library NHS Economic Evaluation Database and Cochrane Library CRD Health Technology 




Figure 19. PRISMA flowchart summarising the selection process of relevant studies.   
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Studies included in 
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(n = 4) 
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A total of 687 papers were identified, resulting in 377 after removal of duplicates. Out of the 377 papers 
screened, a total of 10 papers were included for full-text analysis. Six papers were excluded as they 
did not present an actual evaluation model or framework of medical imaging technologies (n=4), did 
not consider outcomes of interest (n=1) or were not written in English (n=1). Hence, a total of four 
papers were analysed and included in the present systematic literature review: Sistrom (2009); Gazelle 
et al. (2011); Anonychuk et al. (2012); and  Frueh and Quinn (2014). The chronological description of 
the four evaluation frameworks is presented in the following paragraphs, with particular emphasis on 
Gazelle et al. (2011). 
Sistrom (2009) proposed the appropriateness framework. Based on the principle that decision analytic 
models are more efficient than clinical trials, the appropriateness method considers the utilisation of 
experts in the context of a set of clinical scenarios. Two groups of experts rate from 1 (very 
inappropriate) to 9 (most appropriate) the relation between the intervention and the set of clinical 
scenarios. Then, Delphi rounds further discuss the scenarios where no consensus was reached. The 
authors proposed a direct link between the 1-9 scale and the appropriateness scale based on the 
quality-adjusted life years (QALY) approach. Sistrom (2009) proposed, as illustrated in Figure 20, that 
scores: of 1-3=inappropriate; 4-6=equivocal; and 7-9=appropriate.  
 
Figure 20. Schematic proposing a superimposed relation between the appropriateness consensus 
score and the concept of QALY (based on Sistrom 2009). 
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In essence, the authors proposed the use of clinical experts to determine the clinical appropriateness 
and expected benefits from using the medical imaging technology in the context of given clinical 
scenarios. Furthermore, based on the appropriateness score, a recommendation whether or not to 
adopt a given medical imaging technology is considered. This evaluation framework has important 
limitations as it is only focussed on the clinical appropriateness of the technology and seems to fail to 
recognise its cost implications to the healthcare payer or society overall.   
More recent models have aimed to further capture the intrinsic complexity of diagnostic tests, 
particularly: the multiple and dynamic applications of diagnostic tests (e.g. MRI being used across 
different clinical conditions); the rapid change associated with diagnostic technologies; inter-reader 
and machine variability; and the non-clinical impact of diagnostic tests due to their ability to affect 
patients and clinicians’ perceptions and behaviours. One such model was proposed by Gazelle et al. 
(2011). 
2.3.3.3. Gazelle et al. (2011): 6-tier framework with 3 dimensions of analysis 
Further expanding on the original model by Fryback and Thornbury (1991), Gazelle et al. (2011) 
developed a novel conceptual framework that combined different elements from previous frameworks. 
The authors suggested that this framework should be used to guide the approval or introduction of new 
or novel diagnostic technologies (Gazelle et al. 2011). Gazelle and colleagues (2011) based their 
evaluation framework on three key features: (i) size of the at-risk population, i.e. the number of people 
that might benefit from the diagnostic intervention; (ii) the anticipated clinical impact, or, the potential 
net benefits in terms of health outcomes compared to existing alternatives and standard care; and (iii) 
the potential economic impact, i.e. including cost-effectiveness concepts and the potential financial 
and budget implications surrounding the adoption of a diagnostic test (Figure 21).  
 
Figure 21. Dimensions of analysis and level of evidence in the model proposed by Gazelle et al. (2011). 
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In order to enhance its usability, Gazelle et al. (2011) proposed a link between the three features above 
mentioned and the level of evidence required to evaluate a diagnostic test. As illustrated in Figure 21, 
if a large population could benefit from a diagnostic test, a higher level of evidence is required in order 
to evaluate the test’s efficacy [equivalent to the higher tiers of the model proposed by Fryback and 
Thornbury (1991)]. However, if a small number of patients is at risk then a lower level of evidence is 
indicated [equivalent to the lower tiers of the model proposed by Fryback and Thornbury (1991)]. 
Similarly, if the intervention is anticipated to have a small clinical effect or hold a potentially large 
economic impact, there is a need for high-level evidence. In other words, if the potential economic 
impact of the diagnostic test is large, then a higher level of empirical evidence is required to better 
understand the potential health economic and budget implications of implementing the intervention.  
Following on Gazelle and colleagues’ work, Lee, Neumann, and Rizzo (2010) suggested the creation 
of three dimensions of analysis: medical value, i.e. the test’s ability to inform a clinical decision; 
planning value, i.e. the test’s ability to inform patients and clinicians; and ‘psychic’ value, i.e. the test’s 
ability to affect patient satisfaction or behaviours. Anonychuk et al. (2012) also considered the holistic 
impact of diagnostic tests across the continuum of care and suggested three dimensions of analysis 
based on the test’s role in the clinical pathway (screening, diagnosis, treatment selection, prognosis 
and monitoring). These three dimensions are illustrated in Figure 22: (i) optimisation of operational 
efficiencies; (ii) optimisation of patient management; and (iii) influence on patient behaviour and other 
effects.  
 
Figure 22. Three dimensions of analysis in the model proposed by Anonychuk et al. (2012). 
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Compared to Gazelle et al. (2011), the main innovative feature of the evaluation framework suggested 
by Lee, Neumann, and Rizzo (2010) and Anonychuk et al. (2012) was to explicitly consider the human 
component in terms of patient behaviours and well-being in the evaluation of diagnostic tests. 
Intangible human benefits can impact the overall healthcare system. As an example, a diagnostic test 
can provide reassurance to patients, leading to behavioural changes that ultimately affect the entire 
clinical pathway and healthcare resource utilisation.  
Building upon previous evidence, Frueh and Quinn (2014) proposed a six-part framework, based on 
the following set of six questions rather than hierarchical levels [opposed to Fryback and Thornbury 
(1991)]: 
1. Who should be tested and under what circumstances? 
2. What does the test tell us, that we did not know without it? 
3. Can we act on the information provided by the test? 
4. Does the outcome change in a way we find value in, relative to the outcome(s) obtained 
without the test? 
5. Will we act on the information provided by the test? 
6. If the test is to be employed, can we afford it? 
This framework, although developed for molecular diagnostic technologies rather than the medical 
imaging field, aimed to fill the gap between more conceptual frameworks [e.g. Fryback and Thornbury 
(1991) or Houn et al. (2000)] and the actual decision and reimbursement process associated with the 
adoption of new or novel diagnostic tests. More concretely, the authors pointed out that although there 
is an increasingly need for clinical and economic evidence (e.g. cost-effectiveness), there is little 
guidance as to how to pragmatically apply this in the context of complex, real-world healthcare delivery 
settings (Frueh and Quinn 2014). Conversely, this framework’s drawback seems to be due to its lack 
of structure and ability to identify the level of evidence required to evaluate different medical imaging 
modalities in different contexts. 
2.3.3.4. National Institute for Health and Clinical Excellence (2011)  
The National Institute for Health and Clinical Excellence (NICE) is the organisation responsible for 
evaluating the introduction of new or novel technologies in the NHS. Among these, different imaging 
technologies are considered. This subsection describes the evaluation framework proposed by NICE 
and the practical aspects associated with the introduction of technologies in the NHS. 
Two different evaluation programmes are considered in the evaluation of medical imaging 
technologies: the Medical Technologies Evaluation Programme (MTEP); and the Diagnostics 
Assessment Programme (DAP). As illustrated in Figure 23, the two programmes differ in the value 
proposition associated with the diagnostic test. Whilst in the MTEP, the technology must have an 
equivalent or superior clinical performance and no increase in costs, in the DAP the technology must 
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show increased health benefits but at a higher cost or cost savings at expense of reductions in health 
benefits. As suggested by Gazelle et al. (2011), NICE considers the implicit evaluation of two 
dimensions of analysis: the clinical and the economic impact of the intervention. Hence, technologies 
with potential impact in the clinical dimension with no economic impact are routed through the MTEP. 
Conversely, diagnostic technologies with potential to significantly impact the clinical and economic 
dimensions are routed through the DAP.  
 
Figure 23. Two evaluation programmes of diagnostic tests considered by NICE (Crabb, 2011). 
The existence of two programmes with different methodologies to evaluate diagnostic technologies 
reflects not only the potential impact of such technologies but also the complexity associated with their 
evaluation. For illustration purposes, a well-known technology applied to a new clinical pathway that is 
likely to be associated with clinical improvements at no extra cost would be evaluated using the MTEP 
methodology. This methodology is essentially based on a cost-consequence approach (or cost-
minimisation if outcomes are assumed to be equivalent) (NICE 2011d). However, a novel imaging 
modality or a diagnostic test used in a disruptive way is usually associated with a higher degree of 
uncertainty, both in terms of its clinical and economic impact. This technology would be evaluated 
under the DAP methodology, based on cost-effectiveness analyses (NICE, 2011).  
Both evaluation programmes require a systematic literature review of clinical and economic evidence. 
Furthermore, given the limited availability and variability of evidence, NICE does not have specific 
evidence thresholds for the evaluation of diagnostic tests, but rather relies on the existing evidence so 
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as not to delay the introduction of such technology (Crabb, 2011). Thus, compared to pharmaceutical 
products, NICE does not require evidence from randomised trials and instead assesses the level of 
evidence on a case by case basis. 
2.3.3.5. Summary of evaluation frameworks 
Different evaluation frameworks for diagnostic tests have been proposed since the 6-tier model 
originally suggested by Fryback and Thornbury (1991). Recent models have tried to incorporate 
different features to take into consideration usability in the context of real-world decision making 
processes. Among these features, two were dominant: (i) the hierarchical nature of the evaluation 
framework proposed; and (ii) the level of evidence necessary to inform a decision regarding the use of 
diagnostic tests. 
Most evaluation frameworks rely on a hierarchical structure (Fryback and Thornbury 1991; Houn et al. 
2000; Gazelle et al. 2011). Lower tiers of the evaluation frameworks relate to intrinsic characteristics 
of the diagnostic tests, such as sensitivity and specificity, whilst higher tiers evaluate the actual clinical 
and economic impact of the intervention in the context of real-world clinical pathways. Diagnostic tests 
that fulfil the criterion of higher tiers of the evaluation framework inherently meet the criteria of lower 
tiers of the model, i.e. a diagnostic test that presents favourable clinical and economic evidence 
presents higher levels of accuracy for a given clinical condition. The opposite might not be the case, 
i.e. diagnostic tests that fulfil the lower tiers of the evaluation framework might not be associated with 
improved clinical and economic benefits (higher tiers of the model). The hierarchical nature of most 
evaluation frameworks is designed to provide a logical approach to a complex problem.  
The level of evidence necessary for policy makers to adopt/reject specific diagnostic tests in real-world 
clinical contexts is the other key feature of some of the proposed evaluation frameworks. Recent 
models tend to focus more on this aspect. Gazelle et al. (2011) were among the first authors to clearly 
identify the need for evidence thresholds for different types of interventions depending on their impact 
on different dimensions of analysis. For instance, taking into consideration the rapid development of 
technologies in the diagnostic field, if an intervention is anticipated to have large clinical benefits for a 
small number of patients, thus resulting in a limited economic impact, its adoption should not be 
delayed to gain evidence from a high-quality study (e.g. randomised controlled trial). Moreover, 
regardless of the population at risk and the intervention’s anticipated impact, the evaluation of the 
economic impact is relevant even in small populations as the use of interventions that are not cost-
effective is not considered to be value for money. This pragmatic approach poses an important 
question, how to establish the threshold of evidence for the adoption of different diagnostic 
technologies. Is it necessary to use evidence from randomised controlled trials and observational 
studies or does evidence from economic modelling studies suffice? And if so, under which 
circumstances? To better understand this issue, it is relevant to investigate the existing economic 
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evidence around the utilisation of medical imaging. With this in mind, a literature search identified the 
following two systematic literature reviews: 
 Otero, Hansel J., Frank J. Rybicki, Dan Greenberg, and Peter J. Neumann. 2008. “Twenty 
Years of Cost-Effectiveness Analysis in Medical Imaging: Are We Improving?” Radiology 249 
(3): 917–25. This systematic literature review considered the analysis of any published cost-
effectiveness analysis of diagnostic tests for a period of 20 years (1985-2005). 
 Zhou, Alice, David M. Yousem, and Matthew D. Alvin. 2018. “Cost-Effectiveness Analysis in 
Radiology: A Systematic Review.” Journal of the American College of Radiology 15 (11): 
1536–46. Consistent with Otero et al. (2008), this systematic literature review included any 
cost-effectiveness analysis study for a period of five years (2013-2017). 
These two systematic literature reviews cover a large period of time (25 years) and the second review 
was published in November (2018), referring to the last five years of evidence (2013-2017). For these 
two reasons, it was not considered relevant for the student to perform another review but to examine 
the existing evidence, particularly by Zhou, Yousem, and Alvin (2018).  
2.3.4. Economic evidence 
This subsection summarises the methodology regarding the evaluation of medical imaging 
technologies. More than the economic results themselves, which are arguably context and 
intervention-specific, the aim here is to evaluate different features associated with the published 
evidence, and assess the potential impact of evaluation frameworks on the actual assessment of real-
world interventions. 
Otero et al. (2008) performed a systematic literature review of cost-effectiveness analyses in the 
medical imaging field published between 1985 and 2005. The authors searched several databases: 
MEDLINE, HealthStar, CancerLit, Current Contents, EconLit and Health Economic Evaluation 
Databases using broad text keywords such as “QALY”, “quality-adjusted”, “cost-utility” (Otero et al. 
2008). Despite the increase in false positives, the search strategy was designed to capture all relevant 
medical imaging related cost-effectiveness studies with QALYs as the measure of effect. A total of 
1,310 articles were screened, 111 of which were included for full-text analysis (Otero et al. 2008).  
About three quarter of the evidence was generated in the US, with only 9 (8.1%) papers being 
originated in the UK (Otero et al. 2008). A total of 86 (77.5%) papers considered the evaluation of 
medical imaging as a diagnostic procedure, with the remaining 25 (22.5%) manuscripts reporting its 
use as an interventional procedure. Other key characteristics are summarised in Table 2.   
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Table 2. Summary characteristics of the studies analysed by Otero et al. (2008). 
Publishing Year  Number of papers % 
2000-2005 62 55.9% 
1995-1999 41 36.9% 
1990-1994 6 5.4% 
1985-1989 2 1.8% 





Modality of imaging Number of papers % 
Ultrasound 39 35.1% 
Angiography 35 31.5% 
MRI 25 22.5% 
CT 22 19.8% 
Conventional radiography 10 9.0% 
PET or combined PET/CT 8 7.2% 
Other 11 10.0% 
Clinical condition in study Number of papers % 
Peripheral vascular disease (non-
cerebral, non-cardiac disease) 
25 22.5% 
Cancer 20 18.0% 
Cerebrovascular disease 15 13.5% 
Ischaemic heart disease 15 13.5% 
Musculoskeletal and rheumatologic 
diseases 
9 8.1% 
Other 27 24.3% 
Perspective of analysis Number of papers % 
Payer 76 68.5% 
Societal 31 27.9% 
Hospital 4 3.6% 
There was an increase in the volume of papers published in recent years. In fact, the second decade 
in analysis (1995-2005) produced over 90% of the total evidence generated in the two decades 
analysed. Nevertheless, the overall quality of the evidence generated - measured subjectively based 
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on a 1 (low) to 7 (high) Likert scale - did not seem to have improved over this period of time. This 
suggests that, although health economics is increasingly relevant to the medical imaging field, this 
trend has not been followed up by an improvement in the overall quality of the economic evidence. 
Otero et al. (2008) pointed out that this seemed to be due to concerns about the lack of agreement in 
the methodologies used, and potential biases due to data selection and/or model development opacity. 
This finding suggests that, despite the creation and development of several evaluation frameworks 
(previously described) which took place between 1985 and 2005, their respective impact in the 
generation of high-quality economic evidence was limited. 
Ultrasound and angiography were the two modalities of medical imaging with the highest number of 
economic evaluations with 39 (35.1%) and 35 papers (31.5%), respectively. The use of advanced 
imaging modalities, such as CT and MRI, were the third and fourth imaging modalities more commonly 
evaluated. With regards to the clinical condition, peripheral vascular disease (n=25, 22.5%), cancer 
(n=20, 18.0%) - particularly lung cancer - cerebrovascular disease (n=15, 13.5%) and ischaemic heart 
disease (n=15, 8.1%) were the most common. In relation to the study design, only 3 (2.7%) papers 
considered economic data retrieved from randomised clinical trials.  
The second systematic literature review, performed by Zhou, Yousem, and Alvin (2018), analysed the 
economic literature regarding any cost-effectiveness or cost-utility analyses in the imaging field 
between the years 2013 and 2017. The study’s aim was to evaluate the methodological variation in 
the economic assessment of medical imaging interventions and explore impact on the overall results. 
In order to achieve this aim, the authors opted for a broad search criteria, designed to enhance the 
search’s sensitivity (i.e. capture all relevant papers), despite the increase in the number of non-relevant 
hits. The databases MEDLINE, EconLit and Tufts CEA were queried using the following search criteria: 
(((cost-effectiveness) OR (cost-utility)) AND (imaging OR radiology). A total of 2,574 non-duplicate 
records were screened and a total of 240 full-text papers were assessed. Out of these, the authors 
limited the search to cost-utility analyses (i.e. cost per QALY), retrieving 80 articles to be included in 
the systematic literature review (Zhou, Yousem, and Alvin 2018).  
The authors rated the included 80 full-text papers using the Consolidated Health Economic Evaluation 
Reporting Standards (CHEERS) checklist (Husereau et al. 2013), designed to assess cost-utility 
analyses. This checklist includes 24 items against which each paper was evaluated. The economic 
evidence highlighted a wide variation in items, particularly cost estimates, outcome measurement, and 
the analytical and statistical methods used (Zhou, Yousem, and Alvin 2018). The authors pointed out 
a lack of transparency surrounding the methods used with potential to impact the results of the health 
economic evaluations (Zhou, Yousem, and Alvin 2018). According to Zhou, Yousem, and Alvin (2018), 
the clear dissemination of transparent recommendations and evaluation frameworks for cost-
effectiveness analyses in the radiology field is essential to support policy makers in their decision to 
whether or not to include a medical imaging technology as part of standard care. The 80 papers 
included in the systematic review were analysed and grouped by: year of publishing; type of imaging; 
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clinical condition; perspective of analysis; and study design. This evidence is summarised in Table 3 
(Zhou, Yousem, and Alvin 2018).  
With regards to the publishing year, there was no noticeable change over the five year period, with an 
average of 16 papers per year. This in contrast to the increase in evidence reported by Otero and 
colleagues (2008), where over 90% of evidence was generated in the second decade in analysis. 
The use of advanced imaging modalities such as CT (n=45, 56.3%) or MRI (n=28, 35.0%) was 
considered in over 90% of papers. Again, this was a noticeable difference from the evidence reported 
by Otero et al. (2008), where the evaluation of conventional imaging was more prevalent than 
advanced imaging modalities. Nevertheless, the findings reported by Zhou, Yousem, and Alvin (2018) 
were not unexpected as they were consistent with the historical increase in the utilisation rates 
associated with advanced imaging modalities. 
The economic evaluation of medical imaging was used across multiple clinical conditions, with 
particular relevance to cancer (32%) and cardiovascular diseases (12%). The two cancers more 
prevalent were breast and lung cancer, accountable for 39% and 33% of all cancer-related economic 
evaluations.  
Regarding the perspective of the economic analyses, 74% of the papers analysed took a health care 
payer perspective, followed by a societal perspective in 20% of the analyses. This is consistent with 
the evidence reported by Otero et al. (2008) and reflects the typical use of economic evaluations as a 
critical supporting tool to health care decision makers to whether adopt or reject a specific intervention.  
Eighty-seven percent of the papers were based on probabilistic models (mainly Markov and/or discrete 
event simulation models) with the remaining 13% of evidence based on observed data from 
randomised controlled trials (n=4) and prospective cohort studies (n=7). This is similar to the evidence 
reported by Otero et al. (2008). From the supplementary material, only three actual RCTs were 
identified (Dekkers et al. 2016; Thom et al. 2014; Agus et al. 2016). Two of these three RCTs were 
conducted in the NHS (Thom et al. 2014; Agus et al. 2016) and they evaluated the cost-effectiveness 
of advanced imaging (CT) in patients presenting with stable chest pain. The seven prospective studies 
included different stroke (Parody et al. 2015), chest pain (Hlatky et al. 2015) and cancer, both breast 
(Pharoah et al. 2013) and lung cancer (Yang et al. 2017; Pertile et al. 2015; Black et al. 2014; Gómez 
León et al. 2014). In summary, over 9 out of 10 papers were not based on observed data but rather 
decision analytical models or uncontrolled observed data. This situation is explained by multiple 
factors, particularly: (i) the time it takes to generate evidence from real-world studies; (ii) the rapid 
technological developments in the medical imaging field; and (iii) the lack of a common and transparent 
framework to evaluate medical imaging.  
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Table 3. Summary characteristics of the studies analysed by Zhou, Yousem, and Alvin (2018). 
Publishing Year  Number of papers % 
2017 17 21.3% 
2016 14 17.5% 
2015 18 22.5% 
2014 16 20.0% 
2013 15 18.8% 
Modality of imaging Number of papers % 
CT 45 56.3% 
MRI 28 35.0% 
Ultrasound 11 13.8% 
Nuclear Medicine 6 7.5% 
Radiography 3 3.8% 
DEXA 2 2.5% 
Digital mammography 13 16.3% 
Tomosynthesis 2 2.5% 
Clinical decision rule 5 6.3% 
Clinical condition in study Number of papers % 
Cancer 33 41.3% 
Cardiovascular disease 12 15.0% 
Intracerebral haemorrhage 9 11.3% 
Bone imaging 7 8.8% 
Blunt cerebrovascular trauma 4 5.0% 
Varied diagnoses 15 18.8% 
Perspective of analysis Number of papers % 
Payer 56 70.0% 
Societal 15 18.8% 
Hospital 2 2.5% 
Societal and payer 3 3.8% 
Study design Number of papers % 
Probabilistic model 71 88.8% 
Non-model 11 13.8% 
Randomised Controlled Trial 4  




In summary, although there have been iterative improvements in the economic evaluation of medical 
imaging technologies, limited consideration has been given to the potential impact of using evidence 
generated from modelling evidence as opposed to real-world observed data. This poses two questions: 
 Are the economic findings of a new or novel medical imaging intervention dependent on the 
study design (i.e. economic models vs non-model approaches)? 
 If yes to the above, would this difference in economic findings result in different adoption 
scenarios from the decision maker (e.g. adopt, reject, adopt for a limited cohort of patients)? 
The responses to these two questions remain unclear given the limited number of comparative studies. 
Hence, the present thesis aims to contribute to this debate by comparing a priori decision-analytical 
modelling approaches to a real-world randomised clinical trial and prospective cohort studies 
concerning the utilisation of advanced imaging (discussed in chapter 6). The medical imaging 
interventions considered include the use of advanced imaging (either CT or MRI) in the context of three 
specific NHS clinical pathways: (i) suspected scaphoid fracture (chapter 3); (ii) chronic headache 
(chapter 4); and (iii) suspected colorectal cancer (chapter 5). 
2.4. From research to clinical practice 
Faced with ever increasing healthcare research, decision makers struggle to keep up with the rapidly 
evolving evidence (Wensing and Grol 2019). This poses considerable strain on decision makers to 
ensure the rapid uptake of high-value clinical procedures, technologies and organisational models into 
routine clinical practice and, at the same time, stop the use of interventions that no longer represent 
value for money (Wensing and Grol 2019). Many interventions with favourable research evidence have 
failed to translate into meaningful improvements, with some estimates indicating that up to two-thirds 
of initiatives to implement change fail (Damschroder et al. 2009). The understanding of healthcare 
specific, and general barriers to implementation, are essential to ensure that research evidence is 
successfully translated to clinical practice. 
2.4.1. Barriers to implementation 
Silva (2015) conducted a systematic review in twelve bibliographic databases using broad 
implementation terms (e.g. implementation, change, adoption, feasibility) to assess the evidence 
concerning implementation initiatives in the context of the NHS. A total of 73 articles met the inclusion 
criteria, with 53% focused on hospital initiatives, 16% on primary care and 30% on combined primary 
and secondary care services. Regardless of the different nomenclatures used in literature, evidence 
demonstrated that most barriers to implementation resulted from: the intervention itself; characteristics 
of the individuals involved; organisational factors; and contextual or environmental factors.  
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Figure 24 illustrates a diagram (from micro to macro level) with the five most common barriers to 
implementation in healthcare (Grol and Grimshaw 2003; Rubio-Valera et al. 2014; Silva 2015; Fischer 
et al. 2016; Sommerbakk et al. 2016).  
First, some barriers are due to the intervention itself, which may be perceived as too difficult to use, 
incompatible with usual routines, too costly or associated with too little or too much evidence.  
Second, characteristics of the individuals may act as barriers to implementation. These range from 
natural resistance to change to individual beliefs and past experiences (e.g. change as a cost cutting 
exercise), as well as more intrinsic characteristics such as skills, self-confidence and motivation (lack 
of motivation as a barrier to implementation).  
Third, interpersonal relationships can also act as barriers to implementation. Health care delivery is 
characterised by the interaction of multidisciplinary teams and any barriers to communication can 
seriously hinder implementation initiatives. The lack of relationships (formal or informal) between key 
individuals and the lack of engagement of opinion leaders are two examples of interpersonal barriers.  
Fourth, organisational barriers include adverse organisational culture, lack of senior engagement, 
fragmented systems (e.g. IT systems) and the lack of resources, both in terms of staff, and time 
availability dedicated to the implementation initiative.  
Fifth, the wider involvement of the public and society can generate important barriers. Particularly 
relevant are the regulatory context (e.g. guidelines, national targets, financial incentives), the NHS 
setting (e.g. existing culture, fragmented healthcare provision) and patients’ and societal expectations. 





Figure 24. Five domains of barriers or challenges to implementation projects in healthcare (based on Rubio-Valera et al. (2014) and adapted with 
information from Grol and Grimshaw 2003, Silva 2015, Fischer et al. 2016 and Sommerbakk et al. 2016)
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2.4.2. Implementation models 
The field that studies the incorporation of healthcare research into clinical practice is labelled using 
different terms, particularly translational research, dissemination and implementation research and 
knowledge translation (Titler 2018; Wensing and Grol 2019). All these terms describe the process of 
applying evidence to practice and, although with slight differences, they seem to overlap and to be 
used interchangeably in the literature (Wensing and Grol 2019). These terms also seem to be more 
geographically driven rather than due to substantial conceptual differences. For instance, the concept 
dissemination and implementation research is often used in Europe and knowledge translation in the 
USA (Wallace 2013).  
Translational research refers to the application of basic research evidence in clinical practice and is 
commonly divided into multiple stages (T0 to T5). Implementation research focuses on the delivery of 
interventions to promote the uptake and the use of research to impact patient outcomes (Titler 2018). 
A detailed comparison of the two concepts showed that stage T3 of translational research which 
focuses on translation of evidence to clinical practice also includes any type of dissemination and 
implementation research (Zoellner and Porter 2017). Although the use of different terms can be 
confusing and might affect the development of the field, all concepts possess a common denominator 
that is to promote the utilisation of research evidence into clinical practice. For the purpose of this 
thesis, rather than discussing the different concepts, the aim was to review published evidence and 
create new evidence in order to facilitate the uptake of the innovative use of advance imaging in the 
context of three real-world clinical pathways. 
Nilsen (2015) extensively evaluated existing implementation theories and frameworks and identified 
three common aims amongst all models. First, models described or supported the process of 
translating research into practice. Second, models aimed to understand and/or explain what variables 
influenced the outcomes of the implementation project. Third, models aimed to evaluate the level of 
success of the implementation project. Based on the second feature above mentioned, i.e. the model’s 
ability to explain what influenced the implementation outcomes, the author grouped the models or 




Table 4. Five categories of models used in implementation research (Nilsen 2015). 
Category Description Aim(s) 
Process 
models 
Models that use specific steps (stages or phases) in the 
process of translating research into clinical practice. The aim 
of process models is to provide practical guidance in the 
planning and execution of implementation initiatives and/or 
strategies to facilitate implementation. 
Example: The Academic Center for Evidence-Based Practice 
(ACE) Star Model of Knowledge Transformation. 
To describe 
and/or guide 






Models that use specific types (classes or domains) of 
determinants which act as barriers and enablers (independent 
variables) that impact implementation outcomes (dependent 
variables). These models aim to understand and/or predict 
outcomes prior to implementation. 
Example: Promoting Action on Research Implementation in 
Health Services (PARIHS) model; and Consolidated 








Models that originated from the fields of psychology, sociology 
and organisational theory and can be applied to provide 
understanding and/or explanation of aspects of 
implementation. 
Example: Theory of diffusion. 
Implementation 
theories 
Models developed by implementation researchers to provide 
understanding and/or explanation of aspects of 
implementation. 
Example: Organisational readiness. 
Evaluation 
frameworks 
Models that specify aspects of implementation that could be 
evaluated to determine implementation success. 





Given their prominence in the published literature, three models (RE-AIM, PARIHS and CFIR) are 
described below and chronologically summarised in Table 5.  
Table 5. Key features of the three implementation models evaluated (Zoellner and Porter 2017). 
Model Year developed Key features 
RE-AIM 1999 Reach; effectiveness; adoption; implementation; maintenance. 
PARIHS 2004 Evidence; context; facilitation. 
CFIR 2009 
Intervention characteristics; inner setting; outer setting; 
characteristics of individuals; and process of implementation. 
 
2.4.2.1. RE-AIM model 
The RE-AIM framework, originally developed in 1999, aimed to plan and evaluate the implementation 
of public health initiatives (Glasgow et al. 2019). This framework was based on five dimensions: reach, 
effectiveness, adoption, implementation and maintenance (Zoellner and Porter 2017; Zoellner et al. 
2015; Glasgow et al. 2019). Since its inception, this framework has been widely used. The authors 
revised the model in 2019 and added key questions associated with each dimension (Table 6). 
Table 6. Description of the five dimensions considered in the RE-AIM framework (Glasgow et al. 2019). 
Dimension Definition Key question  
Reach 
The number and proportion of the target 
population that participates in the innovation 
and its representativeness of the overall 
population. 
“How do I reach the targeted 
population with the 
intervention?” 
Effectiveness 
The impact of an intervention on important 
outcomes, including quality of life and 
economic outcomes. 
“How do I know my intervention 
is effective?” 
Adoption 
The number, proportion and 
representativeness of: (i) settings; and (ii) 
people who deliver the intervention. 
“How do I develop 
organisational support to deliver 
my intervention?” 
Implementation 
The intervention agents’ fidelity to the 
implementation initiative, including its 
duration, frequency and overall cost. 
“How do I ensure the 
intervention is delivered 
properly?” 
Maintenance 
The intervention’s ability to maintain its 
effects at least 6 months following the 
implementation initiative. 
“How do I incorporate the 
intervention so that is delivered 
over the long term?” 
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2.4.2.2. PARIHS model 
The PARIHS (Promoting Action on Research Implementation in Health Services) framework, 
developed in 2004, proposed a way to implement research into clinical practice based on the 
interaction of three elements: evidence; context; and facilitation (Rycroft-Malone 2004). This 
framework proposed that the successful implementation of evidence into practice depended not only 
on the quality of the evidence but also on the context of setting (local, organisational and health system) 
where the new evidence is introduced as well as the way the evidence is introduced (facilitated into 
practice). In 2016, the revised PARIHS framework proposed innovation, recipients and context as the 
three key elements, with facilitation representing the fourth element responsible for the overall 
alignment and integration of the implementation initiative (Figure 25) (Harvey and Kitson 2015). The 
‘recipient’ element was introduced in the framework following feedback that the original PARIHS 
framework failed to acknowledge the individuals or groups involved in the implementation (Harvey and 
Kitson 2015). Both PARIHS frameworks were unique as they introduced facilitation as pivotal in the 
implementation of any healthcare initiative (Sudsawad 2007). 
 
Figure 25. Description of the four elements considered in the revised PARIHS model (adapted from 
Harvey and Kitson 2015). 
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2.4.2.3. CRIF model 
The Consolidated Framework for Implementation Research (CFIR) embodied a conceptual framework, 
initially developed in 2009 (Damschroder et al. 2009), based on nineteen published implementation 
theories (Zoellner and Porter 2017). This framework took a comprehensive approach based on five 
domains including a total of 37 constructs (see Table 7). Each construct corresponds to a potential 
barrier or enabler to implementation. The CRIF framework provided a pragmatic structure that 
ultimately aimed to help individuals and organisations to successfully complete implementation 
initiatives.  
Given the completeness of the CRIF framework, with a total of 37 detailed barriers to implementation, 
the PhD student decided to use this model to support the NHS implementation of all three advanced 
imaging initiatives considered in the present thesis. This will be discussed in more detail in Chapter 7. 
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Table 7. Description of five domains and 37 constructs comprising the CRIF framework [based on Damschroder et al. (2009) and Zoellner et al. (2015)]. 
Domain Constructs considered and respective definition 
Intervention 
characteristics 
Intervention source: internally vs externally developed idea. The legitimacy of the source may influence the success of the 
implementation (e.g. internal ideas might have more legitimacy compared to external ideas – e.g. consulting company). 
Evidence strength and quality: stakeholders’ perception of the quality and validity of the evidence supporting the intervention 
might impact its implementation. Preferred sources of evidence are published literature and guidelines as opposed to anecdotal 
stories. 
Relative advantage: stakeholder’s perception of the advantage of implementing the intervention versus an alternative solution. 
In healthcare, it typically refers to the advantage of implementing the intervention as opposed to doing nothing (i.e. maintain 
standard care). 
Adaptability: the ability to adapt or tailor the intervention to address local needs. The balance between the need to base the 
implementation on high-quality evidence while addressing specific local challenges. 
Trialability: the ability to test the intervention and, if needed, reverse it. Local pilots or plan-do-study-act (PDSA) cycles are 
commonly used in healthcare. 
Complexity: stakeholder’s perception regarding the difficult of implementation. Disruptive interventions typically require more 
reorientation and implementation efforts as they reflect a clear departure from the status quo. Complexity also increases with 
the number of organisational units (teams, clinics, departments) or types of people (providers, patient, managers). 
Design quality and packaging: stakeholder’s perception of the quality of how the intervention is conducted. The better the 
intervention is presented, the more likely it is for the implementation to be successful. 




Patient needs and resources: the degree as to which the patient’s needs, as well as barriers/facilitators to address those 
needs, are known to the organisation and prioritised with the right resources. Patient-centred organisations are more likely to 
implement change effectively. 
Cosmopolitanism: the degree to which the organisation is linked to external organisations. Organisations that promote 
external networks are more likely to be successful in the implementation of new practices (notion of social capital). 
Peer pressure: competitive pressure to adopt an intervention. The term ‘peers’ can refer to any outside organisation or 
individuals within the same organisation.  
External policies and incentives: external strategies (e.g. governmental or regulatory agencies) that can affect the 
intervention’s implementation (e.g. lack of financial incentives). 
Inner settings 
Structural characteristics: the social architecture (the size and level of independence of each group responsible for delivery 
of care), age, maturity and size of the organisation. The more stable teams are, the more likely they are to successfully 
implement change. 
Network and communications: the nature and quality of the social networks among individuals and groups/services/ 
directorates. Relationships between individuals and cohesive informal communication channels may be more important to a 
successful implementation than attributes from individuals (sense of ‘community’ or ‘ teamness’). 
Culture: norms and values of the organisation. Organisations with culture that embrace change are more likely to successfully 
adopt new clinical practices. 
Implementation climate (with 6 subcategories): tension for change (the degree to which stakeholders perceive the situation as 
intolerable); compatibility (fit between the meaning and values of the intervention and the individual’s own values and 
perceptions); relative priority (individual’s perception of the relevance of the implementation to the organisation); organisational 
incentives and rewards (extrinsic incentives such as performance reviews, promotions, raise in salary and less tangible 
incentives such as increase in respect); goals and feedback (the extent to which goals are clearly communicated and fed back 
to individuals); learning climate (the extent to which individuals feel safe and able to challenge existing methods). 
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Readiness for implementation (with 3 subcategories); leadership engagement (commitment and involvement of local and 
senior leaders); available resources (appropriate level of resources dedicated to support implementation, such as training, 
space and time); access to information and knowledge (ability to access information about the intervention and how to 





Knowledge and beliefs about the intervention: organisations are composed of individuals who have their own knowledge 
and beliefs toward changing behaviours. This construct, along with self-efficacy (below), are the two most common constructs 
used in models based on classic and implementation theories. 
Self-efficacy: the individual’s belief in their own capabilities to achieve implementation goals. The more confident an individual 
or group of individuals feel about their ability/abilities, the more likely they are to embrace the intervention and have the 
commitment to overcome implementation obstacles. 
Individual stage of change: characterisation of the phase an individual is in the change process (e.g. pre-contemplation, 
contemplation, preparation, action and maintenance). 
Individual identification with organisation: the degree of alignment between the individuals’ and the organisation’s values 
and the overall commitment of the individual to the organisation. The higher the level of commitment, the more likely the 
implementation initiative it is to succeed. 
Other personal attributes: other personal traits such as intellectual ability, motivation, competence and capacity. 
Process of 
implementation 
Planning: the extent to which the methods and tasks for implementing an intervention are planned. The plan can be formal or 
informal but should consider all contextual factors. 
Engaging: the extent to which key individuals or groups of individuals (e.g. opinion leaders, formally appointed internal leaders, 
champions or external agents) are involved. The absence/presence of a leader or their role in the organisation can influence 
the success of the implementation. 
Executing: the degree to which the different tasks in the implementation plan are completed or done in a timely fashion. 
Reflecting and evaluating: the ability to dedicate time to reflect or debrief before, during or after the implementation as a way 
to share learnings across the organisation. 
68 
 
Chapter 3. Use of advanced imaging in the management 
of suspected scaphoid fracture 
3.1 Introduction 
3.1.1 Clinical condition 
The scaphoid bone is an obliquely orientated bone on the radial (thumb) side of the wrist, between 
the distal carpal row and the radius (Hackney and Dodds 2011). Wrist injury is a common 
presentation to the Emergency Department (ED) in the UK (Patel et al. 2013). Amongst these 
patients, the scaphoid is the most commonly fractured carpal bone, accounting for 51-90% of 
carpal fractures and between 2-7% of all fractures (Yin et al. 2010, Kaewlai et al. 2008; Brooks et 
al. 2005; Hackney and Dodds 2011). Scaphoid fractures are particularly frequent in young, healthy 
individuals, usually caused by a fall onto an outstretched hand (Yin et al. 2010, Nguyen et al. 2008). 
Reviews have found highly variable estimates for incidence of scaphoid fracture. The systematic 
review performed by Yin et al. (2010) found a minimum incidence of scaphoid fractures of 5% and 
a maximum of 50%. However, these values were derived from different reference tests, explaining 
part of the variation. In addition, inter-hospital inconsistencies in the diagnostic pathway for patients 
with suspected scaphoid fracture may have further impacted the incidence values retrieved from 
literature. Taking this uncertainty into account, clinical evidence suggested a confirmed scaphoid 
fracture incidence value of between 10% and 20% from the overall number of patients presenting 
with suspected scaphoid fracture (Yin et al. 2010). 
3.1.2 The clinical challenge 
The management of suspected scaphoid fractures is particularly challenging due to three factors: 
(i) the low incidence of actual scaphoid fractures in patients presenting with suspected scaphoid 
fracture; (ii) the limited accuracy of conventional radiograph as the initial imaging modality; and (iii) 
the potential for complications resulting from a misdiagnosis. 
First, of the patients presenting with wrist pain and tenderness at the ED, most do not present with 
an obvious scaphoid fracture (Patel et al. 2013). It is estimated that the majority, between 66-84%, 
of patients presenting at the ED will have no definite bone injury at all (Patel et al. 2013; Mallee et 
al. 2011). 
Second, clinical and radiographic diagnosis of scaphoid fracture is often challenging, particularly 
at the time of presentation. According to Nguyen et al. (2008) this situation could lead to under-
diagnosis in up to 40% of cases, and subsequent under-treatment of scaphoid fractures. This would 
affect patient outcomes, mostly in young people of working age, who most commonly suffer 
fractures of the scaphoid.   
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Third, various clinical complications may arise from a misdiagnosed scaphoid fracture. These 
include non-union, avascular necrosis and secondary wrist arthritis (Bergh et al. 2013). Bearing 
this in mind, early diagnosis and prompt treatment are essential to improve patient outcomes and 
reduce the risk of potential complications (Yin et al. 2010). In order to avoid potential clinical 
complications associated with scaphoid fractures, clinicians tend to over-treat patients with 
suspected scaphoid fractures, leading to the routine use of splints and even plaster casts in 
patients with no radiographic evidence of fracture. This can significantly affect patients’ quality of 
life and their overall experience.  
In addition to the financial impact from the NHS perspective, scaphoid fracture over-treatment leads 
to broader societal costs, mainly due to the loss of productivity resulting from the unnecessary use 
of plaster casts (Yin et al. 2010; Yin, Zhang, and Gong, 2015). Yin, Zhang and Gong (2015) created 
a decision tree model using published data and concluded that, from a societal perspective, the 
diagnostic strategy with Computed Tomography (CT) scanning on presentation was the most cost-
effective strategy. This was due to the high societal costs, specifically lost productivity, of using 
immobilisation methods in patients without a scaphoid fracture. 
Based on this evidence, the present study evaluated the pathway associated with suspected 
scaphoid fractures, aimed at providing an early and accurate diagnosis and subsequent 
appropriate and timely treatment.  
3.1.3 Economic evidence: systematic literature review 
Despite the known superior accuracy level of advanced imaging in the diagnosis of suspected 
scaphoid fractures (Yin et al. 2010), it is important to understand its economic impact in the context 
of real-world clinical practice. To this effect, a systematic review, published by the student, 
synthesised the economic evidence on the use of advanced imaging, particularly CT and Magnetic 
Resonance Imaging (MRI), in the management of suspected scaphoid fractures (Rua et al. 2017).  
Search strategy 
The search strategy was based on the PICOS (Population, Intervention, Comparator, Outcome, 
Study design) framework, as below.  
 Population/Patient: Patients with suspected scaphoid fracture. 
 Intervention/treatment: Advanced imaging (e.g. MRI, CT, Ultrasound or Nuclear Medicine 
- bone scintigraphy). 
 Comparator(s): Conventional radiography (x-ray or radiographs). 
 Outcome(s): primary outcome - total costs associated with the use of advanced imaging in 
the acute management of suspected scaphoid fractures; secondary outcomes: economic 
evaluations (e.g. cost-effectiveness analysis).  
 Study Design: Any type of study design. 
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In summary, this review included studies of any design which evaluated any economic data 
associated with the use of any advanced imaging modality in the management of patients with 
suspected scaphoid fractures. 
Inclusion criteria 
The inclusion criteria for this review were: 
 Quantitative study of any design in which the clinical condition was suspected scaphoid fracture. 
 Study analysing the use of any kind of advanced imaging modality, particularly CT, MRI, 
Ultrasound and Nuclear Medicine, with or without a comparison to the traditional use of 
conventional radiography. 
 Study including any form of economic analysis and outcomes, such as healthcare resource use, 
cost analyses, economic evaluations, lost productivity or quality-adjusted life years (QALYs). 
Exclusion criteria 
Studies were excluded if the language was not English, Spanish or Portuguese or if the participants 
were not human. Only studies published from 1990 onwards were included given that formal 
economic evaluations were rarely conducted prior to this date and, furthermore, the imaging field 
has substantially changed since then. Studies that only focused on the treatment of confirmed 
scaphoid fractures were also excluded. 
Databases 
The following databases were searched: Ovid Classic and EMBASE (1990 to 2016 May 20), Ovid 
MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) (1990 to 2016 May 
20), Cochrane Library NHS Economic Evaluation Database and Cochrane Library CRD Health 
Technology Assessment Database (1990 to 2016 May 24). The search strategy, listed in Appendix 
II, was developed and conducted by the student (TR). The search strategy was consistently used 
in the databases searched, with only minor adjustments specific to the database searched. The 
use of truncation, wildcards and Boolean logic, aimed at maximising the number of relevant articles. 
In addition, references cited in the identified papers were also examined. Duplicates were then 
removed using the reference manager software Zotero.  
Screening and quality assessment 
One reviewer (the student, TR) screened titles and abstracts for relevance, whilst a second 
reviewer (research assistant, SH) assessed a random 20% of exclusions determined by a number 
generator in Microsoft Excel. Full texts of selected articles were retrieved and independently 
assessed by two reviewers (TR, SH) based on the defined inclusion and exclusion criteria.  
Data were extracted using the data extraction form produced by the National Institute for Health 
and Care Excellence (NICE). Quality assessment was performed using guidelines on economic 
quality of economic evaluations issued by NICE (NICE 2012b). Further guidance was obtained 
from Drummond et al. (2004). 
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As the studies retrieved presented different methodologies regarding study design, follow-up 
period, type of imaging modality, type of economic/cost data, economic perspective, it was not 
deemed appropriate to summarise the evidence using a meta-analysis. Hence, a descriptive 
synthesis of evidence was undertaken.  
Results 
The full selection process flow chart for the database searches is depicted in Figure 26. The 
database searches generated 211 papers: Medline (57); Embase (93); NHS Economic Evaluation 
Database and Cochrane Library NHS Economic Evaluation Database (61). The screening of 
references cited in identified papers increased the total list of records to 212. A total of 151 papers 
(all written in English) remained after removing duplicates. A total of 130 records were excluded 
following screening of abstracts, leaving a total of 21 full text papers to be reviewed. Of these, 6 
records were excluded for various reasons (see Figure 26), leaving a total of 15 relevant papers to 
be reviewed.  
Descriptive analysis 
The studies were compared in terms of the: (i) study design; (ii) type of intervention (imaging 
modality considered); (iii) timing of the intervention (e.g. utilisation of advanced imaging at day 1 
or day 7 following the injury); and (iv) type of economic outcome measured. Appendix III 
summarises the findings from the 15 studies included in this review focusing on the: study design 
and follow-up duration; intervention(s) and comparator(s); population characteristics and sample 
size; clinical and economic outcomes; main economic findings; and the author's conclusions. 
Country of origin 
Over 50% of the research included was conducted in Europe, with four studies from the UK (Patel 
et al. 2013; Burns et al. 2013; Jenkins et al. 2008; Saxena et al. 2003) and one from the following 
countries: the Netherlands (Tiel-van Buul et al. 1995); Spain (Moreno Ramos et al. 2013); Norway 
(Bergh et al. 2013); and Denmark (Hansen et al. 2014). The remaining evidence included studies 
from Australia (Brooks et al. 2005; Ganeshalingam, Eng, and Page 2013; Kelson, Davidson, and 
Baker 2016), US (Dorsay, Major, and Helms 2001; Karl, Swart, and Strauch 2015), China (Yin, 
Zhang, and Gong 2015) and New Zealand (Gooding A., Coates M., and Rothwell A. 2004). 
Study design 
Three of the studies used randomised designs, with two randomised controlled trials (RCT) (Patel 
et al. 2013; Brooks et al. 2005) and one randomised controlled pilot (Kelson, Davidson, and Baker 
2016). Four quasi-experimental studies, with non-randomised designs, were also identified 
(Moreno Ramos et al. 2013; Bergh et al. 2013; Hansen et al. 2014; Gooding A., Coates M., and 
Rothwell A. 2004). Eight studies were based on economic models, with three being economic 
evaluations (Tiel-van Buul et al. 1995; Karl, Swart, and Strauch 2015; Yin, Zhang, and Gong 2015) 
and five cost analyses (Dorsay, Major, and Helms 2001; Burns et al. 2013; Jenkins et al. 2008; 




Figure 26. PRISMA flow chart summarising the selection process of relevant studies. 
Study samples 
The studies appeared to be based on comparable populations: patients with suspected scaphoid 
fractures but without findings suggestive of scaphoid fracture on the initial radiographs (x-ray). 
Sample sizes for the three randomised studies ranged from 16 participants (Kelson, Davidson, and 
Baker 2016) to a total of 84 (Patel et al. 2013). 
Imaging Modality 
Out of the 15 studies reviewed, all but Tiel-van Buul et al. (1995) studied the inclusion of MRI in 
the management of suspected fractures. However, some studies also included other imaging 
modalities, specifically Bone Scintigraphy (4 studies), CT (3 studies) and Ultrasound (1 study).  
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Time of Intervention 
Along with the type of imaging modality used, the timing of the diagnostic test was of vital 
importance as the same imaging modality used at different points in time might produce different 
clinical and economic outcomes. The three randomised clinical studies considered the use of 
advanced imaging between 2-5 days (Brooks et al. 2005), 1-3 days (Kelson, Davidson, and Baker 
2016) and within 2 days (Patel et al. 2013) following the injury. Other studies, particularly economic 
modelling studies, broadly evaluated the use of advanced imaging on the day of injury and up to 2 
weeks following the injury. As an example, Yin et al. (2015) found that the immediate use of CT 
was the most cost-effective strategy for managing suspected scaphoid fractures (Yin, Zhang, and 
Gong 2015). 
Economic evidence 
The analysis of economic outcomes were grouped according to the respective study design and 
perspective of analysis (either healthcare payer or societal perspectives). Furthermore, the 
distinction between cost analyses and cost-effectiveness and cost-utility analyses was also noted. 
The three studies that used randomised allocation methods did not find statistically significant 
differences in costs from a healthcare payer’s perspective. Two randomised controlled trials, by 
Patel et al. (2013) and Brooks et al. (2005), and one randomised controlled pilot, by Kelson et al. 
(2016), found no statistically significant differences in terms of total mean or median costs due to 
the use of MRI in the management of suspected scaphoid fractures [£504.13 intervention group vs 
£532.87 control, p=0.9 (Patel et al. 2013); median cost of $411.48 intervention group vs $296.42 
control group, p=0.19 (Brooks et al. 2005); and median cost of $335.81 intervention group vs 
$337.09 control group, p=0.74 (Kelson, Davidson, and Baker 2016)]. This seemed to be due to the 
fact that all three studies appeared to be either underpowered, with small sample sizes, or not 
powered to detect statistical significant differences in economic outcomes [e.g. one RCT was 
powered to detect differences in days unnecessarily immobilised (Brooks et al. 2005)]. However, 
when potential societal costs were included, in particular costs associated with time off work, the 
use of advanced imaging, in this case MRI, was likely to be cost saving (Kelson, Davidson, and 
Baker 2016) or cost-effective (Brooks et al. 2005). In one of the RCTs, by Brooks et al. (2005), a 
cost-effectiveness analysis estimated that the use of MRI saved $30.8 (95% CI $2.97 to $69.94) 
per day due to the prevention of unnecessary immobilisation (Brooks et al. 2005). 
Evidence from the four non-randomised empirical studies was, from a healthcare payer’s 
perspective, variable but exhibited a trend of increased healthcare costs associated with the use 
of advanced imaging. Three studies found that standard treatment (i.e. with wrist immobilisation 
and no use of early advanced imaging) was less expensive than the strategy where early advanced 
imaging was available (Moreno Ramos et al. 2013; Hansen et al. 2014; Gooding A., Coates M., 
and Rothwell A. 2004). It is however relevant to note that two studies (Moreno Ramos et al. 2013; 
Gooding A., Coates M., and Rothwell A. 2004) did not perform a statistical analysis (no p-value or 
confidence intervals) around the economic outcomes. Bergh et al. (2014) found no statistically 
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significant cost-differences in the management of scaphoid fractures. Out of the four quasi-
experimental studies, only Gooding and colleagues (2004) performed an economic evaluation (the 
remaining three focused on cost analyses). Findings from this study suggested that advanced 
imaging, in this specific case MRI, despite having increased the total hospital costs, was cost-
effective with an average cost of $692 to exclude a scaphoid fracture (Gooding A., Coates M., and 
Rothwell A. 2004). Finally, as with the RCT studies, the two studies that assumed a societal 
perspective reported that the utilisation of advanced imaging significantly reduced societal costs 
(Bergh et al. 2013; Hansen et al. 2014). Bergh et al. (2014) estimated that indirect costs for 
employees (due to sick leave) accounted for up to 85% of the total management costs. 
Three studies used economic modelling to perform cost-effectiveness analyses around the use 
of advanced imaging in the management of suspected scaphoid fractures (Tiel-van Buul et al. 
1995; Karl, Swart, and Strauch 2015; Yin, Zhang, and Gong 2015).  Yin, Zhang, and Gong (2015) 
evaluated six potential interventions using a decision tree model. These interventions varied in the 
imaging modality and also in the timing of when the actually imaging scan was performed. Cost-
effectiveness analyses showed that immediate CT and day-3 MRI were the most cost-effective 
strategies (Yin, Zhang, and Gong 2015). A second study, by Karl et al. (2015), using QALYs as the 
measure of effect and taking a societal perspective, found that advanced imaging was dominant 
over empiric cast immobilisation. This study also found the use of MRI over CT presented an 
incremental cost-effectiveness ratio (ICER) of $41,000/QALY (£27,350/QALY). Depending on the 
healthcare payer’s willingness to pay thresholds and also local institutional costs and imaging 
availability, a strategy to manage suspected scaphoid fractures using MRI was likely to be both 
feasible and cost-effective (Karl, Swart, and Strauch 2015). A third study, by Tiel-van Buul et al. 
(1995), evaluated the use of bone scintigraphy. The incremental costs incurred to save one non-
union by using bone scintigraphy were found to be one-third of the price of repeated radiography 
at 6 weeks. The authors concluded that the intervention was cost-effective, although no specific 
ICER was presented (Tiel-van Buul et al. 1995). 
Five studies used economic modelling to perform cost analyses (Dorsay, Major, and Helms 
2001; Burns et al. 2013; Jenkins et al. 2008; Saxena et al. 2003; Ganeshalingam, Eng, and Page 
2013). These studies reported divergent findings concerning the cost impact of using advanced 
imaging in the management of suspected scaphoid fractures. One study presented favourable cost 
evidence (Saxena et al. 2003), whilst another one found no cost difference (Dorsay, Major, and 
Helms 2001) and four studies reported unfavourable evidence (Burns et al. 2013; Jenkins et al. 
2008; Saxena et al. 2003; Ganeshalingam, Eng, and Page 2013). Saxena et al. (2003) 
hypothesised five potential interventions using advanced imaging (MRI or bone scintigraphy) at 
different timings (on day 1, within a few days or in 2 weeks). Depending on the type of imaging 
modality, the use of advanced imaging led to an increase or decrease in total management costs 
(Saxena et al. 2003). Two interventions were found to be cost saving, particularly MRI on day 1 
and, to a lesser degree, MRI within few days followed by a review of results on the same day 
(Saxena et al. 2003). One study, by Dorsay et al. (2001), found no significant cost difference 
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between the strategy with screening MRI and the comparator with conventional immobilisation. In 
contrast, four studies found that the use of advanced imaging led to increased healthcare costs. 
Saxena et al. (2003) found that the use of advanced imaging was more expensive if the review of 
the imaging results was not performed on the same day of the scan as it led to an increased number 
of outpatient appointments. Burns et al. (2013) concluded that the costs of management of 
suspected scaphoid injuries was higher than the additional cost of performing an MRI scan by $139 
(£97) (Burns et al. 2013). Jenkins et al. (2008) established that the use of advanced imaging, 
particularly MRI and CT, led to an increased costs of $225 (£158) and $82 (£58), respectively 
(Jenkins et al. 2008). Finally, Ganeshalingam et al. (2013) reported that the use of MRI led to an 
increase of $242 (£168) in costs associated with the management of suspected scaphoid fractures. 
However, as with other studies that included societal costs due to time off work, Ganeshalingam 
et al. (2013) found that the use of MRI led to savings of $1,655 (£1,151) per patient. 
Summary of the systematic review: 
The systematic review published by the student (Rua et al. 2017) identified a number of different 
methodologies such as cost, cost-effectiveness and cost-utility analyses. The findings from 
different studies might not be directly comparable as the country of origin, study design, type of 
imaging, timing after injury and also the economic outcomes varied considerably between studies. 
In addition, papers reviewed included important limitations such as inappropriate reporting 
methods, short follow-up periods and statistical under-powering. Moreover, all three economic 
modelling studies that evaluated the use of immediate advanced imaging (i.e. on the day of injury) 
reported divergent findings and shared important methodological issues, particularly the lack of 
empirical evidence needed to estimate health care resource use following the use of immediate 
advanced imaging. The evidence presented should therefore be interpreted with caution. Taking 
this into consideration, the systematic review found economic findings differences based on the 
perspective of analysis (Rua et al. 2017). If a societal perspective was taken, the use of advanced 
imaging was, regardless of the timing and type of intervention, likely to generate cost savings. In 
contrast, if a healthcare perspective was assumed, the studies reviewed in the systematic review 
did not provide conclusive economic evidence (Rua et al. 2017), although the randomised studies 
did not find statistically significant cost differences. The non-randomised studies, however 
presented two major limitations: (i) lack of empirical data to measure the impact of advanced 
imaging on healthcare resource use (e.g. no resource use was considered following a negative 
finding on the advanced imaging scan); and (ii) the economic models considered did not 
necessarily reflect real-world clinical practice (e.g. the use of immediate advanced imaging did not 
lead to the detection of other bone fractures or soft-tissue injuries).  
Based on this evidence, we concluded that there was a need for a well-designed economic study 
to assess the clinical and economic impact of using immediate advanced imaging in the 
management of suspected scaphoid fractures based on empirical data. 
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3.1.4 Standard care 
The clinical and radiographic diagnosis of scaphoid fractures is often challenging at the time of 
presentation (Yin et al. 2010; Mallee et al. 2011). This is particularly true if imaging protocols are 
limited to conventional radiographs and exacerbated by the lack of standardisation of imaging 
protocols for suspected scaphoid fracture across hospitals (Yin et al. 2010; Mallee et al. 2011). 
Consistent with other healthcare providers, the current diagnostic pathway at GSTT includes an 
initial clinical assessment on arrival (usually via the ED). Subsequently, if a scaphoid fracture is 
suspected, plain radiographs are performed, using a specific, 4-view, scaphoid protocol.  
Based on the results, the clinical pathway and subsequent treatment varies: 
 Positive findings (i.e. abnormal findings on the initial 4-view plain x-ray):  
Patients are given a splint and are referred to an initial fracture clinic consultation between 1-2 
weeks after the initial ED attendance. Subsequently if a scaphoid fracture is confirmed, the patient’s 
arm is put in a plaster cast. 
At the time of their fracture clinic appointment, the majority of patients with a confirmed scaphoid 
fracture undergo a CT scan (or to a lesser degree, an MRI scan) to establish whether the fracture 
is displaced and, if so, the degree of displacement. Based on these imaging findings, the patient’s 
scaphoid fracture is managed in one of two ways: (i) plaster cast for a period of at least 6 to 8 
weeks; or (ii) to a lesser degree, surgery in the case of displaced fractures or proximal pole 
fractures.  
 Negative findings (i.e. no abnormal findings on the initial 4-view plain x-ray):  
Similar to patients with positive findings, patients with negative findings on the initial radiographs 
are referred to a fracture clinic consultation 1-2 weeks after the initial ED attendance. At this point 
repeated conventional radiograph (usually 4-view plain x-ray) and, to a lesser degree, a CT scan 
(or an MRI scan) is carried out. Based on these imaging findings, the patient is either discharged 
or is given the treatment as above (i.e. either plaster cast or surgery).  At subsequent follow-up 
appointments, if the 4-view plain x-ray is negative but the patient remains symptomatic, further 
imaging (usually a CT scan) is carried out (if not performed on the initial outpatient appointment). 
As summarised above, the management of people with scaphoid fractures at GSTT comprised the 
use of several imaging technologies including conventional radiograph and, in some cases, 
advanced imaging (CT and, to a lesser degree, MRI). The rationale for the use of CT, rather than 
MRI, seems to be explained by the limited availability of MRI. In fact, CT scans can generally be 
carried out and reviewed by the referring clinician on the day the patient is seen in the fracture 
clinic. However, as with any radiation based imaging technique, the utilisation of CT is not harmless 




3.1.5 Proposed Intervention 
The proposed intervention was based on the use of immediate MRI, i.e. during the acute episode 
in the ED, as a decision tool for the management of suspected scaphoid fractures. Despite the 
higher cost and reduced availability of MRI when compared to CT, this decision was based on both 
the lack of radiation of MRI and the superior accuracy levels of MRI in the management of 
suspected scaphoid fractures (Rua et al. 2018).  
The results from the MRI subsequently informed the diagnostic and treatment pathway as follows: 
 Positive findings (i.e. abnormal findings on the initial MRI):  
Positive findings such as scaphoid or any other bone fractures were treated with plaster cast during 
the ED episode and referred to the next available fracture clinic appointment where clinical and 
radiographic follow-up is considered. Given the MRI’s very high sensitivity to rule-in scaphoid 
fractures among suspected scaphoid fractures, it was hypothesised that the use of MRI would lead 
to an accurate detection of scaphoid (or other bone) fractures on presentation to the ED.  
 Negative findings (i.e. normal findings on the initial MRI):  
Patients with negative findings for bone fracture (scaphoid or any other bone) or no major soft 
tissue injury were discharged from the ED with no formal follow-up at Fracture Clinic. However, 
given that participants without fractures may still have wrist pain 2 weeks post-injury, to further 
diagnosis or treatment of symptomatic patients should be considered (see section 3.2.5 for further 
detail). Given the very high specificity of MRI to rule-out scaphoid fractures among suspected 
scaphoid fractures, it was hypothesised that the use of MRI would lead to the safe discharge of 
patients without any scaphoid or any other bone fracture. 
3.1.6 Rationale for the trial 
Economic evidence around the use of advanced imaging (particularly MRI) in the assessment of 
suspected scaphoid fractures comes from economic modelling studies, quasi-experimental studies 
and three randomised controlled studies. However, in all empirical studies the use of MRI was not 
performed as a first line investigation during the initial acute episode. This trial considered the use 
of immediate MRI, i.e. during the initial presentation to the ED. To the best knowledge, this 
approach is innovative and could provide a foundation on which to base national and international 
best practice. The rationale and design for this trial was published in the Journal of Clinical Trials, 





3.2.1 Aims, Objectives and Hypotheses 
Aims of the study: 
The aim of the SMaRT (Scaphoid Magnetic Resonance Imaging in Trauma) trial was to assess 
clinical effectiveness and conduct cost and cost-effectiveness analyses around the use of 
immediate MRI in the management of suspected scaphoid fractures compared to conventional 
management with immobilisation and clinical and radiographic follow-up. 
Study objectives:  
One primary and seven secondary objectives were considered.  
Primary Objective: To estimate the 3-month costs associated with two clinical pathways in the 
ED: (a) the control group, with conventional radiograph as the only imaging modality in the ED; or 
(b) the intervention, a hybrid approach that considers the use of wrist MRI in the ED as an add-on 
test for patients with negative findings on the initial conventional radiograph.  
Secondary Objectives: 
I. To perform a cost analysis at 6 months associated with the intervention group compared to 
the control group.  
II. To perform cost-effectiveness analyses at 3 and 6-months to estimate the incremental cost-
effectiveness ratio (ICER) associated with the proposed intervention compared to the control 
group. Two measures of effect were considered: (a) pain levels; and (b) QALY.     
III. To estimate the mean cost per correctly diagnosed scaphoid fracture in the intervention group 
compared to the control group. 
IV. To assess the overall patient satisfaction associated with the intervention group compared to 
the control group. 
V. To estimate the accuracy associated with the proposed intervention (i.e. immediate wrist MRI) 
in the detection of scaphoid fracture compared to the current pathway (i.e. 4-view conventional 
radiographs). 
VI. To estimate the time taken to reach a definitive diagnosis in the intervention group compared 
to the control group. 
VII. To estimate the amount of time off work or informal care needs due to the suspected scaphoid 





The primary hypothesis for the study was that the addition of immediate MRI in the management 
of suspected scaphoid fractures with negative findings on the initial conventional radiograph will 
decrease the overall 3-month NHS costs per patient compared to those in the standard care. 
The standard care pathway, i.e. the control group, includes the use of the initial x-ray only as part 
of the emergency diagnostic pathway, as opposed to the intervention group where an add-on wrist 
MRI test was performed. The 3-month timeline was considered appropriate as all relevant costs 
and benefits should be realised within this timeframe. 
The underlying rationale was that the early use of a more expensive diagnostic tool (i.e. MRI) will 
enable an improved accuracy in the diagnosis of scaphoid fracture and change the subsequent 
treatment. This may avoid unnecessary treatment as up to four out of five patients without a fracture 
are immobilised for long periods of time, and ultimately avoid downstream costs associated with 
fracture clinic appointments and repeated diagnostic tests. 
Secondary Hypotheses: 
Additionally, it was hypothesised that the intervention will:  
 Reduce total 6-month NHS costs. 
 Be cost-effective at 3 and 6-months, using pain levels and QALYs as the measure of effect. 
 Be cost-effective at 3 months, using the number of correctly diagnosed scaphoid fractures 
as the measure of effect. 
 Increase levels of patient satisfaction. 
 Improve diagnostic accuracy in the detection of scaphoid fractures. 
 Reduce the time taken to reach a definitive diagnosis (i.e. to either rule in or rule out a 
scaphoid fracture). 
 Reduce the amount of time off work, informal care or hand immobilisation with plaster cast 
due to the suspected scaphoid fracture. 
3.2.2 Study design 
Randomised Pragmatic Trial 
The SMaRT trial was a single-site, pragmatic, prospective, parallel, non-blinded, randomised trial. 
The SMaRT trial was designed as a pragmatic trial, aimed at assessing the real-world effectiveness 
of the intervention applied as part of routine clinical practice to a heterogeneous population. 
The SMaRT trial presented two key innovative features. First, the use of MRI as part of the initial 
visit to the acute setting (in the ED) was, to our best knowledge, novel. This approach, although 
operationally challenging, aimed simultaneously at: (i) reducing the number of healthcare contacts 
as patients with negative findings on the MRI might not need further appointments; (ii) improving 
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overall patient satisfaction by using a more definitive approach; and (iii) increasing overall NHS 
efficiency by promoting decisive care and reducing the need for unnecessary care (e.g. follow-up 
of patients with no scaphoid fracture). Second, the intervention proposed a holistic transformation 
of the diagnostic and treatment pathways as a direct consequence of the MRI findings. As an 
example, only a proportion of participants with negative findings on the MRI (i.e. no scaphoid or 
other bone fractures) required any form of follow-up at secondary care. Indeed, participants with 
no relevant MRI findings that remain pain-free after two weeks were not expected to require any 
follow-up at all (apart from the 3 month 4-view plain x-ray for the purposes of research). Hence, by 
using a more advanced and accurate imaging modality earlier in the clinical pathway we were able 
to appropriately change the participant’s subsequent care. 
The SMaRT trial was designed to detect differences in resource use between the intervention 
(immediate wrist MRI) and hospital standard care (control group) on an intention to treat basis. The 
trial’s design explicitly aimed to minimise potential sources of biases and maximise the 
generalisability of our results. First, to reduce the selection and/or population bias, block 
randomisation was performed by an external organisation (King’s Clinical Trial Unit). The use of 
random and concealed allocation methods is the most rigorous method to test the direct effect of 
the intervention on outcomes (Dettori, 2010). Second, findings from the SMaRT trial may be 
transferrable to other UK-based hospitals due to two factors: (a) the control group pathway largely 
reflects standard care in the UK; and (b) the trial’s inclusion criteria is broad, reflective of the overall 
population undergoing evaluation of suspected scaphoid fractures.  
Participant Groups 
Participants were randomly allocated to two groups: the control group (standard care); and the 
intervention group (MRI group). Participants in the control group followed standard care that relied 
in the use of conventional radiograph as the only diagnostic tool as part of the ED episode. 
Participants randomised to the intervention group underwent a wrist MRI scan as part of the ED 
episode as an add-on to the initial conventional radiograph. This MRI scan was performed based 
on abbreviated imaging protocols compared to a conventional non-acute wrist MRI scan. The 
rationale for this approach derived from the combination of two reasons: first, not to overburden 
the acute diagnostic pathway; and second, to obtain enough clinical information to accurately rule-




Participants were assigned to groups using a web-based automatic 1:1 block randomisation 
sequence generated by an external organisation, King’s Clinical Trial. A fixed size block of 10 




The randomisation method was based on a web-based system hosted by an organisation exterior 
to the SMaRT trial. Hence, the allocation sequence was fully concealed from both the participants 
and any member of the research staff.  
Blinding: 
The SMaRT trial presented a non-blinded design. Given the nature of the intervention and its 
impact on subsequent care it was not deemed feasible to blind participants or research staff to the 
intervention.  
This lack of blinding might lead to potential conscious or unconscious performance bias. However 
necessary, this constituted a SMaRT trial limitation. As the latter had the potential to affect the 
primary outcome (e.g. over or underutilisation of healthcare resources), strict clinical pathways 
were disseminated prior to the trial’s initiation.  
In addition, the lack of blinding might have led to attrition bias, i.e. different attrition rates associated 
with both randomisation groups. Different preventive steps were put in place to mitigate this risk, 
particularly: (a) ensuring good communication between participants and different members of the 
research team; (b) financial incentives for participants to complete the study follow-up; (c) utilisation 
of databases that were not based on participants’ self-reporting data; and (d) use of intention-to-
treat analysis (i.e. all participants were analysed as per their respective randomisation group 
regardless of any other event) (Tal 2011; Peacock, Kerry, and Balise 2017). 
Follow-up Period 
All participants were followed up to a period of 6 months. Data were collected at baseline and at 1, 
3 and 6 months post-recruitment. 
3.2.3 Ethical Approval, Trial Registration and Funding 
The Health Research Authority and Research Ethics Committee (South East Coast – Surrey REC) 
approved the SMaRT trial research on the 17th May 2016. The REC reference was 16/LO/0826 
and the IRAS project ID was 180601. The SMaRT trial commenced on the 15th June 2016, with 
the first participant being recruited on the 06th July 2016. The SMaRT trial was registered on 
clinicaltrials.gov (Clinical Trial Registration: NCT02801149) on the 15th June 2016.  
The SMaRT trial was fully funded by a grant secured from Guy’s and St Thomas’ Charity. 
3.2.4 Selection, withdrawal of participants and sample size 
Study Setting: 
The study was conducted at an independent single Trust site, at GSTT. Participants were recruited 




Patients were considered to be eligible for the study if at least one of the inclusion criteria was met 
and none of the exclusion criteria was present. Any patient aged 16 years or over presenting at the 
ED with clinical history and examination consistent with suspected scaphoid fracture with negative 
findings on the initial 4-view plain conventional radiograph were considered eligible (Figure 27). It 
was considered that a patient presented a suspected scaphoid fracture if at least one of the 
following criteria was present: 
 Isolated pain / tenderness over the Anatomical Snuff Box or Scaphoid Tubercle or pain in 
the scaphoid region during axial loading of the 1st metacarpal. 
 History of recent fall (< 14 days) on an outstretched hand, wrist injury or poor history 
associated with examination findings suggestive of scaphoid fracture. 
 
Figure 27. 4-view scaphoid initial radiographs at the ED showing no evidence of a scaphoid or any 
other bone fracture. Hence, the participant was deemed eligible for the SMaRT trial. 
Exclusion Criteria: 
Patients were considered to be ineligible if at least one of the exclusion criteria was present: 
 Patients presenting outside GSTT catchment area who were not willing to be followed-up at 
GSTT; 
 Patients with a confirmed scaphoid fracture following the initial radiograph exam; 
 Patients with confirmed ipsilateral upper limb injury/injuries (e.g. wrist/forearm/arm injury) 
following the initial conventional x-ray examinations, regardless of the findings around the 
suspected scaphoid fracture. 
 Patients with suspected scaphoid fracture not admitted through the ED; 
 Patients who lacked capacity to give consent or participate in the study; 
 Patients that were already taking part in a Clinical Trial of an Investigational Medicinal 
Product; 
 Pregnancy; 
 Patients screened for the study at the ED on weekdays before 7.30 am and after 6 pm; 
83 
 
 Patients screened for the study at the ED on weekends or Bank Holidays before 9 am and 
after 4 pm. 
Contrary to previous studies, patients with previous scaphoid or wrist injuries were included in the 
trial. The last two exclusion criteria related to operational challenges associated with the limited 
time provision of MRI services.  
Criteria for Premature Withdrawal: 
At all times, particularly when any follow-up was due, the willingness of participants to take part in 
the study was reassessed. If participants gave a reason for their withdrawal, this was recorded, 
however participants did not need to provide a reason for withdrawing the study. 
Losses to Follow-Up: 
If a patient moved to outside GSTT’s catchment area, the research staff made every effort to ensure 
that the participant was still followed-up. In any case, and in order to decrease the probability of 
losses to follow-up, all participant’s GP were, as per the informed consent, contacted to obtain data 
regarding their primary care and secondary care (whenever outside GSTT’s remit) resource 
utilisation. Only if the participant expressed their wish to withdraw the study, he/she was withdrawn 
from the study. Given the high mobility within the Greater London area, it was estimated that up to 
50% of the participants enrolled in the study could be lost to follow-up. 
Sample Size: 
For the purpose of the primary objective, the estimated sample size was calculated based on 
several parameters or assumptions: 
 Test family: 2-sided t test 
 Statistical test: means – difference between two independent means (two groups) 
 Type of power analysis: a priori 
 Average cost per patient in the current pathway: £325 (estimated using GSTT unit cost 
data); 
 Average cost per patient in the proposed pathway: £225 (estimated using GSTT unit 
cost data); 
 α err probability: 0.05;  
 Power (1- β err probability): 0.85;  
 Allocation ratio N2/N1: 1/1; 
 Standard deviation of average cost per patient in the current pathway: £150 (assumed 
to represent about half the average cost per patient); 
 Standard deviation of average cost per patient in the proposed pathway: £115 
(assumed to represent about half the average cost per patient). 
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Based on the above parameters, the required sample size was 68 patients. Subsequently, it was 
considered that 50% of the patients enrolled could be lost to follow-up. Hence, in order to guarantee 
the 68 patients, the study planned to recruit a total of 136 patients (68 in each group). No interim 
analyses were planned or performed during the trial. 
3.2.5 Interventions 
All participants with suspected scaphoid fracture underwent an initial conventional radiograph 
(scaphoid views) as part of their standard care. If positive findings for fracture were found, the 
participant was deemed ineligible for the SMaRT trial. If no fracture of the scaphoid or any other 
bone was seen in the initial x-ray, the patient was deemed eligible to take part in the SMaRT trial. 
The rationale behind this design was based on the conventional radiograph’s high sensitivity for 
the detection of scaphoid and other bone fractures, i.e. ability to rule-in, not rule-out, scaphoid 
fractures. Hence, the authors decided that immediate MRI should be used as an add-on test 
following negative initial conventional radiographs. The subsections below detailed the diagnostic 
and, if needed, treatment pathway for both groups of the trial. 
Control Group (standard care): 
Participants randomised to the control group followed current standard care, i.e. no further imaging 
tests in the ED (see Figure 28a). Following the initial x-ray, participants were put in a wrist splint 
prior to the discharge from the ED and booked into a Fracture Clinic appointment in 1-2 weeks, 
where further imaging scans (usually CT and/or, to a lesser degree, MRI) might be performed. 
Formal follow-up was deemed appropriate due to the limited ability of conventional radiograph to 
effectively rule out a scaphoid fracture on presentation to the ED.  
In the absence of fractures (scaphoid or otherwise) visible on any imaging test, participants were 
usually discharged following the initial Fracture Clinic. The latter might not be the case if, although 
no fracture was visible on any follow-up imaging test, participants were still symptomatic. In this 
case, participants were periodically followed-up in subsequent outpatient appointments where 
further imaging tests might be performed. 
In the presence of fractures, scaphoid or otherwise, visible on any imaging test, participants were 
immobilised using a below elbow plaster cast. Then participants were followed-up periodically up 
to a period of 4-8 weeks, with the combined use of scaphoid-view x-rays and clinical follow-up with 





Figure 28. Diagnostic and, if needed, treatment pathway for participants randomised to: (a) the control group; and (b) the intervention group. 
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Intervention Group (MRI group): 
Participants randomised to the intervention group did not receive standard care as they underwent 
a wrist MRI scan following the initial negative conventional radiograph. An abbreviated wrist MRI, 
conducted during the ED episode, included two coronal and one sagittal plane (Figure 29). The 
MRI images were interpreted and reported by the radiology team on a ‘live’ basis. The MRI images 
and respective report were released and made available to the ED referrer, who then defined the 
patient’s care as follows and depicted in Figure 28b.  
 
Figure 29. Sequences used in the short-sequence wrist MRI (two coronal and one sagittal plane).  
Participants with no fracture or major soft tissue injuries (e.g. ligament rupture) visible on the MRI 
scan were discharged from the ED with a wrist splint and given a contact card. No formal outpatient 
appointment was booked unless the participant remained symptomatic after 1-2 weeks and, as a 
consequence, contacted the hospital. In this case, participants were asked to come to a wrist pain 
clinic appointment. 
Participants with a fracture or major soft tissue injury visible in the MRI scan had their arm 
immobilised in a plaster cast prior to the ED discharge and a Fracture Clinic appointment was 
booked. As with participants in the control group, the majority of confirmed scaphoid or other bone 
fractures required follow-up appointments and 4-8 weeks immobilisation with plaster cast with a 
small proportion of displaced fractures requiring surgery.  
The MRI scan was interpreted and reported promptly in order to accommodate the current ED 
targets (4-hour from admission to discharge from the ED), and so as not to delay the diagnosis 
and, if needed, treatment. In the event that the MRI report was not available for operational reasons 
during the ED episode, participants were treated and discharged with a supportive splint as per the 
initial conventional radiograph findings. This approach was consistent with current clinical practice 
so participants randomised to the intervention group (i.e. with MRI) were not disadvantaged and 
did not receive inferior care by taking part in this trial. Once the MRI report was available, 
participants were contacted to receive the results and, when applicable, to schedule subsequent 
appointments or treatment. 
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3.2.6 Study Procedures 
Trial promotion: 
The implementation of a randomised trial in an acute setting was expected to be challenging, 
particularly due to the short timeline associated with any research-related task during the acute 
episode and the real-world complications arising from the implementation of a novel diagnostic and 
treatment pathway that involves different stakeholders (Emergency, Radiology and Orthopaedic 
Departments). Taking this into consideration, a few weeks prior to the trial start date, the student 
and other research staff delivered an extensive training programme to over 50 Emergency Nurse 
Practitioners (ENPs). This training programme provided an overview of the trial with a particular 
focus on the trial’s rationale, design and inclusion and exclusion criteria. At the end of the training 
programme, the ENPs were given ample opportunities to ask questions and, if happy to take part 
in the trial, were asked to sign the trial’s delegation log. In the context of a trial conducted in an 
increasingly strained ED, it was considered essential to have the buy-in of key routine care 
stakeholders for the timely identification of potential eligible participants and, if possible, complete 
the consent and recruitment processes. Regular updates and one-to-one or group meetings were 
also implemented on an ongoing basis, particularly when there was an unexpected decrease in 
the proportion of potential eligible participants being screened. 
Screening and Recruitment Procedures: 
All participants with suspected scaphoid fracture underwent wrist radiographs (scaphoid views) as 
part of their standard care. If positive findings for fracture were found, the patient was deemed 
ineligible for the SMaRT trial. If no fracture were seen on the initial radiographs, the patient was 
deemed as eligible. This assessment was performed by a clinician from the routine care team, 
usually an ENP, as part of the ED triage process. Subsequently, the trial was discussed with the 
patient. These tasks were performed by the ENP who screened the patient, with or without support 
from the research staff (with or without the student). During these screening procedures, the 
recruiter was responsible for assessing the participant’s capacity to provide informed consent. This 
process ensured that all participants: (a) were given the updated approved version of the patient 
information sheet; (b) were fully informed about the study, including its risks and benefits; and (c) 
confirmed their willingness to participate by signing the approved informed consent. For patients 
randomised to the intervention group, i.e. with MRI, all GSTT safety and MRI consent procedures 
associated were subsequently completed. 
The flowcharts below describe the processes associated with the recruitment of participants to the 




Figure 30: Processes conducted in the recruitment of participants to the control group. 
 
Figure 31: Processes conducted in the recruitment of participants to the intervention group. 
In order to avoid potential biases, each participant was asked to complete a baseline EQ-5D-5L 
questionnaire prior to any randomisation process. This validated questionnaire assessed the 
participant’s self-reported quality of life and was used for the purposes of the economic evaluation. 
The diagnostic pathway was not delayed for more than the minimum amount of time necessary to 
provide the patient with the study information (estimated to be less than 10-20 minutes). Given the 
patient’s non-critical condition and the timely recruitment process, it was not anticipated that this 
task would have any negative impact on patient outcomes or any performance outcome associated 
with GSTT. Furthermore, it was explained to the participant that they were free to withdraw from 
the study at any point in time. 
 Patient assessed in the ED with suspicion of scaphoid 
fracture undergoes initial conventional radiographs  
 If the patient has no radiograph findings suggestive of 
scaphoid fracture (or any other fracture), he/she will be 
approached by the ENPs and research team and study 
information will be discussed with him/her (using patient 
information sheet) 
 Patient signs consent 
 Patient registered to the study 
 Baseline EQ-5D-5L questionnaire filled out 
 Based on the randomisation process, the participant is 
allocated to the control group (standard care) 
 Registration pack 
given to the 
participant 
 No further imaging 
test is required 
 Patient is 
immobilised with a 
splint 
 Formal follow-up at 
Fracture Clinic in 1-
2 weeks 
 
 Patient assessed in the ED with suspicion of 
scaphoid fracture undergoes initial conventional 
radiographs  
 If the patient has no radiograph findings 
suggestive of scaphoid fracture (or any other 
fracture), he/she will be approached by the 
ENPs and research team and study information 
will be discussed with him/her (using patient 
information sheet) 
 Patient signs consent 
 Patient registered to the study 
 Baseline EQ-5D-5L questionnaire filled out 
 Based on the randomisation process, the 
participant is allocated to the intervention group 
(MRI) 
 Registration pack given to 
the participant 
 MRI consent form is signed 
 MRI test is booked and 
performed  
 Patient is immobilised with a 
splint (in case of negative 
findings) or plaster cast (in 
case of positive findings) 
 Negative MRI Findings: no 
formal follow-up + GSTT 
contact card 
 Positive MRI findings: formal 
follow-up at Fracture Clinic 
in 1-2 weeks  
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Any participant withdrawals were recorded in the screening log alongside with the reason of 
withdrawal, if given. 
Follow up Procedures 
The follow-up procedures are presented in Table 8 and Figure 32).  
Participants enrolled in the study were invited to undergo 4-view wrist radiographs and a research 
consultation with an Orthopaedic Consultant 3 months (±2 weeks) after the initial ED presentation. 
This exam and specialist appointment confirmed whether a: (a) scaphoid or any other bone fracture 
healed appropriately; or (b) scaphoid or any other bone fracture was missed. The 3-month 
radiograph was used as a reference to estimate the accuracy levels in the intervention and control 
groups. 
Participants were asked to complete a validated questionnaire (EQ-5D-5L) at three points in time: 
month 1, 3 and 6 post-recruitment. A second non-validated questionnaire was developed to assess 
patient experience in both the intervention and control group at 3 months post-recruitment. Once 
completed, all questionnaires were posted to GSTT using a pre-paid envelope or, if preferred by 
the patient, emailed to GSTT. Furthermore, all participants were provided with a diary in the 
registration pack. In these diaries, participants were asked to record any scaphoid-related hospital 
and GP visits, community care, medications and investigations. This diary was filled out weekly for 
a period of 13 weeks (i.e. 3 months) and the participant handed it over to the research team once 
they arrived at GSTT for their 3-month conventional radiograph exam. Alternatively, patients filled 
out weekly digital diaries emailed by the research team. 
All participant’s GPs were contacted to collect any scaphoid-related NHS resource use data, (e.g. 
GP appointment, nurse appointment, telephone appointment, physiotherapy appointments, 
secondary care appointments) up to a period of 6 months following recruitment.  
90 
 
Table 8. Study flowchart for both control and intervention groups (presented in chronological order) 
Activity 







into the study 
During 
MRI 
After the ED 
episode (months) 
1 3 6 Responsible 
Pre-registration evaluation by trained clinician and assessment of eligibility 
(following an initial x-ray with negative findings for scaphoid fracture) 
X   
 
  GSTT 
Give patient information sheet, explain study and obtain signed informed 
consent 
X   
 
  GSTT 
Register patient into the study X      GSTT 
Baseline EQ-5D-5L questionnaire  X     GSTT / Participant 
Register demographics (e.g. age, gender, previous scaphoid injury, 
professional occupation) and mechanism of injury 
 X  
 
  GSTT 
Give patient registration pack (patient information sheet, copy of consent)  X     GSTT 
Patient is randomised into one group  X     GSTT 
Discharge patient with supportive splint from the ED (control group) or 
Book and refer to MRI scan (intervention arm)  
 X  
 
  GSTT 
MRI exam and report   X    GSTT 
Post EQ-5D-5L questionnaires    X X X GSTT / Participant 
Patient experience questionnaires     X  GSTT / Participant 
Patient resource diary  X  X X  GSTT / Participant 
3-month research radiographs and research appointment     X  GSTT/ Participant 
Retrieve data from GPs      X GSTT/GPs 




Figure 32. SMaRT trial procedures and respective trial objectives.
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Data collection and outcomes  
Data were collected by a research team member at baseline and then at 1, 3 and 6 months 
following recruitment. Data at baseline was collected face-to-face during the initial acute episode 
whilst follow-up data were collected as per the participant’s preference, either via phone, email or 
post. All data were collected using an electronic case report form (RedCap) and subsequently 
exported to Microsoft Excel 2013 and statistical analyses were conducted on Stata 15.0. 
Participant Demographics: 
A variety of information was captured at baseline as part of the SMaRT trial, including: 
1. Date of birth (dd/mm/yyyy); 
2. Gender (male/female); 
3. Ethnicity (e.g. White British, White Other); 
4. Postcode (e.g. SE1, SE4); 
5. Employment status (e.g. full-time job, part-time job, wholly retired from work); 
6. Previous scaphoid fracture (yes/no); 
7. Mechanism of injury (e.g. fall on outstretched hand, other injury). 
Primary Outcome: 
The primary outcome was the 3-month cost difference between: (i) the control group, with 
radiographs as the only imaging modality in the ED; or (ii) the intervention group, with MRI as an 
add-on test in the ED for patients with negative findings on the initial radiographs. 
Perspective of Analysis 
The trial took a NHS and Personal Social Services analytical perspective. Only costs of scaphoid-
related NHS diagnostic and treatment events were considered. This approach is consistent with 
the methodology recommended by the NICE for the evaluation of interventions with potential 
impact on health outcomes (NICE, 2013). A broader societal perspective was also considered in a 
secondary analysis. 
The estimate of the total costs from a NHS perspective relied on the multiplication of any scaphoid-
related healthcare events by the unit cost of each event.  
Resource Use Measurement 
Resource use data included contacts with an NHS healthcare provider associated with the 
management of suspected or confirmed scaphoid fractures. A more comprehensive approach to 
the NHS resource use included data from the following sources of information (visually depicted in 




Figure 33. Sources of data merged to measure total NHS resources used in the management of the suspected scaphoid fracture. 
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1. Electronic Patient Record (EPR). A secondary care database used to maintain the patients’ 
electronic record, with particular focus on clinical data. This database was used as the 
primary source to individually map the elective diagnostic and treatment pathway timeline 
associated with the management of the suspected scaphoid fractures. This information 
allowed us to determine whether a given healthcare contact was scaphoid-related or not. 
2. Patient Information Management System (PIMS). A secondary care database to keep the 
records of referrals, outpatient appointments and inpatient episodes. This database was 
used as a secondary source to confirm NHS resource use. Furthermore, PIMS provided 
the status of each appointment (cancelled, did not attend, attend). This information was 
used to generate costs associated with ‘did not attend’ events. 
3. Symphony (ED software). A secondary care databased used by the ED. This database 
was used as the primary source to individually map the diagnostic and treatment pathway 
timeline associated with the acute management of the suspected scaphoid fractures. 
4. Computerised Radiology Information System and Picture Archiving and Communication 
System (Radiology software). These two secondary care databases collected all data (e.g. 
images and reports) in relation to any diagnostic examination (e.g. radiographs, CT, MRI) 
performed at GSTT.  
5. Participant self-reported trial data. Participants were asked to complete a weekly 
participant diary and record any visit to any healthcare organisation. This information 
supplemented the information gathered via secondary care databases, particularly any 
activity that happened within primary care or secondary care providers other than GSTT. 
6. Primary care information. All participants’ GPs were contacted to obtain key information 
related to the management of the suspected scaphoid fracture, including: GP 
appointments (face-to-face or via telephone), nurse appointment, physiotherapy or any 
secondary care appointment (at GSTT or other hospitals). This information was used as 
the primary source to individually map the pathway that happens outside GSTT’s remit 
(e.g. derive the number of GP appointments in the first three months following recruitment, 
appointments at other Hospitals). 
Although marginal, medication costs were mainly associated with painkillers (e.g. paracetamol, 
ibuprofen) bought over the counter. Given that any out-of-pocket cost were not considered from 
the NHS payer’s perspective, medication data were not included in the present study.  
Valuation of Unit Costs 
For the purposes of the primary outcome, the valuation of unit costs was, whenever possible, based 
on NHS Reference Costs 2016-17 (Department of Health and Social Care, 2016). All secondary 
care contacts were costed using this strategy with the exception of when no tariff was available 
(e.g. no specific tariff for the intervention, the abbreviated wrist MRI scan). It is important to highlight 
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that NHS Reference Costs include all costs associated with the provision of care and respective 
allocation of overheads.  
Table 9 lists all the unit costs considered to estimate the primary outcome, including the reference 
and a brief rationale or any assumptions. Some healthcare events are costed such as inpatient 
episodes, whilst others, like the provision of a CT or MRI, are presented as individual unbundled 
tariffs. The use of National Reference Costs, rather than individual costs from GSTT, was 
considered to enhance the generalisability of the trial’s findings. In fact, given that hospital unit 
costs (e.g. cost of individual MRI) are known to be highly variable across different NHS Trusts 
(Glick et al. 2007), the use of NHS Reference Costs allows for a better understanding of the cost 
distribution from the NHS payer’s perspective. However, the utilisation of hospital charges, rather 
than actual costs of provision of care, might not reflect opportunity costs and could lead to different 
findings (Drummond et al. 2004; Glick et al. 2007). To explore this effect, a sensitivity analysis was 
considered to evaluate whether the use of existing reimbursement strategies and hospital costs 
would lead to any difference in the cost analyses. 
For primary care contacts, an average cost for appointment (e.g. GP face-to-face appointment, GP 
phone appointment) was derived from the Unit Costs of Health and Social Care 2016 (Curtis and 
Burns, 2016) and then inflated to 2017 using the hospital & community health services index. The 
average GP face-to-face, phone consultation and home visits were estimated to be 9.2, 7.1 and 
23.4 minutes long (Curtis 2013), respectively, i.e. equivalent to £36.47, £14.80 and £118.10. Nurse 
face-to-face and phone appointments were assumed to have the same ratio as the GP 
appointments, with an estimated cost of £19.50 and £8.00, respectively. 
Two additional assumptions were considered in the valuation of unit costs. First, in the case of a 
‘Did Not Attend (DNA)’ event, it was considered that the NHS still incurred in a cost, assumed to 
be equivalent to 50% of the unit cost where the participant had attended. Given its potential 
importance, this assumption was subjected to deterministic sensitivity analysis to better understand 
of its impact on the primary outcome. Second, in the case of an interrupted MRI scan due to an 
unforeseen claustrophobia event (i.e. no images acquired and no written report), a proportion of 
the 25% original unit cost was estimated. This estimate was based on the time it took to position 
and remove the participant from the actual MRI scanner (i.e. the amount of time the scanner was 
unavailable as no report ever took place). 
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Table 9. Unit costs for all primary and secondary care events considered in the SMaRT trial. 







Per appointment £36.47 
Unit Costs of Health and Social Care 
(Curtis and Burns 2017) and inflated to 
2017 using the hospital & community 
health services index 
GP home visit Per appointment £118.10 
GP phone appointment Per appointment £14.80 
Nurse appointment (face-
to-face) 
Per appointment £19.50 
Nurse phone 
appointment 
Per appointment £8.00 
Secondary care 
Short-sequence wrist 
MRI scan in the ED 
Per scan £72.40 
The immediate acute wrist MRI scan 
took on average 15 minutes (as 
opposed to 25 minutes for the full wrist 
MRI scan). The short-sequence wrist 
MRI was estimated as a proportion of 
the cost of the full wrist MRI 
(15/25*£120=£72.40). 
ED episode Per episode £73.00 Emergency episode codes (BB11Z - 
Emergency Medicine, No Investigation 
with No Significant Treatment). 
 
Reference Costs 2016/17 (Department 
of Health and Social Care 2016).  
RD01A: Magnetic Resonance Imaging 
Scan of One Area, without Contrast, 
19 years and over; RD20A - 
Computerised Tomography Scan of 
One Area, without Contrast, 19 years 
and over.  
 
Outpatient appointments (either at 
Fracture Clinic, Physiotherapy or 
occupational therapy) and radiographs 
were based on local hospital costs (no 
specific HRG code on NHS reference 
costs). 







(scaphoid view) – 1 wrist 




Wrist CT Per scan £59.60 
Wrist MRI (full sequence) Per scan £120.70 





Occupational therapy – 





Surgeries Per procedure 
£815 to 
£4,998 
Reference Costs 2016/17 (Department 
of Health and Social Care 2016) – 
codes HB55C, HR06A, HN42B and 
HT43C 
Plaster cast Per cast £36.00 
Internal GSTT costing data. 




This subsection summarises the additional data collection methods used to gather data on the 
seven secondary outcomes. 
I. To perform a cost analysis at 6 months associated with two clinical pathways in the 
Emergency Department (ED).  
This outcome considers the extension of the base case cost analysis up to the 6-months period 
using the same principles of resource measurement and cost valuation.  
II. To perform a cost-effectiveness analyses at 3 and 6 months to estimate the incremental 
cost-effectiveness ratio (ICER) associated with the proposed intervention.    
The cost analysis was performed as per the principles detailed for the primary outcome (3-month 
total costs) and the above mentioned secondary outcome (6-month total costs). The incremental 
analysis of effectiveness considered two measures of effect: (i) pain/discomfort levels reported by 
participants in the resource use diary; and (ii) QALYs, a generic measure of quality of life (i.e. a 
cost-utility analysis). QALYs were estimated from utility scores derived from the EQ-5D-5L 
questionnaire (Devlin et al. 2018) at four points in time: baseline (month 0), 1, 3 and 6 months 
using area under the curve methods assuming linear movement between adjacent points 
(Drummond et al. 2004). Cost-utility analysis is the preferred method of economic evaluation 
according to NICE guidelines (NICE 2011b; 2013).  
III. To estimate the mean cost per correctly diagnosed scaphoid fracture in the intervention 
group compared to the control group. 
In this secondary outcome, correctly diagnosed scaphoid fractures (either correctly ruled-in or 
ruled-out) were considered as the measure of effect. This was estimated based on an incremental 
cost per correct diagnosis (see Equation 1). The decision on whether a correct diagnosis was made 
by a comparison with the 3-month wrist radiographs (assumed to be the reference). For instance, 
if both the initial MRI and the final 3-month radiographs showed no evidence of scaphoid fracture, 
then it was considered to be a correct diagnosis (in this case rule-out diagnosis). This clinical 
information was derived from the CRIS database, where all medical imaging reports are stored.  
Equation 1. Estimate of the cost difference per correct scaphoid diagnosis. 
∆𝑐𝑜𝑠𝑡 𝑝𝑒𝑟 𝑐𝑜𝑟𝑟𝑒𝑐𝑡 𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠 =
𝑡𝑜𝑡𝑎𝑙 𝑑𝑖𝑎𝑔. 𝑐𝑜𝑠𝑡𝑠 𝑀𝑅𝐼 𝑔𝑟𝑜𝑢𝑝 − 𝑡𝑜𝑡𝑎𝑙 𝑑𝑖𝑎𝑔. 𝑐𝑜𝑠𝑡𝑠 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝑔𝑟𝑜𝑢𝑝
𝑡𝑜𝑡𝑎𝑙 𝑜𝑓 𝑐𝑜𝑟𝑟𝑒𝑐𝑡 𝑑𝑖𝑎𝑔. 𝑀𝑅𝐼 𝑔𝑟𝑜𝑢𝑝 − 𝑡𝑜𝑡𝑎𝑙 𝑜𝑓 𝑐𝑜𝑟𝑟𝑒𝑐𝑡 𝑑𝑖𝑎𝑔. 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝑔𝑟𝑜𝑢𝑝
  
IV. To assess the overall patient satisfaction associated with the intervention group compared 
to the control group. 
This outcome was assessed via a participant 5-point Likert scale non-validated questionnaire three 
months post-recruitment.  
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V. To estimate the accuracy associated with the intervention (i.e. immediate wrist MRI) in the 
detection of scaphoid fracture compared to the control group. 
The accuracy of MRI or conventional radiograph during the ED episode was assessed by dividing 
the number of correct diagnoses (either true negative or true positive findings) by the total number 
of assessments (see Equation 2). The decision of whether a correct diagnosis was made by 
comparison against the 3-month wrist radiographs (assumed to be the reference).  
Equation 2. Estimate of the accuracy associated with a diagnostic test. 
𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 =
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑇𝑟𝑢𝑒 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠 + 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠
𝑡𝑜𝑡𝑎𝑙 𝑜𝑓 𝑎𝑠𝑒𝑠𝑠𝑚𝑒𝑛𝑡𝑠
 
VI. To estimate the mean time taken to reach a definitive diagnosis and the first major 
treatment decision in the intervention group compared to the control group. 
The mean time to reach a definitive diagnosis was measured in days as a result of combining 
different secondary care databases, particularly: (i) Symphony (ED), for the acute part of the 
pathway (i.e. during the initial episode); and (ii) Electronic Patient Record (EPR) and (iii) CRIS 
(Radiology database), for the non-acute part of the pathway. The time taken to reach a definitive 
diagnosis was considered to be when a scaphoid fracture was effectively ruled-out or ruled-in. For 
instance, if the immediate MRI correctly ruled-out a scaphoid fracture then that would be the time 
a definitive diagnosis was reached. In contrast, if the findings on the initial MRI were found to be 
inaccurate (e.g. subsequent imaging found a scaphoid fracture), the latter time point was 
considered to be the definitive diagnosis.  
The mean time spent in the ED in both groups was also evaluated. This variable was measured by 
combining information from different databases, particularly ED (software called Symphony) and 
radiology databases. This variable was relevant to plan operational changes and assess potential 
challenges associated with the acute provision of immediate MRI for these patients.  
VII. To estimate the mean time off work or informal care needs due to the suspected scaphoid 
fracture in the intervention group compared to the control group. 
Participants were asked to record the amount of time off work and informal care in a weekly 
scaphoid diary. These self-reported data were then used to evaluate potential differences between 
groups in terms of days off work and informal care and estimate potential implications from a 
societal perspective (as part of a secondary analysis).  
3.2.7 Statistical Analyses 
Analysis Population: 
All analyses were based on the principle of intention-to-treat (ITT), i.e. all participants were 
analysed as per the allocated group, regardless of whether they actually received the intended 
treatment, any protocol deviations or potential losses to follow-up (Gupta 2011). This is in contrast 
to a per-protocol analysis in which only participants that completed the study without any major 
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protocol deviations are included in the analysis (Gupta 2011; Ranganathan, Pramesh, and 
Aggarwal 2016). The ITT analysis reflected the pragmatic design of the SMaRT trial, aimed at 
accepting real-life clinical practice with its non-compliance and protocol deviations and is 
recommended by the International Society for Pharmacoeconomics and Outcomes Research 
(ISPOR) (Ramsey et al. 2005). Additionally, by not excluding non-compliers, statistical power was 
preserved. In summary, the ITT analysis aimed to minimise any potential analytical bias and was 
performed in accordance to the Consolidated Standards of Reporting Trials (CONSORT) checklist 
(Consort 2010). 
Data Cleaning and Data Validation: 
All baseline and follow-up data cleaning were performed prior to data analysis.  
Baseline data were captured via a paper-based Case Report Form (CRF) during the ED episode 
and then added to a web-based CRF. The web-based CRF, designed prior to the start of the trial, 
specified data edit checks (e.g. time of MRI scan prior to the time of randomisation), hence 
preventing major data issues. Furthermore, during this process, the PhD student screened the data 
looking for inconsistencies. In the presence of any potential data errors in the original hand-written 
data packs, participants or members of the research team were asked for clarification (e.g. date of 
birth and age do not match) and amendments were made to the original dataset (data editing). 
The NHS resource use considered in the primary outcome was derived from the merges of six 
different sources of information, grouped in two areas: (1) medical records; and (2) self-reported 
data from participants. These comprehensive data collection methods (detailed in subsection 3.2.6. 
Data collection and outcomes) included the validation of data using multiple datasets. Potential 
data errors or inconsistencies were automatically flagged and subsequently edited in the SMaRT 
trial database. For example, elective secondary care resource use was primarily evaluated using 
information from EPR. Data were then cross-referenced with other datasets, such as: PIMS; CRIS; 
and GP information (for other Hospitals than GSTT). Any data inconsistency was reviewed at by 
the student and edited in the main SMaRT trial database. 
Missing Data: 
Participants were not excluded from the analysis due to missing data, particularly data related to 
the primary outcome. In fact, only data from participants that withdrew the informed consent was 
not considered in the analyses. Data from primary care was considered to be missing completely 
at random as it related to the participant’s GP rather than any participant or disease-related event 
(Gray et al. 2011). Where data could not be retrieved (e.g. missing primary care data), mean values 
from the respective group were imputed. 
Baseline comparability of randomised groups: 
Continuous data were summarised by frequency, mean, standard deviation, minimum, first and 
third quartile, median and maximum. Tabulations of frequencies for categorical data were 
presented, as well as the percentage (%) relative to number of non-missing values within the 
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respective intervention group, unless otherwise specified. Numbers of missing values were 
reported for both continuous and categorical variables. 
The baseline variables described were: age; gender; previous scaphoid fracture (Yes/No); 
professional occupation; mechanism of injury; baseline EQ-5D-5L; and number of wrists with 
suspected scaphoid fracture (one/two; stratification variable). No significance testing was 
performed on the baseline variables between groups given the randomised design of the SMaRT 
trial (de Boer et al. 2015; Peacock, Kerry, and Balise 2017). 
Primary and secondary outcomes: statistical analyses 
Differences in mean outcomes between patients randomised to the control (no MRI) and the 
intervention (MRI) were analysed on an ITT approach. The cost analyses used generalised linear 
models (GLM) to model the outcome, using an appropriate distribution family. The option for a GLM 
with a gamma distribution to model the NHS costs was due to the non-negative and positively 
skewed distribution of costs, with a few patients responsible for very high costs. An identity link 
function instead of a log link was considered in order to avoid potential biases (Polgreen and Brooks 
2012). GLM was used to model the mean cost directly rather than transformation methods 
(Peacock, Kerry, and Balise 2017). In addition, bootstrap models were considered for the analysis 
(Gray et al. 2011) and compared against the GLM analysis. Gray et al. (2011) recommends the 
use of both GLMs and bootstrapping techniques for dealing with skewed cost data. Group 
difference estimates and associated confidence intervals were reported, together with p-values.  
Given the short time period (<1 year) associated with the management of suspected or confirmed 
scaphoid fractures, it was not deemed appropriate to consider discounting of either costs or effects. 
Primary Outcome 
The primary outcome of 3-month cost data were analysed using a GLM, with the following 
predictors used in the model: 
 Randomisation group (intervention group/control group [main predictor]); 
 Number of wrists with suspected fractures (one/two [stratification variable]).  
Secondary Outcomes 
Other cost analyses were conducted using a GLM and bootstrap analyses using the intervention 
group as predictor. Cost-effectiveness analyses at 3 and 6 months were performed using bootstrap 
models using pain scores and QALYs as the measures of effect. If utility data were missing, multiple 
imputation methods were used based on the assumption that the data were missing at random. 
Missing data were imputed using ‘multiple imputation using chained equations’ (MICE), with the 
number of multiply imputed datasets to be equal to the fraction of incomplete service-use 
information (White, Royston, and Wood 2011). 1000-replicate bootstrap analyses showing 
difference in costs and outcomes were presented on cost-effectiveness planes. Cost-effectiveness 
acceptability curves showing the probability that intervention was more cost-effective than control 
101 
 
at varying thresholds of willingness to pay were presented. All analyses were performed using the 
software Stata 15.0 for Windows (StataCorp LLC, Lakeway Drive,Texas). 
NHS resource use was also evaluated. Depending on the normality assessment using the Shapiro-
Wilk test, the use of independent t-test or Mann-Whitney U tests were used to test for differences 
in mean utilisation between groups.  
Differences in clinical findings between the two groups were, given the dichotomous nature of the 
variable (presence/absence of injury), evaluated using the Pearson Chi-square statistical test.  
Patient satisfaction in both groups was assessed based on a 3-month non-validated patient 
satisfaction questionnaire (5-point Likert scale). The use of Chi-square test was used to test the 
hypothesis that there was no differences between groups. 
The time elapsed in the ED and time taken to reach a definitive diagnosis and time taken off work 
and informal care in each group was also evaluated. In both variables, depending on the normality 
assessment using the Shapiro-Wilk test, the use of independent t-test or Mann-Whitney U tests 
were used to test for differences between groups.  
Sensitivity Analyses 
Several deterministic sensitivity analyses around key model parameters were performed. The NHS 
resource use was retrieved from the trial but the unit cost valuation was based on national data 
(e.g. NHS reference costs) or, if not feasible, unit costs from the GSTT’s perspective or 
assumptions. Given potential impact on the trial’s primary outcome, the following unit costs were 
subjected to deterministic sensitivity analyses: (i) immediate wrist MRI in the ED; (ii) fracture clinic 
appointments (both first and follow-up outpatient appointments); (iii) the ‘Did not attend’ and 
interrupted MRI events; (iv) all events using existing reimbursement strategies as a proxy of cost. 
Finally, an additional cost analysis took a broader societal perspective of analysis. 
3.3 Results 
3.3.1 Data Validation and Completeness 
Baseline data were 100% complete, with the exception of data related to the ED timeline (e.g. time 
of MRI scan). In the latter case, missing data were retrospectively collected via secondary care 
databases (ED Symphony and CRIS). These data were used to estimate one of the secondary 
outcomes, time taken to reach a definitive diagnosis or time elapsed in the ED. 
Follow-up data were captured by combining data from primary and secondary care databases and 
self-reported data from participants. Data from secondary care databases were 100% complete. 
Data from primary care databases were 98.5% complete (n=130) and self-reported data were 55% 
(n=72) and 53% (n=70) complete at 3 and 6 months post-recruitment, respectively. In the absence 
of data from both the primary care databases and self-reported data, any resource use outside 
GSTT was missing. Missing values for primary care utilisation were imputed using the mean values 
from the respective group. However, this imputation was unlikely to impact the results given: (i) the 
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completeness of data from primary and secondary care databases; and (ii) the low level of use of 
primary care resources. 
3.3.2 Participant Flow 
Participant flow associated with the SMaRT trial is illustrated in the CONSORT diagram (Figure 
34). 313 patients were assessed for eligibility over a 21 months period in the ED. Out of these, 
43.5% of patients were recruited (n=136) and the remaining 56.5% (n=177) were not recruited. For 
those not recruited, the reasons were as follows: 57.6% of participants did not want to participate 
(n=102), 29.4% of participants did not meet the inclusion criteria (n=52), 8.5% lived outside the 
catchment area and did not want to be followed-up at GSTT (n=15) and 4.5% had significant 






























Figure 34. Participant flow chart for the SMaRT trial. 
Assessed for eligibility (n=313) 
(n = …) 
Excluded (n = 177) 
  Did not want to participate   (n = 102) 
  Other reasons (n = 75) 
Not meeting inclusion criteria (n = 52) 
Living out of catchment area (n= 15) 
Language barrier (n=8) 
 
 
Randomised (n = 136) 
Allocated to control group – 
Standard care with x-ray only (n 
= 68) 
Received allocated intervention 
(n = 68) 
Did not receive allocated 










Allocated to intervention group – MRI group: 
MRI as add-on test  (n = 68) 
Received allocated intervention (n = 63) 
Did not receive allocated intervention (n = 5) 
Event of unforeseen claustrophobia (n = 2) 
MRI not available within 1 hour (n = 1) 
MRI not working (n = 1) 
Cochlear implant not mentioned during the 









Lost to follow up (n = 3)  
Participant withdrew consent (n=3)  
Lost to follow up (n = 1)  
Participant withdrew consent (n = 1)  
Analysed (n = 65) 
Excluded from analysis (n=0) 
Analysed (n = 67) 

















A total of 136 participants were equally randomised to the control group (standard care, n=68) and 
the intervention group (MRI group, n=68). One 100% (n=68) and 92.6% (n=63) of the participants 
randomised, respectively, to the control and intervention groups received the allocated treatment. 
Five participants randomised to the intervention group did not receive the allocated treatment for 
the following circumstances (see Figure 34): unforeseen claustrophobia (n = 2); MRI not available 
within 1 hour (n = 1); MRI not working (n = 1); and cochlear implant not mentioned during the initial 
screening (n = 1). 
With regards to the follow-up period, 4.4% (n=3) and 1.5% (n=1) of participants withdrew the 
informed consent in the control and intervention group, respectively, and were considered lost to 
follow-up. No further participants were lost to follow-up. All participants who did not withdraw their 
informed consent were included in the analysis, equivalent to 95.6% (n=65) and 98.5% (n=67) 
participants in the control and intervention groups, respectively.  
3.3.3 Participant Characteristics – Baseline 
Table 10 (for categorical variables) and Table 11 (for quantitative variables) summarise the 
baseline sociodemographic and baseline outcome variables by randomisation group. All 
participants, apart from four who withdrew consent, were included in the baseline analysis (n=132), 
distributed in the control group (n=65) and the intervention group (n=67). There were no missing 
data, apart from some observations in the ‘mechanism of injury’ variable (detailed below). No 
significance testing between groups was performed given the trial’s randomised design. 
Categorical data: 
Table 10 describes the participant’s characteristics (gender and employment status) and the wrist 
injury (previous scaphoid injury, mechanism of injury, dominant hand and arm injured) organised 
by randomisation group.  
The majority of participants were male, both in the control group (52%) and the intervention group 
(61%). With regards to employment status, the majority of participants were employed full-time 
(over three quarters in both groups), employed in a part-time job (9% and 3% in the control and 
intervention group, respectively) or self-employed (3% and 6% in the control and intervention 
group, respectively). 
The majority of participants (85% and 84% in the control and intervention group, respectively) had 
no previous scaphoid injury. With regards to the current scaphoid injury, 55% of the participants 
identified falling on an outstretched hand as the mechanism of injury. The majority of participants 
were right-handed (89% and 93% in the control and intervention group, respectively). The arm 
injured during the present episode was predominantly the left arm in the control group (51%) 
compared to the right arm in the intervention group (57%). Only three participants in the control 





The average age (SD) of participants was 36.2 (12.6) and 38.2 (13.4) years in the control and 
intervention group, respectively (Table 11). 
When considering the utility at baseline, as measured using the questionnaire EQ-5D-5L, the mean 
utility value (SD) was 0.786 (0.158) and 0.822 (0.139) for the control and intervention group, 
respectively. Similarly, when considering the self-reported health score, participants in the 
intervention group scored higher, with a mean score (SD) of 78.7 (13.8) compared 72.1 (16.8) in 
the control group. It is relevant to note that the EQ-5D-5L questionnaire was applied prior to 
randomisation in order to avoid potential biases.  







N % N % 
Gender Male 34 52% 41 61% 
Employment 
Status 
Employee in full - time job (30 hours 
or more/week) 
51 78% 53 79% 
Employee in part - time job (under 
30 hours/week) 
6 9.2% 2 3.0% 
Self-employed, full or part - time 2 3.1% 4 6.0% 
Full - time education at school, 
college or university 
0 0.0% 3 4.5% 
Looking after the home 0 0.0% 1 1.5% 
Wholly retired from work 1 1.5% 1 1.5% 
Unemployed and available for work 3 4.6% 1 1.5% 
Permanently sick/ disabled 2 3.1% 1 1.5% 
Doing something else 0 0.0% 1 1.5% 
Previous 
Scaphoid Injury 
Yes 10 15% 11 16% 
Mechanism of 
Injury 
Fall on an outstretched hand 36 55% 37 55% 
Other injury 29 45% 30 45% 
Dominant hand 
Left 7 11% 5 7.5% 
Right 58 89% 62 93% 
Arm Injured 
Left 33 51% 27 40% 
Right 31 48% 38 57% 
Both 1 1.5% 2 3.0% 
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Table 11. Descriptive statistics of the three numerical variables at baseline per randomisation group: age; utility at baseline; and overall visual analogue score 
(VAS) at baseline (estimated from EQ-5D-5L questionnaire). 
 
 










Control 65 36.2 12.6 18.0 27.0 32.0 42.0 73.0 
MRI 67 38.2 13.4 20.0 27.0 36.0 46.0 71.0 
Utility at baseline 
Randomisation 
group 
Control 65 0.786 0.158 0.330 0.732 0.825 0.893 1.000 
MRI 67 0.822 0.139 0.273 0.747 0.837 0.927 1.000 
Visual analogue 
score at baseline 
Randomisation 
group 
Control 65 72.1 16.8 30.0 60.0 75.0 85.0 100.0 
MRI 67 78.7 13.8 40.0 70.0 80.0 90.0 100.0 
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3.3.4 Clinical findings 
All recruited participants had negative findings on the initial scaphoid radiographs. Nonetheless, 
given its limited ability to rule-out fractures on presentation, potential injuries, such as scaphoid or 
other bone fractures, might subsequently be diagnosed a few days or weeks further down the line.  
Scaphoid fractures: 
A total of 11 (8.3%) scaphoid fractures were diagnosed, with 7 (10.4%) in the intervention group 
(i.e. MRI group) and 4 (6.2%) in the control group. Table 12 expands on the type of scaphoid injury 
and the time of diagnosis for each injury. For the intervention group, all fractures were detected on 
presentation to the ED, whilst for the control group, scaphoid fractures were detected from 8 to 48 
days after presentation to the ED. One participant in each group underwent surgical treatment for 
confirmed scaphoid fractures. Figure 35 illustrates three views from the immediate MRI performed 
in the ED where a scaphoid waist fracture is visible (despite the initial negative radiographs). 
Given the dichotomous variable, the Pearson Chi-square statistical test was used. The differences 
in the proportion of scaphoid fractures between the two groups were not deemed statistical 
significant (p=0.372).  
Table 12. Number and type of scaphoid fractures diagnosed in both groups. 
 Scaphoid fractures 
 Control group (n=65) Intervention group (n=67) 
1. 
Subtle undisplaced 
fracture line noted on 
one view around the 
waist of the scaphoid.  
Found on repeated 
x-ray 8 days after ED 
visit 
Trabecular scaphoid and undisplaced 
distal pole fractures. 
2. 
Undisplaced or very 
minimally displaced 
fracture of the proximal 
pole of the scaphoid. 
Found on MRI 
48 days after ED visit 
Undisplaced fracture through the waist of 
the scaphoid 
3. 
Undisplaced fracture of 
the scaphoid waist 
Found on MRI 
9 days after ED visit 
Incomplete scaphoid fracture. 
4. 
Closed fracture of the 
scaphoid waist. 
Found on repeated 
x-ray 13 days after 
ED visit  
Scaphoid tubercle fracture. 
5. 
 Impaction fracture of the radial cortex of 
the scaphoid, though no evidence of 
scaphoid waist displacement. 
6. 
Impaction fracture of the scaphoid 
tubercle with no evidence of 
displacement. 
7. 





Figure 35. Imaging of patient with fracture of the scaphoid waist showing the abbreviated MRI: (a) 
coronal T1; (b) coronal PDFS; and (c) sagittal STIR views. 
Other fractures: 
Similarly to the scaphoid bone, other bone injuries might be present despite the negative findings 
in the initial radiographs. These injuries could lead to participants re-presenting to secondary care 
or being diagnosed as part of the follow-up procedures. 
A total of 20 (15.2%) other bone fractures (besides scaphoid fractures) were diagnosed, with 15 
(22.4%) in the intervention group and 5 (7.7%) in the control group. Table 13 expands on the type 
of injury and time of diagnosis for each group. All other bone fractures in the intervention group 
(MRI group) were detected on presentation to the ED except a fracture of the hook of the hamate 
was found on CT 116 days after the ED visit. In the control group, all five fractures were diagnosed 
from 8-12 days after the ED presentation.  
Given the dichotomous variable, the Pearson Chi-square statistical test was again used. The 
differences in the proportion of non-scaphoid fractures between the two groups were statistically 
significant (p=0.019), with the MRI group presenting a higher proportion. 
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Table 13. Number and type of other bone fractures (besides the scaphoid) diagnosed by groups. 
 Other bone fractures 
 Control group (n=65) Intervention group (n=67) 
1. Right radial styloid fracture 
Found on 
repeated x-ray 9 
days after ED visit 
Undisplaced distal radial fracture. 
2. 
Distal radial fracture with 
no displacement. 
Found on CT 12 
days after ED visit 
Undisplaced triquetrum fracture (with 
partial lunotriquetral ligament tear)* 
3. 
Extra-articular undisplaced 
distal radius fracture. 
Found on 
repeated x-ray 8 
days after ED visit 
Impaction fracture of the proximal 




fracture and contusion of 
the pisiform and trapezium 
(from the MRI) 
Found on MRI 8 
days after ED visit 
Distal radial fracture with minimal 
displacement. 
5. 
Undisplaced fracture of 
the distal radius  
Found on MRI 11 
days after ED visit 
Cortical disruption of the articular 
surface of the distal radius. 
6. 
 
Undisplaced fracture of the distal radius 
with minor intraarticular extension, 
involving the radial styloid. 
7. Undisplaced distal radial fracture.  
8. 
Fracture of the hook of the hamate 
(found on CT 116 days after ED visit) 
9. 
Subtle base of fifth metacarpal intra-
articular fracture with no displacement. 
10. Fracture of the distal radius 
11. 
Undisplaced intra-articular distal radial 
fracture and nondisplaced transverse 
trabecular fracture of the base of the 
fifth metacarpal 
12. Closed fracture of the capitate 
13. Pisiform fracture 
14. 
Nondisplaced trabecular fracture of the 
lunate with TFCC injury. * 
15. 
Undisplaced fracture of the distal 
radius. 
* patients with concomitant soft tissue injuries also included in Table 14.
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Soft tissue injuries: 
Finally, major soft tissue injuries can also occur (e.g. ligament rupture). A total of 5 (3.8%) major 
soft tissue injuries were diagnosed, with 4 (6.0%) in the intervention group and 1 (1.5%) in the 
control group. Table 14 expands on the type of wrist injury diagnosed in each arm. It is important 
to note that minor soft tissue injuries (e.g. tissue oedema) were not included in this analysis. 
A participant in the control group underwent two surgeries in order to treat a complete scapholunate 
ligament rupture. Two of the patients in the intervention group in Table 14 with reported soft tissue 
injuries also had bone injuries and were therefore included in Table 13, meaning that 17 patients 
in the intervention group had injuries detected other than scaphoid fractures (Figure 36). 
The differences in the proportion of other soft tissue detected injuries between the two groups 
showed a trend of statistical significance (p =0.102).  
Table 14. Number and type of soft tissue / ligamentous injuries diagnosed in both groups. 
 Soft tissue injuries 
 Control group (n=65) Intervention group (n=67) 
1. 
Complete scapholunate ligament 
injury/rupture (11 days after ED visit) 
Undisplaced triquetrum fracture (with partial 
lunotriquetral ligament tear)* 
2. 
 Partial tear of the ulnar and dorsal ulnolunate 
ligament at the dorsal edge of the TFCC. Partial 
TFCC tear and sprain. 
4. 
 Ulnar TFCC tear with a joint effusion extending to 
the DRUJ and detachment at the meniscocapsular 
homologue, foveal and ulnar styloid attachments. 
Probable ECU tendonosis. 
5. 
 TFCC tear (with undisplaced trabecular fracture of 
the lunate)* 
* patients with concomitant soft tissue injuries also appear in Table 13. 
Normal findings: 
A total of 43 participants (64.2%) randomised to the intervention group had normal findings in the 
initial wrist MRI (Figure 36). In the control group, as part of the inclusion criteria, all participants 
had negative findings in the initial conventional radiograph. Out of the 65 participants randomised 
to the control group, 55 (84.6%) were subsequently found to have normal findings during the 
diagnostic pathway (including the final 3-month X-ray). 
Summary of clinical findings: 
Figure 36 summarises the key clinical findings organised per randomisation group. As detailed in 
the previous subsections, the intervention group was associated with a higher number of clinically 




Figure 36. Distribution of clinical findings grouped per randomisation group. 
3.3.5 Primary Outcome 
Primary Outcome: 
The primary outcome was to estimate the 3-month costs associated with both groups. For this 
purpose, all participants were followed-up for a period of three months to capture all relevant NHS 
resources used in the management of the suspected scaphoid fracture. This included both primary 
and secondary care resources. 
Table 15 summarises the mean number of NHS events per participant for both arms. A mean of 
6.8 and 5.7 NHS episodes were performed in the control (n=65) and intervention groups (n=67) 
(p=0.105), respectively. With regards to primary care contacts, the control group attended a higher 
number of appointments with the difference between groups being statistically significant (p=0.02). 
If all secondary care contacts are considered, the control group presented a slightly higher 
utilisation but this was not statistically significant (p=0.189). 
Table 15. Mean (SD) NHS events per participant per type of healthcare provider for both groups. 




Control group 65 0.59 1.43 
Intervention group 67 0.18 0.63 
Secondary care 
Control group 65 6.25 3.72 
Intervention group 67 5.48 3.01 
Total NHS contacts 
Control group 65 6.83 4.37 
Intervention group 67 5.66 3.11 
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Table 16 details the utilisation of NHS resources per type of event, both for primary and secondary 
care, and organised per randomisation group.  
Table 16. Breakdown of NHS resource use per type of activity by group.  
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The control group presents a higher number of appointments for all primary care, with the 
intervention group reporting a statistically significant lower number of GP face-to-face 
appointments (mean 0.12 vs 0.35, p=0.050). 
In relation to secondary care, both groups had similar number of visits to the ED (p=0.827) and, 
when considering elective appointments, the intervention group had significantly fewer fracture 
clinic appointments, both first appointments (mean 0.48 vs 0.94, p<0.001) and follow-up 
appointments (mean 0.34 vs 0.75, p=0.022). Similar to outpatient appointments, the utilisation of 
radiographs was lower in the intervention group (mean 0.28 vs 1.05, p<0.001). The difference in 
terms of the use of advanced imaging after the initial acute episode was also evaluated. The 
intervention group was associated with a lower utilisation of advanced imaging following ED 
presentation, both for CT (mean 0.09 vs 0.20, p=0.072) and MRI scans (mean 0.0 vs 0.26, p<0.001) 
(Table 16). 
Figure 37 illustrates the high-level follow-up pathway per participant for both randomisation groups. 
Out of patients randomised to the control group, only a small proportion of 7.7% participants (n=5) 
had no formal secondary care follow-up. These were participants that either left the ED prior to 
having a formal Fracture Clinic appointment or did not attend (DNA) secondary care appointments. 
In contrast, 52% (n=35) of participants in the intervention group had negative MRI findings and 
hence no secondary care follow-up.  
Almost 90% (n=58) of participants in the control group had formal follow-up at secondary care with 
imaging follow-up, either with radiographs only (49%) or advanced imaging (40%). This 90% figure 
contrasted with a secondary follow-up of 46% (n=31) in the intervention group. Out of these 31 
intervention group participants, 87% (n=27) of the imaging follow-up was based on radiographs 
only. Four participants (6.0%) had subsequent follow-up with CT as a secondary imaging technique 
to further analyse bone displacement visualised on the initial MRI exam. 
 
Figure 37. High-level follow-up pathway per participants in both randomisation groups. 
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Table 17 summarises the 3-month cost distribution (mean, standard deviation, minimum, median, 
percentiles 25 and 75 and maximum) per randomisation group. As previously detailed, these costs 
were estimated based on the unit costs (see Table 9) multiplied by the NHS resource use (see 
Table 16). The mean cost of management per participant [mean (SD)] was higher in the control 
group compared to the intervention group [£542.40 (£855.20) vs £368.40 (£338.60)], leading to a 
mean cost difference between groups of £174 per participant. Secondary care costs accounted for 
91.4% and 96.8% of the total mean costs of management in the control and intervention groups, 
respectively. 
As expected with cost variables, the cost distribution is positively skewed (mean >> median), as it 
is affected by a small proportion of patients that have significantly higher costs (maximum cost of 
£7,116 and £2,691 for the control and intervention group, respectively). This is summarised in 
Table 17 and illustrated in the histograms in Figure 38 and Figure 39.  
Table 17. Descriptive statistics of the three month costs associated with the control (n=65) and 
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 Control £542.40 £855.20 £94.00 £259.00 £457.00 £601.00 £7,116.00 




Figure 39. Histogram for the 3-month cost distribution for the intervention group (MRI group).  
Taking into consideration the anticipated data skewness, the statistical analysis plan used: (i) GLM 
to model the 3-month cost analysis used outcome, using an appropriate distribution family, the 
Gamma family and identity link; and (ii) bootstrap analysis.  
The a priori Statistical Analysis Plan (SAP) considered the number of wrists with suspected 
scaphoid fractures as a stratification variable. However, due to the fact that only 3 participants had 
injured both wrists (2 in the intervention arm and 1 in the control arm) it was not feasible to use this 
as a stratification variable for the primary outcome.  
(i) Generalised Linear Model (GLM) 
The results from the GLM analysis (Gamma family and identity link function) for the primary 
outcome (3-month cost analysis) are detailed in Table 18.  











95% CI p-value 
  
Total cost at 
3 months 
  
542 (855) 368 (339) -174 -378 to 30 0.094 
 
The mean cost difference per participant between both groups was -£174 (CI 95%: - £378 to £30, 
p=0.094). Hence, at 3 months, no statistically significant difference between the two groups was 
estimated (assuming a p-value of 0.05 as statistical significance). 
Additionally, a diagnostic cost was also estimated for both groups. This diagnostic cost includes all 
NHS costs incurred up to the moment of definitive diagnosis, but exclude any treatment costs, 
particularly surgical procedures costs. The mean diagnostic cost difference between both groups 
was estimated at £113 per participant (CI 95%: - £188 to - £39) (Table 19). The 3-month diagnostic 
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454 (242)  341 (187)  -113  -188 to -39  0.003 
(ii) Bootstrap analysis 
A 1000-replicate bootstrap analysis for the variable total 3 month costs was also performed, 
grouped by randomisation group. The 95% confidence interval for three types of bootstraps 
(normal, percentile and bias-corrected) are presented in Table 20. As with the GLM, the same 
mean difference cost per participant is obtained (- £174) but the 95% confidence intervals varied 
according to the type of bootstrap analysis considered: normal (CI 95%: - £400 to £52); percentile 
(CI 95%: - £428 to £12); and bias-corrected (CI 95%: - £453 to -£8). Only the bias-corrected 
bootstrap analysis showed a statistically significant cost difference per participant (the value 0 is 
not included in the 95% CI). The use of bias-corrected bootstrap analysis is the most appropriate 
to assess skewed cost data (Jiang and Zhou 2004). 
Table 20. Bootstrap analysis for the variable total cost at 3 months (1,000 replicates). 
Variable Reps Observed Bias Std. Err. [95% Conf. Interval] 
Randomisation 
Group 
1000 -£174.07 -1.329021 115.13 
-£400.00 £51.86 (N) 
-£428.49 £11.76 (P) 
-£453.33 -£7.58 (BC) 
Note: N=normal; P=percentile; BC=bias-corrected 
3.3.6 Secondary Outcomes 
I. To perform a cost analysis at 6 months associated with two clinical pathways in the Emergency 
Department (ED).  
(i) Generalised Linear Model (GLM) 
The first secondary outcome considered the time extension of the original cost analysis up to 6 
months following the initial ED episode. Table 21 summarises the 6-month cost distribution per 
randomisation group. The mean cost management per participant (SD) was higher in the control 
group compared to the intervention group [£660.90 (£1,188.80) vs £395.20 (£344.80)].  
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Table 21. Descriptive statistics of the six month costs associated with the control (n=65) and 












Control £660.90 £1,188.80 £94.00 £284.00 £457.00 £666.00 £7,332.00 
Intervention £395.20 £344.80 £166.00 £166.00 £331.00 £491.00 £2,691.00 
The GLM analysis (Gamma family and identity link function) for the primary outcome (6-month cost 
analysis) is detailed below (Table 22).  











95% CI p-value 
  
Total cost at 
6 months 
  
661 (1,189)  395 (345)  -266  -528 to -3.3  0.047 
As with the 3-month cost analysis, the intervention was associated with lower overall cost, with a 
mean cost difference per participant between groups of £266 (CI 95%: - £528.1 to - £3.3, p= 0.047). 
Hence, at 6 months, the cost difference between the two groups was statistically significant.  
(ii) Bootstrap analysis 
As with the primary outcome, a 1000-replicate bootstrap analysis for the variable total 6 month 
costs was also performed, grouped by randomisation group. The 95% confidence intervals for three 
types of bootstraps (normal, percentile and bias-corrected) are presented in Table 23. As with the 
GLM, the same mean difference cost per participant was estimated (-£266) but the 95% confidence 
intervals varied as per the type of bootstrap analysis: normal (CI 95%: - £558 to £27); percentile 
(CI 95%: - £580 to -£9); and bias-corrected (CI 95%: - £635 to -£29). Both the percentile and bias-
corrected bootstrap analyses showed a statistically significant cost difference per participant (the 
value 0 is not included in the 95% CI). 
Table 23. Bootstrap analysis for the variable total cost at 6 months (1,000 replicates). 
Variable Reps Observed Bias Std. Err. [95% Conf. Interval] 
Randomisation 
Group 
1000 -£265.68 7.276311 148.99 
-£558.05 £26.69 (N) 
-£580.13 -£-9.33 (P) 
-£635.49 -£28.61 (BC) 
Note: N=normal; P=percentile; BC=bias-corrected 
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Outcome II. To perform a cost-effectiveness analyses at 3 and 6-months to estimate the ICER 
associated with the proposed intervention using QALYs and pain score as the measure of effect. 
QALY as the measure of effect: Table 24 summarises the key descriptive statistics (mean, SD, 
minimum, percentile 25, median, percentile 75, maximum) associated with the utilities and 
healthcare scores (visual analogue scores), derived from the standardised questionnaire EQ-5D-
5L, at four points in time (baseline, month 1, 3 and 6).  
The mean utility values at baseline (SD) for the control and intervention group were, respectively, 
0.786 (0.158) and 0.822 (0.139) (p=0.166). EQ-5D-5L data completeness decreased during the 
follow-up period, with 60% and 58% of data being complete at month 3 and 6 post-recruitment, 
respectively (see Table 24). The mean utility values at both 3 and 6 months post-recruitment were 
lower in the control group compared to the control group [mean utility at month 3 of 0.924 vs 0.843 
(p=0.089) and mean utility at month 6 of 0.950 vs 0.843 (p=0.019)]. Potential imbalances between 
utilities at baseline need to be taken into account as these were likely to be correlated with the 
utilities over the follow-up period (Manca, Hawkins and Sculpher 2005). 
Table 24. Descriptive statistics for the utility and VAS at baseline and months 1, 3 and 6.  
   Mean 
Standard 
Deviation 










Control (n=65) .786 .158 .330 .825 1.000 
Intervention (n=67) .822 .139 .273 .837 1.000 
VAS 
Control (n=65) 72.1 16.8 30.0 75.0 100.0 









Control (n=42) .747 .238 .073 .825 1.000 
Intervention (n=50) .854 .105 .518 .869 1.000 
VAS 
Control (n=42) 75.6 17.9 25.0 80.0 95.0 









Control (n=36) .843 .227 -.076 .893 1.000 
Intervention (n=46) .924 .077 .743 .942 1.000 
VAS 
Control (n=36) 82.5 16.5 30.0 88.0 100.0 









Control (n=33) .843 .211 -.076 .893 1.000 
Intervention (n=44) .950 .068 .709 1.000 1.000 
VAS 
Control (n=33) 84.6 9.9 65.0 85.5 100.0 
Intervention (n=44) 89.7 7.4 65.0 90.0 100.0 
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In order to adjust for imbalances in the mean baseline utilities, a multiple regression analysis was 
conducted as suggested by Manca, Hawkins, and Sculpher (2005) and detailed below in Equation 
3.  
Equation 3. Multiple regression analysis with adjustment for baseline utility imbalances. 
UtilityI = β0 + β1 . tI + β2 . Qib , 
where the index i is the participant identifier (i =1, 2,..., 136)., ti  is the treatment identifier (0= control; 
1=intervention) and  Qib  is the participant-specific baseline utility value (Manca, Hawkins and 
Sculpher 2005). 
3-month cost-effectiveness analysis: 
Table 25 summarises the output from the multiple regression analysis for the variable utility at 
month 3 adjusted by randomisation group and utility at baseline. Equation 4 summarises the trial-
specific regression analysis in the estimate of the utility at month 3 adjusted by the randomisation 
group and utility at baseline. 
Table 25. Summary of the regression analysis for utility at month 3 adjusted by two variables: 
randomisation group and baseline utility.  
Utility month3 Coef. Std. Err. t P>|t| [95% Conf. Interval] 
Group .0299768 .0382367 0.78 0.436 -.0465346 .1064882 
Baseline utility .4731861 .1159595 4.08 0.000 .2411516 .7052206 
Constant .4655077 .0991758 4.69 0.000 .2670573 .663958 
Number of observations = 70; R-squared = 0.2581; Adjusted R-squared = 0.2329 
Equation 4. Multiple regression analysis for the utility and month 3 adjusted per randomisation 
group and utility baseline. 
Utility at month 3 = 0.4655077 + 0.0299768 * Rand. Group + 0.4731861 * Utility at baseline 
Note: Rand. group (0 = control group; 1 = intervention group). 
Based on Equation 4, for every unit increase in utility at baseline, a 0.473 increase in the utility at 
month 3 was estimated. Hence, based on the adjusted multiple regression, the utility difference 
between groups at month 3 is estimated at 0.0299768 (95% CI -0.0465346 to 0.1064882). Given 
the 3-month period considered, and assuming a linear interpolation, it is equivalent to a QALY 
differential of 0.0075 (95% CI -0.0116 to 0.0266). This compared with a differential utility of 0.0724 
(95% CI -0.0102 to 0.15505) in the case where no adjustment for baseline utility was considered. 
The comparison between adjusted R-squared values (0.2329 vs 0.0328) for each model indicated 
that the adjusted model considering the utility at baseline better estimated the utility at month 3. 
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Cost-effectiveness was estimated based on incremental costs divided by incremental effects, in 
this case measured in QALYs. The mean cost per QALY at month 3 (Equation 5) was estimated 
at -£8,295. The intervention was dominant as it generated a higher number of QALYs at a lower 
cost.  
Equation 5. Estimate of the incremental cost per QALY at month 3. 
𝐼𝐶𝐸𝑅 =
𝐶𝑜𝑠𝑡 𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 − 𝐶𝑜𝑠𝑡 𝑐𝑜𝑛𝑡𝑟𝑜𝑙








Figure 40 illustrates the bootstrap analysis with 1,000 replicates, based on the 3-month cost per 
QALY. At month 3, the intervention with MRI had a probability of 92.3% of being dominant (i.e. 
increased QALYs at a lower cost) compared to the control group. In the obverse quadrant, there 
was a 0.0% probability of the MRI intervention being dominated (i.e. lower QALYs at a higher cost) 
by standard care (i.e. control group). The remaining 7.7% of bootstraps were in the cost-
effectiveness analysis quadrants, where the probability of being cost-effective also depends on the 
overall system willingness-to-pay for each QALY.  
 
Figure 40. Cost-effectiveness plane associated with the 3-month cost per QALY analysis and 
probability associated each quadrant (bootstrap analysis with 1,000 replicates). 
Using a £20,000 and £30,000 willingness-to-pay per QALY (thresholds typically considered by 
NICE) (McCabe, Claxton, and Culyer 2008), there was a 96.0% and 96.4% probability of MRI being 




Figure 41. Cost-effectiveness acceptability curve for several thresholds of willingness-for-pay 
(represented as at λ).  
EQ-5D-5L data completeness decreased during the follow-up period, with 60% of the data being 
complete at month 3 post-recruitment (Table 24). The utilisation of multiple imputation methods for 
missing utility data at months 1 and 3 did not affect the cost-utility analysis, with the intervention 
with MRI estimated at 95.5% and 96.2% probability of being cost-effective (£20,000 - £ 30,000 per 
QALY). 
6-month cost-effectiveness analysis: 
Table 26 summarises the output from the multiple regression analysis for the variable utility at 
month 6 adjusted by randomisation group and utility at baseline. 
Table 26. Summary of the regression analysis for utility at month 6 adjusted by two variables: 
randomisation group; and utility baseline.  
Utility month 6 Coef. Std. Err. t P>|t| [95% Conf. Interval] 
Group .0278441   .02827   0.98 0.332 -.0298131 .0855012 
Baseline utility .0072316 .0687779 0.11 0.917 -.1330419 .1475051 
Constant .906974 .0609558 14.88 0.000   .7826539 1.031294 
The mean cost per QALY at month 6 (Equation 6) was estimated at -£4,687. Again, the intervention 
was dominant as it generated a higher number of QALYs at a lower cost.  
Equation 6. Estimate of the incremental cost per QALY at month 6. 
𝐼𝐶𝐸𝑅 =
𝐶𝑜𝑠𝑡 𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 − 𝐶𝑜𝑠𝑡 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
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Figure 42 illustrates the bootstrap analysis with 1,000 replicates, based on the 6-month cost per 
QALY. At month 6, the intervention with MRI had a probability of 98.3% of being dominant and 
0.0% of being dominated by the control group. The remaining 1.7% of bootstraps were in the cost-
effectiveness analysis quadrants, i.e. the probability of being cost-effective also depends on the 
overall system willingness-to-pay for each QALY. Using a £20,000 and £30,000 willingness-to-pay 
per QALY (thresholds typically considered by NICE), there was a 100% probability of MRI being 
cost-effective at month 6 in both scenarios.  
 
Figure 42. Probability associated with a participant being in a specific cost-effectiveness 
plane quadrant (1,000 bootstraps bootstrap analysis). 
EQ-5D-5L data at 6 months were 58% complete (Table 24). The utilisation of multiple imputation 
methods for missing utility data at months 1, 3 and 6 did not affect the cost-utility analysis, with the 
intervention with MRI presenting a 99.95% and 99.97% probability of being cost-effective (£20,000 
- £30,000 per QALY). 
Pain score as the measure of effect: 
A second cost-effectiveness analysis was based on self-reported pain scores as the measure of 
effect. The pain scores were based on a scale of 0-10, with 0 representing no pain at all and 10 
the worst pain ever. The mean (SD) pain scores over a period of 3 months in the control and 
intervention group were, respectively, 3.61 (2.58) and 2.63 (1.59). The difference between groups 
approached statistical significance (p=0.074) (Table 27). 
Adopt 









Table 27. Mean (SD) pain scores for participants in both randomisation groups.  
Randomisation group Mean pain score Standard Deviation 
Control group (n=22) 3.61 2.58 
Intervention group (n=38) 2.63 1.59 
The ICER using the incremental pain score as the measure of effect at month 3 indicated that the 
MRI intervention dominated the control group (ICER = £178 per pain score avoided), achieving 
better pain outcomes at a lower cost.  
Outcome III. To estimate the mean cost per correctly diagnosed scaphoid fracture using MRI for 
patients with suspected scaphoid fracture and initial negative findings on conventional radiograph 
(with standard care as the comparator). 
The mean cost per correctly diagnosed scaphoid fracture was estimated for both groups. This 
estimate included all diagnostic costs divided by the number of episodes where the correct 
diagnosis was achieved in the initial radiographs or MRI using the final 3-month radiographs as the 
reference. For instance, in the control group, if a scaphoid fracture was not seen in the follow-up 
period (including the final 3-month radiographs), then it was deemed that a correct diagnosis was 
reached on the initial x-ray. The same principle was applied to the intervention group. 
The total and mean diagnostic costs for the control group were, respectively, £29,490 and £454. 
Out of 65 participants, a total of four scaphoid fractures were detected in the control group despite 
the initial negative x-ray. Hence, the correct diagnosis was achieved in 61 participants, leading to 
a mean cost per correct scaphoid fracture of £483. 
The total and mean diagnostic costs for the intervention group were, respectively, £22,815 and 
£341. Out of 67 participants, no scaphoid fracture was diagnosed after the initial MRI exam. Hence, 
the mean cost per correct scaphoid fracture was estimated at £341. This is equivalent to a 30% 
reduction in the cost per correct scaphoid fracture compared to the control group (£341 vs £483).  
If other fractures (e.g. radial or capitate bone) were also included, the number of correct diagnosed 
fractures in the control and intervention group were, respectively, 56 (5 non-scaphoid fractures 
diagnosed during the follow-up period) and 66 (1 non-scaphoid fracture – fracture of the hook of 
the hamate). Therefore, a mean cost per correctly diagnosed fractures were estimated at £526 and 
£346 for the control and intervention group, respectively. This is equivalent to a 34% reduction of 





Outcome IV. To assess overall patient satisfaction associated with the proposed pathway in 
comparison to the current pathway. 
Patient satisfaction was evaluated at month 3 post-recruitment and included three areas: (a) acute 
management of the suspected scaphoid fracture (immediately after recruitment) (Table 28); (b) 
elective management of the clinical condition (diagnostic and treatment pathway) (Table 29); and 
(c) participation in the research study (Table 30). 
A higher proportion of participants in the intervention group were very satisfied with the ED episode 
compared to the control group (Table 28). Although both groups reported similar satisfaction levels 
regarding the overall ED visit (p=0.867), the intervention group was associated with a trend of 
better satisfaction levels regarding: how the injury was explained (question 1.1., p=0.088); the 
information received about the tests (question 1.2., p=0.075); and the information received about 
the test results (question 1.3, p=0.154). Following the discharge from the ED, participants in the 
intervention group reported trends of superior satisfaction levels concerning: the written information 
about their clinical condition (p=0.08).  
With regards to the elective management of the suspected scaphoid fracture (Table 29), a higher 
proportion of participants in the intervention group compared to the control group were either very 
satisfied or satisfied (91.4% vs 80.0%) with the overall journey in the outpatient department. 
However, differences between groups were not statistically significant (p=0.482). The intervention 
was associated with improved trends of information received about any test result (p=0.114).  
Participants were also asked about their experience in taking part in research (Table 30). There 
were no statistically significant differences between the groups when assessing different research 
components, particularly: information about the study explained to the participant (p=0.352); 
enough time to make an informed decision (p=0.436); clear understanding of the aims (p=0.281); 
enough opportunities to ask questions (p=0.854); better understanding of the clinical condition due 
to taking part in the study (p=0.333). Participants in the intervention group showed a statistically 
significant improved satisfaction from taking part in the trial (p=0.043). Likewise, participants in the 
intervention group reported that they believed that taking part in the study improved their clinical 
care (81% vs 19%, p<0.001).  
124 
 
Table 28. Patient experience questionnaire for the acute management of the pathway in the 
control (n=22) and intervention (n=41) groups.  
  Very 
satisfied 
Satisfied Neutral Dissatisfied Very 
dissatisfied 
  N % N % N % N % N % 
1. Presentation to the Emergency Department (ED) 
1.1. How well your 
injury was explained 
to you by staff 
Control 
group 
9 43% 10 48% 1 4.8% 1 4.8% 0 0.0% 
Interv. 
group 
31 76% 8 20% 1 2.4% 1.0 2.4% 0 0.0% 
1.2. The information 
you received about 




7 33% 12 57% 1 4.8% 1 4.8% 0 0.0% 
Interv. 
group 
28 68% 11 27% 1 2.4% 1.0 2.4% 0 0.0% 
1.3. The information 
you received about 




9 47% 7 37% 2 11% 1 5.3% 0 0.0% 
Interv. 
group 
23 56% 12 29% 1 2.4% 5 12% 0 0.0% 
1.4. How you found 
the visit overall 
Control 
group 
11 52% 8 38% 1 4.8% 1 4.8% 0 0.0% 
Interv. 
group 
22 54% 14 34% 4.0 9.8% 1 2.4% 0 0.0% 
            
  Yes 
No, but I would 
have liked it 
No, but I do not 
need this type of 
information 
    
  N % N % N %     
1.5. Were you given 
any printed 
information about 
your condition to 
take away with you?   
Control 
group 
13 62% 6 28% 2 9.5%     
Interv. 
group 
33 81% 3 7.3% 5 12.2%     
1.6. Did a member 
of staff tell you 
when you could 
resume your usual 
activities, such as 
when to go back to 
work or drive a car? 
Control 
group 
11 52% 5 24% 5 24%     
Interv. 
group 






       
  Yes No Don’t know     
  N % N % N %     
1.7. Did hospital 
staff check if you 
would be 
adequately 
supported at home 
when you were 
leaving the ED? 
Control 
group 
12 57% 4 19% 5 24%     
Interv. 
group 
26 65% 9 23% 5 13%     
1.8. Did hospital 
staff tell you who to 
contact if you were 
worried about your 
condition or 
treatment after you 
left the ED? 
Control 
group 
14 67% 5 24% 2 9.5%     
Interv. 
group 




Table 29. Patient experience questionnaire for the elective component of the pathway in the 
control (n=22) and treatment (n=41) groups. 
  1 to 2 weeks 
2 weeks to 1 
month 
1 to 2 
months 
2 to 3 
months 
 
  N % N % N % N %  
2. Outpatient follow-up care  
2.1. Following on 
from your visit to 







12 57% 5 24% 2 9.5% 2 9.5%  
Interv. 
group 
16 42% 1 2.6% 5 13% 16 42%  
           
  1 visit 2 visits 3 visits    
  N % N % N %    
2.2 How many 
outpatient visits 
did you make in 
total between your 
first visit to an ED 
and your final x-
ray at 3 months? 
Control 
group 
7 33% 3 14% 11 52%    
Interv. 
group 
13 42% 8 26% 10 32%    
       
  Very 
satisfied 
Satisfied Neutral Dissatisfied Very 
dissatisfied 
  N % N % N % N % N % 
2.3 Thinking about your visit(s) to the Outpatient Department in general, 
how did you find the following aspects of your care? 
The information you 
were given to 




5 25% 10 50% 3 15% 1 5.0% 1 5.0% 
Interv. 
group 
18 50% 14 39% 3 8.3% 1 2.8% 0 0.0% 
The information you 
received about any 




4 20% 11 55% 5 25% 0 0.0% 0 0.0% 
Interv. 
group 
13 39% 14 42% 5 15% 1 3.0% 0 0.0% 
The information you 
received about the 
results of any tests 
Control 
group 
3 17% 10 56% 3 17% 2 11% 0 0.0% 
Interv. 
group 
17 52% 11 33% 3 9.1% 2.0 6.1% 0 0.0% 
How you found your 




8 40% 8 40% 3 15% 1.0 5.0% 0 0.0% 
Interv. 
group 




Table 30. Patient experience questionnaire for taking part in the trial for participants in the control 
(n=22) and treatment (n=41) groups. 
  Strongly 
agree 
Agree Neutral Disagree Strongly 
disagree 
  N % N % N % N % N % 
3. Participating in the study 
3.1. How far would you agree with the following statements on 
your experience of taking part in this study? 
I was satisfied with 
the way the 
information about 
the study was 
explained to me 
Control 
group 
11 52% 8 38% 2 9.5% 0 0.0% 0 0.0% 
Interv. 
group 
29 71% 10 24% 2 4.9% 0 0.0% 0 0.0% 
I had enough time 
to make an 
informed decision to 




11 52% 7 33% 3 14% 0 0.0% 0 0.0% 
Interv. 
group 
24 59% 15 37% 2 4.9% 0 0.0% 0 0.0% 
I have a clear 
understanding of 
the study aims 
Control 
group 
10 48% 9 43% 2 9.5% 0 0.0% 0 0.0% 
Interv. 
group 
28 68% 11 27% 2 4.9% 0 0.0% 0 0.0% 
I had enough 
opportunities to ask 
questions and for 
support if needed 




9 43% 8 43% 2 9.5% 1 4.8% 0 0.0% 
Interv. 
group 
22 54% 15 37% 3 7.3% 1 2.4% 0 0.0% 
I had a good overall 
experience of taking 
part in this study 
Control 
group 
9 43% 8 38% 4 19% 0 0.0% 0 0.0% 
Interv. 
group 
27 68% 12 30% 1 2.5% 0 0.0% 0 0.0% 
            
  
It improved my 
care 
It made no 
difference 
It had a 
negative 
impact 
    
  N % N % N %     
3.2. Do you think 
taking part in the 
study had any 




4 19% 16 76% 1 4.8%     
Interv. 
group 
33 81% 8 20% 0 0.0%     
         
  
It improved my 
understanding 
It made no 
difference 
It had a 
negative 
impact 
    
  N % N % N %     
3.3. Do you feel that 
taking part in the 
study changed your 
understanding of 




14 67% 6 29% 1 4.8%     
Interv. 
group 





Outcome V. To estimate the accuracy of the proposed intervention (i.e. with scaphoid MRI) in the 
detection of scaphoid fracture compared to the current pathway (i.e. 4-view radiographs only). 
The accuracy of the intervention (immediate acute wrist MRI) and the standard care were 
compared against the 3-month radiographs (assumed to be the reference). Accuracy was 
estimated by calculating the number of correct diagnoses (either true positives – “there is a 
fracture” – or true negatives – “there is not a fracture”) divided by the total number of assessments, 
in this case the number of participants (as summarised in Equation 7).  
Equation 7. General accuracy equation and its respective estimate for both control and intervention 
(MRI) groups in the detection of scaphoid fractures. 
𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 =
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑇𝑟𝑢𝑒 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠 + 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠
𝑡𝑜𝑡𝑎𝑙 𝑜𝑓 𝑎𝑠𝑒𝑠𝑠𝑚𝑒𝑛𝑡𝑠
 
𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 𝑖𝑛 𝑡ℎ𝑒 𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠 𝑜𝑓 𝑠𝑐𝑎𝑝ℎ𝑜𝑖𝑑 𝑓𝑟𝑎𝑐𝑡𝑢𝑟𝑒𝑠 𝑎𝑡 𝐸𝐷 (𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑔𝑟𝑜𝑢𝑝) =
61 +  0
65
= 93.8%;  
𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 𝑖𝑛 𝑡ℎ𝑒 𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠 𝑜𝑓 𝑠𝑐𝑎𝑝ℎ𝑜𝑖𝑑 𝑓𝑟𝑎𝑐𝑡𝑢𝑟𝑒𝑠 𝑎𝑡 𝐸𝐷 (𝑀𝑅𝐼 𝑔𝑟𝑜𝑢𝑝) =
60 +  7
67
= 100%; 
As expressed in Equation 7, the accuracy for the detection of scaphoid fractures in the control 
group, which is determined by the initial radiographs only, was estimated at 93.8%. This contrasts 
with the 100% figure in the intervention group, i.e. the MRI did not generate any false negatives 
(participants with scaphoid fracture that tested negative) or false positives (participants with no 
scaphoid fractures that tested positive).  
When other fractures (e.g. radial or capitate bone) are also included, the accuracy for detection for 
any fractures decreased to 84.6% and 98.5% in the control and intervention groups, respectively 
(see Equation 8).  
Equation 8. General accuracy equation and its respective estimate for both control and intervention 
(MRI) groups in the detection of any bone fracture. 
𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 𝑖𝑛 𝑡ℎ𝑒 𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠 𝑜𝑓 𝑎𝑛𝑦 𝑏𝑜𝑛𝑒 𝑓𝑟𝑎𝑐𝑡𝑢𝑟𝑒 𝑎𝑡 𝐸𝐷 (𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑔𝑟𝑜𝑢𝑝) =
55 +  0
65
= 84.6%; 
𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 𝑖𝑛 𝑡ℎ𝑒 𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠 𝑜𝑓 𝑎𝑛𝑦 𝑏𝑜𝑛𝑒 𝑓𝑟𝑎𝑐𝑡𝑢𝑟𝑒 𝑎𝑡 𝐸𝐷(𝑀𝑅𝐼 𝑔𝑟𝑜𝑢𝑝) =
47 +  19
67
= 98.5%; 
The intervention group had one false negative finding, as one participant with a normal wrist MRI 
was subsequently found to have a fracture of the hook of the hamate. Retrospectively, unaware of 
the original report, a second musculoskeletal radiologist was asked to report the MRI. The second 
radiologist reported bone oedema in the hook of hamate, consistent with a potential fracture seen 
in the initial wrist MRI sagittal plane (Figure 43a) as well as the subsequent wrist CT scan (Figure 
43b). This suggests that the false negative may have been associated with the reporting rather 




Figure 43. (a) Bone oedema seen in the hook of the hamate on original sagittal MRI; and (b) hook 
of hamate fracture demonstrated in wrist CT. 
Outcome VI. To estimate the time taken to reach a definitive diagnosis in the intervention group 
compared to the control group. 
The time taken to reach a definitive diagnosis was considered to be once a scaphoid fracture was 
effectively ruled-out or ruled-in. For instance, if immediate MRI correctly ruled-out a scaphoid 
fracture on presentation to the ED, then that was the time a definitive diagnosis was reached. In 
contrast, if the findings in the initial MRI were found to be inaccurate (e.g. subsequent imaging 
found a scaphoid fracture), the latter time was taken to be the definitive diagnosis.  
The time taken to reach a definitive diagnosis (measured in days) was estimated at 10.2 (0 to 55) 
and 1.7 (0 to 116) in the control and intervention group, respectively. The MRI intervention led to a 
quicker definitive diagnosis (p<0.001).  
The time spent in the ED was also evaluated. The dataset was almost complete with only data for 
one participant in each group missing as both participants left the ED prior to formal discharge. 
The mean time elapsed in the ED (measured in hours: minutes) for participants in the control and 
intervention group were, respectively, 2:12 (1:03) and 3:20 (1:01). The MRI intervention led to 
participants staying on mean 68 minutes longer in the ED (p<0.001). 
Outcome VII. To estimate the amount of time off work or informal care needs due to the suspected 
scaphoid fracture. 
The time participants spent immobilised with a plaster cast was measured as this variable is 
commonly used as a proxy to assess the potential societal impact of the intervention. A total of 14 
and 20 plaster casts were used in the control and intervention groups, respectively. The latter was 
due to the higher proportion of fractures (scaphoid or otherwise) and significant soft issue injuries 
detected in the intervention group. The mean number of days immobilised (SD) with plaster cast 
among patients that needed a plaster cast were 25.9 (8.2) and 36.1 (11.6) days in the control and 
intervention groups, respectively, but the difference was not statistically significant (p=0.397).  
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Time off work or informal care due to the suspected scaphoid fracture episode were also assessed. 
One hypothesis behind the intervention was that the use of immediate MRI may be associated with 
a lower proportion of participants being immobilised and thus requiring time off work or informal 
care. The mean (SD) time off work and informal care in the control (n=22) and the intervention 
groups (n=38) were, respectively, 6.0 (9.42) vs 4.3 (9.55) days. This difference was not statistically 
significant (Mann-Whitney U test, p=0.249). 
3.3.7 Sensitivity Analyses 
Deterministic sensitivity analyses around three model unit cost parameters were performed: (i) 
immediate wrist MRI in the ED; (ii) fracture clinic appointments (both first and follow-up outpatient 
appointments); and (iii) ‘Did not attend’ cost. Two additional scenarios were considered: (iv) using 
existing reimbursement strategies as a proxy of unit costs; and (v) adopting a societal perspective 
of analysis instead of the NHS and Personal and Social Services perspective. Table 31 and Table 
32 summarise the impact in the 3 and 6-month cost analyses and 6-month cost-effectiveness, 
respectively. 
(i) Immediate wrist MRI in the ED. The unit cost per immediate wrist MRI in the ED was a 
fundamental variable associated with the provision of the intervention. The base case scenario 
used a unit cost of £72.40, based on: (a) the unit cost of the non-acute wrist MRI estimated at 
£120.73 (estimate retrieved from NHS Reference Costs 2017-18 code RD01A - Magnetic 
Resonance Imaging Scan of One Area, without Contrast, 19 years and over); and (b) the time it 
took to complete the acute short-sequence wrist MRI (approximately 15 minutes) compared to the 
conventional wrist MRI scan (approximately 25 minutes). Hence, the acute short-sequence wrist 
MRI was estimated as a proportion of the conventional wrist MRI. This assumption applied not only 
to the time it took to complete the actual acquisition time but also the subsequent reporting. 
This deterministic sensitivity analysis assumed that the unit cost of the intervention (abbreviated 
wrist MRI) would equal the cost of the full wrist MRI (£120.73). Under this scenario, the cost 
difference per participant at 3 and 6 months between groups decreased to -£129 (p=0.221) and -
£220 (p=0.105). At 6 months, the intervention remained dominant and cost-effective at both 
willingness-to-pay thresholds (£20,000 and £30,000 per QALY). 
 (ii) Fracture clinic appointments. The unit cost per fracture clinic appointment (first and follow-
up appointments) was varied by -25%. The rationale behind this sensitivity analysis was to estimate 
the potential downstream impact of using MRI as an add-on initial test. A -25% unit cost variation 
led to a decrease of the cost difference per group, estimated at -£134 (p=0.157) and -£234 
(p=0.073) per participant at 3 and 6 months, respectively. In both scenarios, the MRI intervention 
remained dominant and cost-effective at both willingness-to-pay thresholds. 
 (iii) ‘Did not attend’ cost. The unit cost per ‘Did not attend’ (DNA) event was assumed at 50% of 
the base case cost of the event when patients did attend and was particularly relevant in outpatient 
visits (i.e. Fracture Clinic appointments). A -25% variation led to a mean cost difference between 
groups of -£166 (p=0.112) at month 3 and -£258 (p=0.055) at month 6. In both scenarios, the MRI 
intervention remained dominant and cost-effective at both willingness-to-pay thresholds. 
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(iv) Existing reimbursement strategies. The use of existing reimbursement strategies as a proxy 
for measuring the costs from a NHS and Personal Social perspective was also explored. The latter 
means that instead of valuing individual costs associated with each event, the reimbursement 
schedules used to pay healthcare providers for these healthcare events were used instead. This 
sensitivity analysis is relevant as existing NHS reimbursement and incentive strategies might not 
be aligned with the proposed intervention. Ultimately, the intervention might generate cost savings 
to the NHS but simultaneously generate a loss to individual healthcare providers, thus 
compromising the implementation of the intervention and its inclusion in routine clinical practice. 
As one example, the use of advanced imaging in the Fracture Clinic is considered to be part of a 
bundled payment, i.e. the use of CT or MRI in Fracture Clinic is included in the Fracture Clinic tariff 
and therefore there is no increase in income received by the healthcare provider, in this case GSTT.  
This sensitivity scenario led to a mean cost difference between groups of -£185 (p=0.166) at month 
3 and -£273 (p=0.184) at month 6. As with the other sensitivity scenarios, the MRI intervention 
remained dominant and cost-effective at both willingness-to-pay thresholds. 
(v) Societal costs. The broadening of the perspective of analysis was also considered to the 
societal perspective rather than a NHS and PSS perspective (base case). This analysis included 
all non-NHS costs, such as healthcare costs that happened within the private sector and any costs 
associated with time off work. From a societal perspective, the mean cost per participant (SD) 
between groups increased to -£754 (p=0.101), with the intervention remaining dominant and cost-
effective at both willingness-to-pay thresholds. 




p-value            
(using GLM) 
 Month 3 Month 6 Month 3 Month 6 
Base case scenario -£174 -£266 0.094 0.047 
(i) Immediate wrist MRI in the ED:  
equals to full wrist MRI unit cost (£120.74) 
-£129 -£220 0.221 0.105 
(ii) Fracture clinic appointments:  
-25% of unit cost of the initial/follow-up Fracture Clinic 
-£143  -£234  0.157 0.030 
(iii) ‘Did not attend’ cost 
-25% of the absolute proportion of DNA cost compared to 
event where the patient attended (baseline=50%).  
-£166 -£258 0.112 0.055 
(iv) Existing reimbursement strategies. 
The utilisation of existing reimbursement strategies to 
pay for clinical care provided 
-£185 -£273 0.166 0.184 
(v) Societal costs. 





Table 32. Sensitivity analyses scenarios and respective impact on cost-effectiveness at month 6 and probability of being cost-effective at NICE willingness-to-
pay thresholds. 
 Control group vs intervention group at month 6 
 ICER (£/QALY) 
Probability of cost-
effectiveness at given 
threshold 




ICER £20k £30k 










(ii) Fracture clinic appointments. The unit cost per fracture 
clinic appointment (first and follow-up appointments) was 





(iii) ‘Did not attend’ (DNA) cost. Proportion of DNA cost 






(iv) Existing reimbursement strategies. 
The utilisation of existing reimbursement strategies to pay for 











3.3.8 Summary of Results 
The MRI intervention led to lower mean costs per participant at both 3 and 6 months post-
recruitment. Using GLM distributions, the mean cost difference per participant between both groups 
at 3 and 6-months post-recruitment were estimated at -£174 (CI 95%: - £378 to £30) and -£266 (CI 
95%: -£528 to -£3), respectively. Although the use of immediate MRI led to cost savings, these 
were only statistically significant at 6 months. However, if bias-corrected bootstrap analyses are 
considered, the cost difference was also significant at month 3 (95% CI: -£487; -£20).  
Assuming £20,000 and £30,000 willingness-to-pay per QALY thresholds, there was a 96.0% and 
96.4% probability of MRI being cost-effective at month 3, compared to a 100.0% probability at 
month 6. 
A higher number of major injuries (scaphoid or other bone fractures or soft tissue injuries) were 
detected in the initial MRI, allowing for more targeted treatment of patients that required wrist 
immobilisation. The MRI intervention was associated with higher accuracy levels, leading to a 
better and quicker diagnosis, and some areas of improvement in patient satisfaction. However, the 




This section discusses the clinical and economic findings from the SMaRT trial. Furthermore, 
strengths and limitations are also debated, alongside potential implications of this trial both in the 
field of research and clinical practice associated with the management of this clinical condition.  
3.4.2 Findings 
Study design 
To our knowledge, this was the first randomised trial that evaluated the clinical and cost 
implications of using immediate MRI in the acute management of suspected scaphoid fractures 
with negative findings on the initial radiographs. This feature was innovative, as previous empirical 
studies had only evaluated the use of advanced imaging two to five days after presentation to the 
ED (Rua et al. 2017). Given its innovative nature, there was some uncertainty regarding the 
operational feasibility of providing MRI in an acute setting, i.e. as part of an ED pathway. To address 
this, and prior to the SMaRT trial, a 20-patient pilot was conducted to assess the trial’s feasibility 
and inform about its design, particularly feedback regarding the trial’s documentation and 
workflows. 
Participant baseline characteristics 
Several participant characteristics were captured at baseline, prior to any randomisation related 
process. This approach was necessary to avoid any potential bias in self-reported data captured 
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by the EQ-5D-5L questionnaire. As specified in the a priori statistical analysis plan, no significance 
testing on the baseline variables between intervention groups was used given the trial’s 
randomised design. Furthermore, although the variable number of wrists was initially considered 
as a stratification variable, this was not deemed feasible due to the very low number of participants 
with suspected injuries to both wrists (n=3). 
The mean (SD) age per participant in the control and intervention groups were 36.2 (12.6) and 
38.2 years (13.4), respectively. This young age is consistent with the clinical literature, as the 
incidence of suspected clinical fractures is commonly associated with sports-related injuries (Yin 
et al. 2010). With regards to gender, the number (%) of male participants were 34 (52%) and 41 
(61%) in the control and intervention groups, respectively.  
In relation to employment status, a total number (%) of 51 (78%) and 53 (79%) participants were 
employed full-time (30 hours or more) in the control and intervention groups, respectively. This 
situation has implicit economic costs to society, evaluated as part of the sensitivity analysis. 
Clinical findings 
A higher number of scaphoid fractures were detected in the intervention group (7 fractures, 
incidence of 10.4%) compared to the control group (4 fractures, incidence of 6.2%). However, this 
difference was not found to be statistical significant (p=0.37). These findings were consistent with 
the systematic review performed by Yin et al. (2010). All seven scaphoid fractures in the 
intervention group were found at baseline (day 0) whilst in the control group the diagnosis was only 
made, on mean, 20 days (SD=19.1) following the presentation to ED. One participant in each group 
required surgical repair associated with the scaphoid fracture.  
Similarly, the intervention group also reported a higher number of fractures in other bone (excluding 
the scaphoid bone), with 15 (incidence of 22.4%) bone fractures compared to 5 (incidence of 7.7%) 
in the control group. Unlike the detection of scaphoid fractures, this difference was statistically 
significant (p=0.019). Out of the 22 fractures detected in other bones, 50% were radial fractures, 
with 4 and 7 in the control and intervention groups, respectively. 
Additionally, the MRI intervention allowed the diagnosis of soft tissue injuries that otherwise would 
not be detected during the initial ED episode. Four soft tissue injuries were detected, with emphasis 
on ligament tears in the triangular fibrocartilage complex (TFFC). However, none of these injuries 
required surgical repair as opposed to the only significant soft tissue detected in the control group. 
This injury, a complete scapholunate ligament rupture, was detected on CT eleven days after the 
ED presentation and required two surgical repairs (initial procedure to perform reconstruction 
procedures and the second for the removal of k-wires). 
Given the trial’s randomised design, a similar incidence of scaphoid or other bone fractures was 
anticipated. However, that is not the case as the intervention with MRI was associated with a higher 
proportion of injuries being diagnosed. This situation might be due to three clinical scenarios: (i) 
injuries not being diagnosed in the control group; (ii) non-relevant injuries being diagnosed in the 
intervention group; or (iii) a mixture of both phenomena. First, clinically relevant injuries such as 
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soft tissue injuries might remain undiagnosed in the control group, especially if participants are not 
clinically symptomatic. As an example, one participant randomised to the control group was 
symptomatic at month 3 with a TFFC injury. Second, even minor lesions were diagnosed due to 
the increased accuracy levels of the immediate use of MRI during the initial ED episode. Some of 
the fractures detected in the intervention group were trabecular scaphoid fractures that did not 
require immobilisation with plaster cast and would not have been diagnosed in the control group 
unless advanced imaging (CT or MRI) was performed. Given that the control group, i.e. standard 
care, included the splint immobilisation of all participants, it can be assumed that some injuries 
diagnosed in the intervention group had minimal clinical impact. Nevertheless, diagnosis of such 
lesion allowed a targeted follow-up diagnostic pathway in order to ensure the appropriateness of 
the healing process.  
As a corollary, the use of immediate MRI led to a quicker diagnosis, allowing the detection of a 
higher number of bone fractures (scaphoid or otherwise) and soft tissue injuries. 
Primary outcome:  
3-month cost analysis 
The primary outcome was total costs at 3 months post-recruitment associated with the proposed 
intervention (i.e. immediate wrist MRI as an add-on test) compared to standard care that relied on 
the radiographs only during the ED episode. These costs were estimated taking a NHS and 
Personal and Social Services perspective. The choice of primary outcome was due to the absence 
of economic evidence associated with the proposed intervention. The 3-month timeline was 
deemed appropriate to capture all relevant NHS resource use given the short-term nature of the 
clinical condition. As with most cost datasets, these data were expected to be positively skewed. 
Hence, the a priori statistical plan used GLM and bootstrap analysis for the primary and secondary 
statistical analyses.  
The trial found a trend for the intervention to be associated with lower costs per participant (-£174), 
leading to total savings of £11,832 compared to the control group. However, the significance of this 
depended on the statistical method employed. Both methods are recommended to assess skewed 
data such as costs (Glick et al. 2007; Gray et al. 2011) and were specified in the a priori statistical 
analysis plan to estimate the mean cost difference between groups, with GLM being the primary 
method and bootstrap the secondary. The primary GLM analysis found the cost difference to be 
non-statistically significant (95% CI: -£378, £30, p=0.094) whilst with the 1000-replicate bias-
corrected bootstrap analysis the cost difference was statistically significant (95% CI: -£486, -£20). 
Given its potential impact to affect the intervention’s adoption decision, further research should be 
considered to determine the more adequate statistical method to evaluate cost datasets.  
The superior clinical accuracy of MRI compared to conventional radiographs had two contrasting 
cost implications. On one hand, due to its superior sensitivity, MRI detected a higher number of 
clinical conditions, some of these warranting treatment, and hence leading to an increase in costs. 
Due to the MRI’s superior specificity, immediate MRI was able to rule-out major injuries (bone 
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fractures and soft tissue injuries) thus reducing the need for follow-up and decreasing the 
respective costs. In the end, due to the low overall incidence of major injuries, the MRI’s ability to 
quickly rule-out injuries prevailed, leading to a decreased cost per participant in the MRI group. 
The intervention (MRI) group also had a higher number (%) of participants that fell in the low cost 
£0-£250 range, with 27 (40%) and 11 (17%) participants in the MRI and control group, respectively. 
However, the minimum cost in the control group (£94, n=4) was lower than in the intervention group 
(£166, n=22). These four participants in the control group had no formal follow-up as either 
cancelled the appointment (n=2) or left the ED prior to having one appointment booked (n=2). The 
22 participants in the intervention group who had any major injury ruled-out in the ED and had no 
subsequent follow-up whatsoever. This was indeed the rationale for the intervention as the upfront 
costs of providing immediate MRI avoided downstream costs associated with outpatient 
appointments and further diagnostic tests. The intervention and control groups had similar number 
(%) of participants that cost between £251 and £500 with 26 (40%) and 25 (37%) participants, 
respectively. These are typically participants that required one initial fracture clinic appointment 
and none or one follow-up appointment. The cost distribution in the control group is more positively 
skewed than the intervention group, with 28 (43%) participants in the control group with costs 
between £500-£1000 compared to only 13 (19%) in the intervention group. The latter is due to the 
higher number of appointments performed to either rule-in or rule-out a scaphoid fracture in the 
control group. Finally both groups had only one participant that incurred in costs over £1000. These 
two participants required surgical repair of a complete scapholunate ligament injury (control group) 
and an undisplaced fracture of the body of the scaphoid (intervention group). However, the first 
surgical repair entailed specialised reconstruction procedures divided in two actual surgical 
procedures, resulting in a maximum cost of £7,116 and £2,691 in the control and intervention 
group, respectively.  
The intervention with MRI was associated with a lower number of NHS events compared to the 
control group, both in primary and secondary care. In terms of primary care utilisation, the 
intervention led to a statistically significant lower number of GP face-to-face appointments. With 
regards to secondary care, compared to the control group, the intervention led to a reduced 
utilisation of both initial and follow-up fracture clinic appointments as well reduced use of advanced 
imaging (CT or MRI). In fact, almost half of participants in the control group (30/65) ended up 
undergoing advanced imaging, either CT or MRI. The latter meant that, more than just increasing 
the utilisation of advanced imaging, the immediate use of MRI shifted the use of these technologies 
to the beginning rather than the end of the diagnostic pathway. Simultaneously, the use of 
immediate wrist MRI led to the release of slots from GPs and orthopaedists, time that can be used 
to manage other patients that would actually require care.  
Secondary outcomes 
6-month cost analysis. Mindful of the potential limitations associated with the 3-month timeline, 
one secondary outcome considered the extension of the cost analysis up to 6 months post-
randomisation. The mean cost difference between the two groups at month 6 was higher compared 
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to month 3 (£266 vs £174). In addition, the cost difference was found to be statistically significant 
using both the GLM analysis (95% CI: -£528, -£3, p=0.047) and the 1000-replicate bias-corrected 
bootstrap analysis (95% CI: -£635, -£29). The difference from the two groups derived mainly from 
just one participant in the control group that had surgery after the initial 3 months. Although the 
correct diagnosis of the injury was achieved 48 days post-randomisation, the surgical repair was 
delayed on multiple occasions due to an ongoing multi resistant infection (MRSA). Hence, the high 
cost of this participant (£6,986) was not included in the primary outcome (at month 3) but was in 
the secondary outcome (at month 6). This difference in resource utilisation at follow-up, particularly 
in terms of fracture clinic appointments (initial and follow-up), advanced imaging (MRI and CT) and 
surgeries drove the cost difference and allowed the recoup of the costs associated with the 
intervention. Given the low number and high unit cost of surgeries, further cost implications were 
assessed. If only NHS costs incurred up to the moment of definitive diagnosis were included, 
thereby excluding any treatment costs, particularly surgical procedures costs, the cost difference 
between the two groups remained statistically significant, with the intervention leading to mean 
cost savings per participant of £113 (CI 95%: - £188 to - £39). This analysis supported the findings 
supporting the cost savings to the NHS generated by the innovative use of advanced imaging.  
In summary, at 6 months post-recruitment and regardless of the statistical method used, the MRI 
intervention was associated with lower costs per participant. These cost findings from the SMaRT 
trial diverged from existing randomised clinical trials, given that a statistical significant cost 
difference between groups was found (Kelson, Davidson, and Baker 2016; Patel et al. 2013; 
Brooks et al. 2005). This may be due to the fact that: (i) the SMaRT trial was powered to capture 
cost differences; and (ii) the use of immediate MRI was used to streamline the clinical pathway and 
reduce secondary care appointments among patients without any bone fracture. 
3 and 6-month cost-effectiveness. In addition to the cost analyses described, cost-effectiveness 
analyses at month 3 and 6 regarding the intervention were also conducted using two measures of 
effect: (i) QALYs; and (ii) correct diagnosis per suspected scaphoid fracture. No significant 
differences in utilities between groups were detected at baseline. This was consistent with the trial’s 
randomised design. Over the follow-up period, participants in the intervention group reported higher 
quality of life compared to the control group (a trend at month 3). However, a proportion of follow-
up utility data were missing, with a maximum of 42% missing data at month 6. Given its potential 
impact, particularly in the cost-utility analyses, we evaluated whether the follow-up data were 
missing at random. Although no statistical differences were detected, the presence or absence of 
follow-up data seemed to affect the 6-month costs (p=0.131), with participants with no follow-up 
data reporting higher cost differences. For this reason, multiple imputation methods were used to 
deal with the missing utility data.  
The MRI intervention was highly likely to be cost-effective at the traditional willingness-to-pay 
thresholds considered by NICE (£20,000-£30,000). This result was mainly driven by the cost 
reduction associated with the intervention, with a probability of 96% and 100% of being cost-
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effective at month 3 and 6, respectively. Moreover, the utilisation of multiple imputation methods 
for utility data missing at month 1, 3 and 6 did not affect these cost-utility results. 
The second cost-effectiveness analysis considered the cost per correctly diagnosed suspected 
scaphoid fracture. As with the incremental cost per QALY, the intervention is also associated with 
a lower mean cost per correct diagnosis (£483 vs £341), equivalent to a 30% reduction. Hence, 
irrespective of the measure of effect considered, immediate MRI was cost-effective. Despite the 
immediate nature of the intervention (on the day of presentation to the ED) compared to 2-5 days 
after presentation from previous evidence (Yin, Zhang, and Gong 2015; Karl, Swart, and Strauch 
2015), this finding clarified the role of advanced imaging in the management of scaphoid fractures 
as evidence from previous cost-effectiveness and cost-utility studies was inconclusive and 
presented multiple serious methodological issues. Some of these methodological issues 
comprised lack of empirical data, proposed clinical pathways not consistent with the real-world 
deployment of advanced imaging, and other significant clinical findings such as other bone 
fractures or soft tissue injuries not being considered. 
Diagnostic accuracy. The accuracy of radiographs and immediate MRI at diagnosing scaphoid 
fractures in the ED were 93.8% and 100%, respectively. This meant that MRI was able to correctly 
either rule-out or rule-in scaphoid fractures in all patients presenting with a clinical suspicion of 
scaphoid fracture and negative findings on the initial conventional radiograph. In contrast, in 6.2% 
of the cases, radiographs reported false negative findings, i.e. no findings reported on the imaging 
scan despite the patient’s actual scaphoid fracture. If we extend this estimate to all bone fractures, 
conventional radiographs only and MRI have reported accuracies of 84.6% and 98.5%, 
respectively. Hence, immediate MRI contributed to a significant improvement associated with the 
accuracy of the diagnostic component of the pathway, leading to only one false negative result 
compared to ten in the control group. 
Time from ED admission to discharge. The time elapsed in the ED was estimated as providing 
immediate MRI in an acute setting - constrained with provision of care within specific time targets 
- was thought to be challenging. Moreover, this variable was deemed relevant as not meeting 
existing 4-hour ED targets can lead to financial penalties to the healthcare provider.  
The median time (measured in hours : minutes) from ED presentation to discharge was 02:10 and 
03:17 for the control and intervention group, respectively. The mean time from ED presentation to 
discharge was also similar, with 02:12 and 03:21 for the control and intervention groups, 
respectively. A total of 3 (3.1%) and 14 (20.6%) ED episodes took more than 4 hours from ED 
presentation to discharge. The implementation of immediate MRI was associated with an increased 
median and mean ED time of 01:07 and 01:08 (p<0.001), respectively. This time difference 
between groups was consistent with the time from randomisation to ED discharge. Hence, the time 
difference appeared to be directly attributable to the intervention, i.e. the processes associated with 
the provision of the MRI scan and its subsequent reporting. The potential implementation of this 
clinical pathway needs to take into consideration the potential breaches of the NHS 4-hour ED 
target and how to deal with this process outcome. Given that this might be associated with negative 
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financial incentives for the healthcare provider, real-world implementation of the intervention needs 
to be discussed with regulatory agencies in order to incentivise the use of a technology with overall 
improved clinical and financial outcomes (see Chapter 7 for further detail on the implementation 
plan). It is relevant to highlight that these potential negative incentives, as well as scaphoid-related 
litigation costs (scaphoid-related injuries are one the main reasons for litigation costs at GSTT), 
were not considered in the cost analyses.  
Time taken to reach a diagnosis. The time taken to reach a definitive diagnosis in both groups 
was also estimated. The rationale is that the use of MRI would lead to a quicker definitive diagnosis 
and, if needed, treatment. The mean time (SD) taken to reach a definitive diagnosis in the control 
and intervention groups were, respectively, 10.5 (6.5) and 1.7 (14.2) days (p<0.001). The latter is 
due to MRI’s higher ability to either rule-in or rule-out a bone fracture in participants presenting with 
a suspicion of scaphoid fracture.  
Patient satisfaction. The evaluation of self-reported patient satisfaction was considered as the 
intervention holds the potential to impact different dimensions of analysis. Regardless of the 
randomisation group, participants were satisfied by the acute and elective management of the 
suspected scaphoid fracture. Nonetheless, participants in the intervention group exhibited a trend 
of higher satisfaction levels compared to the control group. Despite being for longer in the ED and 
submitted to further tests, participants in the intervention group reported similar levels of 
satisfaction compared to the control group. With regards to the elective follow-up (e.g. fracture 
clinic appointment), participants in the intervention group presented again a trend for higher levels 
of satisfaction compared to the control group. One notable difference between groups was in the 
information provided to participants in both groups, with participants in the intervention group 
reporting higher levels of satisfaction with the information received. The superior satisfaction levels 
in participants randomised to the intervention group seemed to be associated with the downstream 
effect of immediate MRI, i.e. its ability to reach a quicker and definite diagnosis and, despite the 
increase in time in the ED, the sense of better understanding their clinical condition and its clinical 
management. Finally, the trial experience in patients randomised to the intervention group was 
associated with a statistically significant higher perception that the trial improved their clinical care.  
Immobilisation time and time off work and informal care. It was hypothesised that the use of 
immediate MRI would lead to a lower number of participants being immobilised with plaster casts. 
This would then lead to a lower proportion of days off work or informal care. This hypothesis was 
not corroborated by the SMaRT trial as the intervention was associated with the detection of a 
higher proportion of clinically relevant injuries that required immobilisation with plaster cast. 
Nonetheless, time off work or informal care due to the suspected scaphoid fracture episode was 
not statistically different between groups. This seemed be due to the fact that participants with no 
fracture were immobilised with splint only (and not plaster cast) and still required time off work. 
Previous economic evidence, particularly economic modelling evidence, did not consider that 
symptomatic patients with no fractures could require time off work (Rua et al. 2017). 
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3.4.3 Sensitivity analyses 
Sensitivity analyses. Deterministic sensitivity analyses around several parameters were 
considered. Regardless of the variations considered in all scenarios, the mean cost of the 
intervention group was always lower than the control group, i.e. the intervention led to cost savings 
although whether this cost-difference might be or not statistically significant varied. Moreover, in all 
6-month cost-utility analyses, the intervention dominated the control group. 
The first three sensitivity analyses considered changes to unit costs associated with the economic 
model. The increase in the unit cost of the immediate wrist MRI in the ED decreased, as expected, 
the cost savings associated with the intervention. In contrast, the increase in the unit cost of the 
fracture clinic appointments led to greater cost savings. This is explained by the fact that the 
intervention decreased the use of fracture clinic appointments, and thus, any increase in unit costs 
would only generate further cost savings. Variation to the assumed cost, the ‘Did not attend’ (DNA), 
was also subjected to sensitivity analysis. Any increase in the DNA cost led to an increase in the 
mean cost difference between the groups. The latter was due to the fact that the control group 
presented a higher number of missed appointments, particularly fracture clinic appointments. Given 
that a higher proportion of participants in the control group have formal follow-up at secondary care, 
it is more likely for participants in this group not to attend their appointments given that the wrist 
pain might subside between the day of the injury and the fracture clinic appointment (usually 
scheduled 7 to 10 days post-injury). 
The analysis of existing reimbursement strategies was also considered given the potential impact 
on the financial sustainability of incorporating the intervention as part of routine care. This scenario 
led to a marginal increase in cost savings at both 3 and 6 months. However, the existing 
reimbursement strategy might lead to conflicting incentives as the use of immediate acute MRI is 
not currently incentivised given that ED episodes are reimbursed as bundle payments. Even though 
the use of immediate MRI is likely to increase the ED episode’s tariff, this increase will not be 
enough for the provider to recoup the costs associated with the provision of MRI. Hence, in order 
to align the incentives of individual healthcare providers and the NHS, discussions with Clinical 
Commissioning Groups (CCGs) are required (see Chapter 7 for the detailed implementation plan).  
Lastly, a broader perspective of analysis was also taken. From a societal perspective, healthcare 
costs that occurred in the private sector or non-healthcare costs, such as time off work costs, were 
included. Assuming a societal perspective, a higher mean cost difference between groups was 
estimated compared to the healthcare payer perspective (-£754 vs -£266). This finding was aligned 
with established economic literature. The systematic literature review conducted by the student 
found that, from a societal point of view, interventions that used advanced imaging were associated 
with higher cost savings (Rua et al. 2017). However, the cost difference between groups from a 
societal perspective in the SMaRT trial were not statistically significant (p=0.101). The latter 
seemed to be due to high attrition rates (54%) associated with self-reported resource use diaries, 
the instrument used to capture time off work. Hence, this constituted an important limitation to the 
trial’s findings from a societal perspective. 
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3.4.4 Implementation plan: From research to clinical practice 
Backed back by the SMaRT trial evidence, the next phase consisted of the implementation stage 
(Phase 4 in Figure 1). Three steps comprised the implementation plan to bridge the gap between 
research and real-world practice and to incorporate innovation into routine clinical care (Figure 44).  
 
Figure 44. Three phases in the evolution of the project. 
Step 1 comprised a feasibility assessment, of whether provision of immediate MRI in an acute 
setting was feasible. Out of 68 randomised to the MRI group, 63 (93%) received the intervention 
allocation. Five participants did not receive the intervention (i.e. MRI) due to: event of unforeseen 
claustrophobia (n=2), MRI not available within 1 hour (n=1), MRI not working (n=1) and presence 
of cochlear implant not mentioned during the initial screening process (n=1). Hence, despite the 
disruptive nature of using MRI in the ED, it was not feasible due to operational constraints only in 
2.9% of cases (2 out of 68 participants).  
Step 2 comprised the clinical and economic evaluation of the intervention. As summarised in this 
chapter, the intervention simultaneously generated cost savings and improved clinical outcomes 
and satisfaction levels. Hence, the first two phases established that the intervention was not only 
feasible but also associated with improved clinical and economic outcomes. 
Step 3 emphasised incorporating the intervention as part of routine clinical practice at GSTT. 
Operational constraints associated with the provision of MRI for patients presenting to the ED at 
any time, as opposed to the MRI operating hours within the SMaRT trial eligibility criteria, were 
considered. Given the limited availability of MRI (not a 24/7 service), two options were 
contemplated, either: (a) keep the trial’s inclusion criteria as the operating hours; or (b) roll-out the 
pathway for all patients. In the interest of equality and consistency across the patient pathway, it 
was decided that all patients presenting to the ED with a suspected scaphoid fracture should have 
immediate MRI. This posed some issues with the provision of MRI for patients presenting outside 
normal MRI working hours. In order to operationalise the clinical pathway, patients presenting to 
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the ED outside normal MRI working hours (e.g. 5 a.m.) were given the next available MRI slot (early 
morning slots) and discharged to the orthopaedic day care centre. If patients opted not to come 
back for the MRI scan, standard care with a subsequent fracture clinic follow-up was provided as 
per standard care prior to the introduction of immediate MRI (i.e. equivalent to the control group in 
the SMaRT trial). Figure 45 illustrates the clinical scenarios.  
 
Figure 45. High-level description of the operational pathways considered in the provision of MRI 
based on the time patients presented to the ED. 
Chapter 7 provides an in-depth discussion on the implementation plan to make immediate MRI part 
of routine care for all patients presenting at the ED with suspected scaphoid fracture. 
3.4.5 Strengths, limitations and implications 
Strengths: 
The trial’s pragmatic design aimed to assess how a clinical intervention works in a real-world 
clinical setting, particularly in the context of complex clinical settings (MacPherson 2004; S. 
Ramsey et al. 2005; Whicher et al. 2015). The ED is one such clinical setting. The strength of 
pragmatic clinical trials reside on their ability to impact on clinical practice. The positive result in 
the SMaRT trial provided evidence that the intervention was effective in real-world clinical practice. 
This contrasts with explanatory trials that are designed, not to inform decision makers, but to 
estimate a treatment’s efficacy (MacPherson 2004; S. Ramsey et al. 2005; Whicher et al. 2015).  
Several design features considered to minimise potential sources of biases and maximise were 
the trial results generalisability. First, the research question was clearly defined to assess the 
efficiency and effectiveness of immediate acute MRI in the management of suspected scaphoid 
fractures. Second, the inclusion criteria broadly reflected the heterogeneous population undergoing 
evaluation due to a suspected scaphoid fracture. Hence, participants recruited were likely to be 
representative of the wider population, contributing to the generalisability of the results. Third, the 
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comparator group was clearly defined as the standard care with the use of conventional radiograph 
only as part of the acute diagnostic pathway. This made the comparison between groups feasible 
as there was a clear difference between the control and the intervention groups. Fourth, the a priori 
sample size estimate was based on a clinical pilot and incorporated the heterogeneous mix of 
population and the probability of losses to follow-up (3 months for the primary outcome). Fifth, the 
randomised block design minimised biases, particularly allocation and selection biases. Sixth, all 
analyses were conducted on an intention-to-treat basis. Given that the intervention was designed 
as an add-on test (i.e. in addition to the control group), participants could not crossover between 
groups. This is commonly a potential disadvantage associated with other pragmatic trials 
(MacPherson 2004). Seventh, the selected outcomes were meaningful to everyday clinical practice 
and covered a wide range of dimensions, from efficiency to clinical. Eighth, the choice of final health 
outcomes (e.g. successful treatment of fractures, self-perceived health, costs) rather than 
intermediate outcomes (e.g. diagnostic accuracy) contributed to the decision around resource 
allocation (Drummond et al. 2004). Ninth, data-collection methods combined routinely collected 
data with research related data retrieved from an electronic case report form (eCRF). This 
approach contributed to a balance between data quality and interference with clinical practice 
(Meinecke et al. 2017). Tenth, the use of multiple clinical and financial databases, supplemented 
by primary care data provided by GPs, meant that there were no missing data for the primary 
outcome. This comprehensive approach guaranteed that any scaphoid-related NHS event was 
costed regardless of the healthcare provider or their location.  
Limitations: 
The first limitation derived from the SMaRT trial’s single-centre design. To mitigate this limitation, 
the inclusion criteria reflected the heterogeneous population undergoing evaluation due to 
suspected scaphoid fractures across the UK.  
The trial’s exclusion criteria reflected the intervention’s operational challenges. This led to intrinsic 
trial limitations. Most of the exclusion criteria were associated with the provision of MRI and 
subsequent reporting, as the trial only included participants that presented during MRI opening 
hours and the radiologist’s services. This impacted the trial generalisability as findings from this 
trial might not be directly transferrable to different operating hours. In order to minimise this 
limitation and investigate the feasibility and transferability to other NHS-based hospitals, 
particularly outside normal working hours, the SMaRT trial led to another study aimed at evaluating 
the potential first-line use of radiographers to rule in or rule out suspected scaphoid fractures using 
MRI images on presentation to the ED.  
Another important trial limitation was the lack of blinding. Given the clear differences between the 
two imaging modalities (i.e. conventional radiograph and MRI) it was not deemed possible to blind 
participants or staff to study allocation. However necessary, this constituted a trial limitation that 
could lead to conscious or unconscious bias from the participant and/or the routine care team staff. 
In order to mitigate this bias and given that had the potential to affect the primary outcome (e.g. 
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over or underutilisation of NHS resources), clinical pathways were disseminated and followed by 
clinicians. 
Although the use of the EQ-5D-5L questionnaire, a non-disease specific instrument, is arguably 
not the best instrument to capture differences of effect between the groups given the injury’s nature, 
we have opted to use it to follow the methodology suggested by the NICE. 
Implications for Further Research: 
The feasibility of providing an acute 24-hour service with MRI to diagnose suspected scaphoid 
fractures should be further evaluated in different clinical settings, from secondary to tertiary centres. 
Furthermore, particularly for healthcare providers that do not have MRI availability, the use of CT 
or dedicated extremity MRI scanners should be considered. Additionally, lessons learned from the 
design and implementation of the SMaRT trial are likely to provide a valuable insights to other 
researchers designing studies in an acute setting. 
Implications for Policy and Clinical Practice: 
The SMaRT trial was designed to provide evidence on which to base a decision. The results from 
the trial have shown that the immediate use of MRI in the management of scaphoid fractures was 
associated with a decrease in total costs and was cost-effective from a healthcare payer 
perspective. Furthermore, the intervention was linked with improved diagnostic accuracy, clinical 
outcomes and self-reported quality of life. Following on the evidence obtained in this trial, the use 
of immediate acute MRI in the ED is now used as an add-on test in the ED for the management of 
suspected scaphoid fractures with negative initial radiographs at GSTT. 
3.5 Conclusion 
The SMaRT trial evaluated the acute use of immediate MRI in the management of suspected 
scaphoid fractures. Given the intervention’s innovative nature and the trial’s pragmatic design, this 
trial provided empirical clinical and economic evidence on which to base future clinical practice. 
The findings from the SMaRT trial showed that the use of immediate MRI led to both improved 
clinical and self-reported patient satisfaction outcomes whilst being cost-effective and reducing 
overall NHS costs associated with the holistic management of the suspected scaphoid fracture. 
As a corollary, and despite its limitations, the SMaRT trial contributed to the field of knowledge by 
providing solid evidence on which to base UK and international clinical practice in favour of the use 
of immediate MRI in the management of patients with suspected scaphoid fractures. Since 28th 
October 2019, current standard care at GSTT has included the use of immediate MRI in the acute 




Chapter 4. Use of advanced imaging in the management 
of chronic headache 
4.1 Introduction 
4.1.1 Headache  
Headache is the most common symptom reported in the community, affecting more than 90% of 
the population at some point in their lifetime, particularly women (Silberstein and Lipton 1993; 
Rasmussen et al. 1991). Most headaches are primary headache disorders, such as migraine, 
cluster or tension-type headaches, with secondary headaches, due to an underlying serious 
pathology (e.g. tumour, brain aneurysm), being far less common (Rasmussen et al. 1991). In fact, 
less than 0.1% of the lifetime prevalence of headache is associated with a life-threatening 
condition, which can include primary or secondary brain tumours (Symvoulakis et al. 2007, 
Department of Health 2012).  
Headache is in the top ten international causes of disability (Stovner et al. 2007), with nearly half 
of sufferers reporting that it affects work, home or social activities (Boardman et al. 2003). A key 
study published in the Lancet estimated that tension-type headaches and migraines were, 
respectively, the second and third most common diseases in the world in both males and females, 
with migraine being responsible worldwide for about 3% of years lived with a disability (Vos et al. 
2012; Leonardi and Raggi 2013).  
4.1.2 The clinical challenge 
Most people with headache self-manage, but over 4% of adults annually consult their General 
Practitioner (GP) complaining of headache (Latinovic, Gulliford, and Ridsdale 2006). GPs manage 
97% of headache consulters, with 2% of these referred to neurologists and 1% to other specialists 
(Latinovic, Gulliford, and Ridsdale 2006). 
The management of headaches depends on the quality of treatment provided in primary care, 
where this condition is predominantly managed (Ridsdale et al. 2008). Some patients with chronic 
headache tend to return frequently to primary care, concerned that the chronic headache might be 
a symptom of a serious underlying clinical condition, particularly a brain tumour. GPs acknowledge 
that they have made referrals for secondary care, both for a neurologist consultation or 
neuroimaging examination, in situations where they were unable to reassure patients (Morgan, 
Jenkins, and Ridsdale 2007). Morgan, Jenkins and Ridsdale (2007) and Ridsdale et al. (2007) 
found that referral for headache is often the outcome of patient pressure and anxiety interacting 
with GP characteristics, organisational factors and service availability rather than the disease 
severity itself. This contrasts with guidance from the National Institute for Health and Care 
Excellence (NICE), which does not recommend the use of neuroimaging for reassuring purposes 




headache had, respectively, a 39% (95% CI 24–54%) or 51% (95% CI 32–68%) probability of 
having neuroimaging routinely ordered even though guidelines specifically recommended against 
it (Callaghan et al. 2015). 
From the neurologist’s perspective, despite headache being mainly managed within primary care, 
was the most common cause for referral accounting for up to 22% of GP referrals to neurologists 
(Thomas et al. 2010). Similar numbers were found by Patterson and Esmonde (1993) and Ridsdale 
et al. (2011), who reported that between 20 to 30% of new referrals to neurologists were due to 
headache. Local estimates from King’s College Hospital (KCH) and NHS Southwark suggested 
that headache accounts for 25% of local neurology appointments (Community Headache Service 
2011). More recently, in 2018, evidence collected at GSTT showed that headache referrals 
increased over 10% annually between 2015 and 2018. The latter seemed to be due to growing 
patient demand for investigations and a lowering of GP referral thresholds.   
In summary, despite the low level of referrals to secondary care (most patients are managed within 
primary care), the absolute number of headache episodes (due to its high prevalence) makes 
headache the most frequently listed reason for referral to the neurologist and thus eats up already 
severely constrained capacity. To inform future management of chronic headache, this study aimed 
to evaluate two existing pathways used in the management of patients with chronic headache: (i) 
referral to the neurology department; or (ii) direct access to neuroimaging, particularly MRI. These 
two pathways are illustrated in Figure 46 and described below. 
4.1.3 Two pathways at Guy’s and St Thomas’ Hospital  
Referral to a neurologist 
In 2012/2013, it was estimated that GSTT received 672 referrals for headache, around 21% of the 
total number of neurology referrals (3,272). At KCH, over a period of 4 months in 2013, 178/357 
(33%) of referrals were for headache (the equivalent of an annual estimate of 534 referrals). One 
third of referrals to neurology were from local GPs, one third from out of area, and the final third 
cross-referrals from other consultants, some of which were from the emergency department 
(Ridsdale et al., 2011).  
In a study of reasons for attendance at GSTT’s ED, the most common neurological reason was 
headache, accounting in 2006-7 for 1,565 ED visits per year (GSTT internal data). In 2018, the 
number of presentation to St Thomas’ ED had increased over 50%, with an estimated number of 
over 2,500 ED visits with headache as the presenting complaint (GSTT internal information). 
In summary, the management of headaches has led to a historical increase in the utilisation of 
secondary care resources, both acute and elective services. 
Direct access to neuroimaging 
In the absence of neurological signs, neuroimaging for chronic headache is not recommended by 




et al. 2010) or NICE (NICE 2018b). Nevertheless, brain scans – both CT and MRI – are commonly 
performed in patients with normal neurological examinations. As an example, a US study found 
that between 1995 and 2010, neuroimaging utilisation increased from 5.1% (95% CI, 2.7%-7.5%) 
to 14.7% (95% CI, 9.4%-20.0%) of all annual headache visits (p<0.001) (Callaghan et al. 2014).  
The utilisation of advanced neuroimaging in the management of headache is due to its diagnostic 
accuracy, but moreover, the need to reassure patients that no serious underlying condition is 
causing the headache  (Morgan, Jenkins, and Ridsdale, 2007). GPs described high levels of 
anxiety and patient pressure, predominantly caused by a fear of brain tumour as a cause for the 
headache referral (Morgan, Jenkins, and Ridsdale 2007; Elliot and Kernick 2011) although no 
statistical difference in neuroimaging findings between primary headache sufferers and healthy 
controls was found (0.58% vs 0.73%, p>0.05) (Wang et al. 2019).  
In fact, GPs commonly acknowledge that they have made referrals to secondary care, both for a 
neurologist consultation or neuroimaging scan, in situations where they were unable to reassure 
patients (Morgan, Jenkins, and Ridsdale 2007). Scanning the patient’s brain might provide 
reassurance for some patients but for others might not suffice. According to Thomas et al. (2010), 
the GP is in the best position to assess whether a negative or normal scan is likely to reassure the 
patient, decreasing the levels of anxiety and subsequent GP utilisation rates. Furthermore, an 
additional benefit from direct access to head MRI is to enable neurologists to better manage 
patients that end up being referred to them, allowing clinicians to concentrate on the patients’ 
symptoms and headache management with the reassurance that no underlying structural 
pathology is present (Taylor et al. 2014). 
An existing clinical pathway at GSTT has enabled primary care to directly access neuroimaging, 
particularly MRI (please see Figure 46). Overall head MRI utilisation for all types of referrals has 
increased over 120% in just four years, with 465 head MRI scans in 2015 compared to an estimated 
number of over 1,000 scans in 2019 (based on Jan-Sep 2019 departmental activity data). These 
data, however, included all scans in patients directly referred from primary care including, for 
example, patients with primary and secondary headaches. Despite the growth in referral rates, 
GPs pointed out that three aspects that could further increase referral rates: improved access to 
imaging; standardised reporting; and increased awareness about this pathway (Underwood, Kilner, 
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4.1.4 Economic evidence 
A review of the literature assessed the existing economic evidence around the economic burden 
of headaches and the economic impact of using neuroimaging, particularly MRI, in the 
management of chronic headaches. Particular focus was given to evidence from studies conducted 
in the NHS. 
Economic burden of headache 
The Eurolight project (Linde et al. 2012) estimated the societal economic burden of headache in 
the European Union in 2008/09. Despite the benign nature of most headaches, the annual 
economic headache burden was estimated at 173€ billion, 111€ billion (64%) attributed to migraine, 
37€ billion (21%) to medication-overuse, 21€ billion (12%) to tension-type headaches and the 
remaining 4€ billion (2%) to other types of headache (Linde et al. 2012). Although less prevalent, 
the economic burden of migraine was responsible for over half of the economic impact. This 
economic impact was divided in two components: (i) the actual direct cost associated with the 
consumption of healthcare resources; and (ii) the indirect costs due to absenteeism from work or 
lost productivity at work. Migraine or chronic migraine sufferers (>15 days/month) had more 
emergency department episodes, hospital visits and diagnostic tests than those with episodic 
migraine, leading to medical costs three times higher (Bloudek et al. 2012). Other studies, 
particularly in the US, although showing some variability, suggested that the vast majority of 
headache-related costs were indirect costs, particularly due to time off work (Hu et al. 1999; Hazard 
et al. 2009). 
Two studies focused on the economic impact of headache in the UK: McCrone et al. (2011) and 
Osumili et al. (2018). McCrone et al. (2011), using 2003/04 data for patients presenting to primary 
care with headache, estimated a total cost of £956 million due to health service use and £4.8 billion 
including indirect costs, particularly lost productivity. Furthermore, this estimate was thought to 
represent an underestimate as many headache sufferers self-manage and do not consult their GP. 
In 2017, using 2012/14 data for patients presenting to headache specialists (either neurologists or 
GPs with special interest in headache), Osumili et al. (2018) estimated an overall £109 million and 
£850 million for health service use costs and total costs, respectively. In other words, McCrone et 
al. (2011) and Osumili et al. (2018) estimated that health service costs were only responsible for 
20% and 13% of the total costs, respectively. Moreover, there were significant differences in terms 
of indirect costs considered in these two studies. Whilst McCrone et al. (2011) considered that 
most indirect costs derived from lost employment, Osumili et al. (2018) pointed out that informal 
care is responsible for 74% of total indirect costs with lost employment being responsible for only 
13%. A potential explanation for this was that one third of participants were not employed due to 
other health issues and an additional 20% did not report any productivity loss (Osumili et al. 2018). 
Impact of neuroimaging 
This subsection chronologically summarises the evidence regarding direct access to imaging and 
the use of neuroimaging (either CT or MRI) as a direct alternative to management with a referral 




A UK study at the Kent and Canterbury Hospital (data from 1994/95) evaluated direct access to 
MRI from primary care for different clinical reasons (Apthorp et al., 1998). A total of 170 MRI scans 
from 58 GPs were retrospectively evaluated. The authors found that where GPs had direct access 
to imaging, referrals to neurologists had been reduced, avoiding 41% of referrals to secondary 
care. In 24% of patients who were subsequently referred to secondary care, the specialty to which 
the patient was referred changed as a result of the MRI, thus improving referral appropriateness 
(Apthorp et al., 1998). Finally, 43% of GPs reported that direct access to MRI had changed their 
management patterns (Apthorp et al., 1998). 
Howard et al. (2005) conducted a UK-based randomised controlled trial (participants recruited 
between 1999 and 2001, n=150), which showed that the use of neuroimaging in patients with 
chronic headaches had the potential to change patient management. The authors found that 
referral rates to neurology decreased from 23% in the control group compared to 1.3% when GPs 
had direct access to MRI. The cost implications of using direct imaging were estimated for two 
groups: Hospital Anxiety and Depression Scale (HADS) positive patients (n=66); and HADS 
negative patients (n=84). For patients with HADS positive findings, the authors found that the use 
of neuroimaging reduced overall 1-year costs (-£465, 95% CI: -£1028 to -£104) (Howard et al. 
2005). The latter seemed to be due to participant’s reassurance. However, the authors found that 
this reassurance effect seemed to be time limited, with participants being reassured at 3 months 
but not at 1 year post-recruitment.  
Simpson et al. (2010) evaluated the direct use of CT from primary care for the management of 
chronic headaches in Greater Glasgow (data collected between 1999 and 2007, n=4,404). The 
authors aimed to evaluate the clinical and economic impact of direct access to neuroimaging. Out 
of 3,943 scans, 461 scans (10.5%) were reported as abnormal but in only 60 (1.4%) of patients 
were these findings potentially causative of the headache (i.e. non-incidental findings). Twenty-two 
brain tumours were identified in the entire cohort (0.5%). The authors estimated approximate cost 
savings of over £86,681 for the entire cohort (Simpson et al. 2010). It is relevant to highlight, 
however, that this estimate was not based on a rigorous resource use valuation methodology but 
rather a rough estimate based on GP’s feedback. Furthermore, the authors described this as a 
cost-effectiveness analysis but only a cost analysis was reported. 
Thomas et al. (2010) evaluated direct access to brain imaging for a subset of participants from the 
study by Simpson et al. (2010). This study was conducted in Tayside (Scotland) with an overall 
participation of 45% of the 309 local GPs. The utilisation of direct access to imaging, in this case 
CT, reduced referral rates in 86% of the cases during the follow-up period (average of 1.3 years 
per patient) (Thomas et al., 2010). The added number of CT scans performed through the open 
access service accounted for 4% of the annual CT scans performed across Tayside. 
Kernick and Williams (2011) assessed the impact of providing GPs with direct access to 
neuroimaging for patients with headache. Kernick and Williams (2011) claimed that, although the 
yield for clinically significant findings in neuroimaging was below 1% (Tsushima and Endo 2005; 




unknown (Howard et al. 2005; Kernick and Williams 2011). Furthermore, anxiety associated with 
incidental findings should not be disregarded (Kernick and Williams 2011; Taylor et al. 2014). In 
any case, the evidence suggested that neuroimaging affected the clinical pathway associated with 
the management of headache patients (Howard et al. 2005; Thomas et al. 2010; Simpson et al. 
2010).  
In addition, Kernick and Williams (2011) discussed the role of either CT or MRI in the management 
of patients with chronic headache. No decisive data were available to make a recommendation on 
the merits of CT or MRI, with the authors concluding that the utilisation of each modality was usually 
a function of its sensitivity, side effects, availability and costs (Kernick and Williams 2011). A more 
recent guideline, in 2019, from the British Society of Neuroradiologists, favoured the utilisation of 
MRI in a non-acute setting because of its greater accuracy to rule out secondary causes for 
headache (Good, 2019).  
In summary, headache is responsible for a high economic burden across different healthcare 
systems and societies. The utilisation of advanced imaging is commonly used to reassure both 
clinicians and patients that no underlying health threatening condition is causing the headache. 
However, there is limited UK evidence around the economic impact of early advanced imaging in 
the management of chronic headache as well as the clinical management of incidental findings 
found in brain MRI or CT. 
Can direct access to imaging ease bottlenecks? 
The UK government is encouraging open access to scanning for different clinical conditions, 
particularly for suspected cancers (NICE 2016). The objective is to enable early diagnosis, improve 
accessibility to care and reduce pressure on specialist waiting lists and patient self-referral to the 
ED. This constitutes a major policy aim in a cash-strapped NHS.  
The diagnosis and management of neurological diseases is particularly challenging in the UK 
compared to other western countries (Ridsdale et al. 2008). A major reason for this is the limited 
availability of neurologists, which is 5-10 times less than other comparable western countries 
(Ridsdale et al. 2008, Bateman 2011). If we consider that a 1% increase in the pattern of GP 
referrals to neurologists due to headache would almost double the demand for new neurology 
appointments at secondary care (Morgan, Jenkins, and Ridsdale 2007), the use of direct access 
to imaging holds great potential to release resources within the NHS. Some neurological 
conditions, such as epilepsy, are difficult for non-specialists to manage, and lack of primary to 
secondary care access may be a contributing factor in poor management and sudden death in 
epilepsy (Hanna et al. 2002). Freeing up much needed neurology capacity may improve patient 
management and reduce avoidable deaths.  
Direct access to neuroimaging could be associated with a transfer of workload to radiology due to 
the increase in the number of referrals to MRI examinations. This is likely to be the case as not all 
patients directly referred to imaging from primary care would otherwise undergo an MRI 




associated with the downstream management of incidental findings from neuroimaging remains 
unclear.  
In summary, there is conflicting evidence surrounding the role of advanced imaging in the 
management of headaches, particularly with providing GPs with direct access to head MRI. Some 
authors (e.g. Wang et al. 2019) and regulatory agencies (e.g. NICE) do not recommend the 
utilisation of MRI for reassurance purposes in patients without neurological red flags. This decision 
is based on the low yield of relevant clinical findings in MRI among patients with headache. In 
contrast, other authors (e.g. Howard et al. 2005) considered that the role of advanced imaging in 
the management of headaches should be extended because, despite the low probability of finding 
relevant clinical findings, the reassurance of a normal head MRI to both referrers and patients 
improves clinical management and decreases the overall costs to the healthcare system. These 
benefits would justify providing GPs with direct access to head MRI. 
4.1.5 Patient and NHS benefits and disbenefits 
The underlying hypothesis is that the early use of a more expensive diagnostic tool (MRI) will 
reassure both patients and GPs that no serious underlying cause is present. Ultimately this might 
lead to: 
 An overall reduction of costs within:  
o Primary care as patients with chronic headache will tend to: (i) attend less often to GP 
outpatient appointments; and (ii) reduce the use of medication. 
o Secondary care as patients directly referred to neuroimaging are more likely to have a 
lower number of secondary care contacts, particularly within the neurology department 
(reassurance effect). 
 An improvement of patient and GP satisfaction: 
o From the patients’ perspective - direct access to imaging is likely to: (i) improve access 
to care by decreasing overall waiting times; (ii) avoid unnecessary appointments and 
follow-up exams; and (iii) decrease overall pain and discomfort associated with the 
headache. 
o From the GP’s perspective - direct access to imaging is likely to: (i) decrease the 
amount of time elapsed between referral and the initial secondary care appointment 
(compared to conventional referral to the neurology department); and (ii) improve the 
overall patient management strategy as GPs would have access to a standard MRI 





4.2.1 Aims, Objectives and Hypotheses 
Aim of the study 
The primary aim of the headache study was to evaluate whether direct GP access to MRI for patients 
with chronic headache was cost saving at 6 months compared to GP referral to the neurology 
department. The hypothesis was that direct access to MRI from primary care would reassure patients, 
decreasing the need for follow-up contacts and ultimately leading to lower total costs of care per patient 
associated with the management of headache compared to a referral to a neurology appointment. 
Hence, although MRI is an expensive imaging technology, a potential reduction of primary and 
secondary care utilisation - of GP and neurology appointments - might offset the added MRI cost. 
Furthermore, it is important to note that a proportion of patients would have had an MRI scan later 
during their pathway anyway, and so, for these patients, this would simply represent a shift in costs to 
an earlier time point within the clinical pathway rather than additional costs. This hypothesis was 
evaluated in multiple cost analyses. 
Study objectives and hypotheses 
One primary objective and five secondary objectives were considered.  
Primary Objective: To estimate the 6-month costs associated with two existing clinical pathways in the 
management of chronic headaches: (i) referral from the GP to neurology services; or (ii) GP direct 
referral for a head MRI.  
Null Hypothesis 
There is no statistically significant difference between the 6-month cost per patient for patients with 
chronic headache referred from primary care to either: the neurology department; or directly to a head 
MRI.  
Secondary Objectives: 
Five secondary objectives were considered: 
1. To estimate the 12-month costs following the initial episode at secondary care associated with 
direct access to MRI compared with referral to the neurology department. 




2. To perform cost-effectiveness analyses at 6 and 12-month following the initial episode at 
secondary care associated with direct access to MRI compared with referral to the neurology 
department.  
Cost and utility data up to 12 months of follow-up were used for the purposes of this secondary 
objective. The cost-effectiveness analyses took into account both the costs and outcomes related to 
the intervention. Outcomes were expressed in QALYs derived from multiple EQ-5D-5L questionnaires. 
3. To compare the levels of patient satisfaction associated with the two pathways: (i) referral from 
the GP to neurology services; or (ii) GP direct referral for a head MRI. 
Patient satisfaction was evaluated using a non-standard questionnaire at 3 months following the initial 
episode at secondary care (either the initial neurology outpatient appointment or an MRI scan). The 
underlying hypothesis was that the use of MRI would improve the patient’s overall satisfaction as it 
would decrease the overall number of contacts with secondary care and the time taken to obtain formal 
feedback/reassurance in each pathway. 
4. To estimate the condition specific disability (using headache diaries and HIT-6 and MIDAS 
questionnaires and EQ-5D-5L questionnaire) associated with the two pathways: (i) referral 
from the GP to neurology services; or (ii) GP direct referral for a head MRI. 
This objective evaluated the patient’s self-reported quality of life and headache burden in both 
pathways using a generic questionnaire (EQ-5D-5L), two disease-specific questionnaires (HIT-6 and 
MIDAS) and headache diaries. The headache burden was based on the number of headache days 
and self-reported intensity. Data collected during the initial secondary care episode were used for 
baseline purposes. 
5. To compare the time-off work due to chronic headache associated with the two pathways: (i) 
referral from the GP to neurology services; or (ii) GP direct referral for a head MRI. 
The study assessed potential benefits from a broader societal perspective. Time off work due to chronic 
headache was recorded in headache diaries and questionnaires filled out quarterly.  
4.2.2 Study design 
The study was a single site, prospective, observational study. The study compared two existing clinical 
pathways in the management of patients with chronic headache with either GP referral to the neurology 
department or to direct access to head MRI. No changes to the existing clinical pathways were made 
as part of the study. The study was designed to inform future decisions around the management of 




Figure 47 presents the headache MRI study schema. The expected length of time for which each 
patient participated in the study was 12 months. Given the expected short-term impact of the 
intervention, it was considered that all relevant costs and outcomes were captured within the proposed 
12-month follow-up. Data were collected quarterly (as highlighted in Figure 47 and Table 33). 
Intervention groups 
Participants were allocated to two groups: the neurology and the direct access to MRI groups. The 
allocation was decided a priori, by the referrer (in this case the GP) who decided which referral route 
would suit each participant. Subsequent care was consistent with standard care for each clinical 
pathway and is visually depicted in Figure 46.  
Random allocation and blinding 
No randomisation process took place.  
The study was unblinded. Given the nature of the intervention and its impact on subsequent care, it 
was not deemed feasible to blind participants or research staff to the intervention. This lack of blinding 
may have led to potential conscious or unconscious performance bias, with differences in care received 
in both groups potentially affected by this feature. However necessary, this constituted a study 
limitation. The lack of blinding might also have led to attrition bias, i.e. different attrition rates in both 
groups. Different preventive steps were put in place to mitigate this risk, particularly: (a) ensuring good 
communication between participants and different members of the research team; (b) financial 
incentives for participants to comply with the study follow-up; (c) utilisation of databases that were not 
based on participants self-reporting data; and (d) the use of intention-to-treat analysis. 
Follow-up Period 
All participants were followed-up 12 months following study enrolment. Data were collected at baseline 
and follow-up data were collected quarterly, at 3, 6, 9 and 12 months post-recruitment. 
4.2.3 Ethical Approval, Trial Registration and Funding 
The Health Research Authority and Research Ethics Committee (West of Scotland – REC 4) approved 
the study research on 12th April 2016. The REC reference is 16/WS/0028 and the IRAS project ID is 
163140. 
The study started on 15th April 2016, with the first participant being recruited on 19th April 2016. The 
study was registered on clinicaltrials.gov (Clinical Trial Registration: NCT02753933) on 25th April 2016. 















Timing of activity 
Prior to registration 
for study 
Immediately after 
registration into the study 
After the initial episode at secondary 
care 
3 6 9 12 
Give patient information sheet, explain study and 
obtain signed informed consent 
X   
 
  
Register patient demographics and clinical history   X     
Give patient registration pack (patient information 
sheet, copy of informed consent) 
 X  
 
  
Baseline questionnaires (HIT-6, MIDAS and EQ-
5D-5L) 
 X  
 
  
Neurology appointment  X  
 
  
MRI scan  X     
Follow-up questionnaires (HIT-6, MIDAS and EQ-
5D-5L) 
  X X X X 
Patient satisfaction questionnaire   X X   




4.2.4 Selection, withdrawal of participants and sample size 
Study Setting 
Patients were recruited at GSTT, either at the neurology department or the radiology department. 
Inclusion Criteria 
Patients suitable for the study included every patient aged 16 years or over: (i) with chronic 
headache as a primary cause that lasted ≥ 15 days per month for more than 3 months; and (ii) 
referred from GP practices to GSTT, either directly referred to an MRI exam or a neurology 
appointment.    
Exclusion Criteria 
Patients were considered to be ineligible if at least one of the exclusion criteria was present: 
 Children under the age of 16 years old; 
 Patients with red flags as defined in the NICE guideline CG150 (NICE 2018b); 
 Patients without chronic primary headache, i.e. a headache that did not persist for ≥ 15 
days per month for more than 3 months; 
 Patients with headache referred through the two week wait list; 
 Patients who lacked capacity to give consent or participate in the study; 
 Patient not fluent in English; 
 Prisoners; 
 Patients already taking part in a clinical trial of an investigational medicinal product.  
Sample Size 
The sample size estimate was calculated based on the primary endpoint, total 6-month healthcare 
costs. A total of 150 participants were needed in the neurology group and 99 participants in the 
MRI group in order to detect a cost difference of £300 assuming standard deviations of £750 and 
£500, respectively, with 85% power at the 5% two-sided significance level. The sample size was 
inflated by 20% to account for unknown cost distributions and attrition.  
Losses to Follow-Up 
If a patient moved from the GSTT catchment area, every effort was made to ensure the patient 
was followed up. If a patient was not contactable, individual patients’ GPs were contacted to obtain 
information. If the participant requested to be withdrawn from the study, her/his data were excluded 
from the analysis. Given the mobility within the Greater London area and the relatively long follow-




End of Study 
For regulatory purposes, the ‘declaration of end of trial’ form was submitted to ethical committees 
12 months after recruitment of the final participant. The last participant (249th participant) was 
recruited on 22th February 2018. 
4.2.5 Data Collection and outcomes at baseline and follow-up 
Data were collected by a research team member at baseline and then quarterly up to 12 months 
following recruitment. Data collection was completed in February 2019. 
Data at baseline were collected before the participant’s initial appointment (either neurology 
appointment or MRI exam) at GSTT. Follow-up data were collected as per the participants’ 
preference, either via phone, email or post. The participants’ preference was established at 
baseline and recorded in the case report form.  
Participant Demographics 
A variety of information was captured at baseline, including: 
1. Age; 
2. Gender (male/female); 
3. Ethnicity (e.g. White British, White Irish, White Other); 
4. Employment status (e.g. full-time job, part-time job, wholly retired from work); 
5. Qualification (e.g. high school, master’s degree); 
6. Presence of mental health condition (dichotomous variable); 
7. Headache triggers (e.g. stress); 
8. Chronic diseases (e.g. diabetes). This information was obtained from participants’ self-
reported data, data from primary care (classified under ‘active problems’) and secondary 
care clinic letters. 
9. Quality of life questionnaires (headache specific: HIT-6 and MIDAS; non-headache 
specific: EQ-5D-5L). 
At baseline, headache severity was estimated using headache diaries, HIT-6 and MIDAS 
questionnaires. In addition, data on primary care utilisation for the 12 months prior to the study 
recruitment were collected at baseline including how many times the patient used primary care 
resources (e.g. GP outpatient appointment) due to headache before referral to secondary care. 
Following referral from primary care, data on headache severity (using HIT-6, MIDAS and 
headache diaries) were also recorded on a quarterly basis post-recruitment.  
Primary Outcome 
The primary outcome was to estimate the 6-month costs associated with two existing clinical 
pathways in the management of chronic headaches: (i) referral from the GP to neurology services; 




Perspective of Analysis 
The study took a NHS perspective of analysis. Only costs of headache-related NHS events were 
considered. This approach was consistent with the methodology recommended by the NICE and 
other agencies (e.g. EUnetHTA) for the evaluation of interventions with potential impact on health 
outcomes (EUnetHTA 2015).  
The estimate of the total costs from a NHS perspective was based on the multiplication of: (a) any 
headache-related healthcare events; by (b) the unit cost of such event.  
Resource Use Measurement 
Resource use data included contacts with NHS healthcare providers associated with the 
management of headache. The methodology used to measure resource use data was similar to 
the one described in the scaphoid chapter (see section 3.2). 
Valuation of Unit Costs 
For the purposes of the primary outcome, the valuation of unit costs was, whenever possible, based 
on NHS Reference Costs 2016-17 (NHS Improvement 2017). All secondary care contacts were 
costed using this strategy.  
For primary care events, an average cost for appointment (e.g. GP face-to-face appointment, GP 
phone appointment) was derived from the Unit Costs of Health and Social Care 2016 and inflated 
to 2017 using the hospital & community health services (HCHS) index (Curtis and Burns 2017). 
The average GP face-to-face and phone appointments were estimated to be 9.22 and 23.4 minutes 
long, equivalent to, respectively, £36.50 and £118.10 (Curtis and Burns 2017). Nurse face-to-face 
and phone appointments were assumed to have the same time ratio as GP appointments, with an 
estimated cost of £19.50 and £8.00, respectively. 
Medication costs were derived from the Prescription Cost Analysis database (NHS digital 2018) 
and estimated from clinical data, specifically secondary care clinic letters, information provided by 
primary care and participant self-reported data via the resource use diaries.  
In the case of a ‘Did Not Attend (DNA)’ event, it was assumed that the NHS incurred a cost, 
estimated to be equivalent to 30% of the unit cost where the participant had attended. In any 
case, this assumption was subjected to deterministic sensitivity analyses to better understand the 
actual impact on the primary outcome.  
Table 34 lists the valuation of all unit costs considered to estimate the primary outcome, including 
the reference and the rationale behind any assumption. Sensitivity analyses were performed and 








Table 34. Unit costs for primary and secondary care events considered in the headache study. 







Per appointment £36.50 
Unit Costs of Health and Social Care 
2016 (Curtis and Burns 2017) and 
inflated to 2017 using the HCHS 
index. 
GP home visit Per appointment £118.10 
GP phone appointment Per appointment £14.80 
Nurse appointment 
(face-to-face) 
Per appointment £19.50 
Nurse phone 
appointment 
Per appointment £8.00 
Secondary care 
Emergency department 
episode with headache 





NHS Reference Costs 2017 (NHS 
Improvement 2017). Variable cost as 
was dependent on the type of 
episode, particularly the 
investigations performed. 
Head MRI  Per scan £146 
NHS Reference Costs 2017 (NHS 
Improvement 2017). 
Head CT Per scan £100 
Initial neurology 
appointment 
Per appointment £240 
Follow-up neurology 
appointment 
Per appointment £148 
Botox treatment Per treatment £238.80 
Codes AB17Z: Nerve block or 
destruction of nerve, for pain 
management; Botox: Drugs – CCG 
only – no HRG code (NHS 
Improvement 2017). 
Occipital nerve block Per treatment £635.90 
Headache-related 
inpatient episode 







This subsection summarises the methods used to collect data to estimate the five secondary 
outcomes. 
1. To estimate the 12-month costs following the initial episode at secondary care associated 
with direct access to MRI compared with referral to the neurology department. 
Cost analysis at 12 months followed the same principles and methods outlined for the primary 
outcome. 
2. To perform cost-effectiveness analyses at 6 and 12-month following the initial episode at 
secondary care associated with direct access to MRI compared with referral to the 
neurology department.  
The incremental analysis of effectiveness used QALYs as the measure of effect. QALYs are a 
generic measure of quality of life used to perform cost-utility analyses. A linear relationship was 
assumed between two time points (i.e. the QALYs between 0-3 months is the average between 
these two points). The cost-utility analysis, which is the preferred method of economic evaluation 
of NHS interventions, was performed according to NICE recommendations (NICE 2012a). 
3. To estimate and compare the levels of patient satisfaction associated with the two 
pathways. 
This secondary outcome was assessed via a questionnaire at 3 months post-recruitment. This 
questionnaire, based on a 5-point Likert scale, was used to assess any potential differences 
between the two groups. This questionnaire evaluated three dimensions: (i) referral process (time 
elapsed between referral from primary care to initial secondary care appointment); (ii) initial 
appointment (on the day satisfaction); and (iii) the overall experience three months after 
recruitment.  
4. To estimate the patient’s self-perceived quality of life (using EQ-5D-5L questionnaire) and 
disease burden (using headache diaries and HIT-6 and MIDAS questionnaires) associated 
with both pathways.  
Quality of life was assessed using the EQ-5D-5L generic questionnaire. Similarly, the headache 
disability burden was assessed using two validated headache specific questionnaires, HIT-6 
(Figure 48) and MIDAS (Figure 49). In both cases, these questionnaires were applied at baseline 
and quarterly up to 12 months post-recruitment. The HIT-6 questionnaire (Figure 48) measured 
the headache burden based on 6 questions, leading to a score range from 36 to 78. The higher 





Figure 48. Illustration of the headache-specific HIT-6 questionnaire.  
The MIDAS questionnaire (Figure 49) assessed the disability associated with the headache, 
ranging from 0 to 90. As with the HIT-6 questionnaire, the higher the score, the more severe the 
headache. Along with the headache diaries completed by participants, the MIDAS questionnaire 
collected the number of headache days per quarter (maximum of 90 days) and self-reported 
headache pain scores (ranging from 0, no pain at all, to 10, the worst pain ever) (Stewart et al. 
2001). 
Data retrieved from the MIDAS questionnaire were individually screened for errors by participants 
filling out the questionnaire. The total MIDAS score was determined by adding the scores of 5 
questions. However, the sum of questions 1 and 2 and questions 3 and 4 could not exceed 90 




student in order not to exceed the 90 days ceiling. Similarly, whenever the number of headache 
days in the past 3 months exceeded 90 days, this was corrected to a maximum of 90 days. 
 
Figure 49. Illustration of the headache-specific MIDAS questionnaire.  
5. To evaluate time-off work due to the chronic headache associated with the pathway with 
referral to the neurology department compared with direct access to MRI. 
Due to the anticipated attrition rate and potential for missing data, time off work due to chronic 





Participant diaries were either paper-based (Figure 50) or using a mobile app (Figure 51) as per 
participant’s preference established during recruitment. This study involved Patient and Public 
Involvement (PPI) during the design phase, where prior to the start of the research, a group of 
patients suffering from chronic headache were consulted to co-produce the study mobile app. In 
these diaries, participants were asked to periodically record several variables, specifically: 
presence of headache (dichotomous Yes/No variable); headache duration; headache triggers; 
medication taken due to headache; time off work/college; and any healthcare visit due to headache. 
The study diary was based on existing headache diaries used as part of routine clinical practice.  
 





Figure 51. Print screens of the mobile diary app used in the headache study.  
Two questions from the MIDAS questionnaire assessed the number of work days missed in the 
last 3 months and the number of days in the last 3 months where productivity was reduced by more 
than 50% (see Figure 49). Whenever there were discrepancies between the two documents, data 
captured via the MIDAS questionnaire were preferred because they were more likely to reflect the 
period of time considered. No information about participants’ earnings was collected and hence 
the economic cost of lost productivity was estimated by multiplying the number of lost work days 
with the average national wage rate (Office for National Statistics 2019b). 
Data on time off work were used to evaluate potential differences between groups and ultimately 
estimate potential implications from a societal perspective (as a secondary analysis).  
4.2.6 Statistical Analyses 
Analysis Population 
All analyses were based on the principle of intention-to-treat, i.e. all participants recruited were 
analysed as per the study group allocation, regardless of whether they actually received the 
intended treatment, any protocol deviations or potential losses to follow-up (Peacock, Kerry, and 
Balise 2017).  
Data Cleaning and Data Validation 
All baseline and follow-up data cleaning was performed prior to any data analysis.  
Baseline data were captured via a paper-based case report form during recruitment and then 
added to a web-based form. During this process, the PhD student screened the data for 
inconsistencies. For any potential data errors in the original hand-written data packs, participants 
or members of the research team were asked for clarification (e.g. date of birth and age do not 




The NHS resource use measurement constituting the primary outcome was obtained by merging 
six different sources of information, grouped in two areas: medical records; and data self-reported 
by participants. With regards to medical records, multiple primary and secondary care databases 
were used, particularly: (1) Electronic Patient Record (EPR) and (2) Patient Information 
Management System (PIMS), used to map the elective pathway associated with the management 
of chronic headaches; (3) Symphony, an Emergency Department software used to map the acute 
component of the pathway (e.g. attendances to ED with headache as presenting complaint; (4) 
Computerised Radiology Information System (CRIS), used to capture any data related to 
diagnostic scans (e.g. CT, MRI); and (5) primary care data, allowing the mapping of any healthcare 
event that happened outside the GSTT remit (e.g. GP appointments, attendances to ED in other 
hospitals). In addition, data self-reported by participants supplemented this information, providing 
utilisation data, particularly any activity that happened within primary care or at any other secondary 
care provider other than GSTT or even in the private sector. This comprehensive data collection 
methods (already detailed in subsection 3.2 and Figure 33) considered the validation of data using 
multiple datasets.  
Missing Data 
Participants were not excluded from the analysis due to missing data, particularly data related to 
the primary outcome. Only data from participants that formally withdrew informed consent excluded 
from the analyses. A very high degree of costing data completeness was expected given the 
comprehensive data collection methodology.  
Baseline comparability of groups 
Continuous data were summarised by: frequency, mean, standard deviation, minimum, first and 
third quartile, median and maximum. Tabulations of frequencies for categorical data were 
presented, as well as the percentage (%) relative to number of non-missing values within the 
respective intervention group, unless otherwise specified.  
Given the non-randomised study design, significance testing was performed on the baseline 
variables between intervention groups. Chi-square tests were used to assess categorical variables. 
Quantitative variables were tested for normality using the Shapiro-Wilk test and, depending on this 
result, independent t-test or Mann-Whitney U test analyses were performed. The Levene’s test was 
used to assess the homogeneity of variance [consistent with Peacock, Kerry, and Balise (2017)]. 
A p-value of p<0.05 was considered as statistically significant. 
Cost Analyses and Economic Evaluation 
Primary Objective:  
To estimate the 6-month costs associated with two existing clinical pathways in the management 
of chronic headaches: (i) referral from the GP to the neurology services; or (ii) direct referral from 
the GP to the MRI services.  
Total costs were calculated based on the multiplication of any headache-related healthcare events 




provider associated with the management of chronic headache. These included, among others, 
visits to GPs or headache clinical nurse specialist, inpatient care, neurologist or other headache-
related outpatient visits (e.g. psychiatry), physiotherapist, visits to the emergency department, 
advanced imaging such as CT and MRI.  
First, given the skewness associated with cost distributions (Peacock, Kerry, and Balise 2017), all 
cost differences between groups were assessed using GLM with an identity-link and gamma 
distribution. An identity link function instead of a log link was used in order to avoid potential biases 
(Polgreen and Brooks 2012; Barber and Thompson 2000; Peacock, Kerry, and Balise 2017). In the 
identity function covariates provide an additive effect on the mean (Jones 2011), allowing a direct 
interpretation of coefficients due to the lack of data transformation (as opposed to the log link 
function). A gamma distribution assumes a variance proportional to the square of the mean (Jones 
2011). Continuous data such as healthcare costs, with skewed distribution and variation that 
increases with the mean, can be modelled with a gamma distribution (Peacock, Kerry, and Balise 
2017). An unadjusted GLM cost analysis with the study group (neurology group vs MRI group) as 
only covariate was performed as the first step. 
Second, given the study’s observational design, the two groups being compared can be different 
due to the lack of randomisation (Manca and Austin 2008; Moran et al. 2007; Jones 2011; Cepeda 
2003). This might lead to the presence of confounders with potential impact on the outcome being 
assessed. Potential differences in baseline characteristics that might confound the primary 
outcome were assessed. Such baseline characteristics included: (i)  demographic (age, gender, 
qualification); (ii) clinical baseline characteristics [number of headache days, severity of headache 
pain, number of chronic conditions, self-perceived quality of life (EQ-5D-5L), anxiety and 
headache-specific questionnaire scores (HIT-6, MIDAS)]; and (iii) resource use utilisation prior to 
recruitment (number of GP appointments in the last 12 months prior to referral). All these baseline 
variables were assessed for statistical differences at baseline using a conservative threshold 
(p<0.10) and, if statistically different, were included as covariates in a second GLM (adjusted GLM). 
For all GLM analyses, group difference estimates and associated confidence intervals were 
reported, together with p-values. 
An alternative statistical method, bootstrap models were considered for the analysis and compared 
against GLM (Gray et al. 2011). Bootstrap is a robust approach for the analysis of skewed cost 
data and can be recommended as either a secondary analysis to check the use of standard 
parametric methods or used as the primary statistical analysis (Barber and Thompson 2000).  
All analyses were performed using the software Stata 15.0. 
Secondary Objectives: 
1. To estimate the 12-month costs following the initial episode at secondary care associated 




As with the primary outcome, both GLM and bootstrap methods were used for the 12-month cost 
analysis.  
2. To perform cost-effectiveness analyses at 6 and 12-month following the initial episode at 
secondary care associated with direct access to MRI compared with referral to the 
neurology department.  
Cost-effectiveness analyses at 6 and 12-month were performed using bootstrap models with 
QALYs as the measure of effect (Briggs, Claxton, and Sculpher 2011).  QALYs were calculated 
from utility scores at 6 and 12 months derived from the use of EQ-5D-5L questionnaire (Devlin et 
al. 2018) at five points in time: baseline (month 0), 3, 6, 9 and 12-month using area under the curve 
methods assuming linear movement between adjacent time points (Drummond et al. 2004). If utility 
data were missing, multiple imputation methods were used to assess the assumption that the data 
were missing at random. Missing data were imputed using ‘multiple imputation using chained 
equations’ (MICE), with the number of multiply imputed data-sets to be equal to the fraction of 
incomplete service-use information (White, Royston, and Wood 2011). One thousand bootstrapped 
replicates of differences in costs and outcomes were presented on cost-effectiveness planes. Cost-
effectiveness acceptability curves showed the probability of the direct access to head MRI group 
being cost effective compared to the neurology group at varying thresholds of willingness to pay. 
3. To estimate and compare the levels of patient satisfaction associated with the two 
pathways. 
Satisfaction data were evaluated using Chi-square tests. A p-value of p<0.05 was considered as 
statistically significant. 
4. To estimate the patient’s self-perceived quality of life (using EQ-5D-5L questionnaire) and 
disease burden (using headache diaries and HIT-6 and MIDAS questionnaires) associated 
with both pathways.  
Differences in the mean score for the three questionnaires (EQ-5D-5L, HIT-6 and MIDAS) were 
assessed for normality using the Shapiro-Wilk test. Depending on the findings, either independent 
t-test or Mann-Whitney U test were used to assess group differences for these variables. 
5. To evaluate time-off work due to the chronic headache associated with the pathway with 
referral to the neurology department compared with direct access to MRI. 
Differences in the mean pain score and time off-work were assessed for normality using the 
Shapiro-Wilk test. Depending on the findings, either independent t-test or Mann-Whitney U test 




Losses to Follow-Up 
Potential statistically significant differences in losses to follow-up were compared between the two 
groups. The primary outcome estimate was adjusted using a GLM assuming a conservative 
threshold of significance for follow-up differences (p<0.10) between the two study groups (second 
adjusted GLM).  
4.3 Results 
4.3.1 Data Validation and Completeness 
Only participants that withdrew the informed consent were considered lost to follow-up and hence 
not included in the data analysis.  
Baseline data were complete except for some MIDAS questionnaires (missing data in four and five 
participants in the neurology and MRI group, respectively). 
With regards to the primary outcome, data from primary and secondary care databases were, 
respectively, 97% complete (n=124 for the neurology group, n=92 for the MRI group) and 100% 
complete (n=128 for neurology group, n=95 for the MRI group). In the absence of data from both 
primary care databases and self-reported data, any resource use outside GSTT was missing. 
Missing values were imputed using the mean values from the respective group. 
With regards to secondary outcomes, data from the EQ-5D-5L questionnaire at baseline and 6 
months post-recruitment were, respectively, 99.6% complete (n=127 for the neurology group, n=95 
for the MRI group) and 36% complete (n=55 for the neurology group, n=26 for the MRI group). 
Data from the HIT-6 questionnaire at baseline and 6 months post-recruitment were, respectively, 
99% complete (n=128 for the neurology group, n=92 for the MRI group) and 21% complete (n=35 
for the neurology group, n=12 for the MRI group). Data from the MIDAS questionnaire at baseline 
and 6 months post-recruitment were, respectively, 96% complete (n=124 for the neurology group, 
n=90 for the MRI group) and 27% complete (n=46 for the neurology group, n=15 for the MRI group). 
4.3.2 Participant Flow 
Participant flow associated with the headache study is illustrated in the diagram below (Figure 52). 
A total of 249 participants were recruited, 150 in the neurology group and 99 in the MRI group. A 
hundred per cent of participants recruited received the respective allocation treatment.  
With regards to follow-up, 15% (n=22) and 4.0% (n=4) participants withdrew the informed consent 
in the neurology and MRI group, respectively, and hence were considered lost to follow-up. No 
other participants were considered lost to follow-up. 
Participants who did not withdraw their informed consent were included in the analysis, equivalent 
to 128 participants (85% of the original sample size) and 95 (96%) participants in the neurology 


















Figure 52. Participant flow chart for the headache study. 
4.3.3 Participant Characteristics – Baseline 
Table 35 and Table 37 (for categorical variables) and Table 36 (for continuous variables) report 
the baseline sociodemographic and outcome variables organised per study group. All participants 
who did not withdraw consent were included in the baseline analysis (n=223), distributed in the 
neurology group (n=128) and the MRI group (n=95). As documented in the a priori Statistical 
Analysis Plan (SAP), significance testing between intervention groups was performed given the 
non-randomised study design. 
Categorical data 
Table 35 describes the participants’ characteristics (gender, ethnicity, employments status, 
qualification and mental health condition) organised per study group. All statistical analyses were 
based on Chi-square tests. 
The large majority of participants were female, both in the neurology group (81%) and the MRI 
group (68%). This difference was statistically significant between groups (χ2(1)=4.26, p=0.039). 
The largest ethnic group was White British in both groups (42% and 39% in the neurology and the 
MRI group, respectively), followed by Black or Black British African (21% and 14% % in the 
neurology and the MRI group, respectively) and any other white background (8.6% and 22% in the 
neurology and the MRI group, respectively). The difference between groups approached statistical 
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The majority of participants reported high school as the highest education level (45% and 35% in 
the neurology and MRI group), followed by Bachelor’s degree (24% and 31% in the neurology and 
MRI group). The difference between groups was not statistically significant (χ2(6)=4.84, p=0.565). 
With regards to the employment status, most participants were employed full-time (39 and 38% in 
the neurology and MRI group), with 6.3% of participants in both groups being permanently sick or 
disabled. The difference between groups was not statistically significant (χ2(9)=4.95, p=0.839). 
In terms of psychiatric comorbidities, 17% of participants in the neurology and 12% in MRI group 
reported at least one mental health condition. The difference between groups was not statistically 
significant (χ2(1)=1.36, p=0.243). 
Continuous data 
All quantitative variables were assessed for normality using the Shapiro-Wilk test, based on a 
significance value of p<0.001. As the assumption of normality was not met, the Mann-Whitney U 
test was used.  
The mean age (SD) of participants was 38.4 (14.1) and 40.0 (14.6) years old in the neurology and 
the MRI group, respectively (see Table 36 for further detail). The difference between groups was 
not statistically significant (p=0.514). 
The number of active health problems at baseline was estimated. The mean (SD) number of active 
health problems was 2.0 (1.5) and 1.8 (1.4) in the neurology and MRI group, respectively. The 
difference between groups was not statistically significant (p=0.277). 
The mean (SD) number of headache triggers was estimated at 2.1 (1.8) and 1.8 (1.4) in the 
neurology and MRI group, respectively. The difference between groups was not statistically 
significant (p=0.378). 
The mean number of days (SD) from referral to first appointment, either a neurology appointment 
or head MRI scan, was measured as a proxy of accessibility to care. The neurology and MRI group 
represented 110 (35) and 39 days (17), respectively, which was statistically significant (p<0.001). 
It was assumed that the MRI intervention would only be delivered once the actionable information, 
i.e. the MRI report, was available to the referrer (GP). The mean (SD) time elapsed from referral to 
MRI results being available to GP at 70 days (35). Deducting this with the time it took for patients 
to have the first appointment in the neurology group, the difference between groups in waiting times 
remained statistically significant (p<0.001). 
Health-related quality of life (HRQL) at baseline was assessed using three questionnaires, one 
generic (EQ-5D-5L) and two headache-specific (HIT-6 and MIDAS). Again, it is relevant to highlight 
that all questionnaires were administered before the neurology appointment or the MRI scan. The 
mean utility (SD) at baseline (generated from the EQ-5D-5L questionnaire) was 0.809 (0.182) and 
0.830 (0.195) for the neurology and MRI groups, respectively. This trend was found to approach 
statistical significance (p=0.097). The mean (SD) self-reported quality of life score, based on a 0-
100 visual analogue scale, was estimated at 64.0 (18.8) and 70.8 (20.2) for the neurology and MRI 




Table 35. Categorical sociodemographic and baseline characteristics of participants. 
 
Neurology  MRI  
p-value 
N % N % 
Gender 
Male 25 20% 30 32% 
p=0.039 
Female 103 81% 65 68% 
Ethnicity 
White British 54 42% 37 39% 
p=0.079 
White Irish 3 2.3% 2 2.1% 
Any other White background 11 8.6% 21 22% 
Mixed White and Black Caribbean 3 2.3% 4 4.2% 
Mixed White and Asian 0 0.0% 2 2.1% 
Any other Mixed background 2 1.6% 2 2.1% 
Asian or Asian British Indian 3 2.3% 1 1.1% 
Asian or Asian British Bangladeshi 1 0.8% 2 2.1% 
Asian or Asian British Pakistani 3 2.3% 0 0.0% 
Any other Asian background 6 4.7% 3 3.2% 
Black or Black British Caribbean 10 7.8% 4 4.2% 
Black or Black British African 27 21% 13 14% 
Any other Black background 3 2.3% 0 0.0% 
Any other ethnic background 2 1.6% 4 4.2% 
Qualification 
Advanced Graduate Work or PhD 3 2.3% 4 4.2% 
p=0.565 
Master’s Degree 15 12% 12 13% 
Bachelor’s Degree 31 24% 29 31% 
High School 57 45% 33 35% 
Did not finish High School 8 6.3% 10 11% 
Prefer not to answer 14 11% 7 7.4% 
Employment 
Employee in full time job (30 hours 
or more a week) 
50 39% 36 38% 
p=0.839 
Employee in part-time job (under 30 
hours a week) 
18 14% 18 19% 
Self-employed, full or part time 12 9.4% 8 8.4% 
Full-time education at school, 
college or university 
16 13% 9 9.5% 
Doing something else 2 1.6% 2 2.1% 
Permanently sick/ disabled 8 6.3% 6 6.3% 
Looking after the home 4 3.1% 6 6.3% 
Unemployed and available for work 12 9.4% 6 6.3% 
Wholly retired from work 4 3.1% 4 4.2% 
Prefer not to answer 2 1.6% 0 0.0% 
Mental Health 
condition 
Yes 22 17% 11 12% 
p=0.243 




Table 36. Continuous sociodemographic and baseline characteristics of participants. 











Neurology 128 38.4 14.1 16.0 25.0 37.0 51.0 79.0 
p=0.514 
MRI 95 40.0 14.6 16.0 29.0 38.0 49.0 87.0 
Active Health Problems  
Neurology 128 2.0 1.5 0 1.0 2.0 3.0 6.0 
p=0.277 
MRI 95 1.8 1.4 0 1.0 2.0 3.0 6.0 
Number of headache triggers  
Neurology 128 2.1 1.8 0 1.0 2.0 3.0 7.0 
p=0.378 
MRI 95 1.8 1.4 0 1.0 2.0 3.0 8.0 
Days Referral to 1st 
appointment 
 
Neurology 128 110 35 4 97 112 132 227 
p<0.001 
MRI 95 39 17 2 36 41 46 90 
MRI: referral to results  MRI 94 70 35 7 46 76 94 206 p<0.001 
EQ-5D-5L utility baseline  
Neurology 128 0.809 0.182 -0.185 0.747 0.851 0.942 1.000 
p=0.097 
MRI 95 0.830 0.195 -0.170 0.777 0.881 0.942 1.000 
EQ-5D-5L visual analogue 
scale (VAS) baseline 
 
Neurology 128 64.0 18.8 10.0 50.0 70.0 80.0 100.0 
p=0.005 
MRI 95 70.8 20.2 10.0 55.0 70.0 90.0 100.0 
HIT-6 baseline  
Neurology 128 65.0 5.3 44.0 63.0 66.0 68.0 78.0 
p=0.006 
MRI 95 62.6 7.3 36.0 59.0 63.0 68.0 78.0 
MIDAS baseline score  
Neurology 128 57.8 54.0 0 17.0 42.0 79.0 215.0 
p=0.075 
MRI 95 44.8 44.9 0 13.0 29.0 68.0 240.0 
MIDAS headache days  
Neurology 128 51.6 31.5 .0 24.0 48.0 90.0 90.0 
p=0.038 
MRI 95 42.8 30.7 1.0 15.0 36.0 70.0 90.0 
MIDAS headache pain score   
Neurology 128 6.9 1.8 0 6.0 7.0 8.0 10.0 
p=0.778 




The mean (SD) HIT-6 score at baseline was estimated at 65.0 (5.3) and 62.6 (7.3) for the neurology 
and MRI group, respectively (Table 36). This difference was statistically significant (p=0.006). The 
mean (SD) MIDAS score at baseline was estimated at 57.8 (54.0) and 44.8 (44.9) for the neurology 
and MRI group, respectively. This trend approached statistical significance (p=0.075).  
The number of headache days and mean pain score in the three months prior to recruitment were 
assessed at baseline using the MIDAS questionnaire (Table 36). The mean (SD) number of 
headache days was estimated at 51.6 (31.5) and 42.8 (30.7) for the neurology and MRI groups, 
respectively, with the difference being statistically significant (p=0.038). The mean (SD) headache 
pain was estimated at 6.9 (1.8) and 6.9 (1.9) for the neurology and MRI groups (p=0.778).  
The disability score at baseline as per the MIDAS questionnaire is presented in Table 37. A higher 
proportion of patients in the neurology group (70%) presented a grade IV (severe disability) 
compared to the MRI group (60%). However, no statistically significant difference in the distribution 
of grade of headache disability between both groups (p=0.357). 





N % N % 
MIDAS Grade 
Little or No Disability 11 8.6% 13 14% 
p=0.357 
Mild Disability 12 9.4% 7 7.4% 
Moderate Disability 11 8.6% 13 14% 
Severe Disability 90 70 % 57 60% 
 Missing 4 3.1% 5 5.3% 
Notes: * Chi-square test. 
NHS healthcare resources utilised in the management of chronic headache in the 12 months 
prior to study recruitment were collected, including GP appointments and all NHS appointments 
(including GP appointments), are presented in Table 38. The neurology group had a statistically 
significant higher number of both GP appointments [mean (SD) of 3.7 (2.9) vs 2.4 (1.5), p<0.001] 
and all NHS appointments [mean of 4.3 (3.7) vs 2.5 (1.5), p<0.001].  
Table 39 summarises the respective costs in the 12 months prior to recruitment, showing that the 
participants in the neurology group had higher costs compared to the MRI group participants [mean 





Table 38. GP and NHS contacts associated with the management of chronic headache in the 12 
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Total Cost during the 12 






-125 -181 to -70 < 0.001 
4.3.4 Primary Outcome 
The primary outcome was to estimate the 6-month costs condition-related associated with both 
groups. Table 40 summarises the 6-month cost distribution (mean, standard deviation, minimum, 
median, percentiles 25 and 75 and maximum) per group. The mean cost of management per 
participant [mean (SD)] was lower in the MRI group compared to the neurology group [£245 (£172) 
vs £578 (£420)] (Table 40), leading to a mean cost difference between groups of £333 per 
participant.  














£578 £420 £40 £396 £476 £628 £3,758 
MRI         
(n=95) 




The cost distribution is positively skewed (mean >> median), as it is affected by a small proportion 
of patients that had significantly higher costs. A higher proportion of patients in the MRI group were 
in the £0-£250 range compared to the Neurology group (71.6% vs 4.7%). In the over £1000 
category, a lower proportion of participants in the MRI group were found compared to the control 
group (1.1% vs 7.0%, with a maximum cost of £3,758 and £1,494 for the neurology and MRI group, 
respectively). Eighty-five percent of participants in the control group cost between £250 and £750 
compared to 27% in the MRI group. The latter is illustrated in Figure 53 and Figure 54. 
 
Figure 53. Histogram for the 6-month cost distribution for the neurology group.  
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(i) GLM analysis: Unadjusted Generalised Linear Model  
Taking into consideration the anticipated data skewness, the statistical analysis plan used GLM to 
model the 6-month cost analysis, using a Gamma family distribution and identity link. The analysis 
is summarised in Table 41.  
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-413 to  
-253 
< 0.001 
The mean cost difference between both groups at 6 months was -£333 (CI 95%: - £413 to -£253) 
per participant (p<0.001).  
(ii) GLM analyses: Adjusted Generalised Linear Model 
Given the non-randomised study design, a second GLM analysis was performed to adjust using 
baseline characteristics that were statistically different between groups (see Table 42). A 
conservative threshold (p<0.10) was assumed for this purpose. The variable ‘ethnicity’ was not 
included as it was a string variable. For instance, female patients (variable ‘gender’) had costs that 
were on average £53 higher than men (see Table 42). The mean cost difference between both 
groups at 6 months after adjusting for baseline imbalances decreased to -£308 (CI 95%: -£408 to 
-£209) per participant (p<0.001). 
Table 42. GLM analysis for the 6-month cost analysis variable (gamma function, identity link) 
adjusted using statistically significant differences (p<0.1) between groups at baseline. 
6-month cost Coef. Std. Err. t P>|t| [95% CI] 
Group (Neurology/MRI) -308.3 50.8 -6.07 0.000 -407.8 -208.8 
Gender 53.1 37.2 1.43 0.154 -19.9 126.1 
Time referral MRI or Neurologist 0.018 0.305 0.06 0.954 -0.580 0.615 
Baseline EQ-5D-5L utility 0.318 1.155 0.27 0.783 -1.946 2.581 
Baseline EQ-5D-5L VAS -0.341 1.170 -0.29 0.771 -2.634 1.952 
Baseline HIT-6 0.020 0.123 0.17 0.868 -0.220 0.261 
Baseline MIDAS score 0.121 0.463 0.26 0.793 -0.785 1.028 
Baseline MIDAS Headache Days -0.164 0.468 -0.35 0.727 -1.082 0.755 
NHS costs 12 months before  0.139 0.087 1.59 0.112 -0.032 0.310 




Besides the study’s observational nature, the potential impact on the primary outcome due to 
missing follow-up data was also assessed. For this purpose, differences in baseline characteristics 
between participants with complete follow-up up to 6 months compared to those without follow-up 
were assessed. A third GLM, including the follow-up variable (binomial Yes/No), was performed 
and the results are presented in Table 43. The mean cost difference between both groups at 6 
months after adjusting for baseline imbalances decreased to -£302 (CI 95%: -£411 to -£193) per 
participant (p<0.001) 
Table 43. GLM analysis for the 6-month cost analysis variable (gamma function, identity link) 
adjusted using statistically significant differences (p<0.1) between groups at baseline and 
considering the presence/absence of complete follow-up up to month 6. 
6-month cost Coef. Std. Err. t P>|t| [95% CI] 
Group (NE/RA) -302.3 55.7 -5.430 0.000 -411.4 -193.1 
Gender 53.0 37.4 1.410 0.157 -20.4 126.3 
Time from referral to MRI or 
appointment with a neurologist 
0.024 0.304 0.080 0.938 -0.573 0.620 
Baseline EQ-5D-5L utility 0.390 1.188 0.330 0.743 -1.938 2.718 
Baseline EQ-5D-5L VAS -0.414 1.203 -0.340 0.731 -2.773 1.945 
Baseline HIT-6 0.017 0.124 0.140 0.890 -0.227 0.261 
Baseline MIDAS score 0.111 0.461 0.240 0.809 -0.792 1.015 
Baseline MIDAS Headache Days -0.151 0.468 -0.320 0.747 -1.067 0.766 
NHS costs 12 months before 0.134 0.088 1.530 0.127 -0.038 0.306 
Follow-up 13.1 49.6 0.260 0.792 -84.1 110.3 
Constant 772.2 145.1 5.320 0.000 487.8 1056.6 
Table 44 summarises the three GLM analyses performed. The initial unadjusted 6-month cost 
difference between groups (-£333) was robust and not too affected by the observational nature of 
the study (-£308) or follow-up completeness (-£302). In all analyses, direct access to MRI for the 
management of chronic headache was associated with statistically significant NHS cost savings. 
Table 44. Summary table with the three GLM analysis for the 6-month cost analysis: (i) unadjusted; 
(ii) adjusted for imbalance in baseline characteristics; and (iii) adjusted for follow-up completeness. 
 Mean 6-month cost [95% CI] 
 Unadjusted 
Adjusted for baseline 
characteristics (p<0.1) 
Adjusted for baseline 
characteristics and follow-up 
completeness (p<0.1) 
Primary Outcome        










(ii) Bootstrap analysis 
A 1000-replicate bootstrap analysis for the variable total 6 month costs was also performed. The 
95% confidence interval for three types of bootstraps (normal, percentile and bias-corrected) are 
presented in Table 45. As with the GLM, the same mean difference cost per participant was 
obtained (- £333) but the 95% confidence intervals varied based on the type of bootstrap analysis 
considered: normal (CI 95%: - £413 to -£253); percentile (CI 95%: - £414 to -£257); and bias-
corrected (CI 95%: - £419 to -£263). All bootstrap analyses showed a statistically significant cost 
difference per participant (the value 0 is not included in the 95% CI). The use of bias-corrected 
bootstrap analysis is the most appropriate to assess skewed cost data (Jiang and Zhou 2004). 
Table 45. Bootstrap analysis for the variable total cost at 6 months (1,000 replicates). 
Variable Reps Observed Bias Std. Err. [95% Conf. Interval] 
Study Group 1000 -£333 1.132 40.7 
-£413 -£253 (N) 
-£414 -£257 (P) 
-£419 -£263 (BC) 
Note: N=normal; P=percentile; BC=bias-corrected 
4.3.5 Secondary Outcome 
1. To estimate the 12-month costs following the initial episode at secondary care associated 
with direct access to MRI compared with referral to the neurology department. 
The first secondary outcome extended the 6 month cost analysis to the 12 months following 
recruitment into the study. Table 46 summarises the total and mean number of NHS events up to 
12 months post-recruitment, along with the number and percentage of participants responsible for 
such events. With regards to primary care appointments, participants in the neurology group had 
a higher number of GP face-to-face appointments (mean of 1.82 vs 1.19, p=0.006). If secondary 
care appointments are considered, participants in the neurology group had a higher number of 
outpatient appointments (mean of 2.52 vs 0.26, p<0.001) and other treatments such as Botox and 
nerve injection (mean of 0.30 vs 0.05, p<0.001). In contrast, participants in the neurology group 
had a lower number of head MRIs (mean number 0.59 vs 1.05, p<0.001). There were no 





Table 46. Number of NHS appointments organised per type of activity and study group. 
 Neurology group (n=128) MRI group (n=95) 
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The use of NHS resource pre and post-recruitment were also compared. Table 47 summarises the 
difference between headache-related events 12 months post-recruitment compared to the 12 
months pre-recruitment. A reduction of 197 and 87 GP visits, equivalent to a mean reduction of 
1.54/0.92 per participant, was reported in the neurology and MRI group, respectively. Similarly, 
there was a reduction in emergency department utilisation with a decrease of 23 and 6 episodes, 
equivalent to a mean reduction of 0.18 and 0.07 episodes per participant, in the neurology and MRI 





Table 47. Differences in the total number, mean and percentage reduction of NHS appointments 
organised per type of activity and study group in the 12 months post-recruitment compared to the 




MRI group  
(n=95) 







Primary care services 
GP face-to-face appointment -197 -1.54 -87 -0.92 
GP phone appointment -11 -0.09 5 0.05 
Hospital-based services 
Hospital outpatient appointment 301 2.36 23 0.24 
Inpatient episode 3 0.02 1 0.01 
Emergency Department episode -23 -0.18 -6 -0.07 
Head CT -9 -0.07 1 0.01 
Head MRI 55 0.43 100 1.05 
Note: a negative/positive number denotes a decrease/increase in activity following recruitment. 
(i) GLM analysis: Unadjusted Generalised Linear Model  
Similarly to the primary outcome, a GLM analysis using the study group as the only covariate was 
conducted to estimate the 12-month total costs (Table 48). As with the 6-month cost analysis, the 
MRI intervention was associated with lower overall cost, with a mean cost difference between 
groups of -£518 (CI 95%: - £637 to - £401) per participant (p<0.001). 
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(i) GLM analyses: Adjusted Generalised Linear Model 
Two further adjusted GLM analyses were performed and the results are presented in Table 49. As 
with the primary outcome, the intervention with direct access to MRI for the management of chronic 
headache was associated with cost savings despite the observational nature of the study and the 
absence of follow-up data for some participants. 
Table 49. Summary table with the three GLM analysis for the 12-month cost analysis: (i) 
unadjusted; (ii) adjusted for imbalance in baseline characteristics due to non-randomised design; 
and (iii) the addition of differences in terms of follow-up completeness. 
 Mean 12-month cost [95% CI] 
 Unadjusted 
Adjusted for baseline 
characteristics (p<0.1) 
Adjusted for baseline 
characteristics follow-up 
completeness (p<0.1) 
Secondary Outcome        








(ii) Bootstrap analysis 
A 1000-replicate bootstrap analysis for the variable total 12 month costs was also performed. The 
95% confidence intervals for three types of bootstraps (normal, percentile and bias-corrected) are 
presented in Table 50. All bootstrap analyses showed a statistically significant cost difference per 
participant (the value 0 is not included in the 95% CI). 
Table 50. Bootstrap analysis for the variable total cost at 6 months (1,000 replicates). 
Variable Reps Observed Bias Std. Err. [95% Conf. Interval] 
Study Group 1000 -£518 1.188 57.5 
-£632 -£406 (N) 
-£632 -£410 (P) 
-£634 -£411 (BC) 
Note: N= normal; P= percentile; BC= bias-corrected 
2. To perform cost-effectiveness analyses at 6 and 12-month following direct access to MRI 
compared with referral to the neurology department.  
Other secondary outcomes related to cost-effectiveness analyses using measures of effect based 
on a self-reported non-headache specific questionnaire (EQ-5D-5L questionnaire). This is a cost-
utility analysis. The utility values and health rating (based on a 0-100 visual analogue scale) at 




At baseline, participants in the neurology group showed a trend of lower utility (mean utility of 0.809 
vs 0.830, p=0.097) and a statistically significant lower self-perceived health rating (mean score of 
64.0 vs 70.8, p=0.005). No statistically significant difference (p>0.05) between the groups occurred 
at either 6 or 12 months in relation to the utility and self-reported VAS scores.  
A high proportion of data were missing, particularly at 12 months, with 75% and 85% of follow-up 
data missing in the neurology and MRI groups, respectively. For this reason, it was decided not to 
undertake a cost-utility analysis at 12 months. Hence, this section presents the 6-month cost-utility 
analysis only. 
Table 51. Descriptive statistics for the variable utility and VAS values. 













Neurology 127 0.809 .182 
0.097 
Radiology  95 0.830 .195 
VAS  
Neurology 126 64.0 18.8 
0.005 








Neurology 55 0.770 .263 
0.243 
Radiology 26 0.681 .346 
VAS  
Neurology 53 68.2 20.6 
0.463 










Neurology 32 0.667 .335 
0.548 
Radiology 15 0.631 .369 
VAS  
Neurology 28 65.5 21.7 
0.533 
Radiology 15 55.5 30.3 
Cost-effectiveness analyses were based on incremental costs divided by incremental effects, in 
this case measured in QALYs. The mean cost per QALY at month 6 (Equation 9) was estimated 
at £7,483. 
Equation 9. Estimate of the incremental cost per QALY at month 6. 
𝐼𝐶𝐸𝑅 =
𝐶𝑜𝑠𝑡 𝑀𝑅𝐼 − 𝐶𝑜𝑠𝑡 𝑛𝑒𝑢𝑟𝑜𝑙𝑜𝑔𝑦








In order to adjust for imbalance in mean baseline utilities, a multiple regression analysis was used 
as suggested by Manca, Hawkins, and Sculpher (2005) and detailed below in Table 52 and 




Table 52. Summary of the regression analysis for utility at month 6 adjusted by two variables: 
randomisation group and baseline utility.  
Number of observations=76; R-squared = 0.2440; Adjusted R-squared = 0.2233 
Utility month 6 Coef. Std. Err. t P>|t| [95% Conf. Interval] 
Group -0.1206 0.0655 -1.84 0.07 -0.2512 0.0010 
Utility baseline  0.8994 0.1932 4.66 0.00 0.5144 1.2843 
Constant 0.1495 0.1762 0.85 0.399 -0.2017 0.5007 
Equation 10. Multiple regression analysis for the utility at month 6 adjusted per study group and 
utility at baseline. 
Utility at month 6 = 0.1495 - 0.1206 * Study Group + 0.8994 * Utility at baseline 
Note: Study group (0= neurology group; 1= MRI group).  
Figure 55 illustrates the bootstrap analysis with 1,000 replicates, considering the 6-month cost per 
QALY adjusted using the baseline utility. At month 6, the intervention with MRI had a probability of 
4.1% of being dominant (i.e. increased QALYs at a lower cost) compared to the neurology group. 
In the obverse quadrant, there was a 0.0% probability of the MRI intervention being dominated (i.e. 
lower QALYs at a higher cost) by the neurology group. The remaining 95.9% of bootstraps were in 
the cost-effectiveness analysis quadrants, i.e. the probability of being cost-effective depended on 
the overall system willingness-to-pay for each QALY.  
 
Figure 55. Cost-effectiveness plane associated with the 6-month cost per QALY analysis and 




The cost-effectiveness acceptability curve (CEAC) shows the probability of access to MRI being 
more cost-effective than referral to neurology at different willingness-to-pay thresholds (Figure 56). 
For instance, assuming a £20,000 and £30,000 willingness-to-pay per QALY (thresholds typically 
considered by NICE), there was a 7.2% and 4.1% probability that direct access to MRI was more 
cost-effective at month 6, respectively (Figure 56). Unlike the usual situation with replicates located 
in the northeast quadrant (more costly and more effective), in this case the higher the system’s 
willingness-to-pay threshold, the less likely the intervention is to be cost-effective. This is because 
most replicates were within the southwest quadrant (less costly and less effective). The CEAC cuts 
the y axis at 1.0 as it is the probability of the MRI group generating cost savings and asymptotes 
towards 0 as four percent of replicates generated health gains (Fenwick, O’Brien, and Briggs 2004). 
 
Figure 56. CEAC for several thresholds of willingness-for-pay (represented as λ). 
3. To compare the levels of patient satisfaction associated with the two pathways. 
Participant satisfaction was evaluated at month 3 post-recruitment using a non-validated 
questionnaire. This questionnaire evaluated three dimensions: (a) referral process (time elapsed 
between referral from primary care to initial secondary care appointment) (Table 53); (b) initial 
appointment (on the day satisfaction) (Table 54); and (c) the overall experience three months after 
recruitment (Table 55). The Pearson Chi-square statistical test was used in all analyses. 
The first two questions assessed the period elapsed between the GP referral and the initial 
secondary appointment (Table 53), either for a neurologist appointment or a head MRI. More 
participants in the MRI group tended to receive an appointment in an acceptable timeframe 




reported higher satisfaction levels (p=0.005) associated with the information received prior to the 
actual appointment.  
The next two questions evaluated the initial appointment itself (Table 54). No statistical difference 
(p=0.366) between the groups was found regarding the satisfaction levels with both types of 
appointment (MRI scan or neurologist initial appointment). A higher proportion of participants in the 
neurology group reported a better experience compared to their expectation (p=0.002). 
The final six questions (Table 55) assessed the overall patient experience at month 3 post-
recruitment. In all variables, except frequency of appointments (p=0.166), participants in the 
neurology group reported higher levels of satisfaction with: amount of time spent with clinical staff 
(p=0.001); consistency of care (p=0.028); how informed you felt about your condition (p=0.010); 
how informed you felt about your treatment (p=0.004); and the overall experience (p<0.001). 
Table 53. Patient experience questionnaire associated with the referral process to either neurology 
(n=99) or MRI group (n=79). 
Before the appointment 
Not sure Yes No 
N % N % N % 
Did you receive your 
appointment within a 
timeframe acceptable to 
you? 
Neurology (n=99) 8 8.1% 66 67% 25 25% 
MRI (n=79) 3 3.8% 62 79% 14 18% 
 
  Very 
satisfied 
Satisfied Neutral Dissatisfied Very 
dissatisfied 
 N % N % N % N % N % 
How satisfied 
were with the 
information 
you received 
beforehand?   
Neurology 
(n=98) 











Table 54. Patient experience questionnaire associated with either the Neurology (n=99) or the MRI 
group (n=50) appointment. 
  Very 
satisfied 
Satisfied Neutral Dissatisfied Very 
dissatisfied 
































N % N % N % 
How did you find the 
experience in comparison 
to what you had 
expected? 
Neurology (n=95) 57 60% 35 37% 3 3.2% 
MRI (n=45) 13 29% 31 69% 1 2.2% 
Table 55. Overall patient experience for participants in the Neurology (n=56) or the MRI group 
(n=14) group. 
About the entire 




Satisfied Neutral Dissatisfied Very 
dissatisfied 







20 36% 30 54% 6 11% 0 0% 0 0% 





16 55% 0 0% 12 41% 1 3.4% 0 0% 





9 16% 19 35% 22 40% 4 7.3% 1 1.8% 
MRI (n=14) 2 14% 1 7.1% 7 50% 3 21% 1 7.1% 
How informed 




15 28% 24 44% 9 17% 5 9.3% 1 1.9% 
MRI (n=13) 2 15% 2 15% 5 39% 1 7.7% 3 23% 
How informed 




15 27% 18 33% 17 31% 4 7.3% 1 1.8% 





13 24% 32 58% 7 13% 3 5.5% 0 0% 
MRI (n=14) 2 14% 1 7.1% 9 64% 1 7.1% 1 7.1% 
4. To estimate the disease burden (using headache diaries and HIT-6 and MIDAS 
questionnaires) associated with both pathways.  
Two headache-specific questionnaires were used to assess the headache burden associated with 




The Headache Impact Test (HIT-6) questionnaire (Kosinski et al. 2003) measured the headache 
burden based on 6 questions, leading to a score range from 36 to 78. The higher the score, the 
more severe the headache burden is.  
Participants in the neurology group reported a higher headache burden at baseline compared to 
the MRI group (mean score of 65.0 vs 62.6, p=0.006) (Table 56). Over the follow-up period no 
statistically significant differences between the groups, both at 6 months (mean HIT-6: 60.0 vs 
53.1, p=0.968) and 12 months (62.0 vs 56.5, p=0.409). The use of the HIT-6 questionnaire was 
associated with very high attrition rate (79% and 88% at month 6 and 12, respectively).  
Table 56. Descriptive statistics for the HIT-6 questionnaire. 














Neurology 128 65.0 5.3 
0.006 










Neurology 35 60.0 8.7 
0.968 











Neurology 21 62.0 9.9 
0.409 
MRI 5 56.5 10.3 
The Migraine Disability Assessment (MIDAS) questionnaire (Stewart et al. 2001) also assessed 
headache disability. The higher the score (ranges from 0 to 90), the higher the MIDAS grade and 
the respective headache severity. Participants in the neurology group presented a trend of higher 
headache severity at baseline compared to the MRI group (mean MIDAS score of 57.8 vs 44.8, 
p=0.075) (Table 57). Over the follow-up period, neurology participants reported more severe 
headaches both at 6 months (52.6 vs 40.7, p=0.827) and 12 months (45.7 vs 29.3, p=0.498) but 
both differences were not statistically significant. Similar to the HIT-6 questionnaire, the use of 
MIDAS questionnaire was associated with very high attrition rate (80% and 82% at month 6 and 
12, respectively). 
A second variable estimated the number of headache days. Participants in the neurology group 
reported a higher number of headache days at baseline compared to the MRI group (51.6 vs 42.8, 
p=0.038). A similar trend seemed to be kept over the follow-up period, both at 6 months (41.2 vs 
26.5, p=0.152) and 12 months (36.1 vs 9.9, p=0.170). 
A third variable assessed self-reported headache pain scores. Participants at baseline showed 




differences were found at 6 months (4.5 vs 4.2, p=0.663) or 12 months (5.5 vs 6.8, p=0.407). As 
with other outcomes, very high attrition rates were reported over time, particularly at 12 months 
post-recruitment, and in both groups, mostly in the MRI group. 
Table 57. Descriptive statistics for the MIDAS questionnaire. 














Neurology 124 57.8 54.0 
0.075 
MRI 90 44.8 44.9 
Headache 
days 
Neurology 124 51.6 31.5 
0.038 
MRI 90 42.8 30.7 
Pain 
Score  
Neurology 124 6.9 1.8 
0.778 










Neurology 32 52.6 58.1 
0.827 
MRI 12 40.7 36.0 
Headache 
days 
Neurology 46 41.2 28.6 
0.152 
MRI 15 26.5 28.1 
Pain 
Score  
Neurology 44 4.5 2.3 
0.663 











Neurology 29 45.7 55.7 
0.498 
MRI 10 29.3 37.0 
Headache 
days 
Neurology 30 36.1 35.8 
0.170 
MRI 10 9.9 9.7 
Pain 
Score  
Neurology 29 5.5 2.5 
0.407 
MRI 10 6.8 3.0 
Changes in management: 
Changes to care management in both groups were evaluated. It was considered that a change in 
care management occurred when patients were prescribed new medication or underwent new 




Participants in the neurology group were more likely to have a change in therapeutic management 
compared to participants in the MRI group (97% vs 64%, p<0.001). Similarly, among participants 
that had not started on preventative medication pre-recruitment, a higher proportion of participants 
in the neurology group were started on preventative medication as part of their clinical management 
(93% vs 53%, p<0.001). 
Incidental findings: 
Out of the 95 participants recruited into the MRI group, 3 MRIs were not performed during the initial 
appointment due to claustrophobia events. From a total number of 92 MRIs, 85 (92%) were normal 
and 7 (7.6%) presented abnormal findings (Table 58), with one diagnosis being particularly 
significant (two small intracranial aneurysms). This participant was referred to the neurovascular 
team for assessment, at which point no intervention was performed during the follow-up period 
(participant included in an aneurysm active surveillance group). Two other participants had a 
change in their clinical management for less significant findings, leading to either a follow-up 
appointment or an imaging scan. No brain malignancies were diagnosed. 




Changes in diagnostic or 
treatment pathway 
Mature striatocapsular lacune No  
Sinusitis with complete opacification No 
Ear, nose and throat (ENT) 
review only. 
Pituitary abnormality No  
Low lying cerebellar tonsils No  
Previous petrous surgery noted No  
Two aneurysms: anterior communicating 
artery and right internal carotid artery  
Yes 
Referred to neurovascular – no 
coiling (no intervention). 
No definitive lesion No Follow-up MRI only. 
5. To evaluate time-off work due to the chronic headache associated with the pathway with 
referral to the neurology department compared with direct access to MRI. 
The number of days off work were estimated using participant diaries and MIDAS questionnaires.  
Participants in the neurology group (n=83) reported higher mean number of days off work due to 
headache compared to the MRI group (n=35) but these were not statistically significant at 6 months 




Table 59. Descriptive statistics of the number of days off work per group (n=83 for the neurology 
group and n=35 for the MRI group). 













Days off work  
Neurology 14.0 22.7 
0.883 











Days off work 
Neurology 13.9 22.6 
0.563 











Days off work 
Neurology 27.9 44.7 
0.809 
MRI 19.1 18.7 
4.3.6 Sensitivity Analyses 
Deterministic sensitivity analyses around three unit cost parameters were performed: (i) head MRI; 
(ii) neurology appointments (both first and follow-up outpatient appointments); and (iii) ‘Did not 
attend’ cost. One additional sensitivity scenario considered a societal perspective of analysis 
instead of the NHS perspective. The results from the sensitivity analyses are summarised in Table 
60. 
(i) Direct access to MRI. The unit cost per head MRI was a fundamental cost variable associated 
with participants in the MRI group. The £146 unit cost was based on the NHS reference costs, code 
“RD01A (imaging: direct access): Magnetic Resonance Imaging Scan of One Area, without 
Contrast, 19 years and over” (NHS Improvement 2017). This unit cost considered not only to the 
time it took to complete the actual acquisition time but also the subsequent reporting. This unit cost 
was varied - 25%, equivalent to £110. This change was consistent with the historical trend of 
reduction exhibited in the direct access to MRI tariff. Under this scenario, the cost difference per 
participant at 6 and 12 months between groups increased, respectively, to -£367 (p<0.001) and -
£552 (p<0.001). 
(ii) Neurology appointments. The unit cost per neurology appointment (first and follow-up 
appointments) was reduced by 25%, equivalent to £180 and £111 for the initial and follow-up 
neurology appointment, respectively. Again, this variation was consistent with the historical trend 
of decrease in the unit cost per neurology consultation in the NHS reference costs. This unit cost 
variation led to a decrease of the cost difference between groups at 6 and 12 months to, 
respectively, -£263 (p<0.001) and -£482 (p<0.001). 
(iii) ‘Did not attend’ (DNA) assumption. The baseline unit cost per DNA event was considered at 
30% of the cost of the event when patients did attend. The latter is particularly relevant in outpatient 
visits (i.e. neurology appointments). This deterministic sensitivity analysis did not consider DNA 
costs (i.e. equals to £0). This variation led to a mean cost difference between groups of -£327 




(iv) Societal costs. In July 2019, the average full-time weekly earnings was estimated at £503 
(Office for National Statistics 2019a), equivalent to a daily wage of £100.6 per work day. The daily 
wage of participants in part-time occupation or participants unemployed but actively looking for a 
job were assumed to be half of those in full-time occupation. Participants permanently sick or 
disabled, in education (college or university) or wholly retired from work were assumed to have no 
productivity loss (£0). 
Table 60. Sensitivity analyses scenarios considered and respective impact on the cost analyses 




P-value            
(using GLM) 
 Month 6 Month 12 Month 6 Month 12 
Base case scenario -£333 -£518 <0.001 <0.001 
(i) Head MRI:  
-25% of unit cost of the head MRI 
-£367 -£552 <0.001 <0.001 
(ii) Neurology appointments:  
-25% of unit cost of the initial/follow-up neurology 
outpatient appointments 
-£263 -£482 <0.001 <0.001 
(iii) ‘Did not attend’ cost: 
No DNA cost (baseline=30%).  
-£327 -£499 <0.001 <0.001 
(iv) Societal costs. 
The use of a societal perspective of analysis. 
-£417 -£769 0.086 0.037 
Table 61 summarises the findings from non-adjusted and adjusted GLM cost analyses 
incorporating both NHS and time off work related costs from Table 59. There was a trend of cost 
savings up to month 6 associated with the use of direct access to head MRI in both GLM analyses. 
When these analyses were extended up to 12 months, the cost difference between groups was 
statistical significant (p<0.05) for both the non-adjusted and adjusted GLM analyses. 
Table 61. Summary table with the two GLM analysis for the 6 and 12-month total cost analyses: 
(i) unadjusted; (ii) adjusted for imbalance in baseline (p<0.1). 
 Societal perspective [95% CI, p-value] 
 Unadjusted 
Adjusted for baseline 
characteristics (p<0.1) 
Mean total costs 0-6 months  
-£417 [-£1,240, £406] 
p=0.321 
-£576 [-£1234 , £81] 
p=0.086 
Mean total costs 0-12 months  
-£769 [-£1,452, -£85] 
p=0.027 





4.3.7 Summary of Results 
Direct access to head MRI from primary care led to lower mean cost per participant at 6 and 12 
months compared to the conventional route with referral for a neurology appointment. Based on 
adjusted GLM distributions, the mean cost difference per participant between groups at 6 and 12-
month post recruitment were estimated at, respectively, -£302 (95% CI: -£411, -£193) and -£481 
(95% CI: -£635, -£327). When productivity losses were considered, the mean cost difference 
between groups increased as participants in the neurology group were more likely to report time 
off work and loss of productivity. 
However, using the £20,000 and £30,000 willingness-to-pay per QALY thresholds (typically 
considered by NICE), there was only a 7.2% and 4.1% probability of direct access to MRI being 
more cost-effective than neurology referrals at month 6, respectively. The MRI pathway delivered 
statistically lower costs than the neurology pathway, but poorer health outcomes measured in 
QALYs and was not cost-effective using usual NICE willingness-to-pay thresholds. 
At baseline, participants in the neurology group self-reported higher headache burden and lower 
health scores. These findings were not sustained over time at month 6 or 12 post-recruitment. 
Participant satisfaction analyses showed that participants in the MRI group presented higher 
satisfaction levels during the referral process, particularly associated with the information provided 
(p<0.05). However, on the day of the first appointment (either a neurology appointment or head 
MRI scan), participants in the neurology group reported a better experience compared to their 
expectation. In addition, 3 months post-recruitment, participants in the neurology group reported 
statistically significant higher levels of overall satisfaction, particularly associated with the amount 




This section discusses the clinical and economic findings from the headache study. Strengths and 
limitations are also discussed, along with the potential implications for research and clinical practice 
in the management of chronic headache.  
4.4.2 Rationale 
Multiple studies concluded that advanced imaging, either CT or MRI, had the potential to change 
the clinical management of patients with chronic headache. The latter seems to be due to the 
reassurance effect associated with a brain scan with negative findings, particularly for brain cancer. 
Despite these findings and the regular utilisation of brain imaging in the NHS to reassure both GPs 
and patients alike, regulatory agencies (e.g. NICE) do not recommend the utilisation of advanced 
imaging in patients with chronic headache and no clinical red flags (i.e. for reassurance purposes). 




little was known about the economic implications of providing GPs with direct access to 
neuroimaging for the management of chronic headache patients. The study’s primary and 
secondary objectives hence considered the 6 and 12-month cost implications of providing GPs with 
direct access to brain MRI for the management of chronic headache patients compared to the 
conventional management to neurology services. Furthermore, secondary objectives considered 
cost-effectiveness and cost-utility analyses and other dimensions, from accessibility to care, patient 
satisfaction and diagnostic accuracy of both clinical pathways. These outcomes aimed therefore to 
evaluate the real-world implications of direct access to brain MRI compared to neurology services 
across a wide range of dimensions of care. 
4.4.3 Key Findings 
Primary outcome:  
6-month cost analysis 
These results are consistent with previous studies showing that direct access to advanced imaging 
resulted in a large decrease in referral rates to neurology services (Thomas et al. 2010; Howard et 
al. 2005).  
The study’s underlying hypothesis was that the early use of an advanced and accurate diagnostic 
tool (in this case MRI) would reassure both patients and GPs that no serious underlying cause 
(particularly brain tumour) is present. This would, in turn, reduce the headache burden and NHS 
resource use associated with the patient’s subsequent management. Given the high prevalence of 
headache and the increased referral of patients with chronic headaches and other neurological 
conditions from primary care to hospital based care (Latinovic, Gulliford, and Ridsdale 2006), it is 
relevant to assess the implications of using different management strategies. To our knowledge, 
no previous prospective study in the UK assessed the economic implications of these two 
coexisting management strategies based on the GP referral decision.  
The primary outcome considered the total headache-related NHS costs at six months post-
recruitment. This time horizon was considered as most costs were anticipated to be realised within 
this timeline. However, due to increasing waiting times between events (e.g. time elapsed between 
the initial and follow-up neurology appointments), the 12 months’ time horizon was found to be 
more appropriate to evaluate the cost implications of both clinical pathways. The study showed 
that the use of advanced imaging produced cost savings to the NHS compared to referral to 
neurology, with mean cost savings per participant of £333 and £518 at month 6 and 12 post-
recruitment, respectively (p<0.001). This is equivalent to 57% and 64% cost savings per participant 
at, respectively, month 6 and 12 post-recruitment. These cost differences were multifactorial but 
primarily driven by: (i) the lower unit cost of a head MRI scan (£146) compared to the initial 
neurology appointment (£240); (ii) the lower number of outpatient appointments in the MRI group 
(mean 0.26 vs 2.52 appointments); (iii) the fact that 75/128 (59%) of participants in the neurology 




likelihood of patients in the neurology arm receiving management with Botox injections or nerve 
block procedures (mean 0.05 vs 0.30 events). 
The results were similar to an uncontrolled clinical audit published by NICE (Wood 2018). Despite 
the methodology limitations of this study (e.g. only secondary costs seem to be considered, 
apparent 3-month time horizon, unclear as to whether the costs associated with management of 
incidental findings were included) and no formal report or paper could be retrieved, the use of direct 
access to MRI led to cost savings of 65% (£142k vs £410k) compared to management with referral 
to neurology services.  
Direct access to head MRI seemed to reassure most participants as only 17 (18%) participants in 
the MRI group ended up being referred to a neurologist within the study timeline. This number 
confirmed the evidence from previous studies, such as Thomas et al. (2010). Furthermore over 
66% of participants in the MRI group had no further hospital-based care, compared to only 5% in 
the neurology group. Similarly, at primary care level, participants in the MRI group had lower 
utilisation rates per participant when compared to the neurology group (mean GP appointments of 
1.19 vs 1.82, p=0.006). All cost differences between groups remained statistically significant 
(p<0.001) when adjusted for differences in baseline characteristics or follow-up attrition rates.  
A small proportion (7.6%) of participants in the MRI group had abnormal findings in the initial head 
MRI. However, only one participant had clinically significant lesions (two small aneurysms), which 
were incidental findings, and no brain tumour was diagnosed. This was consistent with clinical 
literature that estimated the prevalence of brain tumours among chronic headache sufferers to be 
less than 0.1% (Symvoulakis et al. 2007). 
Secondary outcomes:  
Cost-utility analyses 
The a priori statistical analysis plan specified cost-utility analyses at 6 and 12 months post-
recruitment. However, follow-up data from the EQ-5D-5L questionnaire had particularly poor 
participant compliance, with 12-month attrition rates of 75% and 85% of follow-up data missing in 
the neurology and MRI group, respectively. For this reason, it was decided only to conduct the 6-
month cost-utility analysis. The 6-month cost-utility analysis showed that the use of direct access 
to head MRI a 7.2% and 4.1% of being cost-effective, taking, respectively, a £20,000 and £30,000 
willingness-to-pay per QALY thresholds (typically considered by NICE). Despite saving money to 
the NHS, this very low probability was due to the lower utility values generated in the MRI group 
compared to the neurology group. However, as mentioned, these results are potentially affected 
by the high attrition rate in the MRI group, with a total of 73% (69/95) participants not responding 
to the EQ-5D-5L questionnaire at month 6. For this reason, and before this data are to be used by 
decision makers, further evidence concerning the validity of the utility values reported in both 






Patient satisfaction in both groups was compared based on three dimensions of analysis: during 
the referral period, the initial appointment and overall satisfaction. Twenty five percent of 
participants in the neurology group (vs 18% in the MRI group) reported dissatisfaction with the 
waiting time. This finding was not unexpected as the mean waiting time associated with the 
neurology appointment was almost three times of the one associated with the MRI scan (110 vs 
39 days). Contrary to the referral period, participants in the neurology group had a  trend towards 
satisfaction levels associated with the first appointment (neurology outpatient visit vs MRI scan) 
and a better experience compared to their expectations (60% vs 29% in the neurology and MRI 
group, respectively). Participants in the neurology group reported improved satisfaction levels at 3 
months across different variables (time spent with clinician, consistency of care, information about 
the condition and its treatment). Almost three quarters of neurology participants reported being 
satisfied or very satisfied with their headache management compared to only 21% in the MRI group 
(p<0.001). The latter seems to be associated with the continuity of care provided by neurologists 
as opposed to the more fragmented care provided to participants in the MRI group. Both 
participants and GP referrers in the MRI group reported dissatisfaction associated with the waiting 
time elapsed between the MRI scan and the availability of results (mean time of 31 days). This 
may have contributed to an increased anxiety in some participants as opposed to the anticipated 
reassurance effect. 
Headache burden 
At baseline, participants in the neurology group reported lower quality of life and higher headache 
burden. HIT-6 scores improved over time but we were unable to assess whether there was a 
statistically significant difference in both groups due to high attrition rates, particularly in the MRI 
group.  
As mentioned, out of the 95 participants recruited to the MRI group, 17 (18%) were subsequently 
referred to a neurologist. Interestingly, at baseline, these 17 patients reported higher headache 
burden compared to all 95 patients recruited to the MRI group (MIDAS score: 51.2 vs 44.8; MIDAS 
headache days: 55.8 vs 42.8). This finding seemed to suggest that these data might be useful to 
risk stratify patients and support GPs in their referral criteria. However, further research into this 
area is required.  
Time off work 
Time off work was also evaluated as a proxy of headache burden. Participants in the neurology 
group presented a trend (p>0.05) of higher number of days off work due to headache compared to 
participants in the MRI group. It is important to note though that a high proportion of missing data 
in both groups, particularly in the MRI group. Despite the summarised issues with the follow-up 
data, the current study did not seem to support the findings from previous studies that costs due to 
time off work represented up to 85% of the total costs associated with the management of chronic 




4.4.4 Strengths, limitations and implications 
Strengths  
Several strengths associated with this study have already been discussed in the context of the 
scaphoid trial (subsection 3.4.5). This included a clear research question, a heterogeneous 
population reflective of clinical practice, two clear groups being compared and a priori statistical 
analysis plan. No potential allocation bias was present as referrers were not believed to have an 
interest – conscious or unconscious - in potentially biasing the study findings (most GPs were even 
unaware of the study). The estimate of NHS resource use data was primarily based on 
comprehensive and complete data retrieved from hospital-based databases that captured both the 
acute and elective elements of the pathway associated with the management of patients with 
chronic headache. These data were supplemented by both primary care utilisation data, collected 
from each participant’s GP, and self-reported participant data. The objective was to ensure that all 
chronic headache related NHS events were costed regardless of the healthcare provider or setting. 
The prospective collection of healthcare utilisation and the evaluation of the impact of the 
interventions across different dimensions of analysis (efficiency, quality of care, access to care and 
patient satisfaction) were other key factors that contributed to the overall strength of the study. 
Limitations 
There were some limitations to this study. First, this was a single-centre study with participants 
recruited from one central Trust in London. A multi-centre study would be necessary to extend the 
generalisability of the results. Second, as with any observational study, no randomisation between 
groups was performed and there were significant differences in baseline of headache burden, 
health scores and utilisation of resources, reflecting potential selection bias. Although results were 
adjusted for potential confounders, this represented a study limitation. Third, specific inclusion and 
exclusion criteria were considered and, as such, the study sample might not be representative of 
all patients with chronic headache. Fourth, for the purpose of secondary outcomes, most data were 
self-reported and hence prone to recall bias. Lastly, there were high follow-up attrition rates 
potentially affecting secondary outcomes such as cost-utility analyses or patient satisfaction. A 
large proportion of participants failed to complete the headache diaries and follow-up headache-
specific questionnaires even though these constituted part of their standard care. This was 
particularly the case in the MRI group as participants attended less often secondary care 
appointments. These large attrition rates could be minimised with closer cooperation between the 
clinical and the research teams in the proactive follow-up of participants.  
Implications for Further Research 
Baseline measures of headache burden, such as the HIT-6 or MIDAS, could potentially be used to 
determine which pathway may be suitable for individual patients but further research into the risk 
stratification of chronic headache patients is required (e.g. patients likely to be reassured by a 
negative brain MRI). Future studies should consider a closer engagement with participants in the 




study follow-up requirements. In addition, future research should further assess patient satisfaction 
associated with both clinical pathways. 
Implications for Policy and Clinical Practice 
With regards to clinical practice, the two clinical pathways are expected to face increasing demand 
and different transformation initiatives were identified based on the study findings. Chapter 7 
discusses the different implementation initiatives developed to improve clinical practice for patients 
referred to GSTT with chronic headache.  
The widespread use across the NHS of advanced imaging, particularly MRI, as an alternative to 
neurologist appointments for chronic headache sufferers holds the potential to, simultaneously, 
decrease overall NHS costs and release neurology resources to manage other clinical conditions 
(e.g. epilepsy, Alzheimer disease, dementias). However, it remains unclear as to what impact this 
management pathway will have on patient satisfaction or indeed outcomes such as QALYs. 
4.5 Conclusion 
This study found that the referral from primary care to direct access to head MRI compared to 
referral for a neurologist for patients with chronic headache was associated with lower NHS overall 
costs at 6 and 12 months post-recruitment. Despite waiting longer from referral to appointment, 
participants in the neurology group reported higher satisfaction levels associated with the care 
received compared to the MRI group and were more likely to benefit from changes to their 
therapeutic management.  
The utilisation of direct access to MRI for a selected proportion of chronic headache patients, those 
more likely to be reassured, as a direct alternative to neurology services should be further 
evaluated and implemented within the NHS. This might ultimately contribute to the NHS financial 
sustainability whilst releasing neurology resources for other increasing prevalent neurological 
conditions. However, given the lack of follow-up utility data, further research should be consider to 
assess the cost-effectiveness of providing GPs with direct access to brain MRI for the management 




Chapter 5. Use of advanced imaging in the management of 
low to intermediate risk of suspected colon cancer 
5.1 Introduction 
5.1.1 Colorectal Cancer 
Colorectal cancer (CRC) includes cancerous growths found in the colon, rectum and appendix. Most 
CRCs are the result of the malignant development of adenomatous polyps into invasive 
adenocarcinoma which occurs over many years (Riccioni et al. 2012, NICE 2011).  
CRC is the third most common cancer in the UK (after breast and lung), with an annual incidence of 
approximately 40,000 new cases (NICE 2011a; Cancer Research UK 2015). The incidence of CRC is 
related to age, with almost three-quarters of cases occurring in people aged 65 or over and 83% in 
those over 60 years of age (NICE 2011a). For patients under 50 years of age, both sexes have similar 
rates, but later in life men tend to have an increased incidence of CRC (NICE 2011a). Over the past 
decade, overall CRC incidence rates remained relatively stable, with a small increasing trend (NICE 
2011a).  
CRC is, after lung cancer, the second most common cause of cancer death in the UK (NICE 2011a). 
Evidence gathered between 1997 and 2006 showed a decrease in excess of 30% in CRC mortality 
rates. This improvement seemed to be multifactorial but partly attributed to better detection and 
removal of colonic polyps, improved detection of colorectal cancer at an earlier stage, and the 
development of more effective primary and adjuvant treatments. In particular, early diagnosis of CRC 
is of vital importance as survival rates are stage-dependent at the time of diagnosis, with 5-year survival 
rates in men of 95% at stage 1 and less than 10% at Stage 4 (Cancer Research UK 2015). Despite 
this historical improvement, the UK 5-year survival rates for CRC remained significantly lower 
compared to other countries such as Sweden, Australia, Canada or Norway (Coleman et al. 2011). 
The NHS Long Term Plan, published in the UK in January 2019, set out commitments to improve 
cancer outcomes and services in England over the next 10 years (NHS England 2019). One of its key 
ambitions was that, by 2028, the proportion of cancers diagnosed at stages 1 and 2 should rise from 
around 40% to 75% of cancer patients. Cancer alliances across the country have been established to 
implement the cancer strategy at a local level, with the introduction of faster, more standardised, 
diagnostic pathways. To further facilitate early diagnosis, the threshold for referral for patients with 
suspected colorectal cancer has been lowered (i.e. referral for colonic investigations in the presence 
of less severe symptoms such as change in bowel habits, regardless of its duration), incorporating 
updated NICE guidance (NG12) published in 2015 (NICE 2015). 
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5.1.2 The clinical challenge 
Less than 10% of symptomatic patients referred to NHS outpatient clinics with suspicion of CRC are 
actually diagnosed with the disease (NICE 2011a). However, given the prevalence of the disease and 
the symptoms associated with it, the diagnosis of gastrointestinal diseases currently puts a 
considerable burden on secondary care. The lower threshold for referral for patients with suspected 
colorectal cancer has also led to an increase in demand for colonic investigations. The Department of 
Health has predicted an annual increase of 10% to 15% in the demand for colonic investigations, 
putting an additional burden on the already stretched optical colonoscopy capacity (Bowel Cancer UK 
2019).  
Optical colonoscopy (OC) is the diagnostic reference test for CRC but it is technically difficult and 
resource intensive and capacity constraints means that there are considerable waiting times for an OC 
test. In 2012, over 25% of NHS providers reported waiting times in excess of 4/6 weeks in 25%/5% of 
OC scans. In 2018, it was estimated that about half of NHS hospitals did not meet the 2-week target 
for urgent colonoscopy (Bowel Cancer UK 2019). These waiting times translate into delayed diagnoses 
and, potentially, poorer prognoses.  
The utilisation of non-invasive CTC as a direct alternative to the gold standard OC has been introduced 
in routine clinical practice following clinical evidence of non-inferiority of Computed Tomography 
Colonography (CTC) in the diagnosis of medium to large polyps and CRC (NICE 2018a).  
Clinical evidence: accuracy levels 
The sensitivity of OC for the detection of CRC is estimated at 94.7% (95% CI: 90.4% - 97.2%) 
(Pickhardt et al. 2011) and for detection of  large polyps (i.e. diameter > 10 mm) at 94% (Menardo 
2004). CTC provides similar accuracy levels to OC for the detection of large and medium sized polyps 
and is particularly sensitive in the detection of symptomatic CRC (Halligan et al. 2005). Furthermore, 
systematic reviews showed that sensitivity and specificity of CTC improves with larger polyps (NICE 
2011a). According to a meta-analysis performed by Halligan et al. (2005), CTC has a 93% sensitivity 
(95% CI: 73% - 98%) and 97% specificity (95% CI: 95% - 99%) for large polyps. In the diagnosis of 
CRC, CTC has a 95.9% sensitivity value (95% CI: 91.4% - 98.5%) (Halligan et al. 2005). This value is 
corroborated by Pickhardt et al. (2011), who estimated a sensitivity value of 96.1% (95% CI: 93.8% - 
97.7%). It is relevant to highlight that older studies may underestimate the accuracy of CTC, as newer 
generation CT scanners are likely to improve the performance in the diagnosis of both large polyps 
and CRC. 
Additionally, CTC has the potential to investigate other intra-abdominal organs that are not seen with 
OC. This may be an important benefit as it may reveal clinically relevant extracolonic conditions that 
might warrant treatment, but also a potential disbenefit, leading to further diagnostic and therapeutic 
procedures for conditions without clinical relevance. 
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In summary, CTC is highly sensitive, particularly for medium to large polyps and CRC. Given the 
relatively low prevalence of CRC in those referred with symptoms, CTC is increasingly being 
considered as a potential alternative to OC as a first line colonic investigation. 
A drawback of CTC is that, in the event of positive findings, patients need to undergo a subsequent 
invasive technique for polyp removal and/or tissue biopsy. This means that these patients in effect 
undergo two instead of one diagnostic procedure. A multi-centre randomised trial estimated that 30% 
of patients had additional colonic investigations following CTC, compared to only 8% after OC (Atkin 
et al. 2013). However, it has been shown that less than 10% of symptomatic patients referred to NHS 
outpatient clinics due to suspected CRC are actually diagnosed with the disease (NICE 2011a). This 
means that CTC can potentially reduce the need for an invasive test in the majority of patients. A 
second disadvantage of CTC is associated with the use of ionising radiation and hence an increased 
probability of developing cancer in the medium to long-term. In contrast, CTC’s non-invasive approach 
is an advantage as it minimises the risk of perforation (reported between 0.005%-0.03% with CTC 
compared to 0.06-0.19% with OC) (Berrington de Gonzalez, Kim, and Yee 2010). Furthermore, CTC’s 
patient acceptability and overall satisfaction are likely to be improved by the use of a non-invasive 
imaging technology as opposed to the conventional OC (Halligan et al. 2007).  Despite these 
disadvantages and advantages, both tests (CTC and OC) are deemed safe and are commonly used 
in routine clinical practice. 
In a context of scarce resources, it is essential to take informed decisions on how to allocate the various 
human, technical and financial resources. This study aims to build on the existing evidence and to 
evaluate the clinical and cost implications of using CTC as a substitute test for patients referred from 
primary care with low to intermediate risk of CRC. 
5.1.3 Two pathways at Guy’s and St Thomas’ Hospital  
Patients with suspected CRC are commonly referred from primary care to hospital diagnostic services 
under a ‘two week wait’ referral. Following referral from primary care, the clinical pathway at GSTT 
includes the use of several imaging modalities, particularly OC and, to a lesser extent, CTC.  
Optical Colonoscopy as the initial diagnostic test: 
OC is the diagnostic reference test for CRC and hence the most frequently used initial diagnostic 
imaging tool at GSTT. A retrospective analysis of activity between January 2012 and November 2014 
identified that GSTT performed 9,090 optical colonoscopies (260/60 procedures per month/week). 
The subsequent diagnostic and treatment pathway is determined by the results from the OC (see 
Figure 57): 
 Positive findings (i.e. abnormal findings on the initial optical colonoscopy):  
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Abnormal findings are subdivided into two categories: (i) medium to large polyps (over 6 mm), and (ii) 
CRC. For patients with medium to large polyps, polyps are biopsied and some of them removed. For 
patients with CRC, tissues are biopsied and appropriate cancer treatment options are then considered 
and agreed (e.g. chemotherapy, radiotherapy or surgery).  
 Negative findings (i.e. normal findings on the initial optical colonoscopy):  
No further diagnostic or treatment options are considered and the patient is discharged back to primary 
care (i.e. the referrer).  
 Inconclusive findings (e.g. patient unable to comply with the procedure):  
OC scan that does not produce conclusive results (e.g. suboptimal scan, incomplete bowel 
visualization). Usually, this is due to poor patient compliance prior to the procedure (i.e. patients did 
not follow bowel preparation processes) or during the procedure (e.g. unable to tolerate invasive scan). 
A multi-centre randomised trial reported a non-completion rate of 11% for OC (Atkin et al. 2013). For 
these patients, a repeated OC, flexible sigmoidoscopy or CTC scan are usually performed at GSTT. 
Computed Tomography Colonography as the initial diagnostic test: 
CTC utilisation at GSTT: 
A retrospective analysis of activity between January 2012 and November 2014 identified that GSTT 
performed 1,642 CTC procedures (average of 47/11 procedures per month/week). These procedures 
were primarily performed on: (i) patients who had inconclusive findings in the initial OC and were then 
referred for CTC; (ii) frail patients who were not deemed fit for an invasive OC; (iii) as a direct alternative 
to OC. 
Based on CTC’s diagnostic accuracy and patient acceptability, as well as the increasing waiting times 
for OC, CTC has been increasingly used at GSTT as an alternative tool in the diagnostic pathway of 
symptomatic patients with suspected CRC (see Figure 57). 
 Positive findings (i.e. abnormal findings on the initial CTC):  
As with the OC group, abnormal findings are subdivided into two different categories: medium to large 
polyps (≥6mm) and CRC. For both findings, an invasive colonic test, either OC or flexible 
sigmoidoscopy (depending on the lesion’s location), is subsequently performed in order to either excise 
(e.g. polyps) or biopsy lesions (e.g. CRC) identified on the initial CTC.  
 Extracolonic findings (e.g. findings outside the colon):  
Given the CTC’s ability to visualise organs outside the colon, extracolonic findings include multiple 
clinical conditions, ranging from innocuous findings to potentially life-threating conditions (e.g. 
  
203 
abdominal aortic aneurysm). Based on the radiologist’s report, patients are, if clinically relevant, 
subsequently referred to other clinical specialties for further assessment and/or treatment. 
 Negative findings (i.e. no abnormal findings on the initial CTC):  
No further diagnostic or treatment options are considered and the patient is discharged from secondary 
care.  
 Inconclusive findings (e.g. patient unable to comply with the procedure):  
Similar to OC, CTC might produce inconclusive findings (e.g. suboptimal scan, incomplete bowel 
visualisation). For these patients, a repeated CTC, a flexible sigmoidoscopy or an OC scan are usually 
performed at GSTT. 
 
Figure 57.  Clinical pathway associated with OC or CTC as the initial imaging modality for patients with 
low to intermediate risk of CRC.  
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5.1.4 Economic evidence 
A review of literature was undertaken to evaluate the existing economic evidence around the economic 
impact of using CTC in the management of symptomatic patients with suspected CTC. Particular 
attention was paid to evidence retrieved from the NHS. 
The vast majority of the cost analyses and economic evaluations performed assessed the role of CTC 
in asymptomatic patients, i.e. as a screening tool (Halligan et al. 2015). The economic evidence from 
screening studies was not considered in this chapter as it is unlikely to reflect the use of CTC in a 
symptomatic setting. The latter is due to multiple reasons. First, the prevalence of polyps and CRC is 
likely to be higher in symptomatic patients. Second, CRC diagnosed in the asymptomatic group are 
likely to be different (e.g. less aggressive) compared to those in the symptomatic group. Third, the 
sensitivity and specificity of CTC for the diagnosis of polyps and CRC are likely to be different in 
asymptomatic vs symptomatic patients. For these reasons, the evidence summarised below focused 
on the role of CTC in the diagnosis of symptomatic patients with suspected CRC. 
Halligan et al. (2015) conducted a systematic review to evaluate economic evaluations on the use of 
CTC in asymptomatic and symptomatic patients. Out of sixteen papers, only one compared the use of 
CTC with OC in the diagnosis of symptomatic patients (Gomes et al. 2013). This study was a cost-
utility analysis, which aimed to compare the utilisation of CTC and OC in symptomatic patients in the 
UK NHS using a Markov decision analytic model to estimate disease progression (Gomes et al. 2013). 
The authors concluded that the use of CTC was cost saving (mean costs per patient £467 vs £583) 
and “marginally” cost-effective (ICER of £23,000 per QALY), with a 60% probability of being cost-
effective at the usual NICE willingness-to-pay thresholds values of £20,000-£30,000 per QALY) 
(Gomes et al. 2013). The remaining papers, while assessing the screening role of CTC, found that 
results were strongly influenced by the relative unit costs of CTC and OC and the inclusion or exclusion 
of costs associated with the management of incidental extracolonic findings (in the CTC group) 
(Halligan et al. 2015). A retrospective study of 225 CTC scans assessed the economic impact 
associated with the management of extracolonic findings and concluded that these approximately 
doubled the costs associated with the provision of CTC (Xiong et al. 2006). 
As part of a large multicentre trial (SIGGAR trial, 1610 patients from 21 UK hospitals: OC group 
n=1,072, CTC group n=538), Halligan et al. (2015) performed a cost analysis around the utilisation of 
CTC in symptomatic patients compared to OC in the diagnosis of large polyps (≥10 mm) or CRC. This 
was the first randomised trial to directly compare the use of CTC as a replacement of OC as the initial 
diagnostic scan in the management of symptomatic patients. Based on a mean unit cost of £160 and 
£330 per CTC and OC scan, respectively, the authors estimated a total mean unit cost per participant 
of £674 for CTC and £739 for OC (Halligan et al. 2015). However, this £65 difference was not found to 
be statistical significant. Although cheaper than OC, patients undergoing CTC as the initial test were 
more likely to undergo a second investigation (30% vs 8.2%). In addition, 60% of patients undergoing 
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CTC had at least one extracolonic finding, 8.5% of whom requiring further investigations and around 
2% had extracolonic malignancies detected. On the other hand, adverse events were more likely in 
patients undergoing OC, leading to a total of six admissions in the OC group compared to one in the 
CTC group. These three elements combined seemed to be the reason why there were no significant 
cost differences between groups were observed despite the unit cost of CTC being less than half than 
the unit cost of OC. As a corollary, the authors concluded that CTC was a safe alternative to OC in 
symptomatic patients, with higher patient satisfaction at a similar cost for the NHS (Halligan et al., 
2015). 
More recently, a retrospective study assessed whether constipation as a primary presenting complaint 
should be an indication for an OC or CTC scan (Ratnasingham et al. 2017). A total of 200 NHS patients 
were included in the study (100 in each group), with the authors reporting a 37% rate of incomplete 
OC (51% due to discomfort and 27% due to bowel preparation) and no incomplete CTC scans. Based 
on £434 and £518 unit cost for CTC and OC, respectively, the authors estimated a total cost per 
participant in the CTC group of £550 and £737 in the OC group. The authors concluded that CTC was 
cost-effective (p<0.05). However, there were several important limitations: the paper did not fully 
describe the NHS resource use considered in the cost analysis; it was unclear whether costs due to 
the management of extracolonic findings were included; and was uncertain as to what measure of 
effect was used in the cost-effectiveness analysis. Bearing in mind the study’s retrospective design 
and the mentioned limitations, the authors concluded that CTC may be an acceptable alternative to 
CTC as a first-line investigation in patients presenting complaint of constipation (Ratnasingham et al. 
2017). 
In summary, three NHS studies evaluated the use of CTC among symptomatic patients. First, a cost-
utility analysis, using a Markov model to estimate disease progression, concluded that the use of CTC 
was cost saving and marginally cost-effective (ICER of £23,000 per QALY), presenting a 60% 
probability of being cost-effective at typical willingness-to-pay values of £20,000-£30,000 per QALY) 
(Gomes et al. 2013). Second, a large multicentre randomised trial (SIGGAR trial) evaluated the cost 
implications of using CTC as a replacement of OC as the initial colonic investigation and found a 
statistically non-significant cost difference between groups (Atkin et al. 2013). Third, a retrospective 
study assessed whether constipation as a primary presenting complaint should be an indication for an 
OC or CTC scan (Ratnasingham et al. 2017). Despite the important methodological limitations 
associated with the cost and cost-effectiveness analyses, the authors estimated that CTC led to cost 
savings and was cost-effective (p<0.05). All three studies presented a common feature, the evaluation 
of CTC as a direct replacement of OC for patients with suspected CRC. Nevertheless, the participant’s 
inclusion criteria was different among studies, with the first two studies considering a heterogeneous 
population of patients with suspected CRC whilst the third study focused on a subpopulation, patients 
presenting with constipation and a clinical suspicion of CRC. The decision concerning the inclusion 
criteria is essential as is likely to impact the incidence of CRC. As an illustration, patients with 
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constipation are less likely to have CRC compared to patients with multiple symptoms (e.g. 
constipation, rectal bleeding and anaemia). Given the non-invasive nature of CTC, its added value 
resides mainly in its ability to rule-out CRC or medium to large polyps without the need for an invasive 
technique (e.g. OC or flexible sigmoidoscopy). In fact, patients undergoing CTC that are found to have 
CRC or large polyps routinely undergo an invasive procedure for biopsies and/or therapeutic excision 
of polyps. Hence, the more prevalent polyps and CRC are, the less likely the intervention with CTC will 
lead to cost savings. Based on this rationale, we have chosen to evaluate the use of CTC as the initial 
colonic investigation deliberately among patients with low to intermediate risk of CRC. The study’s 
inclusion criteria included adult patients over 40 years old presenting with constipation or change in 
bowel habits and excluded patients with anaemia, rectal bleeding, with diarrhoea only for more than 6 
weeks, among others.  
5.1.5 Patient and NHS benefits and disbenefits 
It was anticipated that the increased utilisation of CTC could deliver several benefits including: 
 Improved access to care by reducing waiting times for colon imaging;  
 Faster diagnosis and, if needed, subsequent treatment that could lead to better clinical 
outcomes; 
 Diagnosis of potential extracolonic findings that are clinically relevant and would not 
otherwise be picked up by using OC; 
 Improved patient satisfaction as CTC is a non-invasive scan and does not involve the same 
level of discomfort or potential risks (e.g. bleeding) associated with optical colonoscopy;  
 Increased patient compliance with optical colonoscopy for those with positive CTC findings; 
 Freeing up OC capacity to perform procedures in high-risk patients; 
 Potential reduction of overall cost per symptomatic patient. 
The increased utilisation of CTC was thought to be associated with the following disbenefits:  
 An increase in the number of patients who may need to undergo two diagnostic tests (CTC 
and subsequent optical colonoscopy) instead of one, as will happen for those patients where 
there is a major positive finding (either CRC or medium to large polyps) on the initial CTC. 
 Increased exposure to ionising radiation and, therefore, an increased risk of cancer induction, 
particularly in the medium to long-term; 
 Diagnosis of potential extracolonic findings that might not be clinically relevant and would not 




5.2.1 Aims, Objectives and Hypotheses 
Aim of the study 
The aim of this study was to investigate whether the diagnosis of patients with suspected CRC using 
CTC as the first diagnostic imaging tool is cost saving when compared to OC.  
Given the similar accuracy levels and waiting times associated with both imaging modalities, it was not 
deemed likely that the initial use of OC or CTC would be associated with a CRC stage shift. For this 
reason, the primary objective aimed to estimate the cost difference between the OC and CTC groups. 
Primary Objective:  
To evaluate whether the use of CTC as the first imaging modality for a selected subset of patients with 
suspected colon cancer is cost saving at 6 months post-recruitment compared to the utilisation of OC 
as the first imaging modality. The primary analysis included all costs associated with the management 
of colon-related events as well as the management of potential extracolonic findings (incidental or non-
incidental findings) in participants of the CTC group. Costs associated with the treatment of cancer 
were not considered as part of the baseline analysis so not to skew the analysis due to potential 
imbalances in cancer detection rates between both groups. However, cancer treatment costs were 
considered in a secondary cost analysis. 
Secondary Objectives: 
Seven secondary objectives, together with a short rationale, are presented below. 
Objective 1: To evaluate whether the use of CTC as the first imaging modality was cost-effective at 6 
months compared to the utilisation of OC as the first imaging modality. 
Cost and utility data at 3 and 6 months of follow-up were used to assess the intervention’s cost-
effectiveness. The final 6-month follow-up following the initial imaging test (either OC or CTC) was 
considered appropriate as all relevant costs and outcomes associated with both clinical pathways 
should be realised within this timeline. Outcomes were expressed in QALYs based tariff weights 
derived from the EQ-5D-5L questionnaire. It was assumed a linear relationship between two health 
states (i.e. the QALY between 0-6 months is the average between these two points). In order to adjust 
for imbalance in mean baseline utilities, a multiple regression analysis was used. The cost-utility 
analysis, which is the preferred method of economic evaluation of NHS interventions, was performed 
according to NICE recommendations (NICE 2012a). 
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Objective 2: To evaluate the cost per correctly diagnosed CRC using CTC as the initial investigation 
compared with OC. 
The second objective was to evaluate the cost per correctly diagnosed medium to large polyps (≥6mm) 
and colorectal cancer using CTC as the initial colonic investigation.  
For patients with positive findings on CTC (either medium to large polyps and/or CRC), the subsequent 
invasive scan (OC or flexible sigmoidoscopy) was used as the comparator to assess whether the initial 
diagnosis with CTC was correct.  
Patients with negative findings on CTC were followed-up for a period of 12 months. In order to identify 
any cancers missed, all patients with negative findings for CRC were cross referenced against the 
NHS Central Register (NHSCR) and details of new cancer diagnoses and deaths obtained from 
NHSCR. Patients were also matched with national data from the Hospital Episode Statistics (HES) 
database to reduce the time lag between cancer diagnosis and the time of notification. A CRC 
diagnosis was defined as missed if was identified through one of the databases and no diagnosis of 
CRC was present on the initial CTC test. 
Objective 3: To estimate the incidence of extracolonic findings in the CTC group. 
This objective aimed to assess the number of extracolonic findings and the proportion of those who 
warranted further diagnostic or therapeutic management. 
It was anticipated that significant extracolonic findings would be diagnosed based on CTC. Some 
extracolonic findings (e.g. abdominal aneurism and extracolonic cancers) could be life-threatening and 
therefore likely to require treatment within the study’s six month follow-up period, whilst others may not 
warrant any further diagnostic or therapeutic management. 
The presence or absence of extracolonic findings were retrieved from the original CTC report. In the 
event of presence of extracolonic findings, potential subsequent diagnostic or treatment care was 
assessed for a period of six months based on primary and secondary care databases. 
Objective 4: To compare the likelihood ratio of CTC against colonoscopy in patients with initial positive 
CTC findings for medium to large polyps (≥6 mm) and CRC. 
The likelihood ratio of CTC against colonoscopy in patients with initial positive CTC findings were 
assessed using the invasive scan (OC or flexible sigmoidoscopy) as the gold standard. 
As per standard care, all patients with positive findings on the initial CTC underwent an invasive test, 
either an OC or optical flexibility. Findings from both tests were compared using the invasive test as 
the reference. The likelihood ratio for a positive CTC was estimated based on the equation below. 
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Objective 5: To measure the time taken to reach a definitive diagnosis and first major treatment 
decision based on the CTC findings in comparison to the current pathway. 
This objective evaluated access to care for both groups, measuring the time elapsed between the day 
of referral to either OC or CTC and: (i) the day the test was actually performed; (ii) the day a definitive 
diagnosis was reached (OC or flexible sigmoidoscopy were considered the gold standard for patients 
presenting positive findings in the initial CTC); and (iii) the day a treatment decision was reached. For 
this objective, three time points were necessary: date of referral from primary care for a diagnostic test 
(retrieved from referral form); date of diagnostic test (coincident with recruitment date); and date at 
which the OC or CTC report is available to the referrer (retrieved from primary and secondary care 
databases). 
Objective 6: To compare the ‘on the day cancellation’ rates and incomplete (or suboptimal) bowel 
investigations associated with OC or CTC as the initial imaging test. 
This objective assessed the operational efficiency associated with the provision of both tests by 
comparing the ‘on the day cancellation’ rates for either OC or CTC. Given that the bowel preparation 
associated with CTC is thought to be easily tolerated, it was anticipated that the on the day cancellation 
and incomplete bowel investigation rates would be lower in the CTC group. This, in turn, would reduce 
the need for subsequent bowel investigations. 
The information concerning incomplete bowel investigations was obtained from the OC and CTC 
reports. 
Objective 7: To compare patient satisfaction levels associated with the use of OC as the initial imaging 
modality in patients with suspected CRC compared to CTC. 
This objective aimed to assess patient satisfaction in both groups using a participant questionnaire the 
morning after the bowel test. The questionnaire were mainly based on a 5-point Likert scale, used to 
assess any potential differences between the two groups. The design of the post-test patient 
satisfaction questionnaire was based on the RCT conducted by Atkin et al. (2013). The underlying 
hypothesis was that the use of CTC would promote an improvement in the participant’s overall 
satisfaction, both at short and medium-term, compared to OC as it would decrease: (i) patient anxiety 





There is no statistical difference between the six months cost per patient for those referred with 
suspected colorectal cancer to either: (i) an OC scan; or (ii) a CTC scan.  
Alternative Hypothesis 
There is a statistical difference between the six months cost per patient for those referred with 
suspected colorectal cancer to either: (i) an OC scan; or (ii) a CTC scan.  
5.2.2 Study design 
The study was an independent, single-centre site, observational study comparing the utilisation of CTC 
with OC as the first diagnostic tool in patients with suspected CRC. The study compared two existing 
clinical pathways used in the management of patients with low to intermediate risk of colorectal cancer 
following referral from primary care that differed in the initial diagnostic test with either CTC or OC 
(Figure 57). 
As highlighted in Figure 58, the length of time each patient participated in the study was six months. 
Given the expected short-term impact of the intervention (diagnostic scan), it was considered that the 
majority of costs and outcomes were captured within the proposed six month follow-up (as highlighted 
in Figure 58 and Table 62). In addition, all patients were matched against NHSCR or the HES 
databases to determine whether a diagnosis of cancer (CRC or other cancer) had been made in the 
12 months following the initial CTC or OC test.  
Intervention groups and allocation 
Participants were allocated to two groups: (i) the OC group; or (ii) the CTC group. The allocation was 
decided during a telephone clinic with a specialist nurse following referral from primary care, taking 
into account the patient’s clinical history (e.g. clinical symptoms, overall health condition and previous 
colonic investigations) as well as her/his test preference. Given the potential selection bias, the primary 
outcome was adjusted taking into consideration potential imbalances in baseline characteristics 




Figure 58. Colorectal cancer study structure.  
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Table 62. Study flowchart for both groups of patients. 
 
Activity 





















Give patient information sheet, explain 
study and obtain signed informed consent 
X       GSTT 
Register patient into the study X       GSTT 
Register patient demographics and 
clinical history  
 X      GSTT 
Give patient registration pack (patient 
information sheet, copy of informed 
consent) 
 X      GSTT 
OC or CTC scan   X     GSTT/Patient 
Baseline questionnaires (EQ-5D-5L)  X      GSTT/Patient 
Test’s acceptability questionnaire    X    GSTT/Patient 
3 and 6-months Follow-up questionnaires 
(EQ-5D-5L) 
    X X  GSTT/Patient 
3-months Follow-up Questionnaire 
(Patient Experience) 
    X   GSTT/Patient 
Resource use diary     X   GSTT/Patient 




All participants were followed up for 12 months following the recruitment in the trial. Data were 
collected at baseline, 3 and 6 months post-recruitment. In addition, at 12 months post-recruitment, 
all participants were matched against a cancer registry and hospital databases to assess whether 
a diagnosis of cancer (colorectal or otherwise) had been given. 
5.2.3 Ethical Approval, Trial Registration and Funding 
The Health Research Authority and Research Ethics Committee (East Midlands – Leicester Central 
Research Ethics Committee) approved the study research on 04th April 2016. The REC reference 
was 16/EM/0143 and the study was registered on clinicaltrials.gov (Clinical Trial Registration: 
NCT02820389). The first participant was recruited on 14th June 2016. 
The study was fully funded by a grant secured from Guy’s and St Thomas’ Charity. 
5.2.4 Selection, withdrawal of participants and sample size 
Study Setting 
Patients were recruited at GSTT – either in the Colorectal Unit or the Radiology Department – as 
per their standard care. There were no changes to routine clinical practice in both groups as the 
study focused on evaluating two established clinical pathways in the management of patients with 
suspected CRC. 
Inclusion Criteria 
Patients considered to be suitable for the study included every adult patient over 40 years old, 
presenting with constipation or change in bowel habits with a differential diagnosis of suspected 
colorectal cancer. 
Exclusion Criteria 
Patients were considered to be ineligible for the study if at least one of the exclusion criteria was 
present: 
 Patients presenting with anaemia; 
 Patients presenting with diarrhoea only for more than 6 weeks;  
 Patients presenting with rectal bleeding; 
 Patients who had undergone a previous whole-colon examination in the past 6 months; 
 Patients who had been referred for a whole-colon examination to follow-up a known 
colorectal cancer; 
 Patients lacking capacity to give consent or participate in the study; 
 Patients already taking part in any clinical trial of an investigational medicinal product; 




The sample size estimate was calculated based on the primary endpoint, total colon-related six 
months healthcare costs. A total of 110 participants were recruited in the OC group and 70 
participants in the CTC group to achieve a detection a cost difference of £200 assuming standard 
deviations of £400 and £300, respectively, with 90% power at the 5% two-sided significance level. 
A 20% increase in sample size was used to account for unknown cost distributions and attrition 
rate.  
Losses to Follow-Up 
If a participant moved from the GSTT catchment area, every effort was made to ensure the 
participant was still followed up. If a participant was lost to follow-up, individual patients’ GP were 
contacted to obtain information. If a participant requested to be withdrawn from the study, the 
participant’s data were excluded from the analysis.  
End of Study 
For regulatory purposes, the end of the study occurred 12 months after recruitment of the final 
patient at which point the ‘declaration of end of trial’ form was submitted to ethical committees. The 
last participant (180th participant) was recruited on 05th December 2018. 
5.2.5 Data Collection and Outcomes at baseline and follow-up 
Data were collected by a research team member at baseline and then quarterly up to 12 months 
following recruitment. Data collection was completed in December 2019. 
Data at baseline were collected before the initial appointment (either CTC or OC scan) at GSTT. 
Follow-up data were collected as per the participants’ preference, either via phone, email or post. 
Participants’ preferences were established at baseline and recorded in the Case Report Form.  
Participant Demographics 
A variety of information was captured at baseline, including: 
1. Age; 
2. Gender (male/female); 
3. Number and type of bowel related complaints; 
4. Number and type of comorbidities / active health problems. This information was obtained 
from participants’ self-reported data, data from primary care (classified under ‘active 
problems’ in the patient’s electronic record) and secondary care clinic letters. 
5. Number of months with change in bowel habits (numerical variable); 
6. Healthcare utilisation in the 6 months prior to study recruitment; 
7. Quality of life questionnaire (generic questionnaire: EQ-5D-5L). 
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Perspective of Analysis 
The study took a National Health Service perspective of analysis over a six months’ time horizon 
following recruitment. Only costs of all colon-related NHS events were considered. This approach 
is consistent with the methodology recommended by NICE for the evaluation of interventions with 
potential impact on health outcomes (EUnetHTA 2015). 
The estimate of the total costs from a NHS perspective was based on the multiplication of: (a) any 
colon-related healthcare events; by (b) the unit cost of such events.  
Resource Use Measurement 
Resource use data included contacts with NHS healthcare providers associated with the 
management of the suspected colorectal cancer. In addition, given the CTC’s ability to visualise 
extracolonic findings, any healthcare event due to an incidental finding was also included in the 
cost analyses. More details on the methodology used to measure resource use data were already 
described in the scaphoid and headache chapters (refer to sections 3.2.6 and 4.2.6). 
Valuation of Unit Costs 
Table 63 lists the unit costs associated with the primary outcome, including the reference and the 
rationale behind any assumption.  
For the purposes of the primary outcome, the valuation of unit costs was, whenever possible, based 
on National Reference Costs 2016-17 (NHS Improvement 2017). All secondary care contacts were 
costed using this strategy. 
For primary care events, an average cost per appointment (e.g. GP face-to-face appointment, GP 
phone appointment) was derived from the Unit Costs of Health and Social Care 2016 and then 
inflated to 2017 using the hospital & community health services (HCHS) index (Curtis and Burns 
2017).  
No medication costs were considered as differences between the two groups were not anticipated. 
Additionally, medication costs were mainly associated with over-the-counter painkillers (e.g. 
paracetamol, ibuprofen, buscopan) and such out-of-pocket expenditures are outside the NHS 
perspective of analysis. 
If a scan, either a CTC or OC scan was not performed on the day (e.g. due to poor bowel 
preparation in both tests and unexpected claustrophobia in the CTC scan) a 50% of the unit cost 




Table 63. Unit costs for all primary and secondary care events considered in the colon study. 







Per appointment £36.50 
Unit Costs of Health and Social Care 2016 
and inflated to 2017 using the HCHS index ( 
Curtis and Burns 2017). GP phone appointment Per appointment £14.80 
Secondary care 
ED episode due to 
bowel presenting 
complaint 
Per episode £222 




Per appointment £100 
Initial Outpatient 
appointment 
Per appointment £240 
Follow-up Outpatient 
appointment 
Per appointment  £92 
CTC test Per scan £250 
Optical Colonoscopy Per scan 
£515 ; 
 
 £654;  
 
£911 
Diagnostic Colonoscopy 19 years and over 
(FZ51Z HRG code); Diagnostic colonoscopy 
with biopsy ≥ 19 years (FZ52Z); Therapeutic 
Colonoscopy 19 years and over (FZ53Z HRG 
code); Combined Upper and Lower GI Tract 
Diagnostic Endoscopic Procedures with 







Reference Costs 2017, Radiology section 
(NHS Improvement 2017). 
MRI scan (1 zone) Per scan £146 
CT scan (2 zones) Per scan £155 






5.2.6 Statistical Analyses 
Analysis Population 
All analyses were based on the principle of intention-to-treat (ITT).  
Data Cleaning and Data Validation 
All baseline and follow-up data cleaning was performed prior to any data analysis.  
Baseline data were captured via a paper-based Case Report Form (CRF) during recruitment and 
then entered into a web-based CRF. During this process, the PhD student screened the data 
looking for inconsistencies. In the event of any potential data errors in the original hand-written data 
packs, participants or members of the research team were asked for clarification (e.g. date of birth 
and age did not match) and amendments were made to the original data set (data editing). 
The NHS resource use measurement considered in the primary outcome was derived from the 
merge of medical records databases and data self-reported by participants. This comprehensive 
data collection methods (already detailed in subsection 3.2.6 and 4.2.6 for the scaphoid and 
headache studies) considered the validation of data using multiple datasets.  
Missing Data 
Participants were not excluded from the analysis due to any missing data, particularly as data 
related to the primary outcome was expected to be complete given the comprehensive data 
collection methodology. Only data from participants who withdrew their informed consent were not 
included in the analyses. However, where data for the estimate of the total healthcare costs were 
missing (e.g. missing primary care data), mean values from the respective group were imputed.  
Baseline comparability of groups 
Continuous data were summarised by: frequency, mean, standard deviation, minimum, first and 
third quartile, median and maximum. Tabulations of frequencies for categorical data were 
presented, as well as the percentage (%) relative to number of non-missing values within the 
respective intervention group, unless otherwise specified.  
Given the non-randomised study design, significance testing was performed on the baseline 
variables between intervention groups listed under subsection 5.2.5 Data Collection and Outcomes 
at baseline and follow-up. Chi-square test was used to assess categorical variables. Quantitative 
variables were tested for normality using the Shapiro-Wilk test and, depending on this result, 
independent t-test or Mann-Whitney U test analyses were performed. The Levene’s test was used 
to assess the homogeneity of variance [consistent with Peacock, Kerry, and Balise (2017)]. A p-
value of p<0.05 was deemed as statistically significant. 
Primary and secondary objectives 
This study was observational but all analyses were based on the of ‘intention-to-treat’ so that all 




regardless of whether they actually received the intended intervention or not. Given the study’s 
time horizon of 6 months, no discounting of costs or effects was considered.  
Baseline sociodemographic and clinical characteristics were compared in the two intervention 
groups, i.e. gender, age, number of bowel-related complaints, number of active health 
problems/co-morbidities, number of months with change in bowel habits and self-reported quality 
of life (EQ-5D-5L). T tests were used for continuous data assuming a normal distribution, the Mann 
Whitney U test was used for non-normal quantitative data and categorical data were compared 
using chi-squared tests.  
Given the skewness associated with the cost distribution, all cost differences between groups were 
assessed using GLM with an identity-link and gamma distribution. An identity link function instead 
of a log link was used to give estimates as means to avoid potential analytical biases (Polgreen 
and Brooks 2012; Barber and Thompson 2000). An unadjusted GLM cost analysis with the study 
group (OC group vs CTC group) as the only covariate was performed as the first step. Given the 
study’s observational design and potential selection biases during the initial telephone clinic 
appointment, the groups being compared could have potentially been different due to the lack of 
randomisation with subsequent impact on healthcare costs (Moran et al. 2007). For this reason, 
an adjusted analysis was performed including all baseline variables with p<0.10. For all GLM 
analyses, group difference estimates and associated confidence intervals were reported, together 
with p-values.  
The incremental analysis of effectiveness considered QALYs as the measure of effect. EQ-5D-5L 
questionnaires (EuroQol Research Foundation 2019) at four points in time (baseline and 1, 3 and 
6 months post-recruitment) were used to generate quality of life scores (QALYs) based on a UK 
study (Devlin et al. 2018) and using area under the curve methods assuming linear movement 
between adjacent points (Drummond et al. 2004). A multiple regression analysis was used to 
address the potential imbalance between utilities at baseline likely to be correlated with the QALYs 
over the follow-up period (Manca, Hawkins, and Sculpher 2005). If utility data were missing, 
multiple imputation methods were used to assess the assumption that the data were missing at 
random. Missing data were imputed using ‘multiple imputation using chained equations’ (MICE), 
with the number of multiply imputed data-sets to be equal to the fraction of incomplete service-use 
information (White, Royston, and Wood 2011). 1000-replicate bootstrap analyses showing 
difference in costs and outcomes were presented on cost-effectiveness planes. All analyses were 
conducted using Stata version 15 for Windows (StataCorp LLC, Lakeway Drive,Texas). 
5.3 Results 
5.3.1 Data Validation and Completeness 
Only participants that withdrew the informed consent and hence were considered lost to follow-up, 




Data at baseline were complete for all participants, except for the number of comorbidities / active 
health problems (missing 5 and 2 participants in the OC and CTC group, respectively) and the 
number of months with change in bowel habits (missing 7 and 2 participants in the OC and CTC 
group, respectively). 
Follow-up data were captured via the combination of data from primary and secondary care 
databases and self-reported data from participants. Data from secondary care databases was 
100% complete (n=105 for the OC group, n=68 for the CTC group). Data from primary care 
databases was 98% complete (n=102 for the CTC group, n=67 in the CTC group). In the absence 
of data from both the primary care databases, any resource use outside GSTT was missing. 
Missing resource use values were imputed using the mean values from the respective group. 
Data from the EQ-5D-5L questionnaire at baseline and 6 months post-recruitment were, 
respectively, 100% complete (n=105 for the OC group, n=68 for the CTC group) and 59% complete 
(n=58 for the OC group, n=44 for the CTC group). 
5.3.2 Participant Flow 
Participant flow associated with the colorectal cancer study is illustrated in Figure 59. A total of 180 
participants were recruited, 110 to the OC group and 70 to the CTC group. During the follow-up 
duration, 4.5% (n=5) and 2.9% (n=2) of participants withdrew the informed consent in the OC and 
CTC group, respectively, and therefore were considered lost to follow-up. All participants that did 
not withdraw informed consent (n=173) were included in the analysis, 105 and 68 participants in 































Recruited (n = 180) 
Allocated to the OC group (n = 110) 
Received allocated intervention (n=109) 
Did not receive allocated intervention  
(n = 1) 
Allocated to the CTC group (n = 70) 
Received allocated intervention (n=70) 
Did not receive allocated intervention 
(n = 0) 
Lost to follow up (n = 5)  
Participant withdrew consent (n=5)  
Lost to follow up (n = 2)  
Participant withdrew consent (n = 2)  
Analysed (n = 105) 
Excluded from analysis (n=0) 
Analysed (n = 68) 










5.3.3 Participant Characteristics – Baseline 
Table 64 describes the baseline sociodemographic and baseline outcome variables organised by 
study group. All participants, apart from those who withdrew consent, were included in the baseline 
analysis (n=173), distributed in the OC group (n=105) and the CTC group (n=68).  
As summarised in the Statistical Analysis Plan section (section 5.2.6), significance testing between 
intervention groups was performed given the non-randomised study design. 







Age, years: mean (SD) * 61.3 (10.4) 69.2 (11.4) <0.001 
Gender Female, n (%) 54 (51) 36 (53) 0.846 
Number of comorbidities / active health 
problems: mean (SD) * 
2.9 (2.1) 4.0 (2.2) 0.002 
Number of months with change in bowel 
habits: mean (SD) 
3.7 (3.9) 4.1 (3.7) 0.465 
Self-reported health-related quality of life    
EQ-5D-5L: mean utility at baseline (SD) * 0.832 (0.197) 0.793 (0.173) 0.023 
Total NHS costs in the 6 months prior to 
recruitment: mean (SD) 
£187 (£65) £206 (£155) 0.242 
SD= Standard deviation; EQ-5D-5L - 5 level EQ-5D; * denotes a statistically significant difference 
between groups.  
A similar proportion of females were recruited to both groups but participants in the CTC group 
were older, with a mean age of 69.2 years old compared to 61.3 in the OC group (p<0.001). In 
terms of clinical characteristics, participants in the CTC group reported greater disease burden 
levels with: (i) higher mean number of comorbidities / active health problems (4.0 vs 2.9 in OC 
group, p=0.002); and (ii) lower mean utility values at baseline (0.793 in the CTC group vs 0.832 in 
the OC group, p=0.023). With regards to NHS resource use in the 6 months prior to recruitment to 
the study, no statistically significant difference between the two groups was found. 
Clinical findings: 
Out of the 105 participants in the OC group, 5 cancers (4.8%) were diagnosed during the 12-month 




(sigmoid colon T3 N2; descending colon T4a N1b; anal canal T3 N0). Out of the 68 participants in 
the CTC group, a total of 6 cancers (8.8%) were diagnosed, with four being CRCs (2 polyp 
adenocarcinomas extracted; rectal cancer T3 N1 and colon cancer T4b N1c M1) diagnosed during 
the initial CTC. With regards to medium to large polyps, a higher proportion of participants in the 
OC group had one or more polyps diagnosed (40% compared to 13% in the CTC group).  
5.3.4 Primary Objective 
The primary objective was to estimate the 6-month colon-related costs associated with both 
groups. For this purpose, all participants were followed-up for a period of six months to capture all 
relevant NHS resources used in the management of suspected CRC patients. This included both 
primary and secondary care resources. Table 65 summarises the mean number of NHS events 
per participant for both groups. With regards to primary care appointments, participants in both 
groups presented similar utilisation rates of both GP face-to-face and phone appointments. If 
secondary care hospital appointments were considered, participants in both groups had similar 
utilisation rates, except for the diagnostic tests. Out of the 105 participants in the OC group, 12 
(11%) had subsequent investigations, with 5 being repeated OC, 1 flexible sigmoidoscopy and 6 
CTCs. In the CTC group, 22 (32%) participants underwent additional invasive testing, equally split 
between 11 OC and 11 flexible sigmoidoscopy. Participants in the OC group had a higher utilisation 
of OC scans (p<0.001) whilst patients in the CTC group underwent more CTC and flexible 
sigmoidoscopy scans (p<0.001).  
Table 65. Breakdown of number of NHS appointments per type of activity organised per group. 
 OC group (n=105) CTC group (n=68) 
p-value 







Primary care services 
GP face-to-face appointment 59 0.56 41 0.60 0.762 
GP phone appointment 12 0.11 17 0.25 0.155 
Hospital based services 
ED visit 3 0.03 0 0 0.083 
Outpatient appointments 22 0.21 14 0.21 0.001 
CTC scan 6 0.06 68 1.00 <0.001 
OC scan 111 1.06 11 0.16 <0.001 





The mean cost of management per participant [mean (SD)] was lower in the CTC group compared 
to the OC group [£645 (£607) vs £991 (£316)], leading to an unadjusted mean cost difference 
between groups of -£345 per participant (p<0.001) (Table 66). Hence, at 6 months, there was a 
statistically significant difference between the two groups.  







Unadjusted cost difference 




group – OC group; 






- £345 (-£501 to -£190) 
p<0.001 
-£370 (-554 to -£185) 
p<0.001 
 
The cost distribution is positively skewed (mean >> median), as it was affected by a small 
proportion of patients that have significantly higher costs (maximum cost of £2,166 and £1,864 for 
the OC and CTC group, respectively). The cost difference between groups was mainly driven by 
the higher proportion of participants in the CTC group in the £0 to £500 range compared to the OC 
group [41 (60%) vs 0 participants] (Figure 60). At the opposite end, a marginally higher proportion 
of participants in the CTC group [5 participants (7.4%) vs 6 (5.7%)] had very large costs (>£1,500). 
The latter was mainly due to participants that required more than one diagnostic scan and costs 
associated with the management of extracolonic incidental findings. As an example, one participant 
was found to have a mass in the omentum, a situation that led to its surgical excision with a 
laparotomy. 
 
Figure 60. Overlapped histogram for the 6-month cost distribution (in £) for the OC (in blue) and 
























Given the non-randomised study design, a second GLM analysis was performed to adjust for 
baseline characteristics that were statistically different between groups using a conservative 
threshold (p<0.10) (see Table 67). The initial unadjusted 6-month cost difference between groups 
(-£345) was robust and hardly affected by baseline differences between groups (-£370) (Table 66 
and Table 67). In all analyses, the utilisation of CTC as the initial investigation for these cohort of 
participants was associated with statistically significant cost savings for the NHS. 
Table 67. GLM analysis for the 6-month cost analysis variable (gamma function, identity link) 
adjusted using statistically significant differences (p<0.1) between groups at baseline. 
6-month cost Coef. Std. Err. t P>|t| [95% CI] 
Age 3.122 4.503 0.69 0.488 -5.703 11.947 
Bowel complaints 29.335 32.070 0.91 0.360 -33.521 92.191 
Comorbidities -2.532 27.053 -0.09 0.925 -55.556 50.941 
Utilities at baseline -15.716 245.634 -0.06 0.949 -497.15 465.72 
Group -369.679 94.220 -3.92 0.000 -554.35 -185.01 
Constant 1085.13 361.43 3.00 0.003 376.74 1793.51 
(ii) Cost analysis including cancer treatment costs 
A second cost analysis included the costs associated with the treatment of cancer (CRC or 
otherwise). The mean cost per participant increased to £1,537 and £1,423 in the OC and CTC 
group, with the cost difference of -£114 not being statistically significant (p=0.759) (Table 68). 
Table 68. Mean (SD) cost per participant including costs associated with cancer treatment. 
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5.3.5 Secondary Objectives 
Outcome 1: 6-month cost-effectiveness of CTC as the first imaging modality compared to OC. 
At baseline, participants in the OC group showed a trend of higher utility value (mean utility of 0.793 
vs 0.832, p=0.097) using the EQ-5D-5L questionnaire. EQ-5D-5L data were collected at 3 and 6 
months post-recruitment (Table 69). There were no statistically significant differences (p>0.05) 




Table 69. Descriptive statistics for the utility variable at baseline, 3 and 6-month post-recruitment. 




Utility at baseline  
OC 105 0.832 0.197 
0.097 
CTC  68 0.793 0.173 
Utility at 3 months 
OC 58 0.792 0.218 
0.603 
CTC  35 0.802 0.171 
Utility at 6 months 
OC 58 0.818 0.213 
0.390 
CTC  44 0.793 0.217 
 
The mean cost per QALY at month 6 was estimated at -£69,080 (i.e. the intervention dominates, 
producing marginally more QALYs at a lower cost) (Equation 11).  
Equation 11. Point estimate of the incremental cost per QALY at month 6. 
𝐼𝐶𝐸𝑅 =
𝐶𝑜𝑠𝑡 𝐶𝑇𝐶 − 𝐶𝑜𝑠𝑡 𝑂𝐶





Figure 61 illustrates the bootstrap analysis with 1,000 replicates, considering the 6-month cost per 
QALY. At month 6, the use of CTC as the initial investigation had a probability of 56.0% of being 
dominant and 0.0% of being dominated by the control group. The remaining 44.0% of bootstraps 
were in the cost-effectiveness analysis quadrants, i.e. the probability of being cost-effective 
depends on the overall system willingness-to-pay for each QALY. Assuming a £20,000 and 
£30,000 willingness-to-pay per QALY (thresholds typically considered by NICE), there was a 91.4% 
and 83.6% of CTC being cost-effective compared to OC at six months, respectively (Figure 62). 
 
Figure 61. Cost-effectiveness plane associated with the 6-month cost per QALY analysis and 





Figure 62. Cost-effectiveness acceptability curve for several thresholds of willingness-for-pay. 
Objective 2: Cost per correctly diagnosed CRC using CTC as the initial investigation 
compared with OC. 
Out of the 68 CTC scans, 22 invasive colonic investigations were subsequently performed, 11 OC 
and 11 flexible sigmoidoscopy scans. Of the 22 subsequent scans performed, there were no 
discrepancies in the diagnosis of medium/large polyps and CRC between the CTC and a 
subsequent invasive colonic test.  
Objective 3: To estimate the incidence of extracolonic findings in the CTC group. 
Out of the 68 participants in the CTC group, 17/68 (25%) had extracolonic findings, 3/17 (18%) of 
which warranted further assessment. The first participant had a mass in the omentum that led to a 
laparotomy with surgical excision, the second presented an inguinal hernia that led to a follow-up 
CT and an initial outpatient appointment at which no further action was deemed necessary and the 
third participant was diagnosed with a Bosniak type IIF left renal lesion that after a follow-up CT 
warranted no further action. 
Objective 4: Likelihood ratio of CTC against colonoscopy in patients with initial positive CTC 
findings for medium to large polyps (≥6 mm) and CRC. 
No false positive findings in the initial CTC test were found when compared with the reference OC 
/ flexible sigmoidoscopy. Therefore, it was not possible to estimate the test’s likelihood ratio as per 











Objective 5: Time taken to reach a definitive diagnosis and first major treatment decision. 
Access to care was measured using time from: (i) referral to test; and (ii) referral to report being 
available to the referrer as proxies for accessibility (Table 70). In terms of the time elapsed from 
primary care referral to diagnostic test, there were no differences between the two groups 
(p=0.698), with mean time (SD) of 14.6 (6.3) and 12.8 (7.3) days for the OC and CTC group, 
respectively. With regards to the time from referral to the report being available to the referrer, the 
mean (SD) time was 34.2 (18.0) and 27.9 (16.6) days for the OC and CTC group, respectively, with 
the 6.3 days’ time difference being statistically significant (p=0.005). A detailed analysis of both 
variables showed that patients undergoing OC as the initial diagnostic test had a higher probability 
of having biopsies taken that ultimately led to a time delay in the report being available to the 
referrer. 
Table 70. Mean (SD) time elapsed from (i) referral to test; and (ii) referral to report being available 








Mean time elapsed in days (SD) between referral 






Mean time elapsed in days (SD) between referral 






* Non-normal distributions estimated using the Shapiro-Wilk test. Hence, Mann-Whitney tests were 
performed.  
Objective 6: Cancellation rates and incomplete (or suboptimal) bowel investigations. 
OC and CTC had similar rates of incomplete or suboptimal bowel visualisation (p=0.802), with, 
respectively, 9 (8.6%) and 6 (8.8%) scans deemed not suitable and thus requiring a second test. 
Similarly, no differences on the day cancellation rates were found between the groups (p=0.459), 
with 1/105 (1.0%) cancelled OC (refused to undergo procedure on the day) and 2/68 (2.9%) 
cancelled CTC scans (patients could not tolerate the test). In these 2 CTC scans, one patient 
underwent a CTC scan with sedation whilst the second underwent an OC scan instead.  
Objective 7: Patient satisfaction. 
Patient satisfaction was assessed the morning after the diagnostic scan and asked the participant’s 




the test (post-test). Appendix IV summarises the responses from participants in the OC group 
(n=69) and the CTC group (n=45). No statistical differences were detected between the two groups 
before, during or after the initial test (OC or CTC scan). 
5.3.6 Sensitivity Analyses 
Deterministic sensitivity analyses around the unit costs of CTC and OC scan were performed. The 
results from the sensitivity analyses are presented in Table 71. 
(i) CTC scan. The unit cost per CTC scan was a key variable in the cost analyses, particularly in 
the CTC group. The £250 unit cost was based on NHS reference costs and considered both the 
time elapsed in the acquisition of the CT images as well as the subsequent radiologist reporting. 
This unit cost was varied - 25%/+25%, equivalent to £187.50/£312.50, leading to cost differences 
per participant at 6 months of, respectively, -£405 (p<0.001) and -£288 (p<0.001). This meant that 
the use of CTC led to cost savings in both deterministic scenarios. 
(ii) OC scan. Similar to the previous sensitivity scenario, the unit cost per OC was considered as 
a second sensitivity scenario. Contrary to CTC, which unit cost was estimated based on a single 
unbundled tariff, the unit cost of OC scans varied according to the type of procedure (e.g. diagnostic 
colonoscopy, therapeutic colonoscopy, combined upper and lower endoscopic procedures – see 
Table 63 for further detail), leading to a minimum unit cost of £515 and a maximum of £911. All 
unit cost were varied -25%/+25%, leading to cost differences per participant at 6 months of, 
respectively, -£168 (p=0.012) and -£524 (p<0.001). This meant that the use of CTC led again to 
cost savings under both deterministic scenarios. 
Table 71. Sensitivity analyses scenarios considered and respective impact in the cost analyses at 
6 months post-recruitment. 
 Mean cost difference p-value             
Base case scenario - £345 <0.001 
(i) CTC unit cost: -25% / +25% variation -£405 -£288 <0.001 <0.001 







5.3.7 Summary of Results 
Participants in the CTC group were older, with a mean age of 69.2 years old compared to 61.3 in 
the OC group, with a greater disease burden, a higher number of comorbidities / active health 
problems (4.0 vs 2.9 in OC group) and lower utility values at baseline (0.793 in the CTC group vs 
0.832 in the OC group). These imbalances were considered in the adjustment of the primary 
outcome. Five cancers (4.8%) were diagnosed during the 12-month follow-up period in the OC 
group compared to six cancers (8.8%) in the CTC group, with this difference not being statistically 
significant. Out of the 68 participants in the CTC group, 17 (25%) had extracolonic findings, 3/17 
(18%) of which warranted further assessment. 
With regards to the primary outcome, the utilisation of CTC as the first-line colonic investigation for 
patients with low to intermediate risk of CRC led to a lower mean cost per participant at 6 months 
compared to the use of OC. Based on unadjusted GLM distributions, the mean cost difference per 
participant between groups at 6 months was - £345 (CI 95% CI: -£501 to -£190). When taking into 
consideration baseline imbalances, the mean cost difference between groups marginally increased 
and remained statistically significant [-£370, CI 95% CI: -£554 to -£185)]. An additional cost 
analysis included the costs associated with cancer treatment (CRC or other cancers). The mean 
cost per participant increased, respectively, to £1,537 and £1,423 in the OC and CTC group, with 
the cost difference of -£114 not being statistically significant (p=0.759). 
Assuming a £20,000 and £30,000 willingness-to-pay per QALY (thresholds typically considered by 
NICE), there was a 91.4% and 83.6% probability of CTC being cost-effective compared to OC at 
six months, respectively. 
5.4 Discussion 
5.4.1 Overview 
This section discusses the clinical and economic findings from the colon study. Furthermore, 
strengths and limitations are discussed, along with the potential implications for research and 
clinical practice in the management of patients with suspected CRC.  
5.4.2 Aims and Objectives 
The study’s primary objective considered the 6-month cost implications of using CTC as the initial 
colonic investigation compared to OC from a healthcare payer perspective. This decision was 
based on the absence of high-quality economic evidence in the selected subpopulation of patients 
(low to intermediate risk of CRC). Secondary objectives considered cost-effectiveness and cost-
utility analyses and other dimensions of analysis, from accessibility to care, patient satisfaction and 
diagnostic accuracy of both clinical pathways. These outcomes aimed to evaluate the real-world 




5.4.3 Key Findings 
Primary outcome: 
6-month cost analysis 
The study showed that the use of CTC produced cost savings to the NHS at 6 months post-
recruitment, with an unadjusted mean cost difference per participant of -£345 (95% CI: -£501 to -
£190, p<0.001). When adjusting for baseline imbalances between both groups, the mean cost 
difference per participant increased to -£370 (95% CI: -£554 to -£185, p<0.001). The cost 
differences between the unadjusted and adjusted analyses were due to the fact that participants 
in the CTC group were, on average, 8 years older and presented with a higher disease burden.  
The cost difference between the CTC and OC groups were multifactorial, primarily driven by two 
factors: (i) the low incidence of colon findings; and (ii) the lower unit cost (£250) of CTC compared 
to OC (£515 to £760). The study’s underlying hypothesis was that the use of CTC as the initial 
investigation for patients with low to intermediate risk of CRC would avoid the need for invasive 
diagnostic scans (such as OC) that are more expensive to the overall healthcare system. Atkin et 
al. (2013) reported that only 8% of patients had additional colonic investigations following OC, 
compared to 30% after CTC. These findings were corroborated by our study, with 11.4% and 
32.4% participants having a subsequent colonic investigation in the OC and CTC group, 
respectively. These conversion rates drove the overall cost for the healthcare system. In essence, 
more than the tests’ accuracy, that are considered to be equivalent, the presence of positive or 
negative findings was determined by the incidence of medium to large polyps or CRC in the 
population included in the study (overall 4% CRC incidence rate). This was indeed the reason to 
deliberately target the use of CTC to patients with low to intermediate risk of CRC. These patients 
are less likely to require a biopsy during an invasive colonic procedure, thus maximising CTC’s 
ability to rule-out any major colonic finding. Out of the 68 participants in the CTC, 46 (68%) were 
discharged based on the CTC results alone. If patients with red flags (e.g. rectal bleeding, anaemia) 
were to be included, a higher proportion of patients would be expected to require an OC, thus 
reducing the cost savings or even increasing total costs to the healthcare payer. 
The cost difference per patient estimated in this study was compared against the three NHS studies 
considered in the economic review (Table 72). In all four studies, the utilisation of CTC led to cost 
savings compared to OC. However, our study presented significantly higher cost savings compared 
to the other studies, particularly the RCT that showed no statistically significant cost differences 
(Halligan et al. 2015). Compared to the RCT, the unit cost per CTC group was similar (£645 vs 
£674) but there was a difference of £250 in the OC group (£991 in our study vs £739 in the RCT). 
The latter seemed to be due to the combined interaction of three factors. First, the incidence of 
CRC was higher in the RCT compared to our study (5.5% vs 4.3%), leading to increased costs in 
both groups of the RCT. Second, the unit cost of both CTC and OC used in the RCT were 
significantly lower than the ones considered in our study (mean unit cost of OC ranges from £330 
to £450 in the RCT compared to £515 to £911 in our study and the mean unit cost of CTC of £160 




participant in the RCT compared to our study. Third, only applicable to the CTC group, costs in our 
study included the management of extracolonic findings whilst, in the RCT (Halligan et al. 2015) 
and the other two studies (Ratnasingham et al. 2017; Gomes et al. 2013) excluded these costs.  
Table 72. Comparative analysis of the cost findings from the colon study and three NHS cost 
analyses retrieved from literature review. 
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OC group: mean cost 
per participant  
£991 £737 £739 £583 
CTC group: mean 
cost per participant 
£645 £550 £674 £467 
Mean cost difference 
per participant 
-£345 -£187 -£65 -£116 
As a corollary, the colon study produced statistically significant cost savings for patients with low 
to intermediate risk of CRC, contributing to the body of evidence concerning the utilisation of CTC 
as a direct alternative of OC in a major NHS Trust. 
Secondary outcomes:  
Cost-utility analysis 
In addition to the 6-month cost analysis, we conducted a cost-utility analysis, comparing the 
incremental costs and QALYs as the measure of effect (NICE 2011b; 2013). The use of CTC was 
found to be cost effective compared to OC, achieving more QALYs at a lower cost. Considering 
NICE’s traditional willingness-to-pay thresholds of £20,000 to £30,000 per QALY, CTC was found 
to have a probability of 91% and 84% of being cost-effective, respectively. These findings contrast 
to the 60% probability of cost-effectiveness estimated by Gomes et al. (2013). The very high 
likelihood of CTC being cost-effective was mainly driven by cost savings as 44% of replicates CTC 
led to lower QALYs compared to OC. Hence, the more the healthcare system is willing to pay, the 
less likely the intervention with CTC is to be cost-effective (91% vs 84% at £20,000 to £30,000 per 
QALY, respectively). However, these findings were potentially affected by the attrition rates 
associated with the 6-month EQ-5D-5L questionnaire (45% and 35% in the OC and CTC group, 
respectively). The utilisation of multiple imputation methods for missing utility data at months 3 and 
6 did not affect the cost-utility analysis, with the intervention with MRI presenting similar 




Likelihood ratio for a positive CTC 
Previous clinical studies have established the non-inferiority of CTC compared to OC in the 
diagnosis of medium to large polyps (≥5mm) and CRC (NICE 2018a). This finding was 
corroborated by our study as all positive findings in the CTC were confirmed (i.e. true positives) 
based on a subsequent invasive test (either OC or flexible sigmoidoscopy). No CRC was 
diagnosed up to 12 months post-recruitment in participants with negative findings in the initial CTC. 
Although reassuring, this was a study limitation as patients with negative findings in the initial CTC 
did not undergo an invasive test as per routine clinical practice. These findings were compared 
with the SIGGAR trial, which considered a longer follow-up period time (3 years vs 1 year), and 
both studies corroborated the non-inferiority of CTC compared to OC in the management of CRC. 
Extracolonic findings  
CTC enables the visualisation of extracolonic findings that may not relate to the presenting clinical 
condition but may be of clinical significance, e.g. abdominal aortic aneurysms which are potentially 
life threatening if untreated (Pooler, Kim, and Pickhardt 2017). Out of the 68 participants in the 
CTC group, 17 (25%) had an incidental extracolonic finding. Out of these 17 participants, 14 (82%) 
did not warrant any follow-up, with the remaining 3 (18%) requiring follow-up with diagnostic CT 
follow-up and, in one case, a surgical excision of a mass. Evidence from the SIGGAR trial showed 
a much higher proportion of CTC scans with at least one extracolonic finding (59%, 1039/1748), 
with 14% (149/1039) of these patients undergoing subsequent procedures to further investigate 
and/or treat the extracolonic findings. Although the proportion of extracolonic findings reported in 
the SIGGAR trial was much higher compared to the colon study (59% vs 25%), the proportion of 
patients with extracolonic findings requiring further investigations and/or treatment was similar in 
both studies (14% vs 18%). It was hypothesised that, given the randomised controlled design of 
the SIGGAR trial, radiologists reported clinical findings that would not otherwise be reported in real-
world practice (CTC scans in the colon study were performed as part of standard care). 
In addition, the utilisation of CTC led to the diagnosis of two patients with extracolonic cancer, a 
metastatic stomach cancer and a metastatic prostate cancer (2.9%). These extracolonic findings 
were not believed to be incidental but rather related to the presenting bowel complaint. The 
incidence of extracolonic cancers was similar with the evidence from previous studies [2.7% based 
on an extensive study performed by Xiong et al. (2005)] 
Access to care 
The use of CTC as the initial investigation led to the results being available to the referrer, on mean, 
6.3 days earlier compared to the OC group (p=0.005). The longer waiting time in the OC group 
was mainly due to the diagnostic workload associated with biopsies taken during the OC test rather 
than the date of the OC test itself. As part of the OC procedure, biopsies of potential lesions (polyps 
or CRC) were often taken and the time it took to complete the pathological assessment of those 
tissues seemed to be the major contributing factor for the difference in access to care between the 




On the day cancellation and incomplete scans 
OC and CTC had similar rates of incomplete or suboptimal bowel visualisation in the colon study, 
with, respectively, 9 (8.6%) and 6 scans (8.8%) deemed unsuitable and thus requiring a second 
test. The SIGGAR trial reported a higher rate of incomplete OC scans (11%) and a lower rate of 
incomplete CTC scans (5.3%) (Halligan et al. 2015).  
No differences on the day cancellation rates were found between the groups, with 1.0% and 2.9% 
cancellation rates among patients undergoing OC and CTC scans, respectively. Given its 
operational impact, particular emphasis was given to reduce ‘on the day cancellation’ and ‘did not 
attend’ rates as discussed in further detail in Chapter 7. 
Patient satisfaction 
Patient satisfaction was compared using a non-validated questionnaire to be completed the 
morning after the diagnostic scan (CTC or OC) and evaluated the participant’s opinion about: (i) 
the bowel preparation (pre-test); (ii) the bowel test (test); and (iii) the morning after the test (post-
test). No statistically significant differences between groups were found between the two groups at 
any of these three phases. These findings were somewhat unexpected, particularly concerning the 
bowel test itself and the experience on the morning after the bowel test (post-test). It was assumed 
that, given the non-invasive nature of CTC, participants in this group might report shorter recovery 
times, lower levels of discomfort or intrusiveness or improved experience in comparison with their 
expectations. The latter could be due to the small number of questionnaires completed [n=70 (67%) 
for the OC and n=45 (66%) for the CTC group]. For this reason, and bearing in mind the increase 
in the uptake of CTC (see Chapter 7 for further detail), it was recommended to the gastroenterology 
and radiology departments to continue to use patient experience questionnaires. This should 
provide definitive evidence to evaluate any differences in patient satisfaction between the two tests. 
5.4.4 Strengths, limitations and implications 
Strengths 
The estimates of NHS resource use data were primarily based on comprehensive and complete 
data retrieved from hospital-based databases that captured both the acute and elective elements 
of the pathway associated with the management of patients with low to intermediate risk of CRC. 
These data were supplemented by both primary care utilisation data, collected from each 
participant’s GP, and self-reported participant data. The aim was to guarantee that any colon-
related NHS event was costed regardless of the healthcare provider and its location. Moreover, 
the inclusion of costs associated with the management of extracolonic findings were also included. 
This contrasted with the majority of the economic literature and constituted another strength of this 
study. In addition, the prospective collection of healthcare utilisation and self-perceived quality of 
life data, the conduction of economic evaluation analyses (rather than cost analyses only) and the 
use of different dimensions of analysis (efficiency, quality of care, access to care and patient 





There were however some limitations to this study. First, this was a single-centre study with 
participants recruited from one central hospital in London. A multi-centre study would be necessary 
to explore the generalisability of the results. Second, as with any observational study, no 
randomisation between groups was performed. An adjusted GLM was performed to mitigate the 
potential impact of the study observational design on the primary outcome. Third, the study sample 
might not be representative of all patients with low to intermediate risk of CRC. To mitigate this 
potential impact, clear and detailed inclusion and exclusion criteria were used. Fourth, participants 
with negative CTC findings could not be definitively ruled-out as potential false negatives as they 
did not undergo an OC as per routine clinical practice. The supplementary use of cancer databases 
at one year follow-up minimised this limitation. Fifth, there were considerable follow-up attrition 
rates potentially affecting secondary outcomes such as cost-utility analyses or patient satisfaction. 
This issue could be minimised with closer cooperation between the clinical and the research teams 
in the proactive follow-up of participants. Lastly, long-term clinical and economic implications of 
extracolonic findings found in the CTC group were not evaluated as part of this study.  
Implications for Further Research 
The utilisation of CTC as a replacement for OC as the first-line colonic investigation should be 
evaluated across different population subgroups, care providers and healthcare settings. 
Furthermore, any future studies should evaluate the impact of both CTC and OC scans on patient 
satisfaction and test acceptability. Finally, the long-term impact of extracolonic findings in CTC 
scans should be further evaluated in larger sample sizes and modelled beyond the study’s time 
horizon to estimate the cost-effectiveness of CTC compared to OC.  
Implications for Policy and Clinical Practice 
The utilisation of CTC as a first-line replacement test for OC in the diagnosis of symptomatic 
patients with change in bowel habits as the presenting complaint should be considered. CTC is a 
safe, cheaper and more accessible alternative to OC in the diagnosis of symptomatic patients with 
low to intermediate risk of CRC. A quarter of patients undergoing CTC scans presented 
extracolonic findings, most of which did not warrant any further investigation and/or treatment. 
However, clinical literature from the SIGGAR trial reported that more than half of patients had at 
least one extracolonic finding. Given its potential resource implications in the utilisation of CTC as 
a first-line diagnostic tool, report standardisation of extracolonic findings in CTC scans should be 
considered, along with clear diagnostic and/or therapeutic clinical management pathways. 
5.5 Conclusion 
This study found that the use of CTC instead of OC as the initial investigation scan for patients 
referred from primary care with low to intermediate risk led to significantly lower costs to the NHS 




effective at month 6 using NICE’s willingness-to-pay thresholds. The use of CTC also improved 
access to care and no difference in patient satisfaction was noted.  
In summary, the use of CTC for patients with low to intermediate risk of CRC led to savings for the 
NHS whilst enabling the release of vital OC capacity to enhance access to care for patients more 





Chapter 6. Trial-based to model-based economic evaluations 
6.1 Chapter overview  
This chapter summarises the utilisation of economic data from diverse study types. First, a literature 
review discusses the strengths and weaknesses of using economic data from multiple study designs, 
with particular focus on data derived from interventional studies [e.g. randomised controlled trials 
(RCTs)], real-world evidence (e.g. observational studies) and decision analytical modelling studies. 
Second, the potential implications of using different study types in the context of the TOHETI 
programme are discussed. For this purpose, the a priori economic modelling conducted as part of the 
TOHETI bid is compared to the actual findings from the RCT and two observational studies (findings 
already detailed in chapters 3, 4 and 5). Differences in economic evidence between trial-based and 
model-based analyses are presented, together with a discussion of potential implications to policy 
makers and NHS clinical practice. 
6.2 Literature review: trial-based to model-based economic evaluations 
The introduction of new medical technologies has been recognised as one of the main drivers 
associated with a growth in healthcare costs, estimated to be responsible for 40-50% of annual cost 
increases (Clemens, 2017). However, a review by Sorenson, Drummond, and Khan (2013) analysed 
86 studies and found conflicting evidence, with some technologies leading to increased costs (e.g. 
cancer drugs, invasive devices), while others were cost-neutral or even cost saving. The introduction 
of such technologies should therefore be preceded by an economic evaluation based on high-quality 
evidence, focusing not only on costs but also on respective effects.  
One fundamental discussion concerns the data and study design(s) on which any economic evaluation 
is based on. Drummond (1996) first discussed the need to find a balance between ideal clinical-trial 
based economic evaluations, with high internal validity but low external validity, and economic models, 
which may be more relevant to the decision maker. Historically, information collected in RCTs 
represented the dominant paradigm in economic evaluation. A study by Sculpher et al. (2006) reported 
that approximately 30% of economic evaluation studies on the NHS Economic Evaluation Database 
were derived from single RCTs. However, deriving pivotal data, e.g. resource use, from a single-centre 
study could bias economic findings due to potential lack of generalisability. In 2007, ISPOR published 
a recommendation supporting the use of real-world evidence (RWE), i.e. clinical, economic and 
patient-reported data based on studies that were not RCTs such as cohort and case-control studies 
(Garrison et al. 2007). Figure 63 illustrates the different levels of evidence typically produced during 





Figure 63. Schematic illustration of the type of study design and respective data volume generated (graph lines in shades of blue) across the technology 




RCTs are mainly conducted to determine an intervention’s efficacy prior to regulatory approval. 
Contrastingly, a higher volume of RWE is usually generated following regulatory approval, ranging 
from pragmatic RCTs to observational studies and economic models. 
A literature review capturing the strengths and weaknesses of trial-based or model-based economic 
evaluations is detailed in Appendix V. In summary, trial-based economic evaluations are based on 
observed data but typically do not compare all alternatives, present truncated follow-up periods, do not 
assess final outcomes or lack generalisable findings. Model-based evaluations address these issues 
but present potential biases of their own. Some of these biases include: the incorporation of inadequate 
clinical data; unknown effect of the intervention; and inadequate statistical methods to address biases 
from different types of data (e.g. observational studies). The use of pragmatic RCTs is increasingly 
recognised as the most relevant study design to evaluate the cost-effectiveness of interventions in the 
context of real-world clinical practice. Pragmatic RCTs aim to increase the generalisability of findings 
but consideration needs to be given to a potential decrease in internal validity, affecting the trial’s ability 
to make causal inferences (Calvert, Wood, and Freemantle, 2011).  
Data derived from multiple study designs should ideally be used to assist the decision maker in the 
context of specific interventions. The type of data informing a technology economic evaluation depends 
on: (i) the technology itself, particularly its value proposition and likelihood to impact routine clinical 
practice; and (ii) the level of existing clinical and economic evidence. The more disruptive the 
technology, the less likely it is to have published clinical and economic evidence, such as economic 
evaluation conducted alongside an RCT or a pragmatic RCT. In contrast, if the technology’s anticipated 
benefits, both in terms of costs and effects, cannot be estimated based on RCTs or RWE studies, 
economic modelling provides a solid framework for evidence synthesis and decision modelling on 
which to base a funding decision (Katkade, Sanders, and Zou, 2018). Rather than providing a definitive 
answer as to which it is better, one of the aims of this chapter is to provide the reader with an 
understanding that the choice of method is dependent on the context of the technology being 
evaluated. 
The following subsections compare the economic findings from three cases studies based on real-
world studies (one pragmatic RCT and two observational cohort studies, chapter 3 to 5) conducted in 
Phase 3 of the TOHETI programme with the a priori economic models built in Phase 2.  
6.3 Methods 
Phase 2 of the TOHETI programme included the funding proposal where decision-analytical models 
were presented to estimate the potential impact of the proposed interventions. Literature reviews were 
conducted to synthesise the clinical and economic evidence. This process assessed whether existing 
evidence had already evaluated the proposed intervention and, if so, summarised the evidence. 
Furthermore, the review of clinical evidence targeted studies where diagnostic accuracy (sensitivity, 




standard care. Special consideration was given to systematic literature reviews and meta-analyses. 
With regards to economic evidence, any cost analysis or health economic evaluation (cost-
effectiveness, cost-utility, cost-consequence or cost-benefit analyses) evaluating the intervention (or 
similar interventions) directly or indirectly against a comparator were included. Further detail for each 
literature review is presented under each clinical condition in the following subsections (6.4.1, 6.5.1. 
and 6.6.1). This evidence was essential to populate the a priori models built by the PhD student. 
Subsequently, decision-tree models were developed in 2014-15 for each of the three clinical 
interventions considered. A decision tree is a tree-like decision support tool in which each node 
represents a “test” (e.g. patient undergoing MRI scan), each branch represents the outcome of such 
test (e.g. normal or abnormal findings in the MRI), and each leaf node represents a class label (e.g. 
patient with true positive findings). Given that the model probabilities are based on a one-off event (i.e. 
a diagnostic scan), decision tree models are used very often in diagnostic modelling. Each model 
compared the proposed intervention with the existing standard care. Although specific aspects of each 
economic model are presented in the following sections, all three models shared four general features. 
First, the main aim of the economic models was to estimate the cost implications of the different 
interventions from a healthcare payer perspective. A mean cost per participant was estimated for all 
three interventions. Second, the time horizon of the models was consistent with the follow-up period 
for each clinical condition. Third, the decision tree was structured to reflect the accuracy levels 
(sensitivity and specificity) of the proposed imaging interventions. Sensitivity refers to a test’s ability to 
rule-in a clinical condition in patients with such condition, e.g. ability to identify a scaphoid fracture in 
patients with a scaphoid fracture (true positive). Specificity refers to a test’s ability to rule-out a clinical 
condition in healthy patients, e.g. ability to exclude a scaphoid fracture in patients with no actual 
scaphoid fracture (true negative). Diagnostic tests do not have perfect accuracy in real-world clinical 
practice, potentially leading to false negative (e.g. patients with negative test results despite having a 
scaphoid fracture) and false positive findings (e.g. patients with positive test results despite having no 
scaphoid fracture). The different probabilities associated with these scenarios were considered in the 
decision tree models using sensitivity and specificity values retrieved from literature. Fourth, the overall 
incidence or prevalence of the condition being evaluated was included in the model. This was a key 
parameter given that all probability nodes will be affected by the proportion of patients with or without 
the actual condition. The more prevalent the condition is, the higher the proportion of patients with 
positive findings in the diagnostic test. 
6.4 Suspected scaphoid fracture 
6.4.1 Summary of literature review 
This subsection summarises the key evidence used to model the impact of different imaging modalities 
(particularly MRI) in the management of patients with suspected scaphoid fracture. These key variables 
were the incidence of scaphoid fractures, and the accuracy levels of the different imaging modalities 




advanced imaging modalities, like bone scintigraphy or ultrasound, were not included in this literature 
review. 
The incidence of scaphoid fracture was highly variable among patients recruited to the identified 
studies. A systematic review by Yin et al. (2010) showed a minimum incidence value of 5% and a 
maximum of 50%. However, these values derived from different reference tests and from multiple 
clinical pathways at different hospitals, partly explaining the registered variation. Taking this uncertainty 
into consideration, clinical evidence suggested a scaphoid fractures incidence value between 10 and 
20% from the overall number of suspected scaphoid fractures (Yin et al. 2010). This is similar to the 
10% and 16% incidence value reported, respectively, for patients with wrist injuries and patients with 
clinical suspicion of scaphoid fracture and normal initial radiography (Ring and Lozano-Calderón 2008, 
Mallee et al. 2011). For the purpose of the economic model a 10% baseline value was assumed and 
subsequently varied in deterministic sensitivity analyses.  
Clinical literature supported the added diagnostic value of both CT and MRI compared to conventional 
radiography. Particularly, CT and MRI have a very high specificity value in the diagnosis of scaphoid 
fractures, i.e. are able to exclude scaphoid fracture among patients with no scaphoid fractures. High-
quality clinical evidence from systematic reviews (e.g. Yin et al. 2010) supported MRI as the imaging 
modality with the highest accuracy level in the diagnosis of scaphoid fractures and, for this reason, it 
was included in the model. Sensitivity and specificity values of, respectively, 97.7% and 99.8% were 
included in the model based on the meta-analysis performed by Yin et al. (2010). Table 73 summarises 
the baseline incidence and sensitivity/specificity probabilities used in the decision tree model. 
Table 73. Incidence, sensitivity and specificity parameters included in the economic model. 
Parameter Value Source / Description 
Estimated incidence of scaphoid fractures among 
patients with suspected scaphoid fracture 
presenting to the ED. 
10% 
Assumption. Sensitivity 
analysis was performed 
using literature. 
Radiographs sensitivity and specificity in the 
diagnosis of scaphoid fractures at presentation. 
Sens.= 64% 
Spec.= 90% 
Nguyen et al. (2008). 




Yin et al. (2010) 
6.4.2 Economic modelling 
A de novo decision tree model with a time horizon of 3 months, based on a healthcare payer 
perspective, was developed to estimate the cost implications of using immediate MRI as an add-on 
test in the management of suspected scaphoid fractures compared with the standard care, which relied 
on the use of radiographs only in the ED. Figure 64 illustrates the model associated with the control 
group, i.e. current standard care, whilst Figure 65 shows the model structure associated with the 





Figure 64. Short-term model for the control group (standard care) in the scaphoid model. 
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The standard care group (Figure 64) comprised the combined use of two imaging modalities. First 4-
view wrist radiographs were performed on presentation to the ED. If positive, a CT scan might be 
performed on a follow-up outpatient visit. This was usually carried out at an initial fracture clinic visit, a 
week to ten days post the initial ED presentation. Based on the scaphoid fracture incidence and the 
radiographs accuracy levels, 15.4% of findings were estimated to be positive. Applying these estimates 
of incidence and accuracy to an annual cohort of 679 patients attending the ED at GSTT, 105 patients 
would present with abnormal findings in the initial 4-view radiography performed at ED. Out of these 
105 patients, 44 would be expected to be true positives (i.e. patients with scaphoid fractures and 
positive findings on the initial radiographs) and 61 to be false positives (i.e. patients with no scaphoid 
fracture despite positive findings in the initial radiographs). 
The intervention group considered a combined strategy, with initial wrist radiographs and a subsequent 
MRI scan (Figure 65). The use of MRI was used as an add-on test to standard care following the initial 
wrist radiographs. All participants were then grouped into four logical branches as per the MRI findings: 
true positive, false positive, true negative and false negative. Patients with positive findings underwent 
multiple fracture clinic appointments and it was assumed that 5% eventually progress to surgery. 
Participants with true negative findings were discharged, but, based on clinical opinion, it was assumed 
that 25% of participants would still require follow-up due to ongoing pain. Participants with false 
negative findings were assumed to incur additional costs. The rationale was that patients discharged 
with scaphoid fractures would eventually re-present to the ED or to an outpatient appointment for 
further follow-up. Hence, in order for the model to consider this increase in utilisation, a cost of £430 
was added (equivalent to cost of a repeated ED attendance, fracture clinic follow-up and a wrist MRI 
scan).  
Table 74 lists the unit costs and branch probabilities included in the economic model. Unit costs were 




Table 74. Unit costs and other probabilities included in the economic model. 
Parameter Value  Source / Description 
Percentage of patients with positive 
findings in the initial radiography that 
undergo a CT scan (control group) 
80% 
Assumption based on clinical experts 
(orthopaedic consultant). Percentage of patients that undergo 
surgery after positive imaging 
findings (both groups) 
5.0% 
Percentage of patients with a 
negative MRI scan that require a 
subsequent follow-up visit (MRI 
group) 
25% 
Assumption based on clinical experts. 
Sensitivity analysis is to be performed using a 
range of values. 
Initial clinical assessment at the ED £144.70 
Patel et al. (2013). Unit cost included a 
removable scaphoid plaster cast (‘backslab’). 
Consistent with internal hospital data. 
4-view wrist radiographs in the ED £28.70 
Internal hospital data. Also consistent with 
Patel et al. (2013).  
Initial fracture clinic visit £155 
Internal hospital data. Also consistent with 
Patel et al. (2013).  
Follow-up fracture clinic referral £91 
Internal hospital data. Patel et al. (2013) 
reported a higher cost of £150.6.  
CT exam  £60.60 Internal hospital data. 
Cost per wrist MRI scan  £101.60 Internal hospital data.  
Scaphoid plaster £25.20 
Internal hospital data. Patel et al. (2013) 
reported a higher value of £42.7.  
Serial plain radiograph £23.00 
Internal hospital data. Patel et al. (2013) 
reported a similar cost (£18.7).  
Surgery cost £3,763 Internal hospital data.  
Added cost in true positive patients £0 No added cost in true positive patients. 
Added cost in false positive patients £0  
No added cost was considered due to a false 
positive (resource use costs already 
considered in the model). 
Added cost in true negative patients £0 No added cost in true negative patients. 
Added cost in false negative patients £430 
Added cost of a repeated ED attendance, 
fracture clinic appointment and conventional 




Table 75 presents the mean cost per patient for each strategy. The mean cost per participant in the 
control group (standard care) and intervention group (MRI group) were, respectively, £470 and £361, 
yielding potential savings per participant of £109 or 24% compared to the mean cost per participant in 
the control group. An estimate of £100 savings per participant was used in the power calculation for 
the randomised clinical trial summarised in Chapter 3. 
Table 75. Mean cost per participant from the base case scenario for the control and intervention group. 





Control group: standard care -> diagnostic 
pathway in the ED based on radiographs only  
£470 - 
Intervention group -> combined strategy of 
radiographs and MRI 
£361 £109 
Sensitivity analyses: 
One-way deterministic sensitivity analyses were performed around two model parameters. The 
sensitivity scenarios along with their respective results are presented in Table 76. The incidence of 
actual scaphoid fractures was varied to 5% and 50% (base case value of 10%) as per evidence from 
the systematic review by Yin et al. (2010). For the MRI group, the probability of formal follow-up for 
patients with negative findings in the MRI was varied to 0% and 100% (baseline value of 25%). 
Table 76. Mean cost per participant from the base case scenario for the control and intervention group 
(MRI group) based on two deterministic sensitivity analyses. 
Parameter Strategy 
Sensitivity analyses Cost per patient 
Minimum Maximum Minimum Maximum 
1. Incidence of scaphoid 
fracture amongst patients 
with suspected scaphoid 
fracture presenting at ED 
Control Group 
5% 50% 
£ 453 £ 605 
Intervention group £ 337 £ 555 
2. Percentage of patients 
with a negative MRI exam 
that require a subsequent 
follow-up clinic visit 




£ 470 £  470 




If a 5% scaphoid fracture incidence value was assumed, the difference in cost per patient for the control 
and intervention group increased to £116. If the maximum incidence value of 50% was assumed, the 
cost difference per patient for the control and intervention decreased to £50. Hence, the higher the 
incidence of actual scaphoid fractures, the smaller the cost savings associated with the use of MRI. 
The latter is due to the fact that the added value of MRI resides in its ability to rule-out a fracture and 
decrease follow-up costs associated with these patients. 
The probability of patients being discharged following a negative MRI was varied to 0% and 100%, 
given the uncertainty associated with this parameter. The higher the proportion of these patients being 
followed-up, the lower the cost savings associated with the use of immediate MRI. However, even if 
all patients were followed-up, the intervention was still associated with cost savings of £58 per 
participant. 
6.4.3 Comparative analysis: real-world versus model results 
Results from the RCT conducted as part of this thesis are presented in Chapter 3. The SMaRT trial 
was designed as a pragmatic RCT, taking into account different design and analytical considerations 
for trial–based health economics study (Marshall and Hux 2009). The intervention led to mean cost 
savings per participant of £174 and £266 at month 3 and 6 post-recruitment, respectively (Table 77). 
Hence, real-world evidence showed that the actual cost difference per participants was in fact higher 
than anticipated via model-based evidence.  
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The higher cost difference between groups estimated in the pragmatic RCT and in the economic 
modelling was driven mainly by the higher observed mean cost per participant in the control group, 
estimated at £542 and £661 at month 3 and 6, respectively. This was higher than the predicted mean 
cost of £470 using economic modelling. Real-world evidence from the RCT exhibited four trends that 
increased the estimated cost of diagnosing suspected scaphoid fractures in the control group. First, 
there was a considerable utilisation of follow-up radiographic and advanced imaging scans. A mean of 
1.05 radiographs were used whilst advanced imaging (either CT or MRI) represented a mean of 0.46 
scans per participant. That meant that almost half of participants in the control group ended up 
undergoing advanced imaging. Second, a higher utilisation of fracture clinic appointments (initial and 
follow-up appointments) was recorded. Third, the economic model did not consider the costs 
associated with the management of the condition within primary care. Although marginal (less than 3% 
of the total costs), primary care costs contributed to increase the cost difference between groups as 
participants in the control group consumed more primary care healthcare resources (mean number of 
GP visits of 0.35 and 0.11 in the control and intervention group, respectively). Fourth, unit costs 
considered in the real-world evidence were based on the year 2017/18 compared to 2012/13 in the 
economic model. Costs from the economic model were updated using the HCHS index (Curtis and 
Burns 2018), leading to an increased cost difference between groups in the economic model (from 
£109 to £118) that was closer to the estimates from the real-world trial. 
In the intervention group, the mean cost per participant was similar between the RCT (£368 and £395 
at 3 and 6 months, respectively) and the economic model (£361). However, there were differences in 
the composition of costs in the two approaches. First, the prevalence of non-scaphoid fractures was 
not considered in the economic model (only scaphoid fractures were considered). A total of 22% 
(15/67) of participants in the MRI group had non-scaphoid fractures, a proportion of which (around 
50%) required treatment with immobilisation with plaster cast and radiographic follow-up. This led to 
an increase in costs in the RCT, with the economic modelling constituting an oversimplification of the 
clinical practice. Second, a proportion of participants with negative findings in both the initial radiograph 
and MRI still had at least one fracture clinic appointment. This was due to the fact that even in the 
absence of a bone fracture, participants were still symptomatic for wrist pain. The economic model 
assumed that 25% of participants with no findings in the wrist MRI would require at least one fracture 
clinic appointment. This figure, based on clinical experts, considered uncertain given the absence of 
empirical data, was confirmed to be 23% (10/43 participants) in the RCT. Third, as with the control 
group, primary care related costs were considered only in the real-world study. This contributed to an 
increase of less than 1% of the mean cost per participant in the RCT. Fourth, all patients with positive 
findings for fracture were assumed in the economic modelling to be immobilised with a plaster cast. 
Real-world clinical practice showed that this assumption was not correct as some fractures (e.g. 
trabecular fractures or non-displaced fractures) were actually immobilised with a splint rather than a 
plaster cast. The cost of a plaster cast is higher than a splint and tends to require more follow-up visits. 





Figure 66. Changes to the scaphoid economic model based on trial-based data (highlighted inside 
the red squares).  
In summary, the a priori economic model underestimated the cost impact of the intervention compared 
to data retrieved from the RCT. Real-world data showed that many of the assumptions underpinning 
the a priori model were inconsistent. These related mainly to both patient and clinicians behaviours. 
From the patient’s point of view, the key driver to decrease utilisation of healthcare resources, and 
associated costs, derived from the MRI’s ability to immediately rule-out a fracture (scaphoid or 
otherwise) or major soft injury (e.g. ligament rupture) during the acute episode of the pathway. Despite 
the MRI’s reassurance effect, patients with no wrist injury might still remain symptomatic for a few 
weeks and consequently re-present to secondary care. This constituted a major parameter assumption 
for the economic model based on clinical expertise alone (no prior published evidence given the 
innovative nature of the intervention). The higher the proportion of patients re-presenting to secondary 
care, the less cost saving the intervention was. Another important finding from the real-world study, 
which was not considered in the economic model, were costs associated with the treatment of 
trabecular and aligned fractures. The economic modelling assumed that all participants with fractures, 
regardless of the location and nature, would be immobilised with a plaster cast. The real-world 
evidence showed that was not the case as non-scaphoid bone fractures (e.g. radial fracture) were not 
considered in the model and trabecular or aligned bone fractures were typically treated with a wrist 
splint rather than a plaster cast, decreasing the need for follow-up appointments and imaging. Given 
MRI’s very high sensitivity, these types of fractures were detected mainly in the MRI group, ultimately 
decreasing the anticipated costs of treating these fractures. 
6.4.4 Implications 
As discussed in Chapter 2, there are five layers of uncertainty associated with the evaluation of medical 
imaging technologies. The disruptive nature of immediate MRI in the management of suspected 
fractures and consequent absence of empirical evidence from RCTs further increased the uncertainty 
around the cost implications to the NHS. This might ultimately lead to conflicting findings from model-
based and trial-based studies, raising the question as to what level of evidence is required to assess 
such interventions. Gazelle et al. (2011) and the NICE Diagnostics Assessment Programme (Crabb, 
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2011) identified the need to obtain high-quality evidence about the introduction of technologies with 
high potential to significantly impact clinical care. The use of immediate MRI in the management of 
suspected scaphoid fractures was one of such technologies. In this particular intervention, cost 
differences per participant between groups were greater based on real-world data compared to 
modelling estimates. These were mainly due to behaviours from patients and clinicians alike, which 
were not anticipated in the economic model and ultimately increased the relative cost differences. 
However, regardless of the approach used, the economic evidence showed that the intervention was 
associated with cost savings for the NHS. This meant that basing the adoption decision solely on 
economic modelling evidence would have ultimately led to the same conclusion as the real-world 
evidence. Regardless of this individual finding, the uncertainty regarding some key model parameters 
supported the framework models discussed in Chapter 2, favouring the implementation of real-world 
studies prior to the widespread introduction of disruptive diagnostic tests.  
It should also be recognised that the different methods of economic evaluation, in this case an 
economic model and a pragmatic RCT, can complement one another. In the case of the SMaRT trial, 
economic modelling informed the hypothesis testing of the subsequent pragmatic RCT and can be 
useful for other healthcare providers if the RCT setting is not generalisable. 
6.5 Chronic headache 
6.5.1 Summary of literature review  
The literature review informed the modelling around the management of patients with chronic 
headache that were referred from primary care to either: (i) a neurologist; or (ii) direct access to brain 
MRI. The rationale was that the early use of MRI would reassure patients that no underlying life 
threatening condition, particularly brain cancer or brain aneurysms, was present. However, the 
prevalence of such conditions among chronic headache sufferers is almost negligible, with an 
estimated 0.1% prevalence of brain cancer as the underlying cause of chronic headache (Symvoulakis 
et al. 2007). This meant that the headache model was conceptually different from the ones built for 
patients with suspected scaphoid fractures and suspected colorectal cancer. In fact, the value of 
advanced imaging resided in the reassurance effect rather than the diagnostic information associated 
with the potential diagnosis of the chronic headache. This reassurance effect could in turn lead to 
different utilisation rates of healthcare services and ultimately to differences in the mean cost per 
participant in the two groups.  
Howard et al. (2005) performed an RCT that showed that the use of imaging in patients with chronic 
daily headaches had the potential to change patient management. One important change was the 
reduction of referral rates to the neurology service at secondary care from 23% (17/74) in the control 
group to 1.3% (1/76) in the scanned group (Howard et al. 2005). Following on from this study, Thomas 




primary care led to reduced referral rates to secondary care. This study was conducted in Tayside, 
Scotland, with an overall participation of 45% of the 309 local GPs. The findings by Thomas et al. 
(2010) confirmed that imaging reduced referral rates in 86% of the cases during the follow-up period 
(average of 1.3 years per patient). Out of the 215 patients submitted to CT, only 1.4% had a significant 
pathological condition, whilst 10.2% presented non-significant findings and 88.4% normal findings. 
Kernick and Williams (2011) assessed the impact of providing GPs with direct access to neuroimaging 
for patients with headache and concluded that, although the yield for clinically significant findings in 
neuroimaging was below 1%, the reassurance effect associated with neuroimaging remained unknown 
(Howard et al. 2005; Kernick and Williams 2011). Kernick and Williams (2011) added that the anxiety 
associated with incidental findings should not be disregarded and could, in fact, lead to increased 
healthcare utilisation. 
Although the literature review showed that advanced imaging has the potential to decrease overall 
healthcare utilisation, little was known about the actual cost implications of providing GPs with direct 
access to brain MRI for chronic headache patients compared to conventional management with referral 
to neurology services. Given the limited supply of neurologists in the UK, and the potential benefits of 
using neuroimaging, the present subsection presents the economic model used to estimate the cost 
implications associated with both clinical pathways.  
6.5.2 Economic modelling  
A de novo decision tree model with a time horizon of 12 months and a healthcare payer perspective 
was developed to estimate the cost implications of two coexisting clinical pathways in the management 
of chronic headache that differed in the referral from primary care to either neurology services or direct 
access to brain MRI.  
Figure 67 and Figure 68 illustrate, respectively, the model associated with the Neurology referral group 
and direct access to brain MRI group. The model structure included any primary or secondary care 
healthcare utilisation due to the management of chronic headache. This meant that resources that 
were not a consequence of the referral from primary care were included as long as they were due to 
chronic headache. One important example of this was attendances to the ED due to chronic headache, 
following which patients were considered to either be discharged without advanced imaging, 
underwent head CT or were admitted to hospital. 
All participants in the MRI group (Figure 68) underwent an initial brain MRI scan to exclude any 
potential space occupying lesion, particularly brain cancer. Based on the MRI findings, three scenarios 
were considered:  
1. Positive findings for brain cancer. Subsequently, the patient was referred to a neuro-oncology 




2. Clinically relevant incidental findings. Participants attended a consultation with a neurologist 
and subsequent follow-up – if needed – was considered. If discharged back to primary care, 
GPs received  a full report of the MRI performed by a neuroradiologist; 
3. Negative findings (no brain cancer or other significant incidental findings). The remaining 
patients, which included the vast majority of the cohort, followed the ‘normal findings’ branch. 
Patients were referred back to primary care with a full report of the MRI performed by a neuro-
radiologist. 





Figure 67. Economic model for patients with chronic headache managed with referral from primary care to neurology. 
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Table 78. Node probabilities included in the economic model. 
Parameter Value Source / Description 
Estimated prevalence brain cancer amongst 
the cohort of patients selected 
0.1% 
Assumption based on Symvoulakis et 
al. (2007) 
CT sensitivity and specificity values for brain 
cancer 
81% / 
92% Medina et al. (2010) referring to Hutter 




Management with referral to neurology  
Percentage of patients undergoing advanced 
imaging following referral to neurology 
50% 
Assumption based on clinical opinion 
from a consultant neurologist. 
Percentage of patients that have a follow-up 
consultation with a neurologist (when no 
advanced imaging is used) 
39.7% Based on internal clinical audit. 
Number of episodes at the ED with primary 
diagnosis of headache 
5% Based on internal clinical audit. 
Percentage of patients attending the ED that 
are referred to a Computed Tomography 
scan (CT perfusion test) 
45% Based on internal clinical audit. 
Percentage of patients admitted following 
presentation to the ED 
5% Based on internal clinical audit. 
Percentage of patients attending the ED 
discharged back to primary care without 
advanced imaging 
50% Based on internal clinical audit. 
Management with referral to brain MRI 
Percentage of incidental findings with direct 
access MRI 
7.5% 
Assumption based on clinical opinion 
from a consultant neuroradiologist.  
Percentage of reduction of attendance to the 
ED amongst patients with negative MRI 
findings during the subsequent year 
10% 
It was assumed that the increase of 
MRI utilisation rates would halve the 
overall ED utilisation rate amongst 






Table 79. Unit costs included in the economic model. 
Parameter Value  Source / Description 
Primary care cost per patient with 
headache per 3 months  
£125.20 
McCrone et al. (2011). Costs inflated according to 
The HCHS index in Curtis (2012). 
Unit cost per GP consultation £38.50 
The cost per GP consultation was £36, based on 
a 12 minute consultation 
(http://www.nice.org.uk/nicemedia/live/13076/500
58/50058.pdf) and updated using Curtis (2012) 
data. 
Primary care cost per patient with 
headache per 9 months with no 
imaging reassurance 
£375.60 
Estimate based on McCrone et al. (2011) and 
maintenance of utilisation rates and associated 
costs (e.g. medicines). 
Percentage of reduction of 
primary care costs per 9 months 
due to a negative imaging test 
(either MRI or CT) 
10% 
Estimate based on Howard et al. (2005) and 
McCrone et al. (2011).  
Unit cost of clinical assessment of 
patients with headache at the ED 
£316 
Estimate based on internal financial data. It was 
assumed the average unit cost amongst different 
ED episodes without admission and excluding 
dental care.  
Unit cost per patient admitted due 
to headache 
£1,475 
National Reference Costs code PA04A 
(Headaches and Migraines, with CC) in National 
Reference Costs 2011/12. 
Unit cost per head CT test 
(including report) 
£78.70 Estimate based on internal financial data. 
Unit cost per MRI head test 
(including report) 
£148.90 Estimate based on internal financial data.  
Unit cost per neurologist 
consultation (first visit) 
£233 Estimate based on internal financial data. 
Unit cost per neuro-oncologist 
consultation (first visit) 
£233 Assumed to be equivalent to a neurologist. 
Unit cost per neurologist 
consultation (follow-up visit) 
£163 Estimate based on internal hospital costing data.  
Unit cost of a patient admitted to 
the hospital following a positive 
MRI/CT for brain cancer 
£2,319 
National Reference Costs code AA24A (Brain 
Tumours or Cerebral Cysts, with CC) in National 




Lifetime cost associated with 
brain cancer treatment 
£15,086 
Estimate based on the survival rates and annual 
costs (both for the first year, continuing year and 
last year of life) presented at 
http://costprojections.cancer.gov/annual.costs.html 
and assuming a linear survival rate amongst the 
intervals considered. A 15 year survival rate of 0% 
and a 3.5% discount rate were assumed to 
estimate the annual cost with brain cancer 
treatment. 
Unit cost of discharge after 
negative findings 
£0 
Assumed to be included in previous procedures 
(e.g. in the cost of the neurologist consultation). 
Unit cost per False Positive 
episode in MRI or CT 
£381.90 
It was assumed an added cost for a new MRI 
exam and a neuro-oncologist appointment. 
Unit cost per False Negative 
episode in MRI or CT 
£15,585 
Assumed that the patient will re-enter the pathway 
and therefore all costs associated to its diagnosis 
and subsequent treatment. It was considered the 
addition of: (1) costs of primary care for 3 months; 
(2) a new MRI exam; (2) subsequent neuro-
oncologist appointment; and finally (4) the annual 
costs of brain cancer treatment. 
The results from the base case scenario are presented in Table 80. The cost per patient in the 
Neurology and MRI group were estimated at £557 and £542, respectively. The economic model 
showed that direct access to brain MRI was likely to produce marginal cost savings of £15.6 per 
participant, equivalent to a reduction of 3% in the total 12-month healthcare costs. In contrast, if only 
secondary care costs were considered, the MRI pathway was likely to generate a higher proportion of 
cost savings to the healthcare payer, estimated at 43% of the absolute unit cost per patient in the 
neurology pathway. Most healthcare costs were estimated to reside in primary care, particularly in the 
MRI group as only participants with clinically relevant findings in the MRI were assumed to need further 
follow-up at secondary care.  
6.5.3 Comparative analysis: real-world versus model results 
Results from the chronic headache observational study were presented in Chapter 4. The use of direct 
access to MRI led to cost savings at both 6 and 12-month post-recruitment (£333 and £518, 
respectively). Hence, real-world evidence showed that the actual cost difference per participant was 





Table 80. Mean cost per participant from the economic model and observational study for both the 
Neurology and the MRI group. 
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 Direct access to brain MRI £542 £245 £289 
 
The comparison of model-based and real-world evidence showed that modelling costs in the Neurology 
group were underestimated whilst costs in the MRI group were overestimated. These cost differences 
were due to multiple reasons, both in terms of the valuation of key parameters as well as the overall 
model structure.  
In the Neurology group, parameter inconsistencies were identified between the model data and real-
world clinical practice. These inconsistencies related to parameter estimates rather than the actual 
structure of the model. First, primary care utilisation was overestimated in the economic model. In 
practice, referral to neurology services led to a substantial decrease in GP appointments and 
consequent costs (decrease of mean number of 1.5 appointments in the 12 months post-recruitment 
vs 12 months pre-recruitment). This was the only model parameter that contributed to an overestimate 
of total costs in the Neurology group.  
Second, treatment options for chronic headache were not considered. This meant that medication 
costs and procedures such as nerve block injection and Botox treatment were not included, thus 
leading to an important underestimate of costs. The observational data found that patients in the 
Neurology group underwent a mean of 0.30 Botox or nerve injection procedures. Given the high-cost 
of each treatment session (unit cost per nerve block injection session of £587-£636 or Botox treatment 
of £650-£749) (NHS Improvement 2018), and the difference in utilisation between the two groups 
(mean 0.30 vs 0.05 in the Neurology and MRI group, respectively), this led to an important 
underestimation of costs.  
Third, the utilisation of advanced imaging in the Neurology group, estimated at 50%, was 10% higher 
(78 scans in 129 participants). Furthermore, out of these 78 scans, there was only one CT, with the 
remaining 77 scans being head MRI, a more expensive scan. Fourth, the economic model assumed 
that out of the patients referred to Neurology where no advanced imaging is considered (branch ‘No 
MRI or CT strategy’), only 39.7% had at least one follow-up appointment. This estimate was not 
corroborated by real-world data as 77% (41 out of 53) participants had at least one follow-up 




one follow-up appointment, a situation that was not contemplated in the economic model. These 
elements combined, led in the Neurology group, to a mean cost per patient underestimate of £251 
(£557 vs £808) in the economic model compared to the real-world data. 
In the MRI group, both parameter and structural differences were identified in the comparison of model 
data with empirical evidence. The main parameter difference derived from the utilisation of primary 
care resources. Participants in the MRI group were assumed to have a much higher consumption of 
GP face-to-face appointments compared to observed data. The reason was that these patients would 
have no formal follow-up at secondary care so, following the head MRI, the ongoing management of 
chronic headache was assumed to take place in primary care. However, following recruitment to the 
study, a mean number of 1.19 GP appointments per MRI participant was observed (vs 1.82 in the 
Neurology group). This meant that, despite not having formal follow-up at secondary care, some MRI 
participants did not even attend primary care, having the MRI results communicated by GPs either 
over the telephone (lower unit cost compared to face-to-face appointment) or via post. The reduction 
in the overall utilisation of primary and secondary care resources following a negative MRI scan 
confirmed the reassurance effect proposed in the clinical and economic literature. This reassurance 
effect also translated into lower than anticipated utilisation rates of both inpatient and emergency care, 
thus contributing to the overestimation of costs in the MRI group in the economic model (£542 vs £289).  
The structure of the economic model for participants in the MRI group assumed those with normal MRI 
findings (‘True Negative’ findings in Node 22 in Figure 68) were discharged back to primary care where 
the management of chronic headache would occur. This did not accurately reflect routine clinical 
practice as 18% (17/95) participants were re-referred to secondary care, this time for an appointment 
with a neurologist. Figure 69 depicts the changes made to the structure of the economic model. All 88 
participants in the MRI group with true negative findings (7 participants had incidental findings) were 
referred back to primary care. Out of these, 44% (39/88) of participants had no GP appointment and 
the remaining 56% (49/88) had at least one GP appointment. From participants with at least one GP 
appointment, 35% (17/49) were subsequently re-referred to secondary care, this time for a neurologist 
appointment. These were referrals associated with patients that, despite the negative MRI, presented 
higher headache burden compared to the rest of MRI participants. All branch probabilities described 
above are also illustrated in Figure 69. 
 
Figure 69. Changes to the economic model based on data from the observational study (blue cells 
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6.5.4 Potential implications 
Although the two pathways being evaluated had recently been constituted as standard care for the 
management of chronic headache patients, there was little evidence concerning the cost implications 
of each pathway. Hence, given the unknown cost implications, and also the increasing volume of 
chronic headache patients (population at risk) being referred from primary care, it was decided to 
conduct an observational, prospective study to support future decision making processes.  
Data from this observational study and the a priori economic modelling were then compared and 
important differences were identified. In summary, the a priori model underestimated the costs 
associated with provision of care for participants in the Neurology group and overestimated the costs 
in the MRI group. This combination meant that the economic model suggested that direct access to 
MRI compared to management with referral to neurology services would only produce marginal cost 
savings (£16 cost difference per participant) as opposed to the significant cost savings identified in the 
observational study (adjusted 12-month cost differences between groups of over £500 per participant, 
p<0.001). The latter meant that basing the adoption decision of direct access to MRI exclusively on 
modelling data might have misled decision makers and potentially negatively affect the uptake of direct 
access to brain MRI in the context of managing chronic headache patients.  
6.6 Suspected colorectal cancer 
6.6.1 Summary of literature review  
The literature review informed the parameter values and the model structure of the utilisation of 
Computed Tomography Colonography (CTC) or Optical Colonoscopy (OC) as the initial investigation 
of suspected colorectal cancer (CRC). As with the other models presented in this chapter, the literature 
review synthesised the prevalence of the clinical condition (medium to large polyps and CRC) and the 
accuracy of both imaging tests in the diagnosis of the clinical condition.  
The prevalence rate of CRC was estimated at 3.7% based on historical internal hospital data which 
was also consistent with the findings of a systematic review and meta-analysis (Pickhardt et al. 2011). 
A 10% prevalence of large polyps was estimated based on a systematic review and meta-analysis 
(Halligan et al. 2005). 
The accuracy of both imaging tests, CTC and OC, in the diagnosis of CRC and large polyps was 
estimated. OC had a 94.7% sensitivity value for the detection of CRC (95% CI: 90.4%, 97.2%) 





CTC has high accuracy levels in the detection of large and medium polyps and is especially sensitive 
to the detection of symptomatic CRC (Halligan et al. 2005). Systematic reviews showed that sensitivity 
and specificity of CTC increases with larger polyps (NICE 2014). According to a meta-analysis by 
Halligan et al. (2005), CTC had, respectively, 93% (95% CI: 73%, 98%) and 97% (95% CI: 95%, 99%) 
sensitivity and specificity values for large polyps. In the diagnosis of CRC, CTC was shown to present 
a 95.9% sensitivity value (95% CI: 91.4%, 98.5%) (Halligan et al. 2005). The latter value was 
corroborated by Pickhardt et al. (2011), who estimated a sensitivity value of 96.1% (95% CI: 93.8%, 
97.7%). The base case scenario assumed the above mentioned values. Older studies tend to 
underestimate the accuracy levels of CTC as new generation CT scanners are likely to significantly 
improve overall accuracy levels in the diagnosis of both large polyps and CRC. 
NICE (2014) acknowledged that OC holds the highest clinical accuracy for diagnosis of CRC and 
therefore should be considered the gold-standard as a first line examination test. However, this may 
no longer be the case as a recent study showed that no CRC was missed by OC and only one with 
CTC (1 out of 29 patients with CRC, i.e. an average sensitivity of 96.5%) (Atkin et al. 2013). The 
authors concluded that the widespread use of CTC as an alternative to OC was justified, provided that 
suitable guidelines and training schemes were put in place (Atkin et al. 2013).  
In summary, CTC is highly sensitive, particularly for CRC. Given the relatively low prevalence of CRC, 
CTC could be considered as a suitable first line investigation test for low to medium risk symptomatic 
patients, as a direct alternative to OC. 
A critical appraisal conducted by the Centre for Reviews and Dissemination at the University of York 
concluded that findings from cost-effectiveness studies varied greatly in terms of comparative analysis 
of costs and effects associated with CTC and OC (National Institute for Health Research 2009). In 
addition, most economic evaluations were related to screening programmes and not, as considered in 
this evaluation, to symptomatic patients. Nevertheless, this centre highlighted that the relative cost of 
CTC and OC were two critical parameters to the incremental cost-effectiveness ratio. Their findings 
suggested that CTC is likely to be cost-effective if it presents a unit cost between 22% and 52% 
compared to OC (National Institute for Health Research, 2009).  
6.6.2 Economic modelling 
A de novo decision tree model with a time horizon of 6 months and a healthcare payer perspective 
was developed to estimate the cost implications of CTC as a direct alternative to OC in patients with 
low to intermediate risk of CRC. Figure 70 and Figure 71 illustrate the model structure associated with 
the OC and CTC groups, respectively. The incidence and accuracy parameters are summarised below 
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Table 81. Incidence, sensitivity and specificity parameters included in the economic model. 
Parameter Value Source / Description 
Estimated prevalence of CRC 3.7% 
Based on internal hospital data 
and clinical studies. 




Based on Pickhardt et al. (2011). 




Sensitivity based on Menardo 
(2004). Specificity assumed to be 
equal to CRC. 




Based on Pickhardt et al. (2011). 




Based on Halligan et al. (2005). 
Table 82 summarises the different node probabilities and unit costs included in the economic model. 
All data presented were obtained from either: literature review; national reference costs; clinical 
experts; or internal hospital data. 
Table 82. Node probabilities and unit costs included in the economic model. 
Node (Fig. 
6 , Fig. 7) 
Parameter Value Source / Description 
N2/N12 
Probability of complication (bleeding due 
to perforation) associated with OC 
0.25% 
Information retrieved from 
literature (Rabeneck et al. 2008). 
N3/N13 
Probability of death associated with a 
surgery due to bleeding of perforation 
3.0% 
N10 
Inconclusive colonoscopy / patients 
unable to comply 
7.5% 
Retrieved from an internal clinical 
audit with 862 patients. 
N10 
Inconclusive colonoscopy after a positive 
CTC. 
0% 
Assumption. The rationale was 
that patients would find bowel 
preparation easier to follow and 
more tolerable, thus leading to a 
lower proportion of inconclusive 
colonoscopies.  
N18 
Added probability of cancer incidence 
due to CTC scan. 




N/A Unit cost of OC £527.20 
NHS Reference Costs, code 
FZ51Z - Diagnostic Colonoscopy, 
19 years and over.   
N/A Unit cost of CTC £242.20 
NHS Reference Costs, 
unbundled CTC. 
N/A Unit cost of surgery due to bleeding £6,819 
NHS Reference Costs, code 
FZ76A - Distal Colon Procedures, 
19 years and over with Major CC.   
N/A Unit cost of death £0 
Assumption. No cost was 
considered in the base case 
scenario. No sensitivity analysis 
was performed as this event 
probability was negligible (expert 
opinion). 
N/A 
Unit cost of discharge without further 
investigation. 
£0 
Assumption. Cost assumed to be 
included within the surgery 
episode cost. 
N/A Cost of biopsy £43.20 
Assumption. Cost difference 
between the unit cost for a 
colonoscopy with and without 
biopsy (using National Reference 
Codes FZ52Z- Diagnostic 
Colonoscopy with Biopsy, 19 
years and over and code FZ51Z - 
Diagnostic Colonoscopy, 19 
years and over. 
N/A Initial outpatient appointment £132 
Internal financial data. Any 
patient with a positive finding 
(either true positive or false 
positive will have a follow-up 
consultation). 
N/A Lifetime cost of cancer due to CTC £25,500 
Cost of Cancer estimated from 
NHS England (2011). 
N/A Added cost in true positive patients £0 No added cost considered. 
N/A Added cost in false positive patients £527.20 
It was considered the added cost 
of performing a serial 
colonoscopy without biopsy. 
N/A Added cost in true negative patients £0 No added cost considered. 
N/A Added cost in false negative patients £570.50 
Added cost of a repeated 




Table 83 presents the unit cost per participant for each strategy considered. The mean cost per 
participant in the OC and CTC were, respectively, £660 and £393. The use of CTC, instead of OC, as 
the initial colonic investigation led to potential savings per participant of £267 or 40% compared to the 
mean cost per participant in the OC group.  
Table 83. Mean cost per participant from the base case scenario for the OC and CTC groups. 










CTC as the initial imaging modality £393 
 
Sensitivity analyses: 
Deterministic sensitivity analyses were performed on five model parameters, based on a minimum and 
maximum range (Table 84). First, the prevalence of CRC was varied to a minimum of 1% and a 
maximum of 10% (baseline 3.7%). Second, sensitivity and specificity for CTC were decreased to 80% 
and increased to 100% (i.e. no false negative of false positive findings). Third, the incidence of CTC 
cancer-induced was increased to 0.1% and 1.0% from a baseline value of 0.035%. Fourth and fifth, 
the unit cost of CTC and OC was varied ±50%. 
Table 84. Minimum and maximum values considered in the five deterministic sensitivity analyses. 
Parameter Base case value 
Range of values   
(min-max) 
1. Prevalence of CRC amongst the initial cohort of 
symptomatic patients 
3.7% 1%-10% 
2. Sensitivity and specificity of CTC for the diagnosis 
of CRC 
96.1% / 95.0% 
80%/80% - 
100%/100% 
3. Increased cancer incidence due to CTC radiation  0.035% 0.1-1% 
4. Unit cost per CTC £242.20 
±50% (£121.1; 
£363,3) 
5. Unit cost per Optical Colonoscopy £527.40 
±50% (£263.6; 
£790.9) 
Table 85 summarises the results from the base case scenario and all five sensitivity analyses. In all 
analyses, the use of CTC as the initial diagnostic colonic test compared to OC was associated with 
cost savings to the healthcare payer (negative values represent cost savings). First, the increase in 




the CTC group that have positive findings will undergo a subsequent OC (second test), thus increasing 
the overall costs for this group. Second and third, any improvement on the diagnostic test’s accuracy, 
either CTC or OC, will lead to an improvement in the respective costs of such group. Fourth and fifth, 
any changes in the unit cost of CTC or OC will lead to changes in the mean cost difference. For 
instance, any increase to the unit cost of CTC led to a decrease in the cost savings. However, even if 
the unit cost of CTC increased by 50% (to a unit cost of £363), using CTC as the primary investigative 
scan still led to cost savings per participant of £156. 
Table 85. Difference in mean cost per participant based on five deterministic sensitivity analyses. 
Parameter Minimum Maximum 
Base case scenario -£267 
1. Prevalence of CRC amongst the initial cohort of 
symptomatic patients 
-£280 -£241 
2. Sensitivity and specificity of CTC for the diagnosis 
of CRC 
-£192 -£293 
3. Increased cancer incidence due to CTC radiation  -£254 -£58 
4. Unit cost per CTC -£380 -£156 
5. Unit cost per Optical Colonoscopy -£33 -£503 
6.6.3 Comparative analysis: real-world versus model results 
Results from the observational clinical study were presented in Chapter 5. The intervention with CTC 
as the primary colonic investigation led to cost savings per participant of £345, compared to the £267 
figure estimated from the economic model (Table 86). Hence, real-world evidence showed that the 
actual cost difference per participants was higher than anticipated via the economic model. 
Table 86. Mean cost per participant from the economic model and observational study for both groups. 
Strategy 

























In both groups, the economic model underestimated the costs associated with the provision of 
healthcare compared to real-world data although the cost differences were relatively close. These cost 
differences were due to multiple reasons, both in terms of the valuation of key parameters as well as 
the overall model structure, both for the OC and the CTC groups. 
In the OC group, the structure of the model accurately reflected real-world clinical practice as per the 
observational study. However, two parameters contributed to comparatively lower costs of £331 (£991 
- £660) per participant. First, the probability of the initial OC test being inconclusive or patients being 
unable to comply, estimated at 7.5% in the economic model was found to be marginally higher (11.4%). 
This meant that a higher proportion of participants underwent a second test, thus increasing costs. 
Second, and more importantly, the unit cost of OC was found to be significantly higher than the model 
assumption (£527) and variable according to different purposes (e.g. analgesia, upper and lower 
gastrointestinal test done simultaneously, ranging from £515 to £911). Furthermore, as with the CTC 
group, part of the increase in costs was explained by the four year gap between the economic model 
data (2013-14) and the real-world evidence (2017-18). Costs from the economic model were updated 
using the HCHS index (Curtis and Burns 2018), leading to a cost difference between groups in the 
economic model (from £267 to £283) that was closer to the estimates from the real-world trial (£345). 
In the CTC group, the economic model represented an oversimplification of real-world clinical practice 
that led to an underestimate of the CTC unit cost per participant of £252 (£646 - £393). This was due 
to two reasons. First, as with the OC group, the CTC scan can produce inconclusive findings or patients 
may be unable to comply (e.g. unexpected claustrophobia). In both cases, this would lead to a second 
diagnostic test, a situation that was not considered in the economic model despite representing 8.8% 
of all CTC scans. Second, and unlike OC, CTC visualises extra colonic organs. This led to the 
identification of extra colonic findings in 25% of CTC scans, with 4.4% of CTC scans leading to changes 
in the care management pathway. This again represented an oversimplification of the model that 
produced to lower cost estimates. Figure 72 illustrates the two branches added to the CTC model to 
correct these two limitations. 
In both groups, real-world evidence did not find evidence of complications (e.g. bleeding due to bowel 
perforation, adverse reactions to bowel preparation) associated with the OC or CTC scan. However, 









Figure 72. Changes to the structure of the economic model in the CTC group based on the empirical evidence from the colon study (two branches 
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The potential implications of using model-based data compared to real-world evidence were explored 
across three clinical pathways. The literature review showed that the type of data informing the 
technology’s adoption decision depends on the technology itself, particularly its value proposition and 
likelihood to impact routine clinical practice, and the level of existing clinical and economic evidence. 
The more disruptive the technology, the less likely it is to have published clinical and economic 
evidence, thus highlighting the need for real-world evidence.  
This was the case for using immediate MRI in the management of suspected scaphoid fractures. The 
comparative analysis of data from the a priori economic model and the RCT showed that both methods 
supported the adoption of the intervention. However, the economic model represented an 
oversimplication of real-world clinical practice that could have led to differences in the adoption 
process.  
In contrast, if the technology’s anticipated benefits, both in terms of costs and effect, are documented 
in previous real-world evidence, economic modelling can provide a solid framework for evidence 
synthesis on which to base a funding decision. This was the case in the management of suspected 
colorectal cancer, where economic modelling, despite underestimating the costs in both groups, led to 
similar cost differences between groups and would have led to the same conclusion for decision 
makers. The latter was due to the existence of real-world data around the key model parameters, the 
probability for subsequent colonic investigations following the initial test (either CTC or OC) and the 
unit costs of both tests, particularly CTC.  
A different scenario occurred in the evaluation of direct access to MRI for patients with chronic 
headache. In that case, the a priori economic model failed to represent real-world clinical practice, 
leading to substantial cost differences between groups. Ultimately, basing the decision solely on the 
economic model could have led to the non-adoption of direct access to MRI. However, given the 
potential clinical and cost implications, as well as the population at risk (over 500 patients/year), it was 
decided to conduct a prospective, observational study which ultimately showed the existence of 
statistically significant cost savings associated with direct access to MRI.  
As a corollary, the combination of model-based and trial-based economic evaluations should be 





Chapter 7. General discussion 
7.1 Chapter overview 
This chapter discusses the aims and key findings of each study included in the thesis. Subsequently, 
a detailed description is given regarding the implementation work completed to redesign each of the 
clinical pathways as well as its real-world impact at GSTT and broader implications for further research 
and healthcare policy. The chapter ends with the strengths and limitations of the PhD and the overall 
conclusion of the thesis. 
7.2 Aims of the thesis 
Chapter 2 presented the background economics on the new or novel utilisation of advanced imaging. 
In summary, the combination of demand in growth for advanced imaging with technological 
developments that led to the simultaneous increase in diagnostic accuracy and decrease in scanning 
acquisition and processing times, meant that advanced imaging became more accurate, accessible 
and cheaper. However, there is little evidence on the cost and health economic implications associated 
with the use of advanced imaging.  
The overarching aim of the PhD was to evaluate the utilisation of advanced imaging across multiple 
clinical pathways. In the context of NHS financial constraints, the evidence from this PhD challenges 
the established diagnostic paradigm that advanced imaging, being more expensive and less available 
than basic imaging modalities (e.g. radiographs, ultrasound), should be reserved until later stages of 
diagnostic pathways. Although seemingly counter intuitive, it was hypothesised that the upfront 
utilisation of an expensive but more accurate diagnostic test would streamline the subsequent 
diagnostic and, if needed, treatment pathway, leading to an overall decrease in total healthcare costs. 
For this purpose, one prospective randomised clinical trial and two prospective observational studies 
were conducted to investigate the use of advanced imaging in patients with suspected scaphoid 
fracture, chronic headache and suspected colorectal cancer. For all three interventions, the condition-
specific costs from the NHS perspective were considered as the primary outcome. The rationale for 
this approach was three-fold. First, the use of advanced imaging was hypothesised to optimise the use 
of healthcare resources thereby promoting efficiency and avoiding waste, thus contributing to the NHS 
sustainability agenda. Second, the interventions were hypothesised to also improve clinical outcomes 
and self-reported patient satisfaction levels. Third, despite the improvement in both clinical outcomes 
and costs, it was not deemed feasible to power the study based on other outcomes (e.g. difference in 
scaphoid non-union fractures). This was not considered feasible within the scope of the TOHETI 




The clinical studies evaluated the cost and clinical implications of the early use of advanced imaging 
in three specific clinical pathways for patients with: (i) suspected scaphoid pathway (chapter 3); (ii) 
chronic headache (chapter 4); and (iii) suspected colorectal cancer (chapter 5). Albeit different in 
nature, as the first two interventions examined the use of MRI and the third CT, the rationale was 
consistent, i.e. to impact clinical pathways by promoting optimal care based on the innovative use of 
advanced imaging. The following subsections summarise the research findings from the economic 
models produced in the initial stages of this PhD and the subsequent real-world studies conducted 
(detailed in Chapter 6) and particular attention is given to the implementation work completed to 
develop a new clinical pathway (suspected scaphoid fracture pathway) and promote the uptake of 
existing clinical pathways (chronic headache and suspected colorectal cancer pathways).   
7.3 Research and implementation work 
This subsection is organised as per the remaining chapters of the thesis, addressing the three clinical 
pathways investigated. This subsection describes first the research conducted (modelling and 
empirical studies) and, second, the implementation of changes to clinical practice for each pathway. 
Third, for all three clinical pathways, the real-world implications for clinical practice at GSTT are 
quantitatively estimated. 
7.3.1 Suspected scaphoid fracture 
Chapter 3 presented the clinical and economic evidence around the use of immediate MRI in the 
management of suspected scaphoid fractures compared to standard care, which relies on the use of 
radiographs only during the acute episode.  
Model-based evaluation: 
A systematic literature reviewed the evidence around the use of immediate MRI in the management of 
suspected scaphoid fractures. Given the intervention’s innovative nature, there was no empirical data 
and economic modelling data presented important limitations and showed conflicting evidence. 
Furthermore, most economic models considered the utilisation of MRI a few days after the acute 
presentation, rather than at presentation, and also did not consider subsequent changes in care 
management based on the MRI findings. Based on this systematic literature review, it was considered 
that no evidence reflected the evaluation of using immediate MRI in the management of suspected 
scaphoid fractures and therefore a de novo decision tree model was developed.  
A 3-month time horizon model compared the total healthcare costs of the intervention with immediate 
MRI for patients with negative findings in the initial scaphoid radiographs with standard care, which 
relied on the use of radiographs only. Furthermore, subsequent care in the intervention group was 
streamlined based on the MRI findings. Participants with positive findings for fractures were directly 




patients with negative findings were discharged without any follow-up; and the remaining were 
considered to come back to hospital for further assessment. The baseline scenario estimated that the 
intervention with immediate MRI would lead to a 24% 3-month cost reduction compared to standard 
care, equivalent to £109 per participant or over £74,000 annually based on the GSTT historical activity 
data. Furthermore, the deterministic sensitivity analyses showed that even when the incidence of 
scaphoid fractures was doubled or even if all patients with negative MRI findings were followed-up at 
fracture clinic, the intervention still remained cost saving.  
Despite this favourable economic evidence, due to the absence of observed data and the uncertainty 
surrounding the real-world implementation of such an innovative intervention, we established the need 
for empirical data. This decision was consistent with existing frameworks for the evaluation of medical 
imaging technologies, e.g. Gazelle et al. (2011) (see Chapter 2 for further detail), and was based on 
three elements. First, the at-risk population, with over 1,000 yearly presentations to GSTT’s ED due to 
suspected scaphoid fractures. Second, the clinical impact was considered to be large as the 
intervention fundamentally changes the diagnostic and treatment pathway. Third, although the 
potential economic impact for the NHS was not large, the intervention was believed to lead to cost 
savings to the healthcare payer. For these three reasons, a single-centre pragmatic randomised trial 
was conducted at GSTT. 
Trial-based evaluation (SMaRT trial): 
Based on guidance from evaluation frameworks for imaging tests and the absence of robust clinical 
and economic evidence around the intervention, we deemed the use of high-level evidence to be 
appropriate. Consequently, we undertook the SMaRT trial, a pragmatic, randomised clinical trial that 
recruited 136 participants and analysed the total NHS resource utilisation over a period of 6 months. 
The latest evaluation frameworks supported the assessment of the intervention up to a societal level 
(Gazelle et al. 2011; Fryback and Thornbury 1991). Hence, the SMaRT trial also included the 
assessment of costs from a societal perspective as a secondary analysis. However, consistent with 
the recommendations by NICE (Crabb 2011), the present study adopted the NHS perspective for costs 
in order to provide evidence relevant to the UK clinical practice. 
Primary research hypothesis. What are the economic and clinical benefits of using immediate wrist 
MRI in the acute management of suspected scaphoid fractures? 
The primary hypothesis was not rejected as there was no statistically significant cost difference at 3 
months post-recruitment (Table 87). However, when this cost analysis was extended up to 6 months 
post-recruitment (first secondary hypothesis), the use of immediate MRI showed statistically significant 
cost savings between groups. A range of operational and clinical outcomes were also included as 




accuracy, whilst others, like self-reported quality of life and patient satisfaction, were final outcomes. 
This allowed simultaneous understanding of the operational link between the diagnosis and the 
treatment decision whilst addressing uncertainty between the intervention and tangible final clinical 
outcomes (see chapter 2 for further methodological details). 
Table 87. Primary hypothesis considered in the SMaRT trial. 
Primary Null Hypothesis Null hypothesis rejected / not rejected 
There is no difference in 3-month NHS cost per 
patient between the use of immediate MRI in 
the management of suspected scaphoid 
fractures with negative findings in the initial 
radiograph compared to standard care. 
Null hypothesis not rejected. There was no 
significant difference in total costs between both 
groups (-£174, 95% CI: - £378 to £30, 
p=0.094). 
The results from the SMaRT trial indicated that the immediate MRI was associated with cost savings 
at 6 months post-recruitment and was highly likely to be cost-effective at month 3 and 6 post-
recruitment given conventional willingness-to-pay thresholds. With regards to non-economic 
outcomes, the intervention produced quicker and more accurate diagnosis, leading to an improved and 
streamlined treatment pathway. Contrary to previous evidence from a systematic literature review, the 
use of advanced imaging did not produce significant difference in the time off work or hand 
immobilisation with plaster cast. The latter seems to be due to the fact that the use of MRI led to a 
higher number of fractures being detected (p<0.05).  
The findings from the SMaRT trial led to the adoption of immediate wrist MRI as part of standard care 
at GSTT. The implementation work conducted as part of the TOHETI programme to incorporate the 
intervention as part of routine care is presented below. 
Implementation work: 
Main challenges: 
The translation of research findings into routine clinical practice is challenging, with some evidence 
suggesting that it takes too long and quite often it does not happen at all. Balas and Boren (2000) 
estimated that scientific discoveries took around 17 years to be integrated into clinical and community 
practice. Not only does it take too long, they also estimated that only about 14% of research discoveries 
are translated into benefits to patient care (Balas and Boren 2000). Although these figures are skewed 
by the research pipeline associated with innovative interventions, in particular pharmaceutical drugs, 
translational research still remains a challenging field. In fact, despite the different methodological 




frameworks (see 2.3.3), there is wide acceptance around the overarching concept of translational 
research and its increasing importance (Zoellner and Porter, 2017).  
Conscious of these challenges, a two-fold strategy to implement the intervention as part of routine 
clinical practice was considered. First, the intervention, i.e. the immediate use of MRI in an acute 
setting, represents a paradigm shift as MRI is not used in the acute setting. For this reason, a significant 
element of TOHETI was to transform the work across Clinical Imaging and Medical Physics (CLIMP) 
directorate, i.e. the Radiology Department. In fact, it was deemed essential to change the ‘ways we 
work’ in order to implement and sustain changes as part of the day-to-day job of all professionals, from 
clinical staff (e.g. radiologists, radiographers) to administrative and managerial roles. Second, although 
focused in the acute setting, the intervention fundamentally changed the entire diagnostic and 
treatment pathway. As with most clinical pathways, patients with suspected scaphoid fractures crossed 
not only the imaging department but multiple clinical directorates (Figure 73). This second level of 
dissemination thus included multiple stakeholders from different directorates. 
 
Figure 73. Illustration of the suspected scaphoid fracture crossing multiple clinical directorates. 
Although the trial produced favourable clinical and economic results, there are different considerations 
that posed difficulties to the adoption of immediate MRI in routine practice care. These difficulties were 
multi-factorial and grouped into four dimensions (financial, organisational, technological and cultural) 





Figure 74. Implementation challenges per dimension of analysis for all four departments considered. 
Financial dimension. There were challenges associated with the internal cascade of financial 
incentives throughout the healthcare provider’s organisation. Although the intervention led to cost 
savings from the healthcare payer’s perspective (NHS England), existing funding arrangements might 
prevent its adoption as the healthcare provider might incur a financial loss by doing so. Furthermore, 
even if the healthcare provider also benefited financially from the intervention (as is the case of 
immediate MRI), different departments might incur financial gains or losses as a consequence of 
adopting the intervention. From the imaging department perspective, there would be an increase in the 
number of MRIs, thus contributing to a growth in the level of funding. However, the imaging department 
will charge these MRIs internally to the department of the referrer, i.e. the emergency department. 
These charges are internal and might not be associated with the income generated by the intervention. 
In practice, although the income generated by the Emergency Department (ED) increases, this growth 
is only a fraction of the actual cost incurred by the department. In other words, compared to routine 
clinical practice, the ED makes a loss for each immediate MRI requested to manage suspected 
scaphoid fractures. To make matters worse, the introduction of MRI was associated with an increase 
in the proportion of breaches of the NHS 4-hour ED (21% vs 3.1% in the standard care group) and 
potential subsequent negative financial incentives. Similarly, the intervention with immediate MRI, 
reduces the number of outpatient appointments at Fracture Clinic (Orthopaedics department). Even 




outpatient appointments are reimbursed based on activity-based fees (under a contract block 
arrangement), this was not an issue due to existing waiting lists for appointments. 
Organisational dimension. Various organisational challenges arose while implementing the 
intervention. From the imaging department’s perspective, these comprised the limited availability of 
radiologists to support referrers from the ED with ‘live’ reporting of wrist MRI scans and the inherent 
change in the role of both radiographers and radiologists. All four departments (Emergency, Imaging, 
Orthopaedics and Physiotherapy departments) faced multiple challenges. These ranged from 
conflicting views on the intervention (e.g. patient selection criteria), the lack of a defined healthcare 
delivery process agreed by all stakeholders, the potential negative impact in performance targets (4-
hour ED target) and workload transfer between departments. The last point was of particular relevance 
as the intervention led to an increase in the workload for the imaging and emergency departments 
whilst contributing to decreasing the orthopaedics and physiotherapy departments’ workload. 
Technological dimension. The main challenge was the availability of MRI slots to accommodate an 
urgent wrist MRI referral. Given the high utilisation rates of MRI scanners, the appropriateness of 
immediately imaging patients with suspected scaphoid fracture was questioned by different clinicians. 
Cultural dimension. As with any change, cultural challenges arouse. From an imaging department 
point of view, the intervention fundamentally affected the paradigm around the utilisation of MRI, 
moving from a non-acute to an acute setting. This led to multiple staff members expressing opposition 
to this change. From a wider perspective, challenges were related to the limited leadership and 
ownership of the change process (e.g. “this is a radiology-driven change”), the limited network of 
working relationships between the four departments and the lack of time for different stakeholders to 
take time off clinical duties to implement changes across their clinical pathways (continuous change 
as part of the business as usual practice). 
Implementation plan: 
The PhD student, in partnership with other members of GSTT, developed an implementation plan to 
address the challenges previously identified, which comprised the following milestones (Figure 75). 
Appendix VII details the implementation plan based on the Consolidated Framework for 





Figure 75. Illustration of the aims and individual elements in the implementation plan. 
1. Internal dissemination of the research findings across the Trust (via newsletter and internal 
email from the executive team). In addition, research findings from the SMaRT trial were presented 
at different directorate clinical governance meetings across all four departments. This approach 
aimed not only at disseminating the evidence generated but also to give the opportunity for different 
members of staff to ask questions and actively take part in the process of redesigning the pathway.  
2. Multiple operational meetings involving individual departments and all four departments 
combined. These meetings provided a clearer understanding of the intervention’s implications and 
delineated a clear pathway with all clinical and administrative processes associated with its real-
world delivery (e.g. who is eligible for the pathway, what to do when eligible patients present out of 
MRI working hours). In addition, a workflow protocol was put in place to avoid breaches 
associated with the 4-hour ED target. Furthermore, to endorse the priority of the implementation 
project, senior engagement was involved in the implementation plan. As an example, the GSTT’s 
Chief Executive Officer and Medical Director attended multiple ED huddles at 8am. 
3. A one-day workshop concerning the roll-out of the new clinical pathway. This event involved 
clinicians, managers and analysts from all four directorates as well as members of the executive 
team of the hospital. As part of this event, multiple challenges were discussed and addressed. As 
an example, the chief executive’s support for the implementation of the intervention, despite its 




by-product of this top-down approach was to motivate and empower key stakeholders to lead the 
change.   
4. The TOHETI funding allowed for the purchase of additional scanners to increase MRI capacity, 
thus allowing the intervention to be implemented. This was an important element to gain the full 
buy-in from the imaging department.  
5. Ongoing discussions with external stakeholders, in particular Clinical Commissioning Groups 
(CCGs) at Lambeth and Southwark. This aimed to provide CCGs with evidence on the need to 
revisit existing funding schemes associated with the provision of care for patients with suspected 
scaphoid fracture (e.g. new tariff that incentivises the use of immediate MRI in the acute setting). 
6. Education and drop-in sessions were held where members of staff could express their concerns 
and ideas for the two weeks following the adoption of the new clinical pathway. This provided staff 
members with a feedback loop and the ability to flag issues with the provision of the intervention. 
The timeline with the different milestones of the scaphoid project, from the research component to the 
actual implementation in routine clinical practice, is illustrated in Figure 76. The project started back in 
2013 with initial brainstorming of ideas and identification of the intervention to be evaluated. The 
following four years comprised three studies, a modelling study, a feasibility study and a pragmatic 
randomised controlled trial (SMaRT trial). The last year of the project was focused in the 
implementation of the intervention in routine clinical practice (achieved on Monday 28th October 2019).  
 
Figure 76. Timeline associated with the project, from its inception, to its research component and the 




Implications for clinical practice at GSTT: 
The SMaRT trial changed clinical practice at a major London teaching hospital NHS Trust, leading to 
the inclusion of immediate MRI in the ED for the management of suspected scaphoid fractures. This 
meant that care management of over 500 patients annually will potentially be affected as a direct 
consequence of the research conducted as part of this PhD. In addition, and to our best knowledge, 
this is the first NHS clinical pathway that uses MRI during the initial ED episode. 
7.3.2 Chronic headache  
Model-based evaluation: 
A 12-month time horizon decision tree model compared the condition-specific healthcare costs of two 
coexisting clinical pathways in the management of chronic headache that differed in the referral from 
primary care to either neurology services or direct access to brain MRI. The model considered was 
however conceptually different from those developed for the scaphoid and colon cancer pathways. 
The inherent rationale for direct referral for brain MRI for patients with chronic headache was that a 
negative scan would reassure patients that no underlying life threating condition is causing the disease. 
Given the very low incidence of such life threatening conditions (<0.1% for brain cancer), this meant 
that the added value of brain MRI was not driven by its diagnostic accuracy for a given condition but 
for its potential ability to decrease subsequent use of NHS resources. Furthermore, based on clinical 
experts, the economic model also incorporated a branch around the diagnosis and management of 
incidental findings associated with the brain MRI.  
The base case scenario estimated that the management of chronic headache with direct referral to 
brain MRI produced marginal 12-month cost savings (£16) compared to the referral to neurology 
services. Given the level of uncertainty associated with the cost implications of both management 
strategies and at-risk population, a prospective, observational study was conducted at GSTT. 
Study-based evaluation: 
Primary research hypothesis. What are the economic and clinical benefits of using direct referral from 
primary care to head MRI in the management of patients with chronic 
headache? 
Chapter 4 presented the clinical and economic evidence of two existing clinical pathways for the 
management of patients with chronic headache. Despite almost entirely being managed within primary 
care, the increase in referrals to secondary care due to chronic headache has been adding extra 
pressure to resource constrained hospital neurology services. Within the NHS policy of providing GPs 




conventional referral route, i.e. referral to a neurologist. Given the very large population at risk and the 
potential clinical and economic impact, existing evaluation frameworks, such as Gazelle et al. (2011), 
recommend the use of high-level evidence. Given that both pathways were established as standard 
care and, in effect, the referral patterns are selected by the referrer (i.e. the GP), a prospective, 
observational study was designed to capture differences in terms of costs at 6 months post-recruitment 
(i.e. either after initial neurology appointment or the MRI scan) from a NHS perspective. 
This study found that direct access to MRI led to a significant decrease in the total NHS costs both at 
6 and 12 months post-recruitment (Table 88). Given the non-randomised design of the study, the 
generalised linear model analyses were refitted to adjust for baseline factors for potential imbalance 
between groups. The adjusted analyses showed that direct access to MRI remained cost saving at 
both 6 and 12 months post-recruitment. 
Table 88. Primary null hypothesis considered in the headache study. 
Primary Null Hypothesis Null hypothesis rejected / not rejected 
There is no difference in 6-month NHS cost per 
patient between the use of direct referral from 
the GP to the MRI services compared to referral 
from the GP to neurology services. 
Null hypothesis rejected. There was a significant 
difference in total costs between both groups  
(-£333, 95% CI: - £413 to -£253, p<0.001). 
In terms of self-reported quality of life, headache-specific and generic questionnaires were used. 
Unfortunately, due to very high attrition rates, changes in self-reported quality of life over the study’s 
timeline need to be interpreted with caution. At baseline, participants in the Neurology group reported 
lower quality of life and a higher headache burden. 
Due to the limited utility data retrieved from the EQ-5D-5L questionnaires and the imbalances at 
baseline, the cost-utility analyses performed need to be interpreted with caution. Despite the lower cost 
per participant in the MRI group, direct access to MRI does not seem to be cost-effective at 
conventional willingness-to-pay thresholds. This was due to the intervention with direct access MRI 
generating a lower number of QALYs compared to referral to neurology services. However, as 
mentioned in the paragraph above, these results need to be confirmed with further research before 
any policy change is to be made.   
With regards to accessibility, GP direct access to brain MRI led to an improvement, considering the 
time elapsed from referral to first appointment in both groups, i.e. either the initial neurology 
appointment or the MRI scan. Even if the MRI report, rather than the actually MRI scan, is considered 
as the first appointment for reassurance purposes, the intervention with brain MRI still improved access 





The headache study evaluated two existing clinical pathways that GPs in Lewisham and Southwark 
use to manage patients with chronic headache. A qualitative study interviewed 20 GPs from these two 
boroughs and presented two main conclusions (Underwood, Kilner, and Ridsdale 2017). First, that 
GPs had variable awareness of the direct access to MRI pathway, ranging from some GPs that 
commonly referred patients to others that were not aware of this management option. Second, GPs 
mentioned they had difficulty managing incidental findings from the MRI scan and that reports were 
not appropriate to support their subsequent headache management. These two elements were 
commonly given as the reasons why the uptake of direct access for MRI for these patients had been 
slow. 
The implementation plan considered two important tasks to tackle the identified challenges (Figure 77 
and, for further detail, the CRIF framework on Appendix VII). First, in order to increase awareness 
across GPs (i.e. the referrers), a GP with special interest in headache management and a neurologist 
provided training sessions across multiple practices, and also conducted a training workshop with an 
attendance of over 75 GPs. Second, to proactively support GPs in the management of patients 
following an MRI scan, the structure and content of the brain MRI reports needed to better reflect the 
information requirements of the referrer. The latter was particular important if the brain MRI showed 
incidental findings as GPs commonly stated that they struggled to interpret and manage these findings. 
This meant that radiologists were expected to not only report the MRI findings but also support their 
colleagues in primary care with the subsequent management of the chronic headache. For this 
purpose, the student worked with a consultant radiologist and a consultant neurologist to suggest an 
amendment to the existing reporting template. This task (ongoing at the time of the writing this chapter) 
consisted of adding a full section on how the GP should manage the patient’s chronic headache on 
the back of the MRI findings. 
 




Implications for clinical practice at GSTT: 
The implementation plan aimed to empower and reassure GPs (i.e. the referrers) and ultimately 
increase the proportion of patients with chronic headache directly referred for a brain MRI. This was 
corroborated with overall head MRI utilisation at GSTT for all types of referrals, which has increased 
over 120% in four years, with 465 head MRI scans in 2015, compared to over 1,000 scans in 2019. In 
just three years (2017 to 2019), the increase in direct referrals to MRI from GPs has more than doubled. 
As a by-product of this increase, direct access to brain MRI should not only contribute to the NHS 
financial sustainability agenda but also release neurology capacity for other neurological conditions. 
However, this increase was still not enough to offset the overall increase in referrals to secondary care 
due to chronic headache. In other words, although direct access to MRI has diverted some patients 
from the neurology department, the sheer increase in referrals from primary to secondary care has 
also led to an increase in referrals to neurology. 
7.3.3 Suspected colorectal cancer  
Model-based evaluation: 
A 6-month time horizon decision tree model compared the condition-specific healthcare costs of 
Computed Tomography Colonography (CTC) as a direct alternative to optical colonoscopy (OC) in 
patients with low to intermediate risk of Colorectal Cancer (CRC). The underlying rationale was that 
using a non-invasive and less costly diagnostic scan (CTC) would, in a large proportion of patients, 
avoid the need for patients to undergo an invasive, more expensive test (OC). This could ultimately 
lead to cost savings for the healthcare payer. 
The base case scenario estimated that the use of CTC, replacing OC as the initial colonic investigation, 
led to a £267 cost saving for the NHS. This cost difference was driven by four components: (i) the 
prevalence of CRC among patients deemed to be at low to intermediate risk of CRC; (ii) the diagnostic 
accuracy of CTC compared to OC; (iii) the number of extracolonic incidental findings found on CTC; 
and (iv) the unit cost associated with the provision of both diagnostic tests. When subjected to 
extensive deterministic sensitivity analyses, CTC remained a cost saving strategy. Nevertheless, given 
the lack of observed data on the management of extracolonic findings, and the potential clinical 
implications of missing CRC in a large cohort of patients, some clinicians expressed reservations about 
using CTC as a direct alternative to OC without local real-world evidence. For these reasons, a 







Primary research hypothesis. What are the economic and clinical benefits of using CTC in the 
management of patients with low risk suspicion of colorectal cancer? 
The Department of Health forecasted an annual increase of 10% to 15% in the demand for 
endoscopies, putting an additional burden on the already overstretched OC capacity (Department of 
Health 2012b). Backed by evidence of non-inferiority of CTC in the diagnosis of medium to large polyps 
and CRC, the utilisation of non-invasive CTC as a direct alternative to the gold standard OC was 
evaluated. Chapter 5 presented the clinical and economic evidence of two existing clinical pathways 
for the management of patients with suspected colorectal cancer (CRC) that varied in the initial 
diagnostic scan used, either optical colonoscopy (OC) or Computed Tomography Colonography 
(CTC). The intervention with CTC was found to be cost saving to the NHS at 6 months post-recruitment 
(Table 89). Given the non-randomised design of the study, generalised linear model analyses were 
adjusted for baseline factors for potential imbalance between groups. The adjusted analyses showed 
that using CTC as the first imaging scan for patients with low to intermediate risk of CRC remained 
cost saving. In terms of cost-effectiveness, the intervention with CTC had a 91.4% probability of being 
cost-effective compared to OC at month 6 post-recruitment at the £20,000 willingness-to-pay per QALY 
threshold. 
Table 89. Primary null hypothesis considered in the colon study. 
Primary Null Hypothesis Null hypothesis rejected / not rejected 
There is no difference in 6-month NHS cost per 
patient between the use CTC as the first line 
investigation compared to OC for patients with 
low to intermediate risk of CRC. 
Null hypothesis rejected. There was a significant 
difference in total costs per participant between 
both groups (-£345, 95% CI: -£501 to -£190, 
p<0.001). 
Implementation work: 
Two main challenges were associated with the uptake of CTC in the diagnosis of patients with 
suspected CRC. First, there was an existing perception among clinicians (particularly the referrers) 
that the CTC pathway presented issues, particularly around the bowel preparation prior to the 
procedure. Second, capacity issues led to the limited availability of CTC. Faced with these challenges, 
the referrers (i.e. clinicians running the virtual telephone clinic for all patients referred from primary care 
with suspected colorectal cancer) historically opted to mostly direct patients to CTC if they were not fit 
for a colonoscopy.  
The implementation plan considered three tasks to tackle the identified challenges (Figure 78 and for 





Figure 78. Three major tasks considered in the colon cancer implementation plan. 
The first two tasks aimed to address the low awareness and improve the referrer’s confidence around 
the CTC pathway. For this purpose, the entire CTC clinical pathway, from referral to the report being 
available to the referrer, was fully assessed, with particular focus on areas requiring improvement. A 
two-week clinical audit conducted by the student confirmed that over three quarters of issues with the 
pathway resulted from the pre-test bowel preparation. This in turn contributed to an overall 10% CTC 
cancellation rates. In order to minimise this problem, the way the bowel preparation was given to 
patients was profoundly changed, moving from a system where the patients physically attended GSTT 
pharmacy towards an alternative where the bowel preparation and respective patient information sheet 
was posted to the patient. In parallel, a simpler patient information sheet and substitute bowel 
preparation drugs with easier to follow instructions (despite being more expensive) were put in place 
to minimise the risk of non-compliance. In order to further streamline the pathway, revised electronic 
forms were put in place for the referrer to request the scan and for the radiology department to vet 
referrals and sign the prescription for pharmacy to post the bowel preparation. The rationale for these 
changes was to avoid unnecessary patient visits to the hospital and moreover avoid patients turning 
up on the day without bowel preparation (on the day cancellation) or patients with incomplete or 
suboptimal colon diagnostic scans (leading to a repeat test).  
Second, following the colonic investigation, the CTC report was revised to include a section on 
incidental findings, particularly extra-colonic findings. This aimed to support the referrer in terms of 




order to disseminate these changes among referrers, multiple training sessions were organised 
between the radiology and gastroenterology departments. 
Third, in order to enhance the responsiveness of the CTC pathway to patients on a two-week wait 
pathway (suspected colorectal cancer), the number of CTC slots were doubled. In contrast to previous 
scheduled arrangements, these slots were ring-fenced until two days before the actual scan. This 
aimed to protect the CT’s availability for CTC scans whilst avoiding those CT slots not being utilised.  
Implications for clinical practice at GSTT: 
The CTC utilisation rate has expanded by 186% in just four years, from 607 CTC scans in 2015 to 
1,733 in 2019 (Figure 79). Although these numbers included all patients, regardless of their referral 
criteria, the intervention with CTC for low to intermediate risk patients was responsible for more than 
two thirds of this increase. During the same period of time, the number of optical colonoscopies also 
increased, however at a more moderate rate (over 5 to 10% annually between 2015 and 2019). Despite 
the use of CTC as a direct replacement test decreasing the need for OC (workload shift from OC to 
CTC), the sheer increase in referrals for colonic investigations has offset any potential decrease in the 
number of OC scans. Based on the results from the colon cancer study and in order to accommodate 
the expected growth in demand, the imaging department has plans to double the capacity of the 
existing CTC service over the next 2 to 3 years. 
The second implication from the implementation plan was the reduction of the on the day cancellation 
and did not attend (DNA) rates. A reduction of 56% in CTC cancellation or DNA rate was verified, from 
a 16% overall rate in 2015 to 7% in 2019 (Figure 79). The improvement in the workflow and easier to 
follow bowel preparation instructions led to a higher proportion of optimal colonic investigations, thus 
reducing on the day CTC cancellation rates and the need for repeated colonic tests. 
 




7.4 Strengths and limitations 
The strengths and limitations of each studies were discussed in the individual chapters (chapters 3, 4 
and 5). This chapter focusses on the overall strengths and weaknesses of the PhD and the research 
programme TOHETI on which the PhD was based.  
Strengths: 
The greatest strength of the TOHETI programme was its originality, in aiming to transform healthcare 
using the new or novel utilisation of advanced imaging as the driver for change. This constituted a 
paradigm shift as advanced imaging, due to its higher costs and lower availability compared to basic 
imaging (e.g. radiographs), is usually reserved for later, not early stages of diagnostic pathways. 
Although this rationale might have been appropriate in the past, the decrease in the unit cost of 
advanced imaging modalities and their increased availability meant that the proposed interventions led 
to improved diagnostic and, where needed, treatment pathways, whilst generating cost savings in 
multiple clinical settings. 
Potential initiatives were selected based on a bottom-up approach, i.e. the initiatives were 
recommended by the clinical teams responsible for the delivery of care. This process empowered key 
clinicians whilst providing a research framework to assess the holistic use of medical imaging. 
Furthermore, literature reviews and critical appraisal of published clinical and economic evidence 
provided a solid foundation on which to base the interventions considered. Given the central role of 
medical imaging across different clinical pathways, the innovative use of advanced imaging not only 
impacted that section of the clinical pathway but the sections of pathway before and after the imaging 
test. As an example, the inclusion of immediate MRI in the management of suspected scaphoid 
fractures fundamentally changed the subsequent diagnostic and treatment pathway. This meant that, 
although the intervention took place in the Radiology department, its impact was felt prior to the imaging 
test, in the Emergency Department, and following the imaging test, in the Orthopaedic Department. 
This holistic assessment of the pathway, from referral to discharge, regardless of the location of the 
healthcare resources utilised, was a major strength associated with all studies performed as part of 
this research programme.  
Linked to the process of selecting different initiatives, the involvement of multidisciplinary teams and 
expertise (e.g. clinical experts, hospital managers, statisticians, health economists) from the onset of 
the research programme also constituted a major strength of the research programme. This 
multidisciplinary engagement, particularly during the study design process, was essential to evaluate 
all the anticipated clinical and health economic implications of each of the initiatives. Key decisions 
included the pragmatic evaluation in the context of real-world patients and the need to conduct any 
analysis based on intention-to-treat principles. The aim was to provide health policy makers and 




Other strengths of the research programme derived from the methodology considered in the data 
collection and data analysis processes. First, the a priori power calculations used in the sample size 
estimate were performed according to statistical principles and overseen by a Professor of Medical 
Statistics. Second, all data collection methods were designed to comprehensively capture relevant 
clinical and economic data during an appropriate follow-up period (dependent on the clinical condition 
being evaluated). Healthcare utilisation was captured using multiple databases from secondary care 
(up to seven clinical and financial databases) at an individual level (patient by patient). In addition, 
based on the holistic approach mentioned, data from primary care was also individually retrieved to 
obtain healthcare utilisation within primary care (e.g. GP appointments) as well as any other resource 
utilisation in other hospitals other than GSTT. A third layer of data were retrieved from self-reported 
participant diaries collected quarterly. Although very time consuming, this comprehensive methodology 
enabled the use of a large dataset of participants (over 500 patients) with minimal missing resource 
use data and ensured that all relevant costs were included in the economic analyses. The study design 
and methods considered aimed to minimise biases and optimise data completeness and integrity. 
Contrary to the majority of published evidence, the inclusion of healthcare utilisation derived from 
incidental findings was considered. As an example, if an incidental finding was diagnosed in the 
advanced imaging test, i.e. a finding unrelated to the referral or clinical condition, its clinical and cost 
implications were included in the analysis. This rationale was deemed appropriate as the incidental 
finding was a direct consequence of the intervention proposed and its exclusion might have led to 
different results. 
The clinical staff responsible for the delivery of care were included as members of the research team. 
This was an important strength and essential to maximise recruitment rates across the three studies. 
Given the different number of studies simultaneously run by the PhD student at different physical 
locations, it was essential to train staff members for them to become independent in the recruitment of 
participants.  
One final strength of the research programme was its funder, a not for profit organisation (Guy’s and 
St Thomas’ Charity). The PhD student was fortunate to be involved from the onset on a £13 million 
grant that allowed not only the purchase of equipment (MRI and CT scanners) but also to evaluate the 
implications of using those scanners in the context of real-world patients and pathways. The PhD 
student was given intellectual independence to impartially evaluate the different interventions 
considered. 
Limitations: 
In addition to the limitations discussed in each of the individual study chapters, an important weakness 
derived from the single-site design (one NHS Trust) of all three research studies. This raises potential 




designed to recruit across a heterogeneous population reflecting UK clinical practice, this remains as 
one important weakness. Prior to widespread adoption of the interventions evaluated further research 
in different settings and healthcare providers should be considered. The updated models could also 
be used by decision makers in different health care settings. 
All studies were powered on cost differences between groups rather than clinical or cost-effectiveness 
differences. However necessary for feasibility purposes, it constituted a limitation of the research 
programme. In order to mitigate this, secondary outcomes considered the clinical and economic 
evaluation of the intervention. All three interventions were also evaluated based on the incremental 
cost per QALY as per NICE recommendations. 
Lastly, an important limitation in one of the observational studies (chronic headache study) was due to 
the very high follow-up attrition rates of participants’ self-reported data (e.g. utility data). Although 
financial incentives and non-traditional communication methods (e.g. phone app) were put in place to 
maximise participant compliance, the difficulty to gather high-quality information from participants was 
underestimated. This meant that the cost-utility analysis performed lacked robust data and therefore 
only the cost analysis (and not the cost-utility analysis) could be used to inform healthcare policy 
makers. For future studies, the study design should consider this issue by prioritising follow-up 
workload (e.g. using one instead of two headache-specific questionnaires) and consider the resources 
necessary to intensify follow-up contacts. 
7.5 Implications for policy and clinical practice 
The implications for policy and clinical practice were discussed in the three previous sections. This 
section discusses the national implications of using advanced imaging in new or novel ways. 
Value-based healthcare principles aim to provide policy makers with appropriate evidence on which to 
base their decision. The inclusion of different dimensions of analysis, from efficiency (e.g. cost per 
case, cost per QALY), accessibility to care (e.g. time from referral to diagnosis or treatment), clinical 
outcomes (e.g. diagnostic accuracy, proportion of fractures healed) to patient satisfaction (e.g. self-
reported quality of life) aimed to capture meaningful and tangible outcomes while respecting the 
physical and psychosocial needs and expectations of our patients.  
Irrespective of the intervention investigated, this PhD is aligned with existing healthcare policies in 
three key areas. First, all interventions considered in the TOHETI programme aimed at improving 
access to medical imaging. Although only one of the cancer projects was presented in this thesis, 50% 
of the TOHETI projects (3 out of 6) aimed at improving cancer outcomes by promoting access to 
medical imaging (NHS Improvement Diagnostics 2012). Second, all interventions promoted both 
horizontal and vertical integration of care. For instance, the use of immediate MRI in the management 




secondary care, in this case four different directorates. This transformative work had the potential to 
not only improve care for patients with suspected scaphoid fracture but also other patients that flow 
through these departments. Direct access to brain MRI from primary care promoted vertical integration 
of care from primary and secondary/tertiary care. Third, the interventions endorsed the NHS RightCare 
initiative under the “right test, right time, right patient” principles. As an example, the use of immediate 
MRI in the management of suspected scaphoid fractures encouraged of the use of a more accurate 
test (right test) for patients with clinical suspicion of scaphoid fracture and negative radiographic 
evidence (right patient) during the initial acute episode (right time). 
Finally, if advanced imaging is to play a central role in the transformation of healthcare, particular 
attention needs to be given to NHS capacity. As summarised in Chapter 2 and further detailed in Cake, 
Cavanagh, and Gordon (2015) and Bainbridge (2018), medical imaging demand is expected to keep 
increasing due to multiple factors such as the lowering of referral thresholds, inclusion of imaging in 
new pathways, among others. However, in order to accommodate this increase and shift in demand, 
considerations about capacity, of both equipment and personnel, are essential. Even with increased 
efficiency or longer opening hours, the existing capacity within the NHS does not seem to have enough 
operational flexibility to meet this rise in demand without further investment. Bainbridge (2018) 
produced a report highlighting that CCGs seem to be aware of this issue, but limited and contradicting 
evidence around the expansion of diagnostic capacity was presented. Hence, in order to implement 
change and transform care using medical imaging as the driver for change, policy makers should 
address regional disparities in imaging capacity and close the gap in terms of number of scanners per 
inhabitants compared to other developed healthcare systems (e.g. France, Germany). 
7.6 Implications for further research 
A number of implications for further research were previously described as part of the individual studies 
(chapters 3, 4 and 5) and the methodological chapter (chapter 6).  
Two common features were associated with study attrition rates and statistical methods used in the 
cost analysis. First, attrition rates varied based on several parameters such as the follow-up period, 
clinical condition and intervention being evaluated. Longer follow-up periods had higher attrition rates. 
Clinical conditions with higher disease burden seemed more likely to remain engaged in the study 
compared to healthy participants or participants with a lower disease burden. Similarly, interventions 
likely to provide reassurance to participants seems to have led to participant disengagement. For 
instance, in the evaluation of direct access to MRI for patients with chronic headache, a higher attrition 
rate in the MRI group was recorded compared to the neurology group. Second, further research into 
the methodologies used in the cost analyses and the potential impact on the recommendations should 
be considered. Contrary to most published economic literature, GLMs utilising the identity link function 




potential biases (Polgreen and Brooks 2012; Peacock, Kerry, and Balise 2017). Also, the use of 
bootstrap techniques, commonly used to perform cost-effectiveness and cost-utility analyses, should 
be further evaluated and compared against GLMs. Although some differences in the 95% confidence 
intervals for the cost difference between groups using GLM and bootstrap methods were found, the 
recommendations for the adoption of any of the three interventions would not have changed. 
Nevertheless, in theory, different policy recommendations could be reached using different statistical 
methods and therefore further research is required to establish a standard statistical method in the 
analysis of cost variables. 
Another recommendation for further research is to address the rise in demand for advanced medical 
imaging. Besides capital investment in equipment, workforce redesign is essential to address future 
challenges. The development of a workforce redesign framework in the context of real-world delivery 
of care should be considered in the translational research field. Two particular topics were identified 
as part of the TOHETI programme. First, the current workforce roles should be redesigned to adapt to 
the ever changing needs of care delivery. For instance, the SMaRT trial evaluated the use of 
radiographers (technician responsible for the acquisition of images) as a first-line reporter to rule-in or 
rule-out fractures in the ED. The higher availability of radiographers, compared to radiologists, makes 
them an ideal resource to expedite this time sensitive acute pathway. This would not preclude the need 
for a subsequent MRI report from the radiologist but would operationalise the intervention in NHS 
Trusts without or with limited on call radiologists or musculoskeletal radiologists. Supplementary 
research that assesses intra and inter-variability of radiographers compared to radiologists (assumed 
to be the gold standard) should be considered.  
Second, the use of artificial intelligence and computer assisted diagnosis will fundamentally change 
different workflows associated with the reporting of imaging sets. These developments are likely to 
affect all professionals, particularly radiologists. The role of radiologists is likely to evolve, moving 
towards reporting of complex imaging scans where computer aided technologies have less traction, 
interventional radiology and assuming a more proactive role as care coordinator. Future radiology 
reports should be geared towards not only the diagnosis and reporting of the imaging findings but also 
to support the referrer with clear management plans. This subject however is deemed contentious and 
further qualitative and quantitative research is required to assess both the feasibility and the views of 
radiologists towards the expansion of their clinical role. 
7.7 Conclusion 
The clinical and economic impact of three imaging-based interventions were evaluated based on health 
economic and value-based health principles, contributing to new knowledge across these clinical 
conditions. Based on the study findings, the use of immediate MRI in the ED was added to standard 




pathways for management of chronic headache and suspected colorectal patients were promoted as 
alternatives for selected patients. In all, these three interventions hold the potential to improve the 
clinical care of over 3,000 patients annually at GSTT. 
Despite its limitations, this research programme challenged the broadly accepted paradigm that 
advanced imaging should be reserved for later stages of the diagnostic pathway. This new imaging 
paradigm aims to promote the early use of accurate and definitive diagnostic tools, streamlining the 
diagnostic and, if needed, treatment pathway. This will ultimately lead to improvements in both clinical 
and patient outcomes whilst reducing overall costs of care.  
Although intangible or difficult to quantify, a second consequence of this research programme was the 
inherent cultural change across different directorates of one organisation as important as GSTT (over 
15,000 employees). Conscious of the added value of the PhD and the TOHETI programme, the 
hospital executive board decided to incorporate its approach and methodology as part of a novel 
organisational wide transformation programme, called Care Redesign. In many ways, this is one of the 





Appendix I. Systematic literature review search strategy 
Database: Embase <1974 to 2018 Week 48>, Ovid MEDLINE(R) and Epub Ahead of Print, In-
Process & Other Non-Indexed Citations and Daily <1946 to November 26, 2018> 
Search Strategy: 
--------------------------------------------------- 
1     phased approach.ab. (452) 
2     hierarchical approach.ab. (1101) 
3     phased evaluation.ab. (13) 
4     hierarchical approach.ab. (1101) 
5     hierarchical evaluation.ab. (37) 
6     framework.ti. (57932) 
7     diagnosis.ti. (738539) 
8     diagnost*.ti. (318537) 
9     imaging.ti. (507324) 
10     1 or 2 or 3 or 4 or 5 or 6 (59507) 
11     7 or 8 or 9 (1524153) 
12     10 and 11 (962) 
13     limit 12 to yr="2009 -Current" (631) 






Appendix II: Search strategy used in the search of economic evidence around the utilisation of 
advanced imaging in the management of suspected scaphoid fractures.  
Database: Ovid MEDLINE(R) <1946 to May Week 2 2016>, Ovid MEDLINE(R) In-Process & 
Other Non-Indexed Citations <May 18, 2016> 
The search strategy returned 93 papers.  
-------------------------------------------------------------------------------- 
1     (scaphoid adj5 fracture).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] (917) 
2     (suspected adj5 scaphoid).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] (182) 
3     (occult adj5 scaphoid).mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] (79) 
4     scaphoid.ti,ab. (3811) 
5     1 or 2 or 3 or 4 (3812) 
6     exp magnetic resonance imaging/ (347899) 
7     MRI.m_titl. (43994) 
8     Tomography, X-Ray Computed/ (317812) 
9     CT.m_titl. (61578) 
10     "Bone and Bones"/ or Bone Neoplasms/ (130052) 
11     bone scintigraphy.m_titl. (1813) 
12     exp emergencies/ (36558) 
13     acute.m_titl. (410280) 
14     emergency.m_titl. (66567) 
15     advanced imaging.m_titl. (246) 
16     (compute* and tomograph*).mp. (478230) 
17     6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 (1347678) 
18     exp radiography/ (687469) 
19     exp x-ray/ (26428) 
20     (plain adj5 x-ray).mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 




21     (plain adj5 radiography).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] (3188) 
22     (conventional adj5 radiography).mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] (3092) 
23     (scaphoid adj5 radiography).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] (45) 
24     18 or 19 or 20 or 21 or 22 or 23 (714988) 
25     costs.mp. and cost analysis/ [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] (44066) 
26     (economic adj3 evaluation$).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] (8630) 
27     (economic adj3 analy*).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] (6450) 
28     (economic adj3 (study or studies)).mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] (3400) 
29     (cost adj3 evaluation$).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] (2307) 
30     (cost adj3 analy*).mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] (116802) 
31     (cost adj3 (study or studies)).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] (7809) 
32     (cost adj3 effective*).mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] (96096) 
33     (cost adj3 benefit*).mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 




34     (cost adj3 utilit*).mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] (3808) 
35     (cost adj3 minimi*).mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] (2411) 
36     (cost adj3 consequence*).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] (706) 
37     (cost adj3 comparison*).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] (2057) 
38     (cost adj3 identificat*).mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] (394) 
39     25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 (191984) 
40     exp Carpal Bones/ or exp Wrist Injuries/ or exp Scaphoid Bone/ or exp Fractures, Bone/ 
(163724) 
41     5 or 40 (164435) 
42     17 and 24 and 39 and 41 (113) 
43     limit 42 to yr="1990 -Current" (98) 















and sample size 
Economic data/economic 
related outcomes / clinical 
outcomes 










Follow-up: At 42 
days, using 
questionnaires. 
Intervention:  Early MRI scan 
performed 1-3 days from day of 
presentation in patients with 
negative radiographic findings 
in the initial X-ray. 
Comparator:  immobilisation 
with scaphoid plaster and 
periodic clinical and 
radiographic follow-up. 
19 patients in 
total, 11 in the 
MRI group and 8 
in the comparator 
group. 
Costs: Health care resource 
use was obtained via a 
questionnaire at 42 days. The 
cost of healthcare was derived 
from Medicare Benefits 
Schedule 2014. 
Clinical outcomes: pain and 
function scores, immobilisation 
time (measured in days). 
QALYs: None. 
Economic evaluation: not 
applicable (cost analysis only). 
Costs: The comparator group 
has a median cost per person of 
$486.90 (AUD) (149.51–724.63) - 
[$337.09, $103.51-$501.67], 
slightly higher when compared 
with $485.05 (AUD) (448–550.23) 
- [$335.81, $310.16-$380.94] for 
the MRI group (p= 0.74). 
Other results: MRI reduces the 
immobilisation time (2.5 days vs 
29.5 days, p=0.026) and 
treatment time (3 days vs 31 
days, p=0.004). Patient 
satisfaction scores were higher in 
the MRI group, but the difference 
was not statistically significant. 
The use of early 









appears to be 
slightly cost-
saving for the 
healthcare 
perspective. 










up period up to 42 
days. 
Intervention:  Patients with 
negative findings in the initial X-
ray are treated with a 
removable scaphoid cast and 
randomised to the MRI group 
(MRI scan to be performed 
within two working days from 
A&E attendance). Subsequent 
treatment based on MRI 
findings (if negative, no follow-
up is arranged). 
Comparator:  Patients with 
negative findings in the initial X-
ray are immobilised with   
removable scaphoid cast and 
randomised to the control 
group, with clinical follow-up at 
14 days.  
84 patients were 
randomised into 
MRI (45) and 
control (39) 
groups.  There 




injuries in the MRI 







Costs: Mean cost per patient in 
the management of both groups 
(MRI vs X-ray only). 
Management costs for all 
patients were calculated using 
data from the Finance 
Department at West Middlesex 
University Hospital (UK). 
Relevant direct, indirect and 
overheads costs were included 
in the cost analysis. Time off 
work was evaluated but not 
included in the cost analysis. 
Clinical outcomes: Mean pain 
and patient satisfaction scores. 
QALYs: None. 
Economic evaluation: not 
applicable (cost analysis only). 
Costs: No statistically significant 
differences were found in terms of 
mean management costs with 
£504.13 ($728.80) in the MRI 
group and £532.87 ($770.35) in 
the control group (p=0.9). 
Other results: No statistically 
significant differences were found 
in terms of better pain and 
satisfaction scores (MRI was 
found to have a trend of both 
better pain and satisfaction 
scores). 


















Follow-up: period of 
3 months (patients 
contacted monthly to 
collect information on 
resource use and 
recovery of wrist 
function and pain).  
Intervention:  Patients with 
negative findings in the initial 
radiography underwent an MRI 
scan within two to five days 
from A&E attendance. Apart 
from the MRI, no other 
alterations to the clinical 
pathway were made. 
Comparator: current clinical 
practice with immobilisation with 
scaphoid plaster and periodic 
clinical and radiographic follow-
up. 
28 patients were 
randomised into 
MRI (11) and 
control (17) 
groups.  
Costs: Costs of health services 
were retrieved from the 
Medicare Benefits Schedule 
(2002). The study seems to 
assume a societal perspective, 
including healthcare direct costs 
as well as indirect costs, 
associated with days off work.  
QALYs: None 
Economic Evaluation: Cost-
effectiveness analysis, using as 
the measure of effect the 
number of days patients 
unnecessarily spent in plaster.  
Costs/Cost-effectiveness: 
Derived from the bootstrap 
simulation, the study estimates a 
$30.8 per day saving due to 
prevention of unnecessary 
immobilisation by the use of MRI 
(95% CI $2.97 to $69.94). 
The MRI group used fewer 
healthcare units (median 3.0, 
interquartile range 2.0–4.25) than 
the control group (5.0, 3.0–6.5) (p 
= 0.03 for the difference). 
The median cost of healthcare in 
the MRI group ($411.48, 
$381.71– $461.93) was slightly 
higher than in the control group 
($296.42, $86.12– $496.46) (p = 
0.19 for the difference). 
At a median productivity loss of 
50%, the addition of MRI is likely 
to be cost-effective 95.3% of the 
time. 
The use of MRI 
reduces the 
number of days 
of unnecessary 
immobilisation 






relation to the 


















dependent on the 
presentation day).  
Follow-up: short-
term (not specified). 
Patient’s A&E 
records assessed 




Interventions: MRI following 
normal radiography, usually 
performed within mean 1 day 
(0–7) after attending A&E. 
Follow-up consultation was 
booked regardless of the MRI 
results. 
Comparator: conventional 
treatment with a below-elbow 
scaphoid cast for 2 weeks, at 
which point a follow-up 
consultation and/or radiography 
was obtained. If diagnosis is not 
clear after 2 weeks, patients 
would undergo an MRI. 
 
124 patients 
between 18 and 








during 1 year in 
2009–2010. 
Costs:  Direct costs associated 
with the diagnosis/treatment - 
obtained from the Norwegian 
Health Economics 
Administration - and indirect 
costs associated with sick leave 
retrieved from the Norwegian 
Labour and Welfare Service. 
QALYs: None. 
Economic evaluation: Cost-
minimisation evaluation (cost 
analysis). 
Costs: No statistically significant 
differences in the total direct 
medical costs between the two 
groups. However, average direct 
costs in the MRI group (4,308€ or 
$4,805) than in the control group 
(6,999€ or $7,806). Indirect costs 
for employees (due to sick leave) 
represented 85% of the total 
management cost.  
Other results: Patients in the 
MRI group without a scaphoid 
fracture (n=54), but potentially 
with other fractures, used a cast 
for fewer days (mean 8.8 day) 
than patients in the control group 
(n=59) (difference of 6.5 days; p < 
0.005). There is a statistically 
In a Norwegian 
setting, the 
early use of 
MRI was of 












significant difference between 
groups in terms of sick leave (7 










specified but includes 
the full diagnostic 
pathway until a 
definitive diagnosis is 
reached. 
Intervention: MRI study if the 
findings on X-ray continued to 
be negative at the first follow-up 
examination 10 days after 
trauma.   
Comparator:  Immobilisation 
and periodic clinical and 
radiographic follow-up (X-ray 
and CT in the final phase of the 
process).  




fractures of the 
scaphoid and 
negative findings 
on initial X-ray. 
Costs: Direct and indirect costs 
were considered - cost per 
protocol considered in each 
group.  
QALYs: None 
Economic evaluation: not 
applicable (cost analysis only). 
Costs: The cost of the MRI 
protocol was 131.06€ ($194.58) 
per patient whilst the cost of the 
traditional protocol was 114.41€ 
($169.86) or 151.06€ ($224.28) 
per patient, depending on the 
follow-up studies required. 
The cost of the 
MRI protocol is 
similar to the 
comparator and 
even lower in 
some cases 
(patients that 
required the use 










Follow-up: period of 
3 months (patients 
interviewed at 3 
months to ask the 
duration of leave and 
hand function). 
Intervention:  Patients with 
negative findings in the initial X-
ray underwent an MRI scan 
within a week from A&E 
attendance.  Subsequent 
treatment based on MRI 
findings (if negative, no follow-
up was arranged and patient 
was incentivised to use the 
hand for daily activities).  
Comparator:  Standard 
treatment with immobilisation 
with elbow dorsal splint and 
clinical and radiological follow-
up at 2 weeks. If clinically 
suspicious at 2 weeks, the wrist 
was splinted again and 
reviewed after 4 weeks and 
sometimes after 6 weeks. 
27 patients with 
negative findings 
in the initial X-ray 
were assigned to 




one using the 
intervention and 
the second the 
comparator).  
Costs: Average of total costs 
for both groups. The number of 
hospital contacts were retrieved 
from case records. All 
healthcare contacts were 
costed using Danish tariffs. The 
study used both a hospital and 
non-hospital (societal) 
perspectives. Productivity loss 
costs were valued using a 
Danish daily average rate.  
Other outcomes: Time off work 
and immobilisation time per 
group (measured in days). 




effectiveness analysis, using 
the hand function as the 
measure of effect. 
Costs: A difference in hospital 
costs of €151 ($209.89) in favour 
of the standard treatment 
observed (p<0.05). A difference in 
non-hospital costs of €2,869 
($3,988) in favour of the MRI 
group supported the use of 
advanced imaging (p<0.05). 
Other results: Immobilisation 
time reduced from 20 days (range 
6–54) in the radiography group to 
4 days (range 1–19) in the MRI 
group (p<0.01). Time off work 
reduced from 27 days (1–92) in 
the radiography group to 11 days 
(0–28) in the MRI group (p<0.01). 
Median hand function score at 
follow-up in the radiography group 
was 2 (1–3), and 2 (1–4) after 
MRI supported treatment 
(p=0.70). The adjusted difference 
was 0.2 (95% CI, -0.3–0.7) in 
favour of standard treatment 
(p<0.224). 
The use of MRI 
increased 
hospital costs 
(p<0.05), but, at 
the same time, 
reduced non-
hospital costs 
by $4,068, due 
to the reduction 







study (further details 
Intervention(s):  Patients with 
negative findings in the initial 
radiography underwent an MRI 
Patients 
presenting to an 
A&E Department 
Costs: Resource use was 
collected using data from 
patients included in the study. 
Costs/Cost-effectiveness: 
Average medical cost was NZD 
470 ($708) for the standard 
The early use of 
MRI is cost-










(to be performed within 1-3 
days of initial presentation). 
Comparator:  Immobilisation  
with scaphoid plaster and 
periodic clinical and 
radiographic review (at 2, 4 and 
6 weeks). 




ray result were 
allocated to the 
treatment (50 
patients) or the 
comparator group 
(40 patients). 
Key direct costs were 
considered – e.g. X-ray, plaster, 
assessment and MRI - to 




effectiveness analysis, with an 
ICER using the identification of 
fracture as measure of effect. 
intervention group and NZD 533 
($803) for the MRI group. 
Average cost to exclude a 
fracture was NZD 459 ($692) for 
the standard intervention group 
and NZD 437 ($659) for the MRI 
group. 
recommended 
to be offered as 
part of the 
routine 
diagnosis. 
Economic evaluation (using economic models) 





using a decision 
analysis model 
(decision tree). 
Follow-up: 2 weeks 
Interventions: 6 interventions 
were considered: immediate 
CT, day 3 MRI, day 3 bone 
scan, week 2 X-ray alone, week 
2 X-ray and CT, week 2 X-ray 
and MRI, week 2 X-ray and 
bone scan, and immediate MRI 
Comparator: No specific 
comparator was established 
(the 6 interventions were 





in an acute care 
setting. 
Costs: Costs and benefits 
calculated from a societal 
perspective. Resource use and 
benefits retrieved from 
literature. Costs were estimated 
using 2013 Medicare data. 
QALYs: None 
Economic evaluation: cost-
effectiveness analysis. ICER 
per detected scaphoid fracture 
is estimated. 
Costs/cost-effectiveness: 
Immediate imaging (CT or MRI) 
and day 3 MRI were the most 
cost-effective strategies for 
diagnosing suspected scaphoid 
fractures.  ICER of immediate 
MRI compared with immediate CT 
was $7,483 per scaphoid fracture 
detected.  
Immediate CT 
and MRI were 

















specific time horizon 
is defined. 
Interventions: use of advanced 
imaging (CT or MRI) to initially 
diagnosis suspected scaphoid 
fractures (following an initial 
negative radiography).  
Comparator: Empiric cast 
immobilisation following a 
negative X-ray with orthopaedic 
follow-up and repeat X-ray two 
weeks post-injury. 
Reference case 
was an employed 
patient who was 
25 years of age 





but with negative 
initial radiographs 
Costs: Costs and benefits 
retrieved from literature. A 
societal perspective was used 
in the economic model. 
QALYs: Yes. 
Economic evaluation: Cost-
effectiveness and cost-utility 
analyses. 
Cost-effectiveness/cost-utility: 
Advanced imaging was dominant 
over empiric cast immobilisation. 
MRI was slightly more cost-
effective than CT (ICER of 
$41,000/QALY and assuming a 




found to be 
dominant over 
the comparator. 
The decision to 
use either CT or 













retrieved from clinical 
Intervention(s):  Three 
diagnostic strategies: 1) 
repeated X-ray up to week 2; 2) 
repeated X-ray up to week 6; 
A total of 160 
patients was 
included. 
Costs: direct medical costs 
associated with the diagnostic 
(e.g. radiography, bone 
scintigraphy) and therapeutic 
Costs/Cost-effectiveness: The 
mean cost per patient was $238, 
$276 and $275 for strategy 1, 2 











literature for: 1) the 
prevalence of 
scaphoid fractures 
among patients with 
suspected scaphoid 
fracture; 2) accuracy 
for different imaging 
modalities; and 3) 
percentage of non-
union episodes given 
the type of therapy. 
Follow-up: Minimum 
follow-up period of 
one year. 
and 3) X-ray, followed by bone 
scintigraphy (performed at least 
3 days after the injury) in 
patients with negative findings 
in the X-ray. 
Comparator:  imaginary 
scenario, assuming an initial 
radiography. If positive, patients 
are put in a plaster cast for 12 
weeks. If the radiography is 
negative, all patients underwent 
bone scintigraphy and 
subsequent treatment is based 
on its findings. 
(e.g. plaster cast, surgery for 
non-union) pathway were 
included. 
Clinical outcomes: mean 
period of immobilisation 
(measured in days) and non-
union rate (measured as % of 
all patients). 
QALYs: None. 
Economic evaluation:  Cost 
and cost-effective analyses, 
using the increment costs to 
save one non-union as the 
measure of cost-effectiveness. 
incremental cost incurred to save 
one non-union by using bone 
scintigraphy is one-third of the 
price of repeated radiography at 6 
weeks, hence the intervention is 
cost-effective (ICER not 
presented). 
Other results: Assuming a 44% 
prevalence rate, the mean 
immobilisation times were 5.7, 8.6 
and 6.9 for strategy 1, 2 and 3, 
respectively. A non-union rate of 
4.7%, 4.2% and 3.1% were 










of retrospective data 






Intervention: hypothetical early 
use of MRI. 
Comparator: clinical and 
radiographic diagnosis and 
patient’s immobilisation in acute 
setting with subsequent periodic 
clinical and radiographic follow-
up. 
 
537 patients aged 
13 years or older 
referred to 
fracture clinic at 
the Royal 
Infirmary of 
Edinburgh with a 
scaphoid-related 
injury. 
Costs: Cost per type of injury (3 
groups). Clinical notes were 
examined retrospectively and 
three injury groups were 
defined: true fractures, occult 
fractures, and suspected 
scaphoid injuries.  
QALYs: None 
Economic evaluation: not 
applicable (cost analysis). 
Costs: There were 87 true 
fractures, 43 occult fractures, and 
407 suspected injuries, incurring 
average treatment costs of 
£1,173 ($1,675), £773 ($1,104), 
and £384 ($548) respectively. 
The costs involved in the 
treatment of suspected scaphoid 
injuries were found to be higher 
than the additional cost of 



















audit of patients with 
suspected scaphoid 





Intervention:  Patients with 
negative findings in the initial 
radiography underwent an MRI 
performed a mean of 6 days 
from the injury (range 1-21 
days). Subsequent treatment is 
dependent on the MRI findings. 
Comparator:  Traditional 
treatment algorithm, with 
immobilisation with removable 
scaphoid cast and periodic 
clinical follow-up 2.5 weeks 
after injury.  




2004 and March 
2007. 
Costs: Total cost savings 
associated with the use of MRI. 
Medical direct costs (MRI, 
radiography and bone scan) are 
considered, as well as societal 
costs due to time off work. 
Clinical outcomes: Percentage 
of patients that had an alteration 
to their management care as a 
result of the early MRI. 
QALYs: None. 
Economic evaluation: not 
applicable (cost analysis). 
Costs: from a healthcare 
perspective, the use of MRI leads 
to an increase of $242 in costs. 
However, if loss earnings due to 
unnecessary immobilisation are 
included, it is estimated that the 
use of MRI will lead to cost saving 
of $1,655 per patient. 
Other results: 76% of patients 
with normal initial X-ray had an 
alteration to their management 
based on the MRI findings. 



















using the local 
prevalence of the 
condition and 






time is defined as 
patients are followed 
until a fracture is 
demonstrated by 
plain radiography or 
second line imaging 
or full resolution of 
the symptoms with 
no radiographic 
evidence of fracture 
is achieved. 
Interventions: use of advanced 
imaging (CT, MRI, Bone 
Scintigraphy and Ultrasound) as 
the second line investigation for 
patients with suspected 
scaphoid fracture.  
Comparator: Empiric cast 
immobilisation following a 
negative radiography with 
orthopaedic follow-up and 
repeat radiography at 10-14 
days post-injury. 








Costs: Total cost of diagnosis 
and treatment of a patient with 
suspected scaphoid fracture. 
Costs such as staff, materials 
and overheads were considered 
and retrieved from local hospital 
(in Scotland) and the Scottish 
Health Statistics Cost book 
2006. The total cost per patient 
was estimated based on: 1) the 
local prevalence; and 2) the 
accuracy levels of MRI, CT, 
Bone Scintigraphy and 
Ultrasound in the diagnosis of 
scaphoid fractures.  
Clinical outcome: True 
prevalence of scaphoid 
fractures among patients with 
suspected scaphoid fracture. 
QALYs: None 
Economic evaluation: not 
applicable (cost analysis). 
Costs: The mean cost per patient 
was £302 ($482), £243 ($388), 
£113 ($180) and £202 ($322) for 
MRI, Bone Scintigraphy, 
Ultrasound and CT, respectively. 
These figures compare against 
the actual mean cost per patient 
using the standard management 
pathway is £204 ($326) for 
patients with confirmed scaphoid 
fracture and £132 ($211) for 
patients with no confirmed 
scaphoid fracture. 
Other results: The true 
prevalence of patients with 
scaphoid fracture amongst 
patients with suspected scaphoid 
fracture was 16%. 
Clinicians 
should consider 


















until the plaster was 
removed and 
fractures ruled out in 
the last assessment. 
Intervention(s):  Impact of 5 
interventions is hypothesised: i) 
MRI scan on day 1; ii) Bone 
scan within a few days; iii) MRI 
scan within a few days; iv) MRI 
scan within a few days followed 
by a review of results on the 
same day; and v) MRI scan 
after a clinical and/or 
radiological examination in 2 
weeks’ time.  
Comparator:  immobilisation 
with scaphoid plaster and 
periodic clinical and 
radiographic follow-up. 
Clinical audit 
carried out in the 
Leighton General 
Hospital. A total 
of 85 eligible 
patients was 
considered. 
Costs: Costs to the hospital 
budget in ruling out or 
diagnosing scaphoid fractures. 
Non-hospital costs, e.g. indirect 
costs associated with days off 
work were not considered. The 
resource use for the five 
alternative interventions is not 
based on data collected during 
the audit. 
QALYs: None. 
Economic evaluation:  Cost-
minimisation evaluation (cost 
analysis). 
Costs: Projected costs for many 
of the alternative protocols 
involving routine use of scanning 
procedures were found to be 
lower or comparable to the 
comparator, immobilisation with 
periodic clinical and radiographic 
follow-up. 
Protocols based 
on the use of 
advanced 
imaging (either 

















Intervention:  Screening MRI 
at the time of presentation in 
Four actual case 
scenarios are 
Costs: Direct cost associated 
with the intervention and the 
Costs: Cost analysis suggests 










specified but includes 
follow-up 
consultations. 
patients with negative 
radiographic findings in the 
initial conventional radiography. 
Comparator:  Immobilisation 
with scaphoid plaster and 
periodic clinical and 
radiographic follow-up. 
presented and 




standard care) is 
hypothesised.  
comparator. The utilisation of 
healthcare resources is 
hypothesised for four actual 
case scenarios. Cost data were 
based on charges from the US 
healthcare system. 
QALYs: None. 
Economic evaluation: not 
applicable (cost analysis only). 




















Appendix IV. Patient experience questionnaire assessing the pre-test, the test and the post-test 
stages for both groups in the colon study. 












    N % N % N % N % N % 




OC (n= 69) 1 1.4% 4 5.8% 10 15% 14 20% 40 58% 
CTC (n= 
45) 
2 4.4% 1 2.2% 6 13% 12 27% 24 53% 
Quality of the 
written 
instructions 
OC (n= 69) 1 1.4% 2 2.9% 6 8.7% 21 30% 39 57% 
CTC (n= 
44) 




OC (n= 69) 0 0.0% 1 1.4% 7 10% 23 33% 38 55% 
CTC (n= 
45) 
0 0.0% 1 2.2% 2 4.4% 12 27% 30 67% 
How you found the 
process overall 
OC (n= 68) 0 0.0% 6 8.8% 12 18% 27 40% 23 34% 
CTC (n= 
45) 
0 0.0% 0 0.0% 7 16% 16 36% 22 49% 
 








Up to 12 
hours 
Up to 6 
hours 
Up to 3 
hours 
Up to 1 
hour 
Immediately 
    N % N % N % N % N % N % N % 
About the bowel test 
How long 
did it take 




9 13% 10 14% 3 4.3% 7 10% 13 19% 15 21% 13 19% 
CTC  
(n= 45) 






    Not at all A little Moderately Quite a bit Extremely 
    N % N % N % N % N % 
Straightforward 
OC (n= 69) 2 2.9% 4 5.8% 10 15% 19 28% 34 49% 
CTC (n= 42) 1 2.4% 1 2.4% 4 9.5% 17 41% 19 45% 
Dignified 
OC (n= 68) 2 2.9% 3 4.4% 14 21% 31 46% 18 27% 
CTC (n=38) 0 0.0% 3 7.9% 10 26% 11 29% 14 37% 
Uncomfortable 
OC (n= 66) 7 11% 26 39% 16 24% 8 12% 9 14% 
CTC (n= 38) 7 18% 10 26% 10 26% 6 16% 5 13% 
Intrusive 
OC (n= 65) 10 15% 24 37% 16 25% 9 14% 6 9.2% 
CTC (n= 38) 10 26% 16 42% 7 18% 3 7.9% 2 5.3% 
Bearable 
OC (n=66) 3 4.5% 2 3.0% 19 29% 26 39% 16 24% 
CTC (n=38) 2 5.3% 5 13% 11 29% 10 26% 10 26% 
 







    N % N % N % 
Overall experience about the diagnostic test 
How did you find the 
experience in 
comparison to your 
expectation? 
OC (n= 70) 9 13% 31 44% 30 43% 










    
Very slightly 
or not at all 
A little Moderately Quite a bit Extremely 
    N % N % N % N % N % 
Feelings on the morning after the bowel test (post-test) 
Calm 
OC (n= 67) 1 1.5% 3 4.5% 16 24% 29 43% 18 27% 
CTC (n= 42) 3 7.1% 2 4.8% 13 31% 14 33% 10 24% 
Confident 
OC (n= 66) 1 1.5% 5 7.6% 16 24% 31 47% 13 20% 
CTC (n= 40) 3 7.5% 2 5.0% 12 30% 16 40% 7 18 % 
Safe 
OC (n= 67) 1 1.5% 3 4.5% 12 18% 22 33% 29 43% 
CTC (n= 38) 1 2.6% 2 5.3% 7 18% 16 42% 12 32% 
Relieved 
OC (n= 66) 6 9.1% 4 6.1% 14 21% 14 21% 28 42% 
CTC (n= 42) 3 7.1% 3 7.1% 12 29% 14 33% 10 24% 
Concerned 
OC (n=65) 26 40% 19 29% 9 14% 7 11% 4 6.2% 
CTC (n=38) 9 24% 17 45% 6 16% 2 5.3% 4 11% 
Anxious 
OC (n=67) 27 40% 25 37% 9 13% 3 4.5% 3 4.5% 
CTC (n=41) 15 37% 17 42% 4 9.8% 3 7.3% 2 4.9% 
Upset 
OC (n=66) 52 79% 4 6.1% 7 11% 1 1.5% 2 3.0% 
CTC (n=38) 30 79% 4 11% 2 5.3% 1 2.6% 1 2.6% 
Uncertain 
OC (n=64) 29 45% 20 31% 8 13% 4 6.3% 3 4.7% 





Appendix V. Strengths and weaknesses of different types of studies used in the economic evaluations. 
Randomised controlled trials (RCTs) 
RCTs are commonly considered as the gold standard to establish the efficacy of a given technology. This is due to its implicit design that 
eliminates different types of biases, particularly selection bias. It has however been argued that RCTs might not be the best type of study on 
which to base an economic evaluation (Sculpher et al. 2006). RCTs’ high internal validity due to its randomised and controlled design can limit 
external validity and generalisability to other healthcare groups, providers or healthcare settings. 
Strengths: 
 Unbiased estimates of treatment effects. The RCT design aims to ensure that differences in outcomes are attributed to the intervention being 
evaluated. This is achieved using a randomised allocation of participants to the intervention or the control group (e.g. the placebo group in drug 
trials), a well-defined participant inclusion and exclusion criteria and tight protocol-driven processes.  
 Prospective collection of both clinical outcomes and resource use data at the patient-level. Access to individual data allows for the utilisation of 
different statistical and economic techniques to explore the relationship between costs and outcomes such as health-related quality of life 
(Petrou and Gray 2011; Petrou 2012; Glick et al. 2007).  
 Adequately powered and scientifically rigorous. 
Weaknesses: 
 Single-centre RCTs might not provide all the information required and may not be generalisable (Woolacott et al. 2017). RCTs are generally 
designed to assess the technology’s efficacy and therefore relevant data from the economic perspective might be missing. Sculpher et al. 
(2006), based on two cardiology studies, noted that RCTs lacked patient reported outcomes such as quality of life (e.g. QALYs) and failed to 
capture all relevant resource use data. This might lead to the need to use evidence synthesis and modelling techniques to incorporate these 
costs and effects into the economic evaluation.   
 Controlled setting and inclusion criteria. The trial’s inclusion criteria might not be representative of the heterogeneous population that might 




 Insufficient time horizon. Most trial-based economic evaluations present a follow-up period shorter than the time horizon considered in an 
economic model. This is particularly the case for RCTs in chronic diseases that might require valuation of long-term or lifetime costs and effects 
(Sculpher et al. 2006; O’Sullivan, Thompson, and Drummond 2005). This limitation means that cost and effects after the trial’s follow-up period 
are typically derived from decision model extrapolation from cost and outcome observed in the trial. Sculpher et al. (2006) pointed out that the 
latter might not be a problem if the within-trial incremental analysis already satisfies the decision makers’ willingness to pay threshold. 
 Artificially enhanced patient compliance rates. The RCT setting might lead to patient compliances rates with the clinical management that are 
far superior to what might be seen in a real-world clinical practice (S. D. Ramsey et al. 2015). 
 Might not provide information on final endpoints. RCTs might be based on intermediate clinical endpoints rather than the actual final outcome 
required for the economic evaluation. This is quite often the case in the medical imaging field, where intermediate outcomes (e.g. sensitivity 
and specificity) are often reported in RCTs rather than actual clinical outcomes (e.g. mortality rates).  
 Might not compare all relevant alternatives (Sculpher et al. 2006; O’Sullivan, Thompson, and Drummond 2005). Given the research costs and 
feasibility issues, RCTs typically compare a new technology against standard care. However, other technologies, often used to a lesser degree, 
are not included. Thus, RCTs typically do not compare all existing alternatives. In this context, an economic evaluation based on a single RCT 
produces a partial analysis (Sculpher et al. 2006; Cook 2015).  
 Lack of relevance to the decision maker. Quite often RCTs are conducted by the technology’s manufacturer, that might target important 
healthcare markets or markets and providers where recruitment is quicker and/or at lower costs (Sculpher et al. 2006; O’Sullivan, Thompson, 
and Drummond 2005). However, an RCT from a non-UK background might present considerable differences in patient case-mix and routine 
clinical practice, posing generalisability concerns. 
Real-world evidence (RWE) 
More recently, several authors have argued in favour of pragmatic trials-based economic evaluations (Buxton et al. 1997; O’Sullivan, Thompson, 
and Drummond 2005; Glick et al. 2007; Marshall and Hux 2009; Calvert, Wood, and Freemantle 2011; Petrou 2012; S. D. Ramsey et al. 2015). 
This opportunity derives from the naturalistic study design of pragmatic trials, explicitly aimed at: (i) assessing the intervention’s effectiveness in 




representative of a real-world setting. In the context of health economics, RWE has also been described as data used to support an economic 
evaluation based on studies that were not RCTs (Garrison et al. 2007). Real-world studies ranged from: large simple trials, registries, 
administrative data to electronic health records reviews (Garrison et al. 2007). 
Strengths: 
 Large simple trials are, in effect, pragmatic RCTs with broad inclusion criteria, more reflective of clinical practice. Similar to conventional RCTs, 
pragmatic trials have the strengths associated with the randomised allocation of participants. Their pragmatic design however means that a 
wider population is recruited, allowing for a better understanding of resource use for a more heterogeneous population. In addition, the use of 
pragmatic trials has been associated with the inclusion of an economic component in the trial design (Calvert, Wood, and Freemantle, 2011). 
 Registries are prospective, non-randomised, observational cohort studies (Garrison et al. 2007) that involve data collection of uniform clinical, 
economic and/or patient-reported outcomes. Compared to pragmatic trials, registries tend to be cheaper and include a large and more 
heterogeneous population and longer periods of follow-up. Hence, registries are more likely to capture final outcomes and not just intermediate 
outcomes. 
 Observational case-control studies are retrospective studies. Observational studies can be very useful complementing information obtained 
from RCTs, allowing researchers to analyse and generalise to subpopulations not included in the RCTs inclusion criteria (Silverman, 2009). 
However, given the non-randomised design of observational studies, appropriate statistical methods (e.g. regression and matching methods) 
should be used to address potential selection biases. Furthermore, even if the right statistical methods are used, decision makers need to be 
cautious about making inferences based on results from observational studies (Freemantle et al. 2013; Woolacott et al. 2017). 
 Administrative data considers the retrospective, or, if feasible, real-time data collection, of data typically used for reimbursement purposes 
(Garrison et al. 2007). This information not only captures resource use but also diagnoses and procedure codes with information on participants 
(e.g. comorbidities). Administrative data can provide useful retrospective cross-sectional (at a given point in time) or longitudinal (over a specific 
follow-up period) analyses of clinical and economic outcomes for a given patient, group or population (Garrison et al. 2007). Given its low cost 
and ease to perform, retrospective analysis of administrative data might provide useful insights into plausible associations between any given 





 Electronic health records are important sources of real-world data as contain disease-specific information at a patient or group level and are 
accessible, standardise reliable sources of data (Franklin and Thorn 2019). This type of data [e.g. Hospital Episode Statistics (HES)] is 
commonly used alongside other types of real-world data. 
Weaknesses: 
 Large simple trials (pragmatic RCTs) present typically larger sample sizes, being more time and cost consuming to perform (Garrison et al. 
2007). Consistent with conventional RCTs, pragmatic trials do not eliminate the remaining weaknesses associated with RCTs, e.g. not 
comparing all alternatives or inappropriate time horizon. The choice of outcomes (primary and secondary outcomes) and respective 
measurement methods might be constrained in favour of the trial’s feasibility (Welsing et al. 2017). 
 Registries do not include random allocation of participants to an intervention. Thus, results need to be interpreted with caution due to the 
intrinsic limitations of observational studies (Garrison et al. 2007) and the use of analytic methods to address imbalance in baseline 
characteristics should be considered. 
 Retrospective administrative data analyses rely on data entries outside the scope of the researcher that are primarily developed for 
reimbursement purposes. Any economic evaluation based on administrative data could lead to biased findings if its data quality is poor. In fact, 
administrative data quality is usually questioned due: missing data, particularly data not missing at random; coding errors or potential data 
‘gaming’; the utilisation of charges as a proxy for healthcare costs; the variability between healthcare providers and its coding practices; the 
limited availability of clinical, socioeconomic and demographic characteristics; and lack of data on health outcomes and symptoms (Garrison 
et al. 2007). Lastly, even when a research question is clearly articulated, it might be hard to identify the entire population at risk or likely to 
benefit from the intervention (i.e. to determine the population denominator).  
 Electronic health records typically lack data integration to allow the estimate of healthcare utilisation on a patient-level basis. This usually 





Decision models are based on mathematical approaches to simulate uncertain real world scenarios and support the decision making. Buxton et 
al. (1997) proposed two scenarios where modelling is appropriate. First, when in the presence of an innovative technology or when few data are 
available, decision models are used as a first resort for hypothesis generation and inform the design of future studies (Buxton et al. 1997). 
Second, modelling should be used at the opposite end of the spectrum, as a last resort when RCTs studies are not feasible or, when possible, 
do not provide required information. Decision modelling have sometimes been wrongly described as an alternative rather than a complement to 
experimental and real-world studies (Sculpher et al. 2006). 
Strengths: 
 Unlike RCTs or pragmatic RCTs that typically present a head-to-head comparison (e.g. new intervention vs placebo or current standard care), 
decision models allow for the inclusion of all relevant alternatives associated with the decision problem. 
 Extrapolate beyond observed data. Given that clinical trials generally provide comparative data for a limited period of follow-up, economic 
models can extrapolate data (e.g. mortality rates or disease progression) beyond the observed data (Buxton et al. 1997).  
 Link intermediate with final outcomes. Depending on the clinical condition, it is not uncommon for observed data to evaluate an intermediate 
endpoint rather than final endpoints. One example pointed out by Buxton et al. (1997) was the use of variations in total serum cholesterol 
(intermediate outcome) as a surrogate for the assessment of hypercholesterolaemia (final outcome). Economic decision models are then used 
to link intermediate with final outcomes. However, surrogate endpoints tend to over-estimate treatment effects (Woolacott et al. 2017). 
 Increased generalisability of results. Economic evaluations are performed to reflect the real-world setting encountered by the decision maker. 
This means that is usually necessary to generalise data, from trials (efficacy) to real-world clinical practice (effectiveness) and also from different 
healthcare providers (hospital A and hospital B) or even different healthcare systems (e.g. US, UK) (Buxton et al. 1997; Woolacott et al. 2017).  
 Data synthesis and multiple comparison. Economic models are used to synthesise data from multiple sources (e.g. different RCTs, systematic 
literature reviews or observational studies) (Garattini et al. 2016). In the context of multiple RCTs and RWE, decision modelling based on data 




no trial data exists (Buxton et al. 1997; Sculpher et al. 2006) or the use of data from studies with variable follow-up periods (Sculpher et al. 
2006).  
 Uncertainty analysis. Economic models can be useful supporting the decision maker process even in the absence of observed data (Buxton et 
al. 1997; Woolacott et al. 2017). Furthermore, the use of deterministic and Bayesian probabilistic sensitivity analyses across multiple model 
parameters enables the decision make to evaluate under which scenarios the intervention should be adopted (Ades et al. 2006).  
Weaknesses: 
 Inadequate clinical data. Economic modelling based on clinical data is intrinsically associated with the quality of the respective clinical data and 
its study design. Economic models based on flawed or biased clinical data are likely to provide a biased decision to decision makers.  
 Inadequate use of statistical methods associated with data derived from multiple studies (heterogeneity) (Ades et al. 2006).  




Appendix VI. Key literature results, detailing the incidence of suspected scaphoid fracture and the 
sensitivity and specificity for different imaging modalities. 
Reference Incidence Sensitivity Specificity Notes 






Variable:  From 













26 studies were included in 
the systematic review and 
meta-analysis. 
Variable average age of 











fractures. Out of 












CT: 96% (No 
CI identified) 
Values proposed based on 22 
and 8 original research 
publications to address the 
performance of MRI and CT, 
respectively. 




multidetector CT and 
MR Imaging – Initial 
Experience” 
38% (11 














Compared to MRI, 
multidetector CT performs 
better in the detection of 
cortical scaphoid fractures but 
is worst in depicting solely 
trabecular injuries.  
Hackney and Dodds 
2011”. Assessment 









CT: 80%. No 
CI identified) 
Review article. Not a case 
study. 
Mallee et al., 
2011.”Comparison of 









CT: 96% No 
CI identified) 
MRI: 89% No 
CI identified) 
Case study with a small 
sample (n=34). It is also 
relevant to point out that a 
1.0T open field MRI was used 











artefacts and lower image 
quality). 
Brydie and Raby, 
2003. “Early MRI in 











Average patient age was 36 
years. A 0.2T dedicated 
extremity scanner was used 
and the images acquired 
within 14 days of injury. 
The management of 92% of 
the patients was altered due 
to the use of MRI. 106 
patients without any positive 
MRI finding were discharged. 
15 patients were discharged 
after one clinic visit. 
Low and Raby, 2005. 
“Can follow-up 
radiography for acute 
scaphoid fracture still 









Follow-up radiography should 
not be considered a valid 
investigation for the detection 
of scaphoid fracture. 
Pillai and Jain 
(2005). 
“Management of 
clinical fractures of 
the scaphoid: results 






Method: prospective study 
with 90 patients with clinical 




imaging of suspected 
scaphoid fractures 







0.2T extremity MR system 
was used. Management was 





Appendix VII. Description of the five domains and respective constructs considered in the CRIF framework applied to the three implementation projects considered 
in this thesis (suspected scaphoid fracture, chronic headache and colorectal cancer pathways). 





Internally developed by orthopaedics 
and radiologists. 
Internally developed by neurologists and 
radiologists. 
Internally developed by colorectal 




Based on a pragmatic randomised 
clinical trial, perceived as high-quality 
evidence. 
Based on published data and local observational, prospective studies. The 
research studies were perceived as high-quality and allowed a better 




MRI perceived as the best diagnostic 
test to diagnose suspected scaphoid 
fractures. 
Direct access to MRI perceived as a 
valid alternative to some patients. 
Mixed perception among clinicians: 
CTC perceived as inferior or equal 
to reference colonoscopy. 
Adaptability  
Provision of MRI was not continuous 
(24/7). Local plans were made to 
provide equal care to all patients 
regardless of time of presentation to ED. 
Both clinical pathways already constituted standard care. However, changes 
were made to promote uptake of the intervention, both in the chronic headache 
pathway (new MRI reporting templates) and the CRC pathway (new bowel 
preparation workflows).  
Trialability 
Local pilot conducted prior to roll-out of 
the new pathway. 
Not applicable. Both clinical pathways already constituted standard care. 
Complexity 
Disruptive intervention, perceived as 
complex, and involving multiple 
stakeholders 
Implementation not disruptive in nature. Complexity of the chronic headache 






and packaging:  
Similar across all implementation projects. Clinical and cost findings from the real-world studies were presented in detail to 
the different clinical and managerial teams.   
Cost:  
The intervention was associated with 
lower NHS costs. Implementation costs 
included time taken off by clinicians and 
non-clinicians to adopt the new pathway.  
The intervention was associated with 
lower NHS costs. Implementation costs 
were higher compared to other projects 
a GP training programme was 
considered. 
The intervention was associated 
with lower NHS costs. 
Implementation costs were 
marginal, associated with the set-
up of a new workflow for dispensing 




The implementation aimed to improve 
patient satisfaction by reducing the time 
from presentation to diagnosis and 
avoiding unnecessary wrist 
immobilisation. 
The implementation aimed to improve 
uptake with the direct access to brain 
MRI and decrease patient waiting times 
(improve access to care). 
The change in the bowel 




Guy’s and St Thomas’ NHS Foundation Trust (GSTT) is a central hospital with different network links to multiple bespoke 
hospitals. Multiple clinicians at GSTT were responsible to oversee the integration of care between different healthcare 
providers and have been exposed to different implementation initiatives.  
Peer pressure  
Given the non-competitive nature of the UK healthcare market and the innovative nature of the interventions (i.e. not 




Potential increase in the 4-hour ED 
target and no unbundled tariff for MRI 
scans performed as part of the ED 
presentation represented two external 
negative financial incentives. 
Clinical guidelines promoted the 
utilisation of GP direct access to 
imaging. Existing unbundled MRI tariff 
provided external positive financial 
incentives. 
Clinical guidelines did not promote 
the equivalence of CTC and OC 
(negative external policy). However, 
waiting times associated with OC 









The implementation of novel initiatives in 
the ED was challenging due to: a high 
turnover of human resources (teams are 
less stable); large teams; and 
considerable internal pressure to deliver. 
The Radiology department, main responsible for the delivery of direct access 
to MRI (headache pathway) and CTC (CRC pathway), although large in size 
compared to other Hospitals, was characterised for decentralising decision-




Existing internal networks, relationships 
and communication channels between 
the different directorates (ED, Radiology 
and Orthopaedics) were suboptimal. 
Existing external communication channels with GPs were better developed in 
the Neurology and Gastroenterology departments compared to Radiology. 
Lack of appropriate communication channels for interaction between GPs 
(referrer) and the MRI/CTC services.  
Existing internal networks and relationships among directorates were based on 
informal relationships between key clinicians. 
Culture:  
GSTT has recently embarked in a journey of cultural change where adaptive and continuous change is perceived as 
essential to ensure the organisation’s sustainability. However, compared to other healthcare providers (particularly in the 
USA), GSTT is still in the early stages of cultural development.  
Implementation 
climate  
The existing clinical pathway was 
perceived as of poor quality (tension for 
change). The implementation initiative 
was aligned with the individuals and 
organisation’s values and promoted 
sense of belonging among the teams. 
The two implementation initiatives aimed to increase uptake of an existing 
pathway (i.e. no particular tension for change). In both cases, the initiatives 
were compatible with the individuals and organisation’s values and teams were 
given the latitude to improve care for patients. The suspected CRC pathway 








Given its innovative nature, this 
implementation initiative required senior 
leader engagement (e.g. GSTT’s CEO 
and Medical Director attended multiple 
ED huddles at 8am). Furthermore, given 
its complexity, appropriate resources 
(clinician and non-clinicians’ time) were 
dedicated. 
The level of senior engagement required for the implementation was 
considered to be desirable (not essential as with the scaphoid initiative). To 
maximise the implementation’s success, individuals and groups of individuals 







the intervention:  
Individuals, as well as organisations, present a natural resistance to change. The latter may be particularly true in clinical 
areas where disruptive innovation is less common. Individuals in the Radiology Department are commonly exposed to new 
technologies and were expected to be less resistant to change.  
Self-efficacy:  
Individuals at GSTT were believed to be quite self-confident of their own abilities to implement change across their models 
of care. 
Individual stage 
of change:  
Individuals (clinicians and non-clinicians) involved in the empirical studies were towards the last stages of the change 
model (action and maintenance stages). However, other members of staff were at very different stages, with some, 





Staff satisfaction levels at GSTT are above the UK average (measured by national staff surveys). Moreover, given the 







GSTT, being one the main hospitals in the UK and also based in central London, presents multi-cultural staff members 




Detailed formal implementation plans were considered for each initiative. These were based in A3 project sheets and 
disseminated across the different individuals and departments involved. 
Engaging:  
Volunteered clinical leaders within each directorate were pivotal at cascading down key information and actions of the 
implementation plan. This was achieved by the combination of: internal widespread of research findings from the research 
studies; informal and formal operational meetings; multiple education and drop-in sessions; and workshops with multiple 
stakeholders (from administrators to clinicians) 
Executing:  
Implementation plans were, to a large degree, followed by the different teams. However, there were some delays in some 
key activities, particularly: the definitive roll-out of the scaphoid pathway (postponed twice due to discrepancies on who is 
responsible to communicate the MRI findings under circumstances); and the revision of the ‘incidental findings’ section in 
the brain MRI report (ongoing process). 
Reflecting and 
evaluating:  
Monthly meetings for 12 months 
following the implementation roll-out and 
education and drop-in sessions for the 
first 2 months. These meetings are 
based on quantitative data (e.g. number 
of MRI referrals, proportion of patients 
undergoing MRI, distribution of clinical 
findings, cost savings to the NHS). 
Ongoing discussions with CCGs also 
aim at revising existing reimbursement 
tariffs associated with the intervention. 
Key opinion leaders involved in the implementation project were given access 
to a purpose built dashboard where they could see key implementation data 
such as: absolute number of referral to either brain MRI or CTC; number of 
days elapsed between referrals and respective tests; number of days from test 
to report. These aimed at providing these members of staff with enough 
evidence to continuously monitor the progress of the implementation project 
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